

FORM PTO-1390
REV. 2/01T

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

07541.0002

U.S. APPLICATION NO.
(If known, see 37CFR1.5)**10/048008**

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/JP00/04909

July 24, 2000

July 26, 1999

TITLE OF INVENTION**PHARMACEUTICAL COMPOSITIONS EXHIBITING THROMBOPOIETIN RECEPTOR AGONISM****APPLICANT(S) FOR DO/EO/US****Hiroshi TAKEMOTO, Masami TAKAYAMA, and Takeshi SHIOTA**


Applicant(s) herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c)(2)).
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau.
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed with the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154 (d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)).
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☒ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ Information Disclosure Statement under 37 CFR 1.97 and 1.98
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A Substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154 (d)(4).
19. ☐ A second copy of the English language translation of the international application 35 U.S.C. 154 (d)(4).
20. ☒ Other items or information:
 - a. ☒ Copy of cover page of International Publication No. WO 01/07423
 - b. ☐
 - c. ☐

10048008-012502

| | | | | | |
|---|--------------|---|------|--|----------|
| U.S. APPLICATION NO. (If known, see 37CFR 1.5) 10/048008 | | INTERNATIONAL APPLICATION NO. PCT/JP00/04909 | | ATTORNEY'S DOCKET NUMBER 07541.0002 | |
| 21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): | | | | CALCULATIONS PTO USE ONLY | |
| Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1040.00 | | | | | |
| International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00 | | | | | |
| International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00 | | | | | |
| International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00 | | | | | |
| International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33 (1)-(4) \$100.00 | | | | | |
| ENTER APPROPRIATE BASIC FEE AMOUNT = | | | | \$890.00 | |
| Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). <input type="checkbox"/> 20 <input type="checkbox"/> 30 | | | | \$ | |
| CLAIMS | NUMBER FILED | NUMBER EXTRA | RATE | | |
| Total Claims | 39 | - 20 = | 19 | x \$18.00 | \$342.00 |
| Independent Claims | 4 | - 3 = | 1 | x \$84.00 | \$84.00 |
| MULTIPLE DEPENDENT CLAIM(S) (if applicable) | | | | + \$280.00 | \$280.00 |
| TOTAL OF THE ABOVE CALCULATIONS = | | | | \$1596.00 | |
| <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2. | | | | \$ | |
| SUBTOTAL = | | | | \$1596.00 | |
| Processing fee of \$130.00 for furnishing the English translation later than months from the earliest priority date (37 CFR 1.492(f)). <input type="checkbox"/> 20 <input type="checkbox"/> 30 | | | | \$ | |
| TOTAL NATIONAL FEE = | | | | \$1596.00 | |
| Fee for recording the enclosed assignment (37 CFR 1.21 (h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property. | | | | +\$40.00 | |
| TOTAL FEES ENCLOSED = | | | | \$1636.00 | |
| | | | | Amount to be refunded: \$ | |
| | | | | charged: \$ | |
| a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>1636.00</u> to cover the above fees is enclosed. | | | | | |
| b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. | | | | | |
| c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>06-0916</u> . A duplicate copy of this sheet is enclosed. | | | | | |
| d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. | | | | | |
| NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status. | | | | | |
| SEND ALL CORRESPONDENCE TO: Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P. 1300 I Street, N.W. Washington, D.C. 20005-3315 | | | | | |
| DATED: January 25, 2002 | | | |  SIGNATURE Ernest F. Chapman /25,961 NAME/REGISTRATION NO. | |

10048008.012502

2/pst

DESCRIPTION

Pharmaceutical compositions exhibiting thrombopoietin receptor agonism

5

Technical Field

The present invention relates to pharmaceutical compositions exhibiting thrombopoietin receptor agonism.

10

Background Art

Thrombopoietin, polypeptide cytokine composed of 332 amino acids, activates the production of platelets by stimulating the differentiation and proliferation of megakaryocytes through the receptor and is expected as a medicine for hemopathy accompanied with the unusual number of platelets, for example, thrombocytopenia and the like. DNA sequences encoding the thrombopoietin receptor have been described in Proc. Natl. Acad. Sci., 89:5640-5644 (1992). Low molecular peptides having an affinity for the thrombopoietin receptor is also known (JP98/72492A, and WO96/40750), but these peptide derivatives are not generally practical for oral administration.

20

1,4-Benzodiazepine derivatives as a low molecule compound having an affinity to the thrombopoietin receptor is described in JP99/1477A.

The compounds having a similar structure of the present invention compound are described in JP92/99770A, Chem. Pharm. Bull., 1982, 30, 3580, JP94/172339A (EP512899), JP90/308240A, WO97/32863, Arzneim. Forsch/Drug Res., 1998, 48, 651, JP95/173143A, JP93/85551A, JP85/443A,

JP96/245602A JP96/157462A, JP96/143556A and the like, but the affinity for thrombopoietin receptor is not described therein.

Disclosure of Invention

5 The object of the present invention is to prepare pharmaceutical compositions exhibiting thrombopoietin receptor agonism and provide orally administrable platelet production modifiers.

In the above situation, the inventors of the present invention have
10 found that the following compounds exhibit strong thrombopoietin receptor
agonism.

The present invention relates to:

15 1) A pharmaceutical composition exhibiting thrombopoietin agonism which contains as an active ingredient a compound of the formula (I):



wherein X¹ is optionally substituted aryl, optionally substituted aralkyl,
optionally substituted heteroaryl, optionally substituted heteroarylalkyl, or
optionally substituted non-aromatic heterocyclic group;


Y¹ is -NR^ACO-(CH₂)₀₋₂-, -NR^ACO-(CH₂)₀₋₂-W-, -NR^ACO-CH=CH-, -W-(CH₂)₁₋₅-
NR^ACO-(CH₂)₀₋₂-, -W-(CH₂)₁₋₅-CONR^A-(CH₂)₀₋₂-, -CONR^A-(CH₂)₀₋₂-, -(CH₂)₀₋₅-
NR^A-SO₂-(CH₂)₀₋₅-, -(CH₂)₀₋₅-SO₂-NR^A-(CH₂)₀₋₅-, -NR^A-(CH₂)₀₋₂-, -NR^A-CO-
NR^A-, -NR^A-CS-NR^A-, -N=C(SR^A)-NR^A-, -NR^ACSNR^ACO-, -N=C(SR^A)-NR^ACO-,
25 -NR^A-(CH₂)₁₋₂-NR^A-CO-, -NR^ACONR^ANR^FCO-, or -N=C(NR^AR^A)-NR^A-CO-,

wherein R^A is each independently a hydrogen atom, optionally substituted

lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl, R^F is a hydrogen atom or optionally substituted aryl, W is an oxygen atom or a sulfur atom;

- 5 Z¹ is optionally substituted arylene, optionally substituted heteroarylene, optionally substituted non-aromatic heterocycle-diyl, or optionally substituted cycloalkyl-diyl;


A¹ is a ring represented by the formula:



- 10 wherein R¹ and R² are both hydrogen atoms or taken together may form an oxygen atom or a sulfur atom; R³ and R⁴ are both hydrogen atoms or taken together may form an oxygen atom or a sulfur atom; R⁵ is a hydrogen atom or lower alkyl; Q and V are each independently -O-, -S-, -NR^B- (wherein R^B is a hydrogen atom or lower alkyl), or -CH₂-; m is 1, 2, or 3;
- 15 a broken line (---) represents the presence or absence of a bond, its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.

In more detail, the invention relates to the following II) to XX).

- 20 II) A pharmaceutical composition exhibiting thrombopoietin agonism which contains a compound of I), wherein X¹ is optionally substituted 5-member heteroaryl or a group represented by the formula:




wherein E is $-(CH_2)_{1-3}-$, $-O-CH_2-$, or $-S-CH_2-$; R^6 and R^7 are each independently a hydrogen atom, optionally substituted lower alkyl, carboxy, lower alkyloxycarbonyl, optionally substituted aminocarbonyl, optionally substituted thienyl, or optionally substituted phenyl.

5

Preferred is a pharmaceutical composition exhibiting thrombopoietin agonism which contains a compound of I), wherein X^1 is phenyl optionally substituted with one or more group(s) selected from lower alkyl, lower alkyloxy, lower alkylthio, arylazo, aralkyloxy, aryl, halo(lower)alkyl, halogen, and hydroxy.

10

III) A pharmaceutical composition exhibiting thrombopoietin agonism which contains a compound of I), wherein X^1 is a group represented by the formula:



15

wherein E is $-(CH_2)_{1-3}-$, $-O-CH_2-$, or $-S-CH_2-$; R^6 and R^7 are each independently a hydrogen atom, optionally substituted lower alkyl, carboxy, lower alkyloxycarbonyl, optionally substituted aminocarbonyl, optionally substituted thienyl, or optionally substituted phenyl; R^8 is a hydrogen atom or lower alkyl.


20

IV) A pharmaceutical composition of any one of I) to III), wherein Y^1 is $-NHCO-$, $-CONH-$, $-NHCH_2-$, or $-NHSO_2-$.

V) A pharmaceutical composition of any one of I) to IV), wherein Z^1 is 1,4-phenylene.


25

VI) A pharmaceutical composition of any one of I) to V), wherein A¹ is a ring represented by the formula:



wherein R⁸ is a hydrogen atom or lower alkyl; M is -S-, -O-, -N(R^c)-, or -CH₂- (wherein R^c is a hydrogen atom or lower alkyl); T is an oxygen atom or a sulfur atom.

10 A pharmaceutical composition exhibiting thrombopoietin agonism of any one of I) to V), wherein A¹ is a ring represented by the formula:



is preferred.

15 VII) A pharmaceutical composition of any one of I) to VI), wherein the broken line represents the presence of a bond.


VIII) A pharmaceutical composition exhibiting thrombopoietin agonism of any one of I) to VII), which is for treating or preventing hemopathy.

IX) A pharmaceutical composition exhibiting thrombopoietin agonism of any

104808-0120

5

10 XII) A compound represented by the formula (II)




20 Y² is -NR^αCO-(CH₂)₀₋₂-, -NR^αCO-(CH₂)₀₋₂-W-, -NR^αCO-CH=CH-, -W-(CH₂)₁₋₅-
NR^αCO-(CH₂)₀₋₂-, -W-(CH₂)₁₋₅-CONR^α-(CH₂)₀₋₂-, -CONR^α-(CH₂)₀₋₂-, -(CH₂)₀₋₅-
NR^α-SO₂-(CH₂)₀₋₅-, -(CH₂)₀₋₅-SO₂-NR^α-(CH₂)₀₋₅-, -NR^α-(CH₂)₀₋₂-, -NR^α-CO-
NR^α-, -NR^α-CS-NR^α-, -N=C(SR^α)-NR^α-, -NR^αCSNR^αCO-, -N=C(SR^α)-
NR^αCO-, -NR^α-(CH₂)₁₋₂-NR^α-CO-, -NR^αCONR^βNR^βCO-, or -N=C(NR^αNR^β)-

NR^G-CO-,

wherein R^G is each independently a hydrogen atom or optionally substituted lower alkyl, R^F is a hydrogen atom or optionally substituted aryl, W is an oxygen atom or a sulfur atom;

- 5 Z² is optionally substituted phenylene, optionally substituted 2,5-pyridine-diyl, optionally substituted 2,5-thiophene-diyl, or optionally substituted 2,5-furan-diyl;

A² is a ring represented by the formula:




- 10 wherein R¹ and R² are both hydrogen atoms or taken together may form an oxygen atom or a sulfur atom; R³ and R⁴ are both hydrogen atoms or taken together may form an oxygen atom or a sulfur atom; R⁵ is a hydrogen atom or lower alkyl; Q and V are each independently -O-, -S-, -NR^B- (wherein R^B is a hydrogen atom or lower alkyl), or -CH₂-; m is 1, 2, or 3;

- 15 a broken line (---) represents the presence or absence of a bond, provided that X² is not oxazole,

its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.

XIII) A compound of XII), wherein X² is a group represented by the formula:




wherein E is -(CH₂)₁₋₃-, -O-CH₂-, or -S-CH₂-; R⁶ and R⁷ are each independently a hydrogen atom, optionally substituted lower alkyl, carboxy, lower alkyloxycarbonyl, optionally substituted aminocarbonyl, optionally

substituted thienyl, or optionally substituted phenyl; R⁸ is a hydrogen atom or lower alkyl,

its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.

- 5 XIV) A compound of XII), wherein X² is a group represented by the formula:



wherein E is as defined in XII;

R⁹ is a hydrogen atom, optionally substituted lower alkyl, carboxy, lower alkyloxycarbonyl, or optionally substituted aminocarbonyl;

- 10 R¹⁰ and R¹¹ are each independently a hydrogen atom, halogen, carboxy, lower alkyloxycarbonyl, optionally substituted aminocarbonyl, nitro, or optionally substituted amino,

its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.


- 15 XV) A compound of any one of XII) to XIV), wherein Y² is -NHCO-, -CONH-, -NHCH₂-, or -NHSO₂-,

its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.

XVI) A compound of any one of XII) to XIV), wherein Z² is 1,4-phenylene,

- 20 its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.

XVII) A compound of any one of XII) to XVI), wherein A² is a ring represented by the formula:




wherein R⁸ is a hydrogen atom or lower alkyl; M is -S-, -O-, -N(R⁶)-, or -CH₂-
 5 (wherein R⁶ is a hydrogen atom or lower alkyl); T is an oxygen atom or a sulfur atom,

its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.

XVIII) A compound of any one of XII) to XVII), wherein the broken line
 10 represents the presence of a bond,

its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.

XIX) A compound represented by the formula III-A:




15 wherein, R⁹ is a hydrogen atom, optionally substituted lower alkyl, carboxy, lower alkyloxycarbonyl, or optionally substituted aminocarbonyl;

R¹⁰ and R¹¹ are each independently a hydrogen atom, halogen, carboxy, lower alkyloxycarbonyl, optionally substituted aminocarbonyl, nitro, or optionally substituted amino;

20 Y³ is -NHCO- or -CONH-;


A³ is a ring represented by the formula:



wherein R^8 is a hydrogen atom or lower alkyl; M is $-S-$, $-O-$, $-N(R^c)-$, or $-CH_2-$ (wherein R^c is a hydrogen atom or lower alkyl); T is an oxygen atom or a sulfur atom,

5 its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.

XX) A compound represented by the formula III-B:



wherein R^9 , R^{10} , R^{11} , Y^3 , and A^3 ring are as defined in XIX,

10 its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.

XXI) A pharmaceutical composition containing a compound of any one of XII) to XX) as an active ingredient.

15 XXII) A pharmaceutical composition which contains as an active ingredient a compound of any one of XII) to XX), which is for exhibiting for thrombopoietin agonism.

XXIII) A pharmaceutical composition containing as the active ingredient a 20 compound of any one of XII) to XX), which is a platelet production modifier

XXIV) A platelet production modifier which contains as the active ingredient a compound of any one of XII) to XX).

XXV) Use of a compound of any one of XII) to XX) for preparation of a pharmaceutical composition for treating hemopathy.

- 5 XXVI) A method for treating hemopathy of a mammal, including a human, which comprises administration to said mammal of a compound of any one of XII) to XX) in a pharmaceutically effective amount.

10 In the present specification, the term "halogen" means fluoro, chloro, bromo, and iodo.

15 In the present specification, the term "lower alkyl" employed alone or in combination with other terms means a straight- or branched chain monovalent hydrocarbon group having 1 to 8 carbon atom(s). Examples of alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, isohexyl, n-heptyl, n-octyl and the like. C1 to C6 alkyl is preferred. C1 to C3 alkyl is more preferred.

20 The term "alkenyl" in the present specification means a straight- or branched chain monovalent hydrocarbon group having 2 to 8 carbon atoms and at least one double bond. Examples of the alkenyl include vinyl, allyl, 1-propenyl, 2-propenyl, crotonyl, isopentenyl, a variety of butenyl isomers and the like. C2 to C6 alkenyl is preferred. C2 to C4 alkenyl is more preferred.

25 The term "lower alkynyl" used in the present specification means a straight or branched chain monovalent hydrocarbon group having 2 to 8 carbon atoms and at least one triple bond. The alkynyl may contain (a) double bond(s). Examples of the alkynyl include ethynyl, 2-propynyl, 6-

heptynyl, 7-octynyl and the like.

In the present specification, the term "cycloalkyl" employed alone or in combination with other terms means cycloalkyl group having 3 to 8 carbon atoms. Examples of cycloalkyl group include cyclopropyl, cyclobutyl, 5 cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like. C3 to C6 cycloalkyl is preferred.

In the present specification, the term "aryl" employed alone or in combination with other terms means monocyclic or condensed ring aromatic 10 hydrocarbons. Examples of aryl include phenyl, 1-naphtyl, 2-naphtyl, anthryl, and the like.

The term "aralkyl" herein used means the above mentioned "lower alkyl" substituted with the above mentioned "aryl" at any possible position. 15 Examples of the aralkyl are benzyl, phenethyl (e.g., 2-phenethyl and the like), phenylpropyl (e.g., 3-phenylpropyl and the like), naphthylmethyl (e.g., 1-naphthylmethyl and 2-naphthylmethyl and the like), anthrylmethyl (e.g., 9-anthrylmethyl and the like), and the like. Benzyl and phenylethy are preferred.

20

In the present specification, the term "heteroaryl" employed alone or in combination with other terms means a 5 to 6 membered aromatic heterocyclic group which contains one or more hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen atoms in the ring and may be 25 fused with cycloalkyl, aryl, non-aromatic heterocyclic group, and other heteroaryl at any possible position. Examples of the heteroaryl are pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), furyl (e.g., 2-furyl, 3-furyl), thienyl

- (e.g., 2-thienyl 3-thienyl), imidazolyl (e.g., 2- imidazolyl, 4- imidazolyl), pyrazolyl (e.g., 1-pyrazolyl, 3-pyrazolyl), isothiazolyl (e.g., 3-isothiazolyl), isoxazolyl (e.g., 3-isoxazolyl), oxazolyl (e.g., 2-oxazolyl), thiazolyl (e.g., 2-thiazolyl), pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyrazinyl (e.g., 2-pyrazinyl), pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl), pyridazinyl (e.g., 3-pyridazinyl), tetrazolyl(e.g., 1H-tetrazolyl), oxadiazolyl (e.g., 1,3,4-oxadiazolyl), thiadiazolyl (e.g., 1,3,4- thiadiazolyl), indolizinyl (e.g., 2-indolizinyl, 6-indolizinyl), isoindolyl (2-isoindolyl), indolyl (e.g., 1-indolyl, 2-indolyl, 3-indolyl), indazolyl (e.g., 3-indazolyl), puriyl (e.g., 8-puriyl),
- 10 quinolizinyl (e.g., 2-quinolizinyl), isoquinolyl (e.g., 3-isoquinolyl), quinolyl (e.g., 3-quinolyl, 5-quinolyl), phthalazinyl (e.g., 1-phthalazinyl), naphthyridinyl (e.g., 2-naphthyridinyl), quinolanyl (2-quinolanyl), quinazoliny (e.g., 2-quinazoliny), cinnoliny (e.g., 3-cinnoliny), pteridinyl (e.g., 2- pteridinyl), carbazolyl (e.g., 2-carbazolyl, 4-carbazolyl),
- 15 phenanthridinyl (e.g., 2-phenanthridinyl, 3-phenanthridinyl), acridinyl (e.g., 1-acridinyl, 2-acridinyl), dibenzofuranyl (e.g., 1-dibenzofuranyl, 2-dibenzofuranyl), benzimidazolyl (e.g., 2-benzimidazolyl), benzisoxazolyl (e.g., 3-benzisoxazolyl), benzoxazolyl (e.g., 2-benzoxazolyl), benzoxadiazolyl (e.g., 4-benzoxadiazolyl), benzisothiazolyl (e.g., 3-benzisothiazolyl), benzothiazolyl
- 20 (e.g., 2-benzothiazolyl), benzofuryl (e.g., 3-benzofuryl), benzothienyl (e.g., 2-benzothienyl) and the like.

Preferable are thiazolyl, isoxazolyl, isothiazolyl, thienyl, furyl, pyrrolyl, imidazolyl, carbazolyl benzothiazolyl, pyridyl, and pyrazolyl as "heteroaryl" for X¹.

25

In the present specification, the term "5-membered heteroaryl" means a 5 membered aromatic heterocyclic group which contains one or more

hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen atoms. Examples of the 5-membered heteroaryl are thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, thiazolyl and the like. Preferable is thiazolyl,

5

The term "heteroarylalkyl" herein used means the above-mentioned "lower alkyl" substituted with the above-mentioned "heteroaryl" at any possible position. Examples of the heteroarylalkyl are thiazolylmethyl (e.g., 2-thiazolylmethyl), thiazolylethyl (e.g., 2-thiazolyl-2-ethyl), imidazolylmethyl (e.g., 4-imidazolylmethyl), pyridylmethyl (e.g., 2-pyridylmethyl, 3-pyridylmethyl, 4-pyridylmethyl), pyridylethyl (e.g., 2-pyridylethyl) and the like.

In the present specification, the term "non-aromatic heterocyclic group" employed alone or in combination with other terms means a 5 to 7 membered non-aromatic ring which contains one or more hetero atoms selected from the group consisting of oxygen, sulfur, and nitrogen atoms in the ring and the 5 to 7 membered non-aromatic ring may be condensed with two or more rings selected from the group consisting of cycloalkyl, aryl, heteroaryl, and the 5 to 7 membered non-aromatic ring. Examples of the non-aromatic heterocyclic group are pyrrolidinyl (e.g., 1-pyrrolidinyl, 2-pyrrolidinyl), pyrrolinyl (e.g., 3-pyrrolinyl), imidazolidinyl (e.g., 2-imidazolidinyl), imidazolinyl (e.g., imidazolinyl), pyrazolidinyl (e.g., 1-pyrazolidinyl, 2-pyrazolidinyl), pyrazolinyl (e.g., pyrazolinyl), piperidinyl (e.g., piperidino, 2-piperidinyl), piperazinyl (e.g., 1-piperazinyl), indolynyl (e.g., 1-indolynyl), isoindolynyl (e.g., isoindolynyl), morpholinyl (e.g., morpholino, 3-morpholinyl), indenothiazole (e.g., 8H-indeno[1,2-d]thiazole), dihydronaphtothiazole (4,5-

10448008-012502
5 dihydronaphtho[1,2-d]thiazole), dihydrothiazabenzazulene (e.g., 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulene), chromenothiazole (e.g., 4H-chromeno[4,3-d]thiazole), thiochromenothiazole (e.g., 4H-thiochromeno[4,3-d]thiazole), and the like.

10 The term "arylene" herein used means a divalent group of the above-mentioned "aryl". Examples of the arylene are phenylene, naphthylene, and the like. Mentioned in more detail, it is exemplified by 1,2-phenylene, 1,3-phenylene, 1,4-phenylene, and the like. Preferable is 1,4-phenylene.

15 The term "heteroarylene" herein used means a divalent group of the above-mentioned "heteroaryl". Examples of the heteroarylene are thionophene-diyl, furan-diyl, pyridine-diyl, and the like. Mentioned in more detail, it is exemplified by 2,5-thionophene-diyl, 2,5-furan-diyl, 2,5-pyridine-diyl, and the like.

20 The term "non-aromatic heterocycle-diyl" herein used means a divalent group of an above-mentioned "non-aromatic heterocyclic group". Examples of the non-aromatic heterocycle-diyl are pyrrolidine-diyl, piperidine-diyl, pyrazine-diyl and the like

25 The term "cycloalkyl-diyl" herein used means a divalent group of the above-mentioned "cycloalkyl". Examples of the cycloalkyl-diyl are cyclopentyl-diyl, cyclohexyl-diyl and the like.

The term "lower alkyloxycarbonyl" herein used are methyloxycarbonyl, ethyloxycarbonyl, n-propyloxycarbonyl, isopropyloxycarbonyl, n-

butyloxycarbonyl, t-butyloxycarbonyl, n-pentyloxycarbonyl and the like.

In the present specification, the term "acyl" employed alone or in combination with other terms means alkylcarbonyl in which alkyl group is the above-mentioned "lower alkyl" and arylcarbonyl in which aryl group is the above-mentioned "aryl". Examples of the acyl are acetyl, propionyl, benzoyl, and the like. "Lower alkyl" and "aryl" may be substituted respectively with substituents mentioned below.

The term "lower alkyloxy" herein used are methyloxy, ethyloxy, n-propyloxy, i-propyloxy, n-butyloxy, i-butyloxy, sec-butyloxy, tert-butyloxy, and the like. Methyloxy, ethyloxy, n-propyloxy, i-propyloxy and n-butyloxy are preferred.

The term "lower alkylthio" herein used are methylthio, ethylthio, and the like.

In the present specification, the term "halo(lower)alkyl" employed alone or in combination with other terms means the above-mentioned "lower alkyl" which is substituted with the above mentioned "halogen" at 1 to 8 positions, preferably, at 1 to 5. Examples of the halo(lower)alkyl are trifluoromethyl, trichloromethyl, difluoroethyl, trifluoroethyl, dichloroethyl, trichloroethyl, and the like. Preferable is trifluoromethyl.

Examples of the term "acyloxy" herein used are acetyloxy, propionyloxy, benzoyloxy and the like.

In the present specification, the term "optionally substituted amino" employed alone or in combination with other terms includes amino substituted with one or two of the above mentioned "lower alkyl", "aralkyl", "heteroarylalkyl" or "acyl". Examples of the optionally substituted amino are amino, methylamino, dimethylamino, ethylmethylamino, diethylamino, benzylamino, acetylamino, benzoylamino and the like. Preferable are amino, methylamino, dimethylamino, ethylmethylamino, diethylamino and acetylamino.

Examples of the term "optionally substituted aminocarbonyl" herein used are aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, ethylmethylaminocarbonyl, diethylaminocarbonyl and the like. Preferable are aminocarbonyl, methylaminocarbonyl, and dimethylaminocarbonyl.

The substituents of "optionally substituted lower alkyl" are cycloalkyl, lower alkenyl, lower alkyliden, hydroxy, lower alkyloxy, mercapto, lower alkylthio, halogen, nitro, cyano, carboxy, lower alkyloxycarbonyl, halo(lower)alkyl, halo(lower)alkyloxy, substituted or unsubstituted amino, substituted or unsubstituted aminocarbonyl, acyl, acyloxy, optionally substituted non-aromatic heterocyclic group, aryloxy (e.g., phenyloxy), aralkyloxy (e.g., benzyloxy), lower alkylsulfonyl, guanidino, azo group, optionally substituted ureide, =N-O- (acyl) and the like. These substituents are able to locate at one or more of any possible positions.

Preferable are lower alkyloxycarbonyl, ethyliden, or =N-O-COCH₃, as substituents of "optionally substituted lower alkyl" for R⁶, R⁷ and R⁹.

Preferable are unsubstituted alkyl, as "optionally substituted lower alkyl" for R^A. Lower alkyloxycarbonyl as substituents is preferred.

The substituents of "optionally substituted arylene", "optionally substituted phenylene", "optionally substituted heteroarylene", "optionally substituted 2,5-pyridine-diyl", "optionally substituted 2,5-thiophene-diyl", "optionally substituted 2,5-furan-diyl", "optionally substituted non-aromatic heterocycle-diyl", "optionally substituted cycloalkyl-diyl", "optionally substituted aryl", "optionally substituted thienyl", "optionally substituted phenyl", "optionally substituted heteroaryl", "optionally substituted 5-membered heteroaryl", "optionally substituted aralkyl", "optionally substituted heteroarylalkyl", "optionally substituted non-aromatic heterocyclic group", and "optionally substituted ureide" herein used are optionally substituted lower alkyl, cycloalkyl, lower alkenyl, lower alkynyl, hydroxy, lower alkoxy, aralkyloxy, mercapto, lower alkylthio, halogen, nitro, cyano, carboxy, lower alkyloxycarbonyl, halo(lower)alkyl, halo(lower)alkyloxy, unsubstituted or substituted amino, unsubstituted or substituted aminocarbonyl, acyl, acyloxy, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted non-aromatic heterocyclic group, optionally substituted aralkyl, lower alkylsulfonyl, guanidino, azo group, -N=N-(optionally substituted phenyl) or optionally substituted ureide and the like. These substituents are able to locate at one or more of any possible positions.

Preferable are unsubstituted groups as substituents of "optionally substituted arylene", "optionally substituted phenylene", "optionally substituted heteroarylene", "optionally substituted 2,5-pyridine-diyl",

“optionally substituted 2,5-thiophene-diyl”, “optionally substituted 2,5-furan-diyl”, “optionally substituted non-aromatic heterocycle-diyl”, “optionally substituted cycloalkyl-diyl”. Halogen, nitro, cyano, lower alkyl, lower alkyloxy as substituents are preferred.

5

The examples of substituents of “optionally substituted aryl” and “optionally substituted aralkyl” for X^1 are lower alkyl, hydroxy lower alkyl, hydroxy, lower alkyloxy, lower alkylthio, halogen, nitro, cyano, carboxy, lower halo(lower)alkyl, halo(lower)alkyloxy, aralkyloxy, unsubstituted or substituted amino, unsubstituted or substituted aminocarbonyl, aryl, heteroaryl, non-aromatic heterocyclic group, arylazo (e.g., phenylazo), and the like. Preferable substituents are lower alkyl, hydroxy, lower alkyloxy, lower alkylthio, halogen, halo(lower)alkyl, halo(lower)alkyloxy, aralkyloxy, -N=N-(phenyl), alkylendioxy, and the like.

10

15

The examples of “optionally substituted aryl” for X^1 are phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3,4-dimethylphenyl, 4-ethylphenyl, 4-*t*-butylphenyl, 4-*n*-butylphenyl, 4-*n*-hexylphenyl, 4-*n*-octylphenyl, 3,5-di-*t*-butyl-4-hydroxyphenyl, 4-ethyloxyphenyl, 4-fluorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 4-iodophenyl, 4-trifluoromethylphenyl, 4-methylthiophenyl, 4-phenylmethyloxyphenyl, 4-phenyazophenyl, 4-phenylphenyl, 2-naphtyl, benzodioxoryl (e.g., 1,3-benzodioxoryl), and the like..

20

25

The substituents of “optionally substituted thienyl” and “optionally substituted phenyl” for R^6 and R^7 are lower alkyl, lower alkyl substituted with unsubstituted or substituted amino, lower alkenyl, lower alkynyl, hydroxy,

lower alkyloxy, mercapto, lower alkylthio, halogen, nitro, cyano, carboxy, lower alkyloxycarbonyl, halo(lower)alkyl, halo(lower)alkyloxy, unsubstituted or substituted amino, unsubstituted or substituted aminocarbonyl, acyl, formyl, acyloxy, optionally substituted phenyl, aryl (e.g., phenyl), heteroaryl (imidazolyl), non-aromatic heterocyclic group (e.g., morpholino, piperazinyl), aralkyl, arylazo, and the like. Preferable are lower alkyl, lower alkyloxy, halogen, nitro, carboxy, lower alkyloxycarbonyl, halo(lower)alkyl, halo(lower)alkyloxy, unsubstituted or substituted amino, unsubstituted or substituted aminocarbonyl, aryl, arylazo and the like.

10

The examples of "optionally substituted phenyl" for R⁶ and R⁷ are phenyl, 3-methylphenyl, 4-methylphenyl, 4-t-butylphenyl, 4-n-pentylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-carboxyphenyl, 4-methyloxycarbonylphenyl, 4-ethyloxycarbonylphenyl, 4-isopropoxyloxycarbonyl, 4-n-butyloxycarbonyl, 4-t-butyloxycarbonyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-difluorophenyl, 2,6-difluorophenyl, 3,4-difluorophenyl, 2,4,5-trifluorophenyl, 2,3,4,5,6-pentafluorophenyl, 4-chlorophenyl, 2,4-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 3-bromophenyl, 4-bromophenyl, 4-iodophenyl, 3-fuluro-4-methoxyphenyl, 3-trifluoromethylphenyl, 4-trifluoromethylphenyl, 2-trifluoromethoxyphenyl, 4-acetylaminophenyl, 4-aminocarbonylphenyl, 4-N-methylaminocarbonylphenyl, 4-N,N-dimethylaminocarbonyl, 2-nitrophenyl, 4-nitrophenyl, 4-phenylphenyl, 4-phenylazophenyl, and the like.

25

Preferable are lower alkyl, cycloalkyl, lower alkenyl, lower alkynyl, hydroxy, lower alkyloxy, aralkyloxy, mercapto, lower alkylthio, halogen, nitro, cyano, carboxy, lower alkyloxycarbonyl, halo(lower)alkyl, halo(lower)alkyloxy,

10048008.012502

5 unsubstituted or substituted amino, unsubstituted or substituted aminocarbonyl, acyl, acyloxy, guanidino, azo group, and the like as substituents of "optionally substituted aryl", "optionally substituted heteroaryl", "optionally substituted aralkyl", and "optionally substituted heteroarylalkyl" for R^A. These substituents are able to locate at one or more of any possible positions.

Preferable is phenyl as "optionally substituted aryl" for R^F.

10 The substituents of "optionally substituted heteroaryl", "optionally substituted heteroarylalkyl", "optionally substituted non-aromatic heterocyclic group" for X¹ and the substituents of "optionally substituted 5-membered heteroaryl" for X² are optionally substituted lower alkyl, lower alkenyl (e.g., =CH-CH₃), lower alkynyl, hydroxy, lower alkyloxy, mercapto, lower alkylthio, 15 halogen, nitro, cyano, carboxy, lower alkyloxyccarbonyl, halo(lower)alkyl, halo(lower)alkyloxy, substituted or unsubstituted amino, substituted or unsubstituted aminocarbonyl, acyl (e.g., aryloxyccarbonyl optionally substituted with halogen, nitro, cyano and the like), acyloxy, optionally substituted phenyl, aryl, optionally substituted heteroaryl (e.g., 2-pyridyl, 3- 20 pyridyl, 4-pyridyl, 3-thienyl, 5-methylpyridine-2-yl, 3-quinolyl, 5-chlorothiophene-2-yl, 5-bromothiophene-2-yl), non-aromatic heterocyclic group, aralkyl, =N-O-(acyl), and the like. Preferable are optionally substituted lower alkyl, lower alkenyl, lower alkyloxyccarbonyl, optionally substitute phenyl, heteroaryl, =N-O-(acyl), and the like.

25 When hetero atom is nitrogen atom, the nitrogen atom may be substituted with alkyl, oxo and the like.

In the present specification, the term "hemopathy" means hemopathy accompanied with the unusual number of platelet. For example the hemopathy is thrombocytopenia (after bone marrow transplantation, after chemotherapy, aplastic anemia, bone marrow dysplasia syndrome, acquired thrombopenia of intractable sudden thrombocytopenic purpura and the like, congenital thrombopenia of thrombopoietin deficiency and the like) and the like.

Brief description of the drawing

Figure 1: The chart shows the stimulation activity of a present invention for the proliferation and differentiation of megakaryocyte precursor cells, by counting megakaryocyte colonies formed from human bone marrow cells.

Figure 2: The chart represents proliferation of the human TPO dependent cells manifesting human TPO receptors by the present invention compound, wherein the x-axis is concentration of the present invention compound, and the y-axis is absorption as an indicator of cell proliferation. White circle is a response of human TPO, and black circle is a response of the compound (B-17).

Figure 3: The chart represents proliferation of the human TPO independent cell manifesting no human TPO receptor by the present invention compound, wherein the x-axis is a concentration of the present invention compound, and the y-axis is absorption as an indicator of cell proliferation. White circle is a response of human TPO, and black circle is a response of the compound (B-17).


Figure 4: The chart represents proliferation of the murine TPO independent cell manifesting murine TPO receptor by the present invention compound,

wherein the x-axis is a concentration of the present invention compound, and the y-axis is absorption as an indicator of cell proliferation. White circle is a response of human TPO, and black circle is a response of the compound (B-17)

Best Mode for Carrying Out the Invention

Compounds (I) of the invention can be synthesized by the following methods A-C and the similar process. And it is possible to produce the compounds in accordance with the procedure described in WO97/05135 and WO97/39737.

(Method A)



wherein A¹ is as defined above, Z³ is optionally substituted arylene, optionally substituted heteroarylene, optionally substituted non-aromatic heterocycle-diyl, or optionally substituted cycloalkyl-diyl, X³ is optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl, R¹² is lower alkyl.

(Process 1)

Commercial available compound Z¹ (compound (IV)) having lower alkyloxycarbonyl and aldehyde groups as substituents is used as a starting material.

The compound (IV) is also obtained by the following methods 1)-3). 1)

A carboxy group of the compound having lower alkyloxycarbonyl and carboxy groups as substituents is treated with ethyl chlorocarbonate to give mixed acid anhydride. 2) A usual reductive reaction (e.g., reductive reaction with sodium borohydride) gives a compound having lower alkyloxycarbonyl and hydroxy groups. 3) A usual oxidative reaction (e.g., Swern oxidation, Dess-Martin Oxidation and the like) obtains compound (IV) having alkyloxycarbonyl and aldehyde groups.

This is the process of obtaining bezyliden derivatives by the reaction of aldehyde derivatives with 2,4-thiazolidine-dione. Compound (IV) is reacted with 2,4-thiazolidine-dione under reflux in the presence of acetic acid and piperidine as a catalyst in a solvent such as benzene, toluene to obtain the desired compound. (Knoevenagel Reaction).

A derived double bond may be reduced by a usual reductive reaction (e.g., hydrogenation) at any appropriate process. In case of a presence of a functional group(s) possibly interfering the reaction, the group(s) can be protected in accordance with a method described in "Protective Groups in Organic Synthesis" (Theodora W. Green (John Wiley & Sons)) and the like, and then deprotected at an appropriate process.

(Process 2)

This is the conversion of alkyloxy derivatives to carboxylic acid derivatives by the hydrolysis. It can be carried out by usual hydrolysis. For example, compound (V) is reacted in the presence of acetic acid, hydrochloric acid, and the like to give the carboxylic acid derivative (compound (VI)).


(Process 3)

This process is the reaction of carboxylic acid derivatives (VI) and amine derivatives (VII) to obtain amide derivative (I-A) by an active ester method, an acid chloride method, a mixed acid anhydride method, and the like. This process is performed in a solvent such as tetrahydrofuran, dioxane,

5 dichloromethane, toluene, benzene. An active ester method can be carried out by using 1-hydroxybenzotriazole, hydroxysuccinimide, dimethylaminopyridine and the like, dicyclohexylcarbodiimide 1-ethyl-3-(dimethylaminopropyl)carbodiimide hydrochloride, and the like as a condensing agent. A acid chloride method can be performed by conversion of
10 a free carboxylic acid with thionyl chloride, oxalyl chloride as a reagent to an acid chloride. A mixed acid anhydride method can be carried out by the reaction of carboxylic acid with ethyl chloroformate isobutyl chloroformate and the like to obtain acid mix anhydride. Bases such as triethylamine, pyridine may be used in the reaction, if necessary.

15 Commercial available compound Z¹ (compound (IV)) having lower alkyloxycarbonyl and aldehyde groups as substituents is used as a starting material.

The compound (VII) is commercial available but it is also obtained by means of the following methods. 1) Compound (VII) having two successive
20 rings can be obtained by Suzuki Reaction when X³ is optionally substituted aryl, optionally substituted aryl, or the like and when above-mentioned substituents are aryl or heteroaryl. 2) Compound (VII') can be given by the following method when X³ is optionally substituted thiazole.



wherein R^D and R^E are hydrogen atoms, optionally substituted lower alkyl, carboxy, lower alkyloxycarbonyl, optionally substituted aminocarbonyl, or optionally substituted phenyl and the like, Hal is halogen.


5 (Process 1)

This process is halogenation. It can be carried out by a usual halogenation. For example, bromination can be performed by the reaction with bromine in mixed solvent of methanol and chloroform.

10 (Process 2)

This is a process of constructing a thiazole ring. For example, the desired thiazole (VII') derivative can be obtained by the reaction with thiourea in a solvent such as methanol.

15 (Method B)




wherein A^1 , X^3 , and Z^3 are as defined above, Boc is t-butyloxycarbonyl

(Process 1)


20 The present process is the conversion of a carboxy group to an amino group protected with Boc. For example, the desired compound can be obtained by the reaction of the compound (IV) with diphenylphosphoryl azide

N-alkylation can be carried by a usual alkylation.

When Y¹ is -N(alkyl)-CO-, Z¹ is optionally substituted thiazole, the said compound is represented by equilibrium as follows.



Both a cis isomer and a trans isomer are included when a broken line represents a presence of a bond in the formulae (I), (II), and (III). For example, a cis isomer and a trans isomer can be as follows, when A¹ ring is thiazolidine-dione.



15 The term "solvate" includes, for example, solvates with organic solvents, hydrates, and the like.

The term "compound of the present invention" herein used includes a pharmaceutically acceptable salt or solvate thereof. The salt is exemplified by a salt with alkali metals (e.g., lithium, sodium, potassium, and the like), alkaline earth metals (e.g., magnesium, calcium, and the like), ammonium, organic bases, amino acids, mineral acids (e.g., hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and the like), or organic acids (e.g., acetic

acid, citric acid, maleic acid, fumaric acid, benzenesulfonic acid, p-toluenesulfonic acid, and the like). These salts can be formed by the usual method. These hydrates can coordinate with any water molecules when hydrates are formed.

5

Prodrug is a derivative of the compound having a group which can be decomposed chemically or metabolically, and such prodrug is a compound according to the present invention which becomes pharmaceutically active by means of solvolysis or by placing the compound in vivo under a physiological condition. The method of both selection and manufacture of appropriate prodrug derivatives is described in, for example, Design of Prodrugs, Elsevier, Amsterdam, 1985). For instance, prodrugs such as an ester derivative which is prepared by reacting a basal acid compound with a suitable alcohol, or an amide derivative which is prepared by reacting a basal acid compound with a suitable amine are exemplified when the compounds according to present invention have a carboxylic group. Particularly preferred esters as prodrugs are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, morpholinoethyl, and N,N-diethylglycolamido, and the like. For instance, prodrugs such as an acyloxy derivative which is prepared by reacting a basal hydroxy compound with a suitable acyl halide or a suitable acid anhydride, or an amide derivative which is prepared by reacting a basal acid compound with a suitable amine are exemplified when the compounds according to present invention have a hydroxy group.. Particularly preferred acyloxy derivatives as prodrugs -OCOC₂H₅, -OCO(t-Bu), -OCOC₁₅H₃₁, -OCO(m-COONa-Ph), -COCH₂CH₂COONa, -OCOCH(NH₂)CH₃, -OCOCH₂N(CH₃)₂, and the like. For instance, prodrugs such as an amide derivative which is prepared by reacting a basal amino compound with a suitable acid halide or a suitable acid anhydride are exemplified when the compounds according to present invention have an amino group. Particularly preferred amide as prodrugs are -NHCO(CH₂)₂₀CH₃, -NHCOCH(NH₂)CH₃, and the like.

10046008-012502

The compound of the present invention is not restricted to any particular isomers but includes all possible isomers and racemic modifications.

5

The present invention compounds show excellent thrombopoietin receptor agonism as described in examples mentioned later, and may be used as a pharmaceutical composition (platelet production modifier) for hemopathy accompanied with the unusual number of platelet, for example thrombocytopenia and the like. And the present compound may be used as a peripheral blood stem cell releasing promoter, a differentiation-inducer of megakaryocytic leukemic cell, a platelet increasing agent of a platelet donor and the like.

10

15

When the compound of the present invention is administered to a person for the treatment of the above diseases, it can be administered orally as powder, granules, tablets, capsules, pilulae, and liquid medicines, or parenterally as injections, suppositories, percutaneous formulations, insufflation, or the like. An effective dose of the compound is formulated by being mixed with appropriate medicinal admixtures such as excipient, binder, penetrant, disintegrators, lubricant, and the like if necessary. Parenteral injections are prepared by sterilizing the compound together with an appropriate carrier.

20

25

The dosage varies with the conditions of the patients, administration route, their age, and body weight. In the case of oral administration, the dosage can generally be between 0.1 to 100 mg/kg/day, and preferably 1 to 20

mg/kg/day for adult.

The following examples are provided to further illustrate the present invention and are not to be constructed as limiting the scope thereof.

5

Abbreviations described below are used in the following examples.

Me : methyl

Et : ethyl

ⁱPr : isopropyl

10 ⁿBu : butyl

^tBu : tert-butyl

ⁱBu : isobutyl

ⁿPen : n-pentyl

ⁿHex : n-hexyl

15 ⁿOct : n-octyl

Ph : phenyl

Bn : benzyl

Bz : benzoyl

Py : pyridyl

20 Ac : acetyl


Boc : t-butyloxycarbonyl

DMF : dimethylformamide シ^oメチルホルムアミド^o

DMSO : dimethylsulfoxide

Example

25 Example 1 The preparation of compound (A-1)



(Process 1)

To a solution of methyl terephthalaldehyde (25 g) and rhodanine (23.3 g) in toluene, 1M piperazine-toluene solution (6.2 ml) and 1M acetic acid - toluene solution (6.2 ml) were added, and the resulting solution was heated under reflux overnight. After cooling, filtration of the resulting crystal gave compound (2) 34.6 g.

^1H NMR(DMSO- d_6 , δ ppm) 13.18 (bs, 1H), 8.07 (d, 2H, $J = 8.7$ Hz), 7.73 (d, 2H, $J = 8.7$ Hz), 7.68 (s, 1H), 3.88 (s, 1H).

(Process 2)

A suspension of compound (2) (34.6 g) in dioxane (160 ml), acetic acid (250 ml), and 6N hydrochloric acid (88 ml) was refluxed at 120°C for 5 h. Water (350 ml) was poured into the reaction mixture and after cooling the filtration of crystal gave compound (3) 30.0 g.

^1H NMR (DMSO- d_6 , δ ppm): 13.95 (bs, 1H), 13.24 (bs, 1H), 8.06 (d, 2H, $J =$

8.4 Hz), 7.72 (d, 2H, J = 8.4 Hz), 7.69 (s, 1H).

(Process 3)

A mixture of compound (3) (3 g) in dioxane (20 ml) and thionyl chloride (10 ml) was heated to dissolve at 100°C. Evaporation of the solvent under the reduced pressure gave carboxylic acid chloride. The obtained carboxylic acid chloride was not purified to proceed to a further reaction. To the solution of carboxylic acid chloride (286 mg) and compound (4) (368 mg) synthesized by process 4 in dioxane (50 ml), pyridine (162 μ l) was added and the reaction mixture heated at 100°C for 2 h. After cooling and evaporation of the solvent under the reduced pressure, methanol (6 ml) and water (2 ml) were added to the residue and then the resulting crystal was filtrated. Recrystallization from DMF yielded 220 mg of compound (A-1).

¹H NMR (DMSO-d₆, δ ppm): 13.94 (bs, 1H), 12.93 (s, 1H), 8.23 (d, 2H, J = 8.5 Hz), 8.21 (d, 1H, J = 2.1 Hz), 7.91 – 7.97 (m, 1H), 7.93 (s, 1H), 7.76 (d, 2H, J = 8.5 Hz), 7.73 (s, 1H), 7.70 (s, 1H).

(Process 4)


To a solution of 3', 4'-dichloroacetophenone (5) (5.67 g) in 10% methanol-chloroform, bromine (1.52 ml) was added, and then the reaction solution was stirred at room temperature until the color of bromine disappeared. After evaporation of the solvent under the reduced pressure, the residue was dissolved in ethanol, thiourea (2.28 g) was added and the mixture was refluxed for 2 hours. After removing the solvent by evaporation under reduced pressure, ethyl acetate - water was added to the residue, then the precipitated crystal was collected by filtration. To the crystal was added ethyl acetate – a saturated sodium carbonate solution, then the ethyl acetate

layer was separated, dried, and evaporated to obtain 3.38 g of compound (4).

^1H NMR (CDCl_3 δ ppm): 7.89 (d, 1H, $J = 2.2$ Hz), 7.69 (dd, 1H, $J = 8.5$ Hz, 2.2 Hz), 7.43 (d, 1H, $J = 8.2$ Hz), 6.74 (s, 1H), 5.06 (bs, 1H).

Compound (A-2) to Compound (A-73) were synthesized in a manner
5 similar to Example 1. Their physical data were shown in Tables 1 to 8.

Table 1



| Example No. | Compound No. | R ⁶ | R ⁷ | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|----------------|----------------|---|
| 2 | A-2 | | H | 13.90 (bs, 1H), 12.94 (s, 1H), 8.25 (d, 2H, J = 8.1 Hz), 7.96 (d, 1H, J = 6.9 Hz), 7.77 (d, 1H, J = 8.1 Hz), 7.73 (s, 1H), 7.71 (s, 1H), 7.46 (t, 2H, J = 7.5 Hz), 7.35 (t, 2H, J = 6.9 Hz) |
| 3 | A-3 | | H | 13.95 (bs, 1H), 12.92 (s, 1H), 8.24 (d, 2H, J = 8.1 Hz), 7.97 - 8.02 (m, 2H), 7.76 (d, 1H, J = 8.1 Hz), 7.72 (s, 1H), 7.70 (s, 1H), 7.26 - 7.31 (m, 2H) |
| 4 | A-4 | | H | 13.90 (bs, 1H), 12.95 (s, 1H), 8.24 (d, 2H, J = 8.4 Hz), 7.92 (d, 2H, J = 8.7 Hz), 7.80 (s, 1H), 7.76 (d, 2H, J = 8.4 Hz), 7.70 (s, 1H), 7.66 (d, 2H, J = 8.7 Hz) |
| 5 | A-5 | | H | 13.90 (bs, 1H), 12.92 (s, 1H), 8.24 (d, 2H, J = 7.8 Hz), 7.98 (d, 2H, J = 8.7 Hz), 7.79 (s, 1H), 7.76 (d, 2H, J = 8.4 Hz), 7.71 (s, 1H), 7.52 (d, 2H, J = 7.8 Hz) |
| 6 | A-6 | | H | 13.92 (bs, 1H), 12.89 (s, 1H), 8.25 (d, 2H, J = 8.2 Hz), 7.76 (d, 1H, J = 8.2 Hz), 7.71 (s, 1H), 7.26 (d, 2H, J = 8.5 Hz), 2.34 (s, 3H) |
| 7 | A-7 | | H | 13.90 (bs, 1H), 12.95 (s, 1H), 8.26 (d, 2H, J = 8.4 Hz), 8.06 (d, 2H, J = 7.5 Hz), 7.92 - 8.12 (m, 8H), 7.47 - 7.52 (m, 2H), 7.36 - 7.41 (m, 2H) |
| 8 | A-8 | | H | 13.90 (bs, 1H), 12.88 (s, 1H), 8.24 (d, 2H, J = 8.4 Hz), 7.89 (d, 2H, J = 7.8 Hz), 7.76 (d, 2H, J = 7.8 Hz), 7.70 (s, 1H), 7.55 (s, 1H), 7.01 (d, 2H, J = 8.4 Hz), 3.80 (s, 3H) |
| 9 | A-9 | | H | 13.90 (bs, 1H), 12.93 (s, 1H), 8.21 (d, 2H, J = 8.1 Hz), 7.94 (d, 1H, J = 7.5 Hz), 7.79 - 7.83 (m, 2H), 7.75 (d, 2H, J = 8.1 Hz), 7.70 (s, 1H), 7.61 - 7.66 (m, 1H), 7.59 (s, 1H) |
| 10 | A-10 | t-Bu | H | 13.85 (bs, 1H), 12.30 (s, 1H), 8.21 (d, 2H, J = 8.1 Hz), 7.73 (d, 2H, J = 8.1 Hz), 7.70 (s, 1H), 6.84 (s, 1H), 1.31 (s, 9H) |

Table 2

| Example No. | Compound No. | R ⁶ | R ⁷ | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|----------------|----------------|--|
| 11 | A-11 | | H | 13.92 (bs, 1H), 12.93 (s, 1H), 8.25 (d, 2H, J = 8.5 Hz), 7.87 (d, 2H, J = 8.5 Hz), 7.75 (d, 2H, J = 8.5 Hz), 7.72 (s, 1H), 7.65 (s, 1H), 7.47 (d, 2H, J = 8.5 Hz), 1.32 (s, 9H) |
| 12 | A-12 | | H | 13.97 (bs, 1H), 13.00 (s, 1H), 8.25 (d, 2H, J = 8.5 Hz), 8.08 (dd, 4H, J = 19.2 Hz, 8.5 Hz), 7.94 (s, 1H), 7.76 (d, 2H, J = 8.5 Hz), 7.72 (s, 1H), 3.81 (s, 3H) |
| 13 | A-13 | | H | 13.88 (bs, 1H), 12.91 (s, 1H), 8.24 (d, 2H, J = 8.5 Hz), 7.86 (d, 2H, J = 8.5 Hz), 7.76 (d, 2H, J = 8.5 Hz), 7.72 (s, 1H), 7.64 (s, 1H), 7.27 (d, 2H, J = 8.1 Hz), 2.60 (t, 2H, J = 7.8 Hz), 1.60 (q, 2H, J = 6.6 Hz), 1.27 - 1.36 (m, 2H), 0.87 (t, 3H, J = 6.6 Hz) |
| 14 | A-14 | | H | 13.90 (bs, 1H), 13.05 (s, 1H), 8.34 (d, 2H, J = 8.5 Hz), 8.24 (t, 4H, J = 8.2 Hz), 8.10 (s, 1H), 7.77 (d, 2H, J = 8.5 Hz), 7.71 (s, 1H) |
| 15 | A-15 | | H | 13.92 (bs, 1H), 12.99 (s, 1H), 8.23 (d, 2H, J = 8.5 Hz), 7.75 (d, 1H, J = 8.5 Hz), 7.71 (s, 1H), 7.64 (s, 1H), 7.44 (d, 1H, J = 4.1 Hz), 7.14 (d, 1H, J = 4.1 Hz) |
| 16 | A-16 | | H | 13.90 (bs, 1H), 12.93 (s, 1H), 8.24 (d, 2H, J = 8.5 Hz), 7.84 (bs, 1H), 7.76 (d, 2H, J = 8.5 Hz), 7.72 (s, 1H), 7.61 - 7.62 (m, 2H), 7.56 (s, 2H) |
| 17 | A-17 | | H | 13.95 (bs, 1H), 13.00 (s, 1H), 8.65 - 8.67 (m, 1H), 8.26 (d, 2H, J = 8.4 Hz), 8.09 - 8.12 (m, 1H), 7.80 - 8.05 (m, 1H), 8.03 (s, 1H), 7.78 (d, 2H, J = 8.4 Hz), 7.70 (s, 1H), 7.55 (s, 1H), 7.73 (s, 1H), 7.43 - 7.47 (m, 3H) |
| 18 | A-18 | | H | 13.01 (s, 1H), 9.22 (d, 1H, J = 2.1 Hz), 8.62 (dd, 1H, J = 5.1 Hz, 1.2 Hz), 8.45 (d, 1H, J = 8.4 Hz), 8.25 (d, 2H, J = 8.1 Hz), 7.98 (s, 1H), 7.77 (d, 2H, J = 8.1 Hz), 7.72 (s, 1H), 7.64 (dd, 1H, J = 8.1 Hz, 5.1 Hz) |
| 19 | A-19 | | H | 13.15 (s, 1H), 8.92 (d, 2H, J = 6.3 Hz), 8.56 (s, 1H), 8.40 (d, 2H, J = 6.3 Hz), 8.25 (d, 2H, J = 8.5 Hz), 7.77 (d, 2H, J = 8.5 Hz), 7.72 (s, 1H) |

Table 3









| Example No. | Compound No. | R ⁶ | R ⁷ | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|---|----------------|---|
| 20 | A-20 |  | H | 13.93 (bs, 1H), 12.93 (s, 1H), 8.23 (d, 2H, J = 8.4 Hz), 7.93 - 8.01 (m, 1H), 7.82 (s, 1H), 7.80 - 7.82 (m, 1H), 7.76 (d, 2H, J = 8.4 Hz), 7.71 (s, 1H) |
| 21 | A-21 |  | H | 13.97 (bs, 1H), 13.00 (s, 1H), 8.23 (d, 2H, J = 8.5 Hz), 7.75 (d, 2H, J = 8.5 Hz), 7.71 (s, 1H), 7.64 (s, 1H), 7.41 (d, 1H, J = 3.8 Hz), 7.24 (d, 1H, J = 3.8 Hz) |
| 22 | A-22 |  | H | 13.94 (bs, 1H), 12.97 (s, 1H), 8.25 (d, 2H, J = 8.5 Hz), 8.04 (d, 2H, J = 8.7 Hz), 7.96 (d, 2H, J = 8.7 Hz), 7.99 (bs, 2H), 7.88 (s, 1H), 7.77 (d, 2H, J = 8.5 Hz), 7.73 (s, 1H) |
| 23 | A-23 |  | H | 13.94 (bs, 1H), 12.97 (s, 1H), 8.25 (d, 2H, J = 8.5 Hz), 8.04 (d, 2H, J = 8.7 Hz), 7.96 (d, 2H, J = 8.7 Hz), 7.99 (bs, 2H), 7.88 (s, 1H), 7.77 (d, 2H, J = 8.5 Hz), 7.73 (s, 1H), 2.81 (d, 3H, J = 4.2 Hz) |
| 24 | A-24 |  | H | 14.01 (bs, 1H), 12.94 (s, 1H), 8.25 (d, 2H, J = 8.5 Hz), 8.01 (d, 2H, J = 8.2 Hz), 7.82 (s, 1H), 7.77 (d, 2H, J = 8.5 Hz), 7.72 (s, 1H), 7.49 (d, 2H, J = 8.2 Hz), 2.98 (s, 6H) |
| 25 | A-25 |  | H | 13.90 (bs, 1H), 13.01 (s, 1H), 8.25 (d, 2H, J = 8.5 Hz), 8.01 - 8.12 (m, 4H), 7.93 (s, 1H), 7.76 (d, 2H, J = 8.5 Hz), 7.72 (s, 1H), 5.16 (quint, 1H, J = 6.0 Hz), 1.35 (d, 6H, J = 6.0 Hz) |
| 26 | A-26 |  | H | 13.92 (bs, 1H), 13.01 (s, 1H), 8.25 (d, 2H, J = 8.4 Hz), 8.03 - 8.12 (m, 4H), 7.93 (s, 1H), 7.77 (d, 2H, J = 8.4 Hz), 7.72 (s, 1H), 4.30 (t, 2H, J = 6.6 Hz), 1.67 - 1.76 (m, 2H), 1.41 - 1.51 (2-m., 2H), 0.95 (t, 3H, J = 7.2 Hz) |
| 27 | A-27 |  | H | 13.05 (s, 1H), 9.16 (s, 1H), 8.80 (d, 1H, J = 7.8 Hz), 8.24 (d, 2H, J = 8.4 Hz), 7.16 (s, 1H), 7.90 (d, 1H, J = 8.7 Hz), 7.77 (d, 2H, J = 8.4 Hz), 7.72 (s, 1H), 2.74 (d, 3H) |
| 28 | A-28 | -CH ₂ COOEt | H | 13.94 (bs, 1H), 12.82 (s, 1H), 8.21 (d, 2H, J = 8.7 Hz), 7.74 (d, 2H, J = 8.7 Hz), 7.71 (s, 1H), 7.08 (s, 1H), 4.09 (q, 2H, J = 6.9 Hz), 3.75 (s, 2H), 1.20 (t, 3H, J = 7.2 Hz) |

Table 4









| Example No. | Compound No. | R ⁶ | R ⁷ | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|---|----------------|--|
| 29 | A-29 |  | H | 13.91 (bs, 1H), 12.86 (s, 1H), 8.22 (d, 2H, J = 8.5 Hz), 7.75 (d, 2H, J = 8.5 Hz), 7.71 (s, 1H), 7.22 (s, 1H), 7.09 (q, 1H, J = 6.9 Hz), 3.68 (s, 3H), 1.89 (d, 3H, J = 6.9 Hz) |
| 30 | A-30 |  | H | 13.94 (bs, 1H), 13.23 (s, 1H), 8.24 (d, 2H, J = 8.1 Hz), 7.98 (s, 1H), 7.75 (d, 2H, J = 8.1 Hz), 7.71 (s, 1H), 4.46 (q, 1H, J = 7.2 Hz), 2.10 (s, 3H), 1.35 (t, 3H, J = 7.2 Hz) |
| 31 | A-31 |  | H | 13.90 (bs, 1H), 13.08 (s, 1H), 9.64 (d, 1H, J = 2.1 Hz), 9.10 (s, 1H), 8.27 (d, 2H, J = 8.5 Hz), 8.20 (d, 2H, J = 8.1 Hz), 8.17 (s, 1H), 7.92 (td, 1H, J = 8.7 Hz, 1.8 Hz), 7.76 - 7.81 (m, 3H), 7.72 (s, 1H) |
| 32 | A-32 |  | -COOEt | 14.04 (bs, 1H), 13.30 (s, 1H), 8.25 (d, 2H, J = 8.5 Hz), 7.73 - 7.76 (m, 4H), 7.70 (s, 1H), 7.44 - 7.46 (m, 3H), 4.22 (q, 2H, J = 6.9 Hz), 1.23 (t, 3H, J = 6.9 Hz) |
| 33 | A-33 |  | -COOMe | 13.97 (bs, 1H), 13.31 (s, 1H), 8.24 (d, 2H, J = 8.4 Hz), 8.76 (d, 2H, J = 8.4 Hz), 7.73 - 7.76 (m, 2H), 7.70 (s, 1H), 7.44 - 7.46 (m, 3H), 3.75 (s, 1H) |
| 34 | A-34 |  | -CH2COOMe | 13.88 (bs, 1H), 12.89 (s, 1H), 8.24 (d, 2H, J = 8.5 Hz), 7.76 (d, 2H, J = 8.5 Hz), 7.71 (s, 1H), 7.60 - 7.63 (m, 2H), 7.38 - 7.51 (d, 3H), 3.99 (s, 2H), 3.68 (s, 3H) |
| 35 | A-35 |  | -(CH2)2CO2Me | 13.93 (bs, 1H), 12.80 (s, 1H), 8.22 (d, 2H, J = 8.5 Hz), 7.75 (d, 2H, J = 8.5 Hz), 7.71 (s, 1H), 7.46 - 7.51 (m, 2H), 7.46 - 7.51 (m, 2H), 7.36 - 7.42 (m, 1H), 3.6 (s, 3H), 3.17 (t, 2H, J = 7.4 Hz), 2.72 (t, 2H, J = 7.4 Hz) |
| 36 | A-36 |  | -(CH2)2CO2Et | 13.93 (bs, 1H), 12.80 (s, 1H), 8.22 (d, 2H, J = 8.5 Hz), 7.75 (d, 2H, J = 8.5 Hz), 7.71 (s, 1H), 7.46 - 7.51 (m, 2H), 7.46 - 7.51 (m, 2H), 7.36 - 7.42 (m, 1H), 4.05 (q, 2H, J = 7.1 Hz), 3.17 (t, 2H, J = 7.4 Hz), 2.72 (t, 2H, J = 7.4 Hz), 1.16 (t, 2H, J = 7.1 Hz) |

Table 5











| Example No. | Compound No. | R ⁶ | R ⁷ | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|---|---|--|
| 37 | A-37 |  | CH ₃ | 13.90 (bs, 1H), 12.80 (s, 1H), 8.22 (d, 2H, J = 8.5 Hz), 7.74 (d, 2H, J = 8.5 Hz), 7.72 (d, 2H, J = 8.2 Hz), 7.71 (s, 1H), 7.53 (d, 2H, J = 8.2 Hz), 2.51 (s, 3H) |
| 38 | A-38 |  | Et | 13.87 (bs, 1H), 12.76 (s, 1H), 8.22 (d, 2H, J = 8.5 Hz), 7.75 (d, 2H, J = 8.5 Hz), 7.70 (s, 1H), 7.62 - 7.65 (m, 2H), 7.45 - 7.50 (m, 2H), 7.35 - 7.40 (m, 1H), 2.93 (q, 2H, J = 7.7 Hz), 1.29 (t, 3H, J = 7.7 Hz) |
| 39 | A-39 | Me |  | 13.93 (bs, 1H), 12.98 (s, 1H), 8.30 (d, 2H, J = 9.0 Hz), 8.23 (d, 2H, J = 8.2 Hz), 7.79 (d, 2H, J = 9.0 Hz), 7.75 (d, 2H, J = 8.2 Hz), 7.70 (s, 1H), 2.50 (s, 1H) |
| 40 | A-40 |  | H | 13.92 (bs, 1H), 12.76 (s, 1H), 8.19 (d, 4H, J = 8.8 Hz), 7.72 (d, 2H, J = 8.2 Hz), 7.69 (s, 1H), 7.54 (d, 2H, J = 8.2 Hz), 7.05 (s, 1H), 4.17 (s, 2H) |
| 41 | A-41 |  | Me | 13.15 (s, 1H), 8.92 (d, 2H, J = 6.3 Hz), 8.56 (s, 1H), 8.40 (d, 2H, J = 6.3 Hz), 8.25 (d, 2H, J = 8.5 Hz), 7.77 (d, 2H, J = 8.5 Hz), 7.72 (s, 1H) |
| 42 | A-42 |  | COOMe | 13.90 (bs, 1H), 13.31 (s, 1H), 8.24 (d, 2H, J = 8.7 Hz), 7.80 - 7.84 (m, 2H), 7.75 (d, 1H, J = 8.7 Hz), 7.70 (s, 1H), 7.26 - 7.32 (m, 2H), 3.76 (s, 3H) |
| 43 | A-43 |  | CH ₂ CH ₂ Cl | 13.92 (bs, 1H), 12.86 (s, 1H), 8.22 (d, 2H, J = 8.5 Hz), 7.75 (d, 1H, J = 8.5 Hz), 7.71 (s, 1H), 7.65 - 7.69 (m, 2H), 7.28 - 7.34 (m, 2H), 3.91 (t, 2H, J = 6.6 Hz), 3.33 (t, 2H, J = 6.6 Hz) |
| 44 | A-44 |  | Me | 13.92 (bs, 1H), 12.81 (s, 1H), 8.22 (d, 2H, J = 8.5 Hz), 7.74 (d, 2H, J = 8.5 Hz), 7.70 (s, 1H), 7.52 - 7.63 (m, 2H), 7.28 - 7.34 (m, 2H), 2.38 (s, 3H) |
| 45 | A-45 |  | CON(Me) ₂ | 13.96 (bs, 1H), 13.15 (s, 1H), 8.25 (d, 2H, J = 8.5 Hz), 7.77 (d, 2H, J = 8.5 Hz), 7.23 (s, 1H), 7.65 - 7.69 (m, 2H), 7.37 - 7.51 (m, 3H), 2.97 (s, 3H), 2.67 (s, 3H) |
| 46 | A-46 |  | CONH ₂ | 13.94 (bs, 1H), 13.10 (s, 1H), 8.25 (d, 2H, J = 8.5 Hz), 7.72 - 7.81 (m, 5H), 7.52 (bs, 2H), 7.41 - 7.49 (m, 3H) |

Table 6











| Example No. | Compound No. | R ⁶ | R ⁷ | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|---|---|---|
| 47 | A-47 |  | CONHMe | 13.90 (bs, 1H), 13.11 (s, 1H), 8.25 (d, 2H, J = 8.5 Hz), 8.18 (q, 1H, J = 4.7 Hz), 7.76 (d, 2H, J = 8.5 Hz), 7.71 - 7.74 (m, 3H), 7.37 - 7.48 (m, 3H), 2.71 (d, 3H, J = 4.7 Hz) |
| 48 | A-48 |  | *-CH ₂ - | 13.95 (bs, 1H), 13.00 (s, 1H), 8.25 (d, 2H, J = 8.5 Hz), 7.75 (d, 2H, J = 8.5 Hz), 7.71 (s, 1H), 7.56 - 7.60 (m, 2H), 7.36 - 7.41 (m, 1H), 7.23 - 7.29 (m, 1H), 3.92 (s, 2H) |
| 49 | A-49 |  | *-(CH ₂) ₂ - | 13.92 (bs, 1H), 12.85 (s, 1H), 8.24 (d, 2H, J = 8.5 Hz), 7.72 - 7.77 (m, 4H), 7.18 - 7.32 (m, 3H), 2.96 - 3.05 (m, 4H) |
| 50 | A-50 |  | *-(CH ₂) ₃ - | 13.89 (bs, 1H), 12.76 (s, 1H), 8.23 (d, 2H, J = 8.5 Hz), 7.99 (d, 1H, J = 7.1 Hz), 7.75 (d, 2H, J = 8.1 Hz), 7.71 (s, 1H), 7.19 - 7.34 (m, 3H), 72.96 (t, 2H, J = 7.1 Hz), 2.78 - 2.81 (m, 2H), 2.07 - 2.15 (m, 2H) |
| 51 | A-51 |  | CH ₂ CH ₂ Cl | 13.95 (bs, 1H), 12.90 (s, 1H), 8.22 (d, 2H, J = 8.5 Hz), 7.75 (d, 2H, J = 8.5 Hz), 7.71 (s, 1H), 7.66 - 7.71 (m, 2H), 7.57 - 7.62 (m, 2H), 3.91 (t, 2H, J = 6.8 Hz), 3.33 (t, 2H, J = 6.8 Hz) |
| 52 | A-52 |  | H | 13.99 (bs, 1H), 12.92 (s, 1H), 10.03 (s, 1H), 8.24 (d, 2H, J = 8.5 Hz), 7.88 (d, 2H, J = 8.5 Hz), 7.75 (d, 2H, J = 8.5 Hz), 7.72 (s, 1H), 7.66 (d, 2H, J = 8.5 Hz), 7.59 (s, 1H), 2.07 (s, 3H) |
| 53 | A-53 |  | H | 13.98 (bs, 1H), 12.95 (s, 1H), 8.33 (s, 1H), 8.25 (d, 2H, J = 8.5 Hz), 8.23 - 8.27 (m, 1H), 7.98 (s, 1H), 7.77 (d, 2H, J = 8.5 Hz), 7.69 - 7.72 (m, 3H) |
| 54 | A-54 | H |  | 13.90 (bs, 1H), 8.22 (d, 2H, J = 8.5 Hz), 8.14 (s, 1H), 7.76 (d, 2H, J = 8.5 Hz), 7.75 (s, 1H), 7.62 - 7.70 (m, 2H) |
| 55 | A-55 | H |  | 13.87 (bs, 1H), 12.86 (s, 1H), 8.23 (d, 2H, J = 8.5 Hz), 7.98 (s, 1H), 7.76 (d, 2H, J = 8.5 Hz), 7.71 (s, 1H), 7.68 - 7.52 (m, 2H), 7.42 - 7.47 (m, 2H), 7.30 - 7.35 (m, 1H) |
| 56 | A-56 |  | H | 13.89 (bs, 1H), 12.95 (s, 1H), 8.23 (d, 2H, J = 8.5 Hz), 7.75 (d, 2H, J = 8.5 Hz), 7.71 (s, 1H), 7.36 (s, 1H), 7.11 (s, 1H), 2.40 (s, 3H) |

Table 7



















| Example No. | Compound No. | R ⁶ | R ⁷ | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|---|----------------------|--|
| 57 | A-57 |  | H | 13.89 (bs, 1H), 12.77 (s, 1H), 8.23 (d, 2H, J = 8.5 Hz), 7.76 (d, 2H, J = 8.5 Hz), 7.71 (s, 1H), 7.29 (s, 1H), 7.07 (d, 1H, J = 1.1 Hz), 2.60 (s, 3H), 2.40 (s, 3H) |
| 58 | A-58 |  | *-OCH ₂ - | 14.03 (bs, 1H), 12.99 (s, 1H), 8.23 (d, 2H, J = 8.2 Hz), 7.75 (d, 2H, J = 8.2 Hz), 7.69 (s, 1H), 7.54 (d, 1H, J = 2.5 Hz), 7.24 (dd, 1H, J = 8.5 Hz, 2.5 Hz), 6.97 (d, 1H, J = 8.5 Hz), 5.54 (s, 2H) |
| 59 | A-59 |  | *-SCH ₂ - | 13.84 (bs, 1H), 12.95 (s, 1H), 8.34 (d, 2H, J = 8.5 Hz), 7.86 - 7.90 (m, 1H), 7.76 (d, 2H, J = 8.5 Hz), 7.72 (s, 1H), 7.34 - 7.37 (m, 1H), 7.19 - 7.30 (m, 2H), 4.32 (s, 2H) |
| 60 | A-60 |  | H | 13.93 (bs, 1H), 12.93 (s, 1H), 8.23 (d, 2H, J = 8.4 Hz), 7.93 - 8.01 (m, 1H), 7.82 (s, 1H), 7.80 - 7.82 (m, 1H), 7.76 (d, 2H, J = 8.4 Hz), 7.71 (s, 1H) |
| 61 | A-61 |  | H | 13.94 (bs, 1H), 13.01 (s, 1H), 8.25 (d, 2H, J = 8.2 Hz), 8.18 (d, 2H, J = 8.2 Hz), 7.96 (s, 1H), 7.82 (d, 2H, J = 8.2 Hz), 7.76 (d, 2H, J = 8.2 Hz), 7.71 (s, 1H) |
| 62 | A-62 |  | H | 13.94 (bs, 1H), 12.91 (s, 1H), 8.24 (d, 2H, J = 8.5 Hz), 7.96 (s, 1H), 7.67 - 7.80 (m, 6H), 7.22 - 7.28 (m, 1H), 3.88 (s, 3H) |
| 63 | A-63 |  | H | 13.95 (bs, 1H), 12.97 (s, 1H), 8.25 (d, 2H, J = 8.5 Hz), 8.00 - 8.02 (m, 1H), 7.94 - 7.96 (m, 6H), 7.77 (d, 2H, J = 8.5 Hz), 7.73 (s, 1H), 7.60 (t, 1H, J = 7.8 Hz), 7.34 - 7.36 (m, 1H) |
| 64 | A-64 |  | H | 13.97 (bs, 1H), 12.97 (s, 1H), 8.24 (d, 2H, J = 8.5 Hz), 7.87 (s, 1H), 7.26 - 7.84 (m, 6H), 7.72 (s, 1H), 7.47 - 7.54 (m, 1H), 7.15 - 7.21 (m, 1H) |
| 65 | A-65 |  | CO ₂ Me | 13.40 (s, 1H), 8.24 (d, 2H, J = 8.2 Hz), 7.97 (d, 2H, J = 8.5 Hz), 7.83 (d, 2H, J = 8.0 Hz), 7.76 (d, 2H, J = 8.0 Hz), 7.70 (s, 1H), 3.77 (s, 3H) |
| 66 | A-66 |  | H | 8.24 (d, 2H, J = 8.5 Hz), 7.77 (d, 2H, J = 8.5 Hz), 7.73 (s, 1H), 7.72 (s, 1H) |

Table 8

| Example No. | Compound No. | R ⁶ | R ⁷ | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|---|----------------|---|
| 67 | A-67 |  | H | 13.96 (bs, 1H), 12.98 (s, 1H), 8.25 (d, 2H, J = 8.2 Hz), 8.09 - 8.15 (m, 1H), 7.77 (d, 2H, J = 8.5 Hz), 7.73 (s, 1H), 7.63 (d, 1H, J = 2.5 Hz), 7.31 - 7.45 (m, 3H) |
| 68 | A-68 |  | H | 13.96 (bs, 1H), 12.96 (s, 1H), 8.23 (d, 2H, J = 8.2 Hz), 7.86 (d, 1H, J = 7.9 Hz), 7.62 - 7.78 (m, 6H), 7.35 (s, 1H) |
| 69 | A-69 |  | H | 13.93 (bs, 1H), 13.03 (s, 1H), 8.24 (d, 2H, J = 8.2 Hz), 7.76 (d, 2H, J = 8.5 Hz), 7.72 (s, 1H), 7.47 - 7.57 (m, 1H), 7.55 (s, 1H), 7.17 - 7.28 (m, 2H) |
| 70 | A-70 |  | H | 13.95 (bs, 1H), 12.97 (s, 1H), 8.25 (d, 2H, J = 8.2 Hz), 8.09 - 7.18 (m, 1H), 7.76 (d, 2H, J = 8.2 Hz), 7.72 (m, 1H), 7.60 (d, 1H, J = 2.7 Hz), 7.36 - 7.44 (m, 1H), 7.20 - 7.27 (m, 1H) |
| 71 | A-71 |  | H | 13.96 (bs, 1H), 12.94 (s, 1H), 8.23 (d, 2H, J = 8.2 Hz), 7.97 - 8.06 (m, 1H), 7.75 (d, 2H, J = 8.2 Hz), 7.67 - 7.72 (m, 1H), 7.69 (s, 1H), 7.67 (d, 1H, J = 2.5 Hz) |
| 72 | A-72 |  | H | 13.99 (bs, 1H), 12.92 (s, 1H), 8.24 (d, 2H, J = 8.5 Hz), 8.19 (t, 2H, J = 1.6 Hz), 7.95 - 7.98 (m, 1H), 7.87 (s, 1H), 7.77 (d, 2H, J = 8.5 Hz), 7.52 - 7.56 (m, 1H), 7.42 (t, 1H, J = 8.0 Hz) |
| 73 | A-73 |  | H | 13.97 (bs, 1H), 12.95 (s, 1H), 8.24 (d, 2H, J = 8.5 Hz), 7.72 - 7.84 (m, 8H), |

Compound (B-1) to Compound (B-25) were synthesized in a manner similar to Example 1 by using 1,4-thiazolidine-dione instead of rhodanine. Their physical data were shown in Tables 9 to 11.

Table 9



| Example No. | Compound No. | R ⁶ | R ⁷ | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|----------------|----------------|--|
| 74 | B-1 | | H | 12.92 (s, 1H), 12.72 (bs, 1H), 8.24 (d, 2H, J = 8.4 Hz), 7.95 - 7.98 (m, 2H), 7.87 (s, 1H), 7.76 (d, 2H, J = 8.4 Hz), 7.73 (s, 1H), 7.43 - 7.48 (m, 2H), 7.32 - 7.37 (m, 1H) |
| 75 | B-2 | | H | 12.89 (s, 1H), 12.75 (bs, 1H), 8.24 (d, 2H, J = 8.4 Hz), 7.97 - 8.02 (m, 2H), 7.87 (s, 1H), 7.76 (d, 2H, J = 8.4 Hz), 7.70 (s, 1H), 7.26 - 7.32 (m, 2H) |
| 76 | B-3 | | H | 12.92 (s, 1H), 12.73 (bs, 1H), 8.24 (d, 2H, J = 8.5 Hz), 7.94 (d, 2H, J = 7.1 Hz), 7.90 (s, 1H), 7.86 (s, 1H), 7.76 (d, 2H, J = 8.5 Hz), 7.65 (d, 2H, J = 7.1 Hz) |
| 77 | B-4 | | H | 12.91 (s, 1H), 12.72 (bs, 1H), 8.24 (d, 2H, J = 8.5 Hz), 7.98 (d, 2H, J = 8.5 Hz), 7.86 (s, 1H), 7.79 (s, 1H), 7.76 (d, 2H, J = 8.5 Hz), 7.52 (d, 2H, J = 8.5 Hz) |
| 78 | B-5 | | H | 12.89 (s, 1H), 12.75 (bs, 1H), 8.24 (d, 2H, J = 8.5 Hz), 7.87 (s, 1H), 7.85 (d, 1H, J = 8.1 Hz), 7.76 (d, 2H, J = 8.5 Hz), 7.64 (s, 1H), 7.26 (d, 1H, J = 8.1 Hz), 2.34 (s, 3H) |
| 79 | B-6 | | H | 12.94 (s, 1H), 12.74 (bs, 1H), 8.25 (d, 2H, J = 8.4 Hz), 8.06 (d, 2H, J = 8.1 Hz), 7.87 (s, 1H), 7.72 - 7.79 (m, 7H), 7.49 (t, 2H, J = 7.5 Hz), 7.38 (t, 2H, J = 7.5 Hz) |
| 80 | B-7 | | H | 12.89 (s, 1H), 12.76 (bs, 1H), 8.24 (d, 2H, J = 8.4 Hz), 7.99 (d, 2H, J = 8.7 Hz), 7.86 (s, 1H), 7.76 (d, 2H, J = 8.4 Hz), 7.56 (s, 1H), 7.01 (d, 2H, J = 8.7 Hz), 3.80 (s, 3H) |
| 81 | B-8 | | H | 12.85 (s, 1H), 12.73 (bs, 1H), 8.21 (d, 2H, J = 8.7 Hz), 7.94 (dd, 1H, J = 7.8 Hz, 1.2 Hz), 7.86 (s, 1H), 7.78 - 7.83 (m, 2H), 7.74 (d, 2H, J = 8.7 Hz), 7.61 - 7.67 (m, 1H), 7.59 (s, 1H) |

Table 10

















| Example No. | Compound No. | R ⁶ | R ⁷ | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|---|----------------|---|
| 82 | B-9 | t-Bu | H | 12.70 (s, 1H), 8.20 (d, 2H, J = 8.7 Hz), 7.84 (s, 1H), 7.73 (d, 2H, J = 8.7 Hz), 6.84 (s, 1H), 1.31 (s, 9H) |
| 83 | B-10 |  | H | 12.90 (s, 1H), 12.73 (bs, 1H), 8.24 (d, 2H, J = 8.5 Hz), 7.88 (d, 2H, J = 8.5 Hz), 7.87 (s, 1H), 7.76 (d, 2H, J = 8.5 Hz), 7.64 (s, 1H), 7.47 (d, 2H, J = 8.5 Hz), 1.32 (s, 9H) |
| 84 | B-11 |  | H | 12.97 (s, 1H), 12.72 (bs, 1H), 8.25 (d, 2H, J = 8.5 Hz), 8.08 (dd, 4H, J = 18.9 Hz, 8.8 Hz), 7.94 (s, 1H), 7.87 (s, 1H), 7.76 (d, 2H, J = 8.5 Hz), 3.81 (s, 3H) |
| 85 | B-12 |  | H | 12.89 (s, 1H), 12.72 (bs, 1H), 8.24 (d, 2H, J = 8.7 Hz), 7.87 (s, 1H), 7.85 (d, 2H, J = 8.4 Hz), 7.75 (d, 2H, J = 8.4 Hz), 7.63 (s, 1H), 7.26 (d, 2H, J = 8.7 Hz), 2.60 (t, 2H, J = 7.8 Hz), 1.55 - 1.65 (m, 2H), 1.27 - 1.36 (m, 2H), 0.87 (t, 3H, J = 7.8 Hz) |
| 86 | B-13 |  | H | 13.03 (s, 1H), 12.73 (bs, 1H), 8.34 (d, 2H, J = 8.5 Hz), 8.24 (d, 2H, J = 8.7 Hz), 8.22 (d, 2H, J = 8.7 Hz), 8.09 (s, 1H), 7.86 (s, 1H), 7.76 (d, 2H, J = 8.5 Hz) |
| 87 | B-14 |  | H | 12.89 (s, 1H), 12.73 (bs, 1H), 8.23 (d, 2H, J = 8.7 Hz), 7.87 (s, 1H), 7.75 (d, 2H, J = 8.7 Hz), 7.64 (s, 1H), 7.44 (d, 1H, J = 3.9 Hz), 7.15 (d, 1H, J = 3.9 Hz) |
| 88 | B-15 |  | H | 12.89 (s, 1H), 12.72 (bs, 1H), 8.24 (d, 2H, J = 8.5 Hz), 7.87 (s, 1H), 7.83 - 7.84 (m, 1H), 7.75 (d, 2H, J = 8.5 Hz), 7.62 - 7.63 (m, 2H), 7.56 (s, 1H) |
| 89 | B-16 |  | H | 12.92 (s, 1H), 12.73 (bs, 1H), 8.24 (d, 2H, J = 8.7 Hz), 8.22 (d, 1H, J = 2.4 Hz), 7.95 (dd, 1H, J = 8.4 Hz, 2.4 Hz), 7.94 (s, 1H), 7.86 (s, 1H), 7.77 (d, 2H, J = 8.7 Hz), 7.73 (d, 1H, J = 8.4 Hz) |
| 90 | B-17 |  | H | 12.99 (s, 1H), 12.75 (bs, 1H), 8.38 (m, 1H), 8.25 (m, 2H), 7.99 (m, 2H), 7.87 (s, 1H), 7.77 (d, 2H, J = 8.4 Hz), 7.55 (m, 4H), 7.73 (m, 1H) |
| 91 | B-18 |  | H | 12.91 (s, 1H), 12.76 (bs, 1H), 8.86 (s, 1H), 8.23 (d, 2H, J = 8.7 Hz), 7.96 (m, 1H), 7.83 (m, 1H), 7.82 (s, 1H), 7.75 (d, 2H, J = 8.7 Hz), 7.52 (m, 1H) |

Table 11

| Example No. | Compound No. | R ⁶ | R ⁷ | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|---|-------------------------------------|--|
| 92 | B-19 |  | H | 12.99(s, 1H), 12.75 (bs, 1H), 8.38 (1H, m), 8.26 (d, 2H, J=8.7 Hz), 7.99 (m, 2H), 7.87(s, 1H), 7.77 (d, 2H, J=8.7 Hz), 7.56 (m, 4H), 7.73 (m, 1H) |
| 93 | B-20 | H | H | 12.72 (bs, 2H), 8.22 (d, 2H, J=8.7 Hz), 7.86 (s, 1H), 7.58 (d, 1H, J=3.6 Hz), 7.75 (d, 2H, J=8.7 Hz), 7.31 (d, 1H, J=3.6 Hz) |
| 94 | B-21 |  | *-(CH ₂) ₂ - | 12.84 (s, 1H), 12.73 (bs, 1H), 8.23 (d, 2H, J = 8.5 Hz), 7.86 (s, 1H), 7.75 (d, 2H, J = 8.5 Hz), 7.74 (d, 1H, J = 6.9 Hz), 7.18 - 7.32 (m, 3H), 2.96 - 3.05 (m, 4H) |
| 95 | B-22 |  | *-(CH ₂) ₂ - | 12.75 (s, 2H), 8.23 (d, 2H, J = 8.5 Hz), 8.00 (d, 2H, J = 7.4 Hz), 7.86 (s, 1H), 7.75 (d, 2H, J = 8.5 Hz), 7.19 - 7.33 (m, 3H), 2.96 (t, 2H, J = 6.8 Hz), 2.78 - 2.82 (m, 2H), 2.06 - 2.15 (m, 2H) |
| 96 | B-23 |  | CH ₂ CH ₂ Cl | 12.86 (s, 1H), 12.74 (bs, 1H), 8.22 (d, 2H, J = 8.5 Hz), 7.86 (s, 1H), 7.75 (d, 2H, J = 8.5 Hz), 7.65 - 7.69 (m, 2H), 7.29 - 7.35 (m, 2H), 3.91 (t, 2H, J = 6.8 Hz), 3.32 (t, 2H, J = 6.8 Hz) |
| 97 | B-24 |  | Me | 12.76 (s, 1H), 12.70 (bs, 1H), 8.22 (d, 2H, J = 8.5 Hz), 7.85 (s, 1H), 7.74 (d, 2H, J = 8.5 Hz), 7.72 (d, 2H, J = 8.5 Hz), 7.53 (d, 2H, J = 8.5 Hz), 2.51 (s, 1H) |
| 98 | B-25 |  | CH ₂ Me | 12.77 (s, 1H), 12.70 (bs, 1H), 8.22 (d, 2H, J = 8.5 Hz), 7.86 (s, 1H), 7.75 (d, 2H, J = 8.5 Hz), 7.62 - 7.65 (m, 2H), 7.45 - 7.50 (m, 2H), 7.35 - 7.40 (m, 1H), 2.93 (q, 2H, J = 7.4 Hz), 1.29 (t, 3H, J = 7.4 Hz) |

Compound (C-1) to Compound (C-9) were synthesized in a manner similar to Example 1 by using 1,4-oxazolidine-dione instead of rhodanine. Their physical data were shown in Tables 12.

Table 12




| Example No. | Compound No. | R ⁶ | R ⁷ | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|----------------|-------------------------------------|--|
| 99 | C-1 | | H | 12.88 (s, 1H), 12.54 (bs, 1H), 8.22 (s, 1H), 8.20 (d, 2H, J = 5.8 Hz), 7.91 - 7.97 (m, 4H), 7.72 (d, 1H, J = 8.5 Hz), 6.83 (s, 1H) |
| 100 | C-2 | | H | 12.96 (s, 1H), 12.54 (bs, 1H), 8.22 (d, 2H, J = 8.7 Hz), 8.04 - 8.13 (m, 1H), 7.94 (s, 1H), 7.93 (d, 2H, J = 6.9 Hz), 6.84 (s, 1H), 3.88 (s, 3H) |
| 101 | C-3 | | H | 12.89 (s, 1H), 12.55 (bs, 1H), 8.21 (d, 2H, J = 8.5 Hz), 7.89 - 8.03 (m, 1H), 7.93 (d, 2H, J = 8.5 Hz), 7.89 - 7.86 (m, 1H), 7.82 (s, 1H), 7.48 - 7.57 (m, 1H), 6.83 (s, 1H) |
| 102 | C-4 | | H | 12.96 (s, 1H), 12.55 (bs, 1H), 8.20 (d, 2H, J = 8.5 Hz), 7.92 (d, 2H, J = 8.5 Hz), 7.34 (s, 1H), 7.42 (d, 1H, J = 3.8 Hz), 7.24 (d, 2H, J = 3.8 Hz), 6.83 (s, 1H) |
| 103 | C-5 | | *-(CH ₂) ₂ - | 12.81 (s, 1H), 12.54 (bs, 1H), 8.21 (d, 2H, J = 8.5 Hz), 7.92 (d, 2H, J = 8.5 Hz), 7.74 (d, 2H, J = 7.4 Hz), 7.18 - 7.32 (m, 3H), 6.83 (s, 1H), 2.95 - 3.05 (m, 4H) |
| 104 | C-6 | | *-(CH ₂) ₃ - | 12.72 (s, 1H), 12.56 (bs, 1H), 8.20 (d, 2H, J = 8.5 Hz), 8.01 (d, 1H, J = 7.4 Hz), 7.92 (d, 2H, J = 8.5 Hz), 7.20 - 7.34 (m, 3H), 6.82 (s, 1H), 2.97 (t, 2H, J = 6.8 Hz), 2.79 - 2.81 (m, 2H), 2.09 - 2.13 (m, 2H) |
| 105 | C-7 | | CH ₂ CH ₂ Cl | 12.83 (s, 1H), 12.55 (bs, 1H), 8.19 (d, 2H, J = 8.5 Hz), 7.92 (d, 2H, J = 8.5 Hz), 7.65 - 7.70 (m, 2H), 8.28 - 7.35 (m, 2H), 6.83 (s, 1H), 3.91 (t, 2H, J = 6.9 Hz), 3.34 (t, 2H, J = 6.9 Hz) |
| 106 | C-8 | | Me | 12.75 (s, 1H), 12.53 (bs, 1H), 8.19 (d, 2H, J = 8.5 Hz), 7.91 (d, 2H, J = 8.5 Hz), 7.72 (d, 2H, J = 8.5 Hz), 7.53 (d, 2H, J = 8.5 Hz), 6.82 (s, 1H), 2.51 (s, 3H) |
| 107 | C-9 | | CH ₂ Me | 12.74 (s, 1H), 12.55 (bs, 1H), 8.19 (d, 2H, J = 8.5 Hz), 7.92 (d, 2H, J = 8.5 Hz), 7.62 - 7.65 (m, 2H), 7.45 - 7.50 (m, 2H), 7.35 - 7.40 (m, 1H), 6.83 (s, 1H), 2.93 (q, 2H, J = 7.4 Hz), 1.30 (t, 3H, J = 7.4 Hz) |

Compound (D-1) to Compound (D-20) were synthesized in a manner similar to Example 1 by using commercial available amines instead of compound (4) in process 3. Their physical data were shown in Tables 13 to 15.

10048008.012502

Table 13



| Example No. | Compound No. | X | R ^A | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|---|----------------|--|
| 108 | D-1 | | H | 7.64 (2H, d, J = 8.7 Hz), 7.71 (2H, d, J = 8.7 Hz), 7.74 (2H, d, J = 8.7 Hz), 7.86 (1H, s), 8.06 (2H, d, J = 8.1 Hz), 12.70 (1H, br.s) |
| 109 | D-2 | | H | 7.21 (2H, dd, J = 8.7 Hz, J _{HF} = 8.7 Hz), 7.75 (2H, d, J = 8.7 Hz), 7.80 (2H, m), 7.86 (1H, s), 8.06 (2H, d, J = 8.7 Hz), 10.42 (1H, s), 12.72 (1H, bs) |
| 110 | D-3 | | H | 1.33 (3H, t, J = 6.9 Hz), 4.45 (2H, q, J = 6.9 Hz), 7.20 (1H, dd, J = 8.1 Hz, 8.1 Hz), 7.46 (1H, dd, J = 8.1 Hz, 8.1 Hz), 7.60 (2H, m), 7.75 (1H, m), 7.76 (2H, d, J = 8.7 Hz), 7.88 (1H, s), 8.15 (2H, d, J = 8.7 Hz), 8.58 (1H, s), 10.43 (1H, s), 12.72 (1H, bs) |
| 111 | D-4 | | H | 1.16 (3H, t, J = 7.2 Hz), 2.30 (3H, s), 3.40 (2H, q, J = 7.2 Hz), 3.56 (2H, t, 5.4 Hz), 3.68 (2H, m), 6.44 (1H, bs), 6.58 (1H, d, J = 7.5 Hz), 6.63 (1H, s), 6.64 (1H, d, J = 7.5 Hz), 7.14 (1H, dd, J = 7.5 Hz, 7.5 Hz), 7.52 (2H, d, J = 8.7 Hz), 7.77 (2H, d, J = 8.7 Hz), 7.83 (1H, s) |
| 112 | D-5 | | Ph | 6.95 (1H, dd, J = 7.5 Hz, 7.5 Hz), 7.23 (3H, m), 7.38 (6H, m), 7.60 (2H, m), 7.69 (2H, m), 7.77 (1H, s), 9.02 (1H, s), 9.25 (1H, s), 12.66 (1H, bs) |
| 113 | D-6 | | Me | 3.47 (3H, s), 7.41 (2H, d, J = 9.0 Hz), 7.47 (4H, m), 7.58 (3H, m), 7.78 (2H, d, J = 9.0 Hz), 7.84 (2H, m), 12.62 (1H, bs) |
| 114 | D-7 | | H | 3.83 (3H, s), 7.07 (1H, dd, J = 2.4 Hz, 9.0 Hz), 7.62 (1H, d, J = 2.4 Hz), 7.68 (1H, d, J = 9.0 Hz), 7.76 (2H, d, J = 8.4 Hz), 7.87 (1H, s), 8.23 (2H, d, J = 8.4 Hz), 12.75 (1H, s), 12.88 (1H, s) |
| 115 | D-8 | | H | 7.58 (3H, m), 7.77 (2H, d, J = 8.7 Hz), 7.88 (2H, m), 7.95 (3H, m), 8.06 (2H, m), 8.11 (2H, d, J = 8.7 Hz), 10.72 (1H, s), 12.72 (1H, bs) |
| 116 | D-9 | | H | 4.49 (2H, d, J = 6.0 Hz), 7.25 (1H, m), 7.33 (4H, m), 7.69 (2H, d, J = 8.1 Hz), 7.83 (1H, s), 8.01 (2H, d, J = 8.1 Hz), 9.17 (1H, t, J = 6.0 Hz), 12.69 (1H, bs) |

Table 14











| Example No. | Compound No. | X | R ^A | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|--|----------------|---|
| 117 | D-10 |  | H | 2.47 (3H, s), 7.27 (2H, d, J = 9.0 Hz), 7.74 (4H, m), 7.85 (1H, s), 8.06 (2H, d, J = 9.0 Hz), 12.60 (1H, bs) |
| 118 | D-11 |  | H | 12.45 (bs, 1H), 10.29 (s, 1H), 8.07 (d, 2H, J = 8.1 Hz), 7.87 (s, 1H), 7.74 (d, 2H, J = 8.1 Hz), 7.67 (d, 2H, 8.7 Hz), 7.18 (d, 2H, J = 8.7 Hz), 2.56 (t, 2H, J = 7.5 Hz), 1.50 - 1.61 (m, 2H), 1.25 - 1.37 (m, 2H), 0.91 (t, 3H, J = 7.5 Hz) |
| 119 | D-12 |  | H | 13.94 (bs, 1H), 12.25 (s, 1H), 8.17 (d, 2H, J = 8.4 Hz), 7.88 - 7.92 (m, 2H), 7.77 (d, 2H, J = 8.4 Hz), 7.72 (s, 1H), 7.52 - 7.53 (m, 3H), 6.96 (s, 3H) |
| 120 | D-13 |  | H | 3.893 (3H, s), 7.026 (1H, s), 7.756 (2H, d, J = 8.4 Hz), 7.851 (1H, s), 8.028-8.100 (4H, m), 8.156 (2H, d, J = 8.4 Hz), 12.277 (1H, s), 12.714 (1H, br) |
| 121 | D-14 |  | H | 7.556 (1H, dd, J = 2.1, 8.4 Hz), 7.730-7.769 (4H, m), 7.865 (1H, s), 7.943 (1H, d, J = 8.4 Hz), 8.236 (2H, d, J = 8.4 Hz), 12.732 (1H, s), 12.963 (1H, br) |
| 122 | D-15 |  | H | 7.019 (1H, br), 7.332-7.381 (1H, m), 7.467 (2H, t, J = 7.7 Hz), 7.711-7.785 (4H, m), 7.862 (1H, s), 8.147 (2H, d, J = 8.7 Hz), 11.024 (1H, s), 12.5 (1H, br) |
| 123 | D-16 |  | H | 3.879 (3H, s), 7.107 (1H, s), 7.732 (2H, d, J = 8.4 Hz), 7.861 (1H, s), 7.933 (2H, d, J = 8.7 Hz), 8.036 (2H, d, J = 8.7 Hz), 8.152 (2H, d, J = 8.4 Hz), 11.124 (1H, s), 12.711 (1H, br) |
| 124 | D-17 |  | H | 7.31-7.37 (2H, m), 7.735 (2H, d, J = 9.0 Hz), 7.86-7.83 (2H, m), 7.871 (1H, s), 8.149-8.178 (3H, m), 8.298 (2H, d, J = 8.7 Hz), 8.73 (1H, s), 11.058 (1H, s), 12.707 (1H, br) |
| 125 | D-18 |  | H | 1.352 (3H, t, J = 7.2 Hz), 4.350 (2H, q, J = 7.2 Hz), 7.728 (2H, d, J = 8.4 Hz), 7.862 (1H, s), 7.919 (2H, d, J = 8.4 Hz), 8.062 (2H, d, J = 8.4 Hz), 8.164 (2H, d, J = 8.7 Hz), 11.119 (1H, s), 12.716 (1H, br) |


Table 15



| Example No. | Compound No. | X | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|---|---|
| 126 | D-19 | | 13.98(bs, 1H), 11.82(s, 1H), 8.15(d, 2H, J = 8.2 Hz), 7.80(d, 2H, J = 8.2 Hz), 7.72(s, 1H), 7.65(d, 2H, J = 8.0 Hz), 7.43(t, 2H, J = 8.0 Hz), 7.39(s, 1H), 7.30(t, 1H, J = 8.0 Hz), 7.30(s, 1H) |
| 127 | D-20 | | 12.1(bs, 2H), 11.9(bs, 1H), 8.19 (d, 2H, J = 8.5 Hz), 7.79 (d, 2H, J = 8.5 Hz), 7.74 (d, 2H, J = 8.5 Hz), 7.71 (s, 1H), 7.46 (s, 1H), 7.40(d, 2 H, J = 8.5 Hz) |

Compound (E-1) to Compound (E-5) were synthesized in a manner similar to Example 1 by using methyl 5-formyl-furancarboxylate, methyl 5-formyl-thiophenecarboxylate, and methyl 4-formyl-nicotinate instead of methyl terephthalaldehyde. Their physical data were shown in Tables 16.


Table 16



| Exempl eNo. | Com pound No. | X | Z | ¹ H-NMR (δ) ppm (DMSO d-6) |
|----------------|---------------------|---|---|--|
| 128 | E-1 | | | 7.23 (1H, d, J = 3.9 Hz), 7.65 (1H, s), 7.71 (1H, d, J = 8.4 Hz), 7.88-7.94 (3H, m), 8.19 (1H, d, J = 2.4 Hz), 12.6 (1H, br), 12.92 (1H, s) |
| 129 | E-2 | | | 7.69-7.73 (2H, m), 7.90-7.94 (2H, m), 8.05 (1H, s), 8.19 (1H, d, J = 2.1 Hz), 8.33 (1H, d, J = 4.2 Hz), 12.7 (1H, br), 13.06 (1H, s) |
| 130 | E-3 | | | 3.87 (3H, s), 7.72 (1H, d, J = 4.2 Hz), 7.91 (1H, s), 8.02-8.10 (5H, m), 8.34 (1H, d, J = 4.2 Hz), 12.7 (1H, br), 13.11 (1H, s) |
| 131 | E-4 | | | 13.75 (bs, 1H), 13.08 (s, 1H), 9.37 (d, 1H, J = 2.1 Hz), 8.56 (dd, 1H, J = 8.2 Hz, 2.4 Hz), 8.21 (d, 1H, J = 1.8 Hz), 8.05 (d, 1H, J = 7.9 Hz), 7.95 (s, 1H), 7.94 (dd, 1H, J = 9.1 Hz), 2.1 Hz), 7.75 (s, 1H), 7.33 (d, 1H, J = 8.5 Hz) |
| 132 | E-5 | | | 13.77 (bs, 1H), 13.15 (s, 1H), 9.48 (d, 1H, J = 2.7 Hz), 8.57 (dd, 1H, J = 8.4 Hz, 2.4 Hz), 8.02 - 8.12 (m, 4H), 7.96 (s, 1H), 7.92 - 8.02 (m, 1H), 7.75 (s, 1H), 3.88 (s, 3H) |


Compound (F-1) to Compound (F-4) were synthesized in a manner similar to Example 1 by using methyl 4-formyl-phenoxyacetate, methyl 4-formyl-cinnamate, instead of methyl terephthaldehydate. Their physical data were shown in Tables 17.

Table 17



| Example No. | Compound No. | R ⁶ | Y | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|----------------|---|--|
| 133 | F-1 | | | 4.50 (2H, s), 7.15 (2H, d, J = 8.7 Hz), 7.58 (2H, d, 8.7 Hz), 7.76 (1H, s), 7.88-7.918 (2H, m), 8.15 (1H, d, J = 1.8 Hz), 12.52 (1H, br), 12.60 (1H, s) |
| 134 | F-2 | | | 3.87 (3H, s), 5.00 (2H, s), 7.16 (2H, d, J = 8.7 Hz), 7.59 (2H, d, J = 8.7 Hz), 7.76 (1H, s), 7.88 (1H, s), 8.01-8.08 (4H, m), 12.50 (1H, br), 12.65 (1H, s) |
| 135 | F-3 | | | 3.87 (3H, s), 7.01 (1H, d, J = 16.2 Hz), 7.66-7.88 (7H, m), 8.01-8.10 (4H, m), 12.64 (1H, s) |
| 136 | F-4 | | | 6.99 (1H, d, J = 15.9 Hz), 7.65-7.79 (7H, m), 7.86 (1H, s), 7.89 (1H, dd, J = 2.1 Hz, 8.7 Hz), 8.13 (1H, d, J = 2.1 Hz), 12.58 (1H, s) |

Example 137



(Process 1)

To a suspension of compound (3)(1.10 g) synthesized by Process 2 in Example 1 in methanol (300 ml), 10% Palladium-Carbon (0.55 g) was added and the reaction mixture was stirred under hydrogen atmosphere. Removing Palladium-Carbon by filtration and evaporation of the solvent under reduced pressure yielded 1.05 g of compound (6).

¹H NMR (DMSO-d₆, δ ppm): 12.46 (bs, 1H), 7.99 (d, 2H, J = 8.4 Hz), 7.37 (d, 2H, J = 8.4 Hz), 4.95 (dd, 1H, J = 9.0 Hz, 4.5 Hz), 3.45 (dd, 1H, J = 14.4 Hz, 4.5 Hz), 3.22 (dd, 1H, J = 14.4 Hz, 9.0 Hz)


(Process 2)

A mixture of compound (6)(1.0 g) in dioxane (20 ml) and thionyl chloride (10 ml) was heated to dissolve at 100°C. Evaporation of the solvent under reduced pressure gave carboxylic acid chloride. The obtained carboxylic acid chloride was not purified to proceed to the further reaction. To the solution of the carboxylic acid chloride (286 mg), and 2-amino-4-(3',4'-difluorophenyl)thiazole (212 mg) in dioxane (50 ml), pyridine (121 μl) was added and the reaction mixture was heated at 100°C for 2 hours. After evaporation of the solvent under reduced pressure, the residue was purified by silica gel column chromatography (hexane - ethyl acetate ; 2 : 1) to obtain compound (G-1).

¹H NMR (DMSO-d₆, δ ppm): 12.75 (s, 1H), 12.11 (bs, 1H), 8.08 (d, 2H, J = 8.2

Hz), 7.93 - 8.01 (m, 1H), 7.80 - 7.84 (m, 1H), 7.80 (s, 1H), 7.48 - 7.59 (m, 1H), 7.44 (d, 2H, J = 8.2 Hz), 5.01 (dd, 1H, J = 8.8 Hz, 4.7 Hz), 3.48 (dd, 1H, J = 14.0 Hz, 4.7 Hz), 3.26 (dd, 1H, J = 14.0 Hz, 8.8 Hz)



5 Example 138



Compound (G-2) was synthesized in a manner similar to Example 137 by using 2-amino-5-(5'-bromothiophenyl)thiazole instead of 2-amino-4-(3',4'-difluorophenyl)thiazole.

¹H NMR (DMSO-d₆, δ ppm): 12.81 (s, 1H), 12.10 (bs, 1H), 8.08 (d, 2H, J = 8.2 Hz), 7.61 (s, 1H), 7.43 (d, 2H, J = 8.2 Hz), 7.40 (d, 1H, J = 4.1 Hz), 7.24 (d, 1H, J = 4.1 Hz), 5.01 (dd, 1H, J = 8.8 Hz, 4.4 Hz), 3.58 (dd, 1H, J = 14.0 Hz, 4.4 Hz), 3.25 (dd, 1H, J = 14.0 Hz, 8.8 Hz)

Example 139



(Process 1)

To a suspension of p-formyl-benzoic acid (3.0 g) in chloroform (30 ml) and thionyl chloride (6 ml), one drop of DMF was added and the mixture was refluxed. After confirmation of the dissolution of the mixture, evaporation of the solvent under reduced pressure gave 3.0 g of compound (7). The obtained compound (7) was subjected to the reaction without further purification. To the solution of compound (4) (2.52 g) in DMF, sodium hydride (0.45 mg) was added in an ice bath. After the reaction mixture was stirred at room temperature for 30 min, 1.36 g of compound (7) was added. After stirring for further 30 min, the resulting mixture was quenched with methanol and acidified with 1N hydrochloric acid. Extraction with ethyl acetate, evaporation of the solvent, and recrystallization from chloroform gave 1.06 g of compound (8).

^1H NMR(DMSO- d_6 , δ ppm) 13.04 (bs, 1H), 10.13 (s, 1H), 8.30 (d, 2H, J = 8.4 Hz), 8.22 (d, 1H, J = 2.1 Hz), 8.07 (d, 2H, J = 8.4 Hz), 7.95 (dd, 1H, J = 8.4 Hz, 2.1 Hz), 7.95 (s, 1H), 7.73 (d, 1H, J = 8.4 Hz).

(Process 2)

To a solution of hydantoin (2.0 g) in acetic acid, bromine (1.3 ml) was added at 85°C. The reaction solution was stirred at 85°C for 30 min and then cooled to 30°C, triethyl phosphite (4.8 ml) was added to the solution maintaining the temperature from 40 to 45°C. After the reaction mixture is stirred at room temperature for 90 min, ether was added and then filtration of the precipitated crystal gave 1.1 g of the compound.

^1H NMR(DMSO- d_6 , δ ppm) 10.91 (s, 1H), 8.41 (s, 1H), 4.76 (dd, 1H, J = 14.7 Hz, 1.2 Hz), 4.04 - 4.13 (m, 4H), 1.25 (t, 6H, J = 7.2 Hz).

(Process 3)

A mixture of sodium (10 mg) in ethanol (1m l) was stirred at room temperature. After confirmation of dissolution of sodium, compound (10)(108 mg) was added and the reaction mixture was stirred at room temperature for 10 min. After compound (10)(159 mg) was added, the reaction mixture was stirred at room temperature. Evaporation of the solvent under reduced pressure and recrystallization of the residue from methanol obtained compound (H-1). Compound (H-1) was obtained as the mixture of E isomer and Z isomer.

E isomer:


^1H NMR (DMSO- d_6 , δ ppm): 12.81 (bs, 1H), 10.76 (bs, 1H), 10.46 (s, 1H), 8.22 (d, 1H, $J = 2.4$ Hz), 8.15 (d, 2H, $J = 8.7$ Hz), 7.95 (dd, 1H, $J = 8.7$ Hz, 2.4 Hz), 7.91 (s, 1H), 7.78 (d, 2H, $J = 8.7$ Hz), 7.73 (d, 1H, $J = 8.7$ Hz), 6.48 (s, 1H).

Z isomer:

^1H NMR (DMSO- d_6 , δ ppm): 11.35 (bs, 1H), 11.26 (bs, 1H), 10.13 (s, 1H), 8.22 (d, 1H, $J = 2.4$ Hz), 8.10 (d, 2H, $J = 9.0$ Hz), 8.05 (d, 2H, $J = 9.0$ Hz), 7.95 (dd, 1H, $J = 8.7$ Hz, 2.4 Hz), 7.91 (s, 1H), 7.73 (d, 1H, $J = 8.7$ Hz), 6.38 (s, 1H).


Compound (H-2) to Compound (H-5) were synthesized in a manner similar to above-mentioned method. Their physical data were shown in Tables 18.

Table 18



| Example No. | Compound No. | M | T | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|-----------------|---|---|
| 140 | H-2 | NH | S | 12.85 (bs, 1H), 12.47 (bs, 1H), 12.33 (bs, 1H), 8.22 (d, 1H, J = 1.8 Hz), 8.16 (d, 2H, J = 8.2 Hz), 7.91 - 7.97 (m, 4H), 7.73 (d, 1H, J = 8.5 Hz), 6.54 (s, 1H) |
| 141 | H-3 | CH ₂ | O | 12.88 (s, 1H), 11.51 (s, 1H), 8.21 (d, 1H, J = 2.1 Hz), 8.20 (d, 2H, J = 9.3 Hz), 7.95 (dd, 1H, J = 8.1 Hz, 2.1 Hz), 7.92 (s, 1H), 7.80 (d, 2H, J = 9.3 Hz), 7.72 (d, 1H, J = 8.1 Hz), 7.46 (t, 1H, J = 2.1 Hz), 3.74 (d, 1H, J = 2.1 Hz) |
| 142 | H-4 | NMe | O | 9.48 (bs, 1H), 8.21 (s, 1H), 8.19 (dd, 4H, J = 13.2 Hz, 7.8 Hz), 7.94 (d, 1H, J = 6.6 Hz), 7.89 (s, 1H), 7.72 (d, 1H, J = 8.1 Hz), 6.47 (s, 1H), 2.71 (d, 3H, J = 4.8 Hz) |
| 143 | H-5 | O | S | 12.91 (s, 1H), 8.21 - 8.24 (m, 3H), 7.93 - 8.01 (m, 4H), 7.72 (d, 1H, J = 8.2 Hz), 6.57 (s, 1H) |

Example 144, 145



(Process 1)

- 5 To a solution of the compound (8)(0.2 g) prepared in accordance to Example 139 - Process 1 in DMF was added sodium hydride (32 mg) in an ice bath and the reaction solution was stirred at room temperature for 30 min. To the solution was added methyl iodide (0.2 ml) and then the reaction mixture was stirred for one hour. The reaction mixture was quenched with
- 10 iced water and extracted with ethyl acetate. After evaporation of the solvent under reduced pressure, the residue was purified with a column chromatography (hexane - ethyl acetate; 4 : 1) to give 100 mg of the compound (11) and 33 mg of the compound (12).

Compound (11)

¹H NMR(DMSO-d₆, δ ppm) 10.12 (s, 1H), 8.22 (d, 1H, J = 2.1 Hz), 8.07 (d, 2H, J = 8.1 Hz), 8.03 (s, 1H), 7.97 (dd, 1H, J = 8.1 Hz, 2.1 Hz), 7.89 (d, 2H, J = 8.4 Hz), 7.72 (d, 1H, J = 8.4 Hz), 3.63 (s, 3H).

Compound (12)

- 5 ¹H NMR(CDCl₃, δ ppm) 10.16 (s, 1H), 8.49 (d, 2H, J = 8.0 Hz), 7.97 (d, 2H, J = 8.0 Hz), 7.61 (d, 1H, J = 8.2 Hz), 7.55 (d, 1H, J = 2.2 Hz), 7.27 (dd, 1H, J = 8.2 Hz, 2.2 Hz), 6.67 (s, 1H), 3.78 (s, 3H).

(Process 2)


- 10 To a solution of the compound (11) (84 mg), and rhodanine (32 mg) in toluene (4 ml) were added 1M piperidine-toluene solution (20 μl) and 1M acetic acid-toluene (20 μl), and then the reaction mixture was refluxed for one hour. After cooling, filtration of the precipitated crystal gave 77 mg of compound (I-1).

- 15 ¹H NMR(DMSO-d₆, δ ppm) 13.85 (bs, 1H), 8.21(d, 1H, J = 1.8 Hz), 8.003 (s, 1H), 7.97 (dd, 1H, J = 8.7 Hz, 2.1 Hz), 7.83 (d, 2H, J = 8.1 Hz), 7.76 (d, 2H, J = 8.1 Hz), 7.72 (s, 1H), 7.71 (d, 1H, J = 8.7 Hz), 3.65 (s, 3H).

- To a solution of the compound (12) (42 mg), and rhodanine (16 mg) in toluene (2 ml) were added 1M piperidine-toluene solution (10 μl) and 1M acetic acid-toluene (10 μl), and then the reaction mixture was refluxed for two hours. After cooling, filtration of the precipitated crystal gave 36 mg of compound (I-2).

- 25 ¹H NMR(DMSO-d₆, δ ppm) 13.90 (bs, 1H), 8.36 (d, 2H, J = 8.5 Hz), 7.93 (d, 1H, J = 1.9 Hz), 7.83 (d, 1H, J = 8.2 Hz), 7.72 (d, 2H, J = 8.5 Hz), 7.70 (s, 1H), 7.62 (dd, 1H, J = 8.2 Hz, 1.9 Hz), 3.75 (s, 3H).

Example 146, 147, 148



The compound (A-12)(120 mg) prepared in a manner of Example 1 was dissolved in dioxane (5 ml) and 1N sodium hydroxide (5 ml) and the reaction solution was stirred at room temperature for 30 min. And then the mixture was acidified with 1N hydrochloric acid (5 ml) and evaporated under reduced pressure. The residue was washed with water and recrystallization from DMF-methanol obtained 72 mg of (J-1).

^1H NMR (DMSO- d_6 , δ ppm): 8.20 (d, 2H, $J = 8.5$ Hz), 7.98 (s, 4H), 7.74 (s, 1H), 7.64 (d, 2H, $J = 8.5$ Hz), 7.22 (s, 1H).


Neutralization of compound (I-1) with one equivalent of sodium hydroxide obtained (J-2)

^1H NMR (DMSO- d_6 , δ ppm): 13.92 (bs, 1H), 12.98 (s, 1H), 8.25 (d, 2H, $J = 8.4$ Hz), 8.01 - 8.10 (m, 4H), 7.92 (s, 1H), 7.77 (d, 2H, $J = 8.4$ Hz), 7.71 (s, 1H).

Neutralization of compound (J-1) with two equivalents of sodium hydroxide obtained (I-3)

^1H NMR (DMSO- d_6 , δ ppm): 8.20 (d, 2H, $J = 8.1$ Hz), 7.93 (dd, 4H, $J = 11.4$ Hz, 8.4 Hz), 7.71 (s, 1H), 7.61 (d, 2H, $J = 8.1$ Hz), 7.21 (s, 1H).

Example 149



(Process 1)

To a solution of compound (3)(10 g) synthesized in Example 1-Process 2 in tert-buthanol (200 ml) and dioxane (66 ml) was added triethylamine (5.6 ml) and diphenylphosphoryl azide (8.63 ml), and the reaction solution was refluxed for 2 hours. After evaporation of the solvent under reduced pressure, water was added to the mixture and extracted with ethyl acetate. After evaporation of the solvent under reduced pressure, the residue was purified with recrystallization (ethyl acetate) to yield 4.41 g of the compound (13).

^1H NMR(DMSO- d_6 , δ ppm) 12.50 (bs, 1H), 9.78 (s, 1H), 7.69 (s, 1H), 7.61 (d, 2H, $J = 9.0$ Hz), 7.51 (d, 2H, $J = 9.0$ Hz), 1.49 (s, 9H).

(Process 2)

The compound (13)(3.15 g) was dissolved in trifluoroacetic acid (15 ml) and the solution was stirred at room temperature for 15 min. After evaporation of the solvent under reduced pressure, recrystallization of the residue from diisopropyl ether gave 2.10g of (14).

^1H NMR(DMSO- d_6 , δ ppm) 12.29 (bs, 1H), 7.60 (s, 1H), 7.29 (d, 2H, $J = 8.7$ Hz), 6.67 (d, 2H, $J = 8.7$ Hz).


(Process 3)

To a solution of the compound (14)(220 mg) in dioxane (50 ml) were added pyridine (121 μ l) and 4-n-butyl benzoyl chloride (187 μ l) and the reaction solution was stirred at room temperature for 3 hours. After evaporation of the solvent, to the residue were added methanol (6 ml) and water (2 ml) and then the precipitated crystal was filtrated. Recrystallization from methanol yielded 232 mg of the compound (K-1).

^1H NMR(DMSO- d_6 , δ ppm) 12.56 (bs, 1H), 10.47 (s, 1H), 7.75 (s, 1H), 7.78 (d, 2H, $J = 8.7$ Hz), 7.63 (d, 2H, $J = 8.7$ Hz), 2.67 (t, 2H, $J = 7.5$ Hz), 1.59 (quant, 2H, $J = 7.5$ Hz), 1.32 (sexth, 2H, $J = 7.2$ Hz), 0.91 (t, 3H, $J = 7.5$ Hz)

Compound (K-2) to Compound (K-29) were synthesized in a manner similar to above-mentioned method. Their physical data were shown in Tables 19-22.

Table 19



| Example No. | Compound No. | X | T | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|---|---|---|
| 150 | K-2 | | O | 12.56 (bs, 1H), 10.73 (s, 1H), 8.61 (s, 1H), 8.01 - 8.12 (m, 6H), 7.78 (s, 1H), 7.63 - 7.69 (m, 4H) |
| 151 | K-3 | | O | 10.35 (s, 1H), 7.95 (d, 2H, J = 8.8 Hz), 7.75 (s, 1H), 8.52 - 7.75 (m, 4H), 7.08 (d, 1H, J = 8.2 Hz), 6.15 (s, 2H) |
| 152 | K-4 | | O | 12.55 (bs, 1H), 10.39 (s, 1H), 7.98 (d, 2H, J = 8.9 Hz), 7.96 (d, 2H, J = 8.9 Hz), 7.75 (s, 1H), 7.59 (d, 2H, J = 8.9 Hz), 7.32 - 7.50 (m, 5H), 7.16 (d, 2H, J = 8.9 Hz), 8.22 (s, 2H) |
| 153 | K-5 | | O | 12.56 (bs, 1H), 10.59 (s, 1H), 8.08 (d, 2H, J = 8.5 Hz), 7.86 (d, 2H, J = 8.2 Hz), 7.76 - 7.79 (m, 2H), 7.76 (s, 1H), 7.62 (d, 2H, J = 8.8 Hz), 7.50 - 7.55 (m, 2H), 7.41 - 7.46 (m, 1H) |
| 154 | K-6 | | O | 12.56 (bs, 1H), 10.47 (s, 1H), 7.97 (d, 2H, J = 9.0 Hz), 7.89 (d, 2H, J = 8.1 Hz), 7.76 (s, 1H), 7.63 (d, 2H, J = 9.0 Hz), 7.35 (d, 2H, J = 8.1 Hz), 2.66 (t, 2H, J = 7.2 Hz), 1.60 (quant, 2H, J = 7.2 Hz), 1.29 (bs, 6H), 0.84 - 0.88 (m, 3H) |
| 155 | K-7 | | O | 12.55 (bs, 1H), 10.38 (s, 1H), 7.96 (d, 4H, J = 9.0 Hz), 7.75 (s, 1H), 7.69 (d, 2H, J = 9.0 Hz), 7.06 (d, 2H, J = 9.0 Hz), 4.12 (q, 2H, J = 6.9 Hz), 1.36 (t, 3H, J = 6.9 Hz) |
| 156 | K-8 | | O | 12.56 (bs, 1H), 10.46 (s, 1H), 7.97 (d, 2H, J = 8.7 Hz), 7.89 (d, 2H, J = 8.4 Hz), 7.75 (s, 1H), 7.60 (d, 2H, J = 8.4 Hz), 7.36 (d, 2H, J = 8.7 Hz), 2.66 (t, 2H, J = 7.2 Hz), 1.58 - 1.62 (m, 2H), 1.24 - 1.27 (m, 8H), 0.83 - 0.88 (m, 3H) |
| 157 | K-9 | | O | 12.55 (bs, 1H), 10.42 (s, 1H), 7.97 (d, 2H, J = 8.7 Hz), 7.70 - 7.76 (m, 3H), 7.60 (d, 2H, J = 8.7 Hz), 7.30 (d, 2H, J = 8.1 Hz), 2.32 (s, 1H), 2.31 (s, 1H) |
| 158 | K-10 | | O | 12.55 (bs, 1H), 10.75 (s, 1H), 8.17 (d, 2H, J = 8.0 Hz), 7.97 (d, 2H, J = 8.8 Hz), 7.93 (t, 1H, J = 8.0 Hz), 7.76 (s, 1H), 7.63 (d, 2H, J = 8.8 Hz) |

Table 20

| Examp eNo. | Com pound No. | X | T | ¹ H-NMR (δ) ppm (DMSO d-6) |
|---------------|---------------------|---|---|---|
| 159 | K-11 | | O | 12.56 (bs, 1H), 10.47 (s, 1H), 7.97 (d, 2H, J = 9.0 Hz), 7.90 (d, 2H, J = 8.4 Hz), 7.76 (s, 1H), 7.60 (d, 2H, J = 9.0 Hz), 7.57 (d, 2H, J = 8.4 Hz), 1.33 (s, 9H) |
| 160 | K-12 | | O | 12.57 (bs, 1H), 10.69 (s, 1H), 7.99 (d, 2H, J = 2.1 Hz), 7.94 (d, 2H, J = 9.0 Hz), 7.89 (t, 1H, J = 1.8 Hz), 7.76 (s, 1H), 7.63 (d, 2H, J = 9.0 Hz) |
| 161 | K-13 | | O | 12.55 (bs, 1H), 10.46 (s, 1H), 7.97 (d, 2H, J = 8.8 Hz), 7.90 (d, 2H, J = 8.1 Hz), 7.76 (s, 1H), 7.50 (d, 2H, J = 8.8 Hz), 7.38 (d, 2H, J = 8.1 Hz), 2.69 (q, 2H, J = 7.7 Hz), 1.22 (t, 3H, J = 7.7 Hz) |
| 162 | K-14 | | O | 12.59 (bs, 1H), 10.67 (s, 1H), 8.23 (d, 1H, J = 2.1 Hz), 7.95 (d, 1H, J = 8.4 Hz), 7.94 (d, 2H, J = 8.4 Hz), 7.84 (d, 2H, J = 8.4 Hz), 7.76 (s, 1H), 7.62 (d, 1H, J = 9.0 Hz) |
| 163 | K-15 | | O | 12.55 (bs, 1H), 10.45 (s, 1H), 7.97 (d, 2H, J = 8.7 Hz), 7.89 (d, 2H, J = 8.4 Hz), 7.75 (s, 1H), 7.60 (d, 2H, J = 8.7 Hz), 7.35 (d, 1H, J = 8.4 Hz), 2.37 (s, 3H) |
| 164 | K-16 | | S | 13.79 (bs, 1H), 10.53 (s, 1H), 7.98 (d, 2H, J = 8.8 Hz), 7.74 - 7.78 (m, 2H), 7.62 (d, 2H, J = 8.8 Hz), 7.61 (s, 1H), 7.24 - 7.44 (m, 2H), 2.41 (s, 3H) |
| 165 | K-17 | | S | 13.79 (bs, 1H), 10.36 (s, 1H), 7.93 (d, 2H, J = 8.7 Hz), 7.68 (s, 1H), 7.60 (d, 2H, J = 8.7 Hz), 7.59 (d, 1H, J = 6.9 Hz), 5.75 (s, 1H), 1.44 (s, 1H) |
| 166 | K-18 | | S | 10.50 (s, 1H), 7.98 (d, 2H, J = 8.7 Hz), 7.90 (d, 2H, J = 8.7 Hz), 7.61 (d, 2H, J = 8.7 Hz), 7.59 (d, 2H, J = 8.5 Hz), 7.55 (s, 1H), 1.33 (s, 9H) |
| 167 | K-19 | | S | 13.79 (bs, 1H), 10.62 (s, 1H), 8.09 (d, 2H, J = 8.5 Hz), 7.86 (d, 2H, J = 8.5 Hz), 7.77 (d, 2H, J = 8.5 Hz), 7.63 (d, 2H, J = 8.5 Hz), 7.62 (s, 1H), 7.50 - 7.55 (m, 2H), 7.41 - 7.46 (m, 1H) |
| 168 | K-20 | | S | 13.81 (bs, 1H), 10.77 (s, 1H), 8.61 (s, 1H), 8.02 - 8.13 (m, 6H), 7.63 - 7.68 (m, 5H) |

Table 21









| Example No. | Compound No. | X | T | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|---|---|---|
| 169 | K-21 |  | S | 13.79 (bs, 1H), 10.39 (s, 1H), 7.97 (d, 2H, J = 8.8 Hz), 7.61 (s, 1H), 7.60 (d, 2H, J = 8.8 Hz), 7.59 (d, 1H, J = 9.9 Hz), 7.53 (d, 1H, J = 1.8 Hz), 7.07 (d, 1H, J = 8.2 Hz), 6.15 (s, 2H) |
| 170 | K-22 |  | S | 13.79 (s, 1H), 10.49 (s, 1H), 7.99 (d, 2H, J = 8.8 Hz), 7.91 (d, 2H, J = 8.2 Hz), 7.61 (d, 2H, J = 8.8 Hz), 7.61 (s, 1H), 7.38 (d, 2H, J = 8.2 Hz), 2.70 (q, 2H, J = 7.4 Hz), 1.22 (t, 3H, J = 7.4 Hz) |
| 171 | K-23 |  | S | 13.79 (bs, 1H), 10.49 (s, 1H), 7.99 (d, 2H, J = 8.8 Hz), 7.89 (d, 2H, J = 8.2 Hz), 7.61 (d, 2H, J = 8.8 Hz), 7.61 (s, 1H), 7.37 (d, 2H, J = 8.2 Hz), 2.37 (t, 2H, J = 7.4 Hz), 1.57 - 1.64 (m, 2H), 1.26 - 1.38 (m, 2H), 0.91 (t, 3H, J = 7.1 Hz) |
| 172 | K-24 |  | S | 13.80 (bs, 1H), 10.79 (s, 1H), 8.17 (d, 2H, J = 8.4 Hz), 7.99 (d, 2H, J = 8.7 Hz), 7.94 (d, 2H, J = 8.4 Hz), 7.64 (d, 1H, J = 8.7 Hz), 7.65 (s, 1H) |
| 173 | K-25 |  | S | 13.80 (bs, 1H), 10.71 (s, 1H), 7.99 (d, 2H, J = 1.6 Hz), 7.95 (d, 2H, J = 8.5 Hz), 7.89 (t, 1H, J = 1.9 Hz), 7.63 (d, 2H, J = 8.5 Hz), 7.61 (s, 1H) |
| 174 | K-26 |  | S | 13.78 (bs, 1H), 10.48 (s, 1H), 7.98 (d, 2H, J = 9.0 Hz), 7.89 (d, 2H, J = 8.1 Hz), 7.61 (d, 2H, J = 9.0 Hz), 7.61 (s, 1H), 7.36 (d, 2H, J = 8.1 Hz), 2.40 (s, 3H) |

Table 22



| Example No. | Compound No. | X | T | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|---|---|--|
| 175 | K-27 | | O | 12.57 (bs, 1H), 10.88 (s, 1H), 8.53 (s, 1H), 8.15 - 8.19 (m, 2H), 8.07 (d, 2H, J = 8.8 Hz), 7.78 (s, 1H), 7.65 (d, 2H, J = 8.8 Hz), 7.50 - 7.55 (m, 2H), 7.40 - 7.45 (m, 1H) |
| 176 | K-28 | | O | 12.58 (bs, 1H), 10.91 (s, 1H), 8.69 (s, 1H), 8.48 (d, 1H, J = 1.9 Hz), 8.15 (dd, 1H, J = 8.8 Hz, 1.9 Hz), 8.04 (d, 2H, J = 8.8 Hz), 7.78 (d, 1H, J = 8.8 Hz), 7.76 (s, 1H), 7.64 (d, 1H, J = 8.8 Hz) |
| 177 | K-29 | | S | 13.82 (bs, 1H), 10.95 (s, 1H), 8.72 (s, 1H), 8.50 (d, 1H, J = 1.9 Hz), 8.16 (dd, 1H, J = 8.5 Hz, 1.9 Hz), 8.08 (d, 2H, J = 8.8 Hz), 7.80 (d, 1H, J = 8.5 Hz), 7.67 (d, 1H, J = 8.8 Hz), 7.63 (s, 1H) |

Example 178



(Process 1)

To a solution of the compound (13)(1.7 g) synthesized in Example 149-Process 1 in dioxane (200 ml) was added 10% palladium-carbon (0.7 g) and the reaction mixture was stirred under hydrogen atmosphere. Filtration of palladium-carbon and evaporation of the solvent under reduced pressure obtained 1.39 g of the compound (15).

¹H NMR (CDCl₃, δ ppm): 8.38 (s, 1H), 7.32 (d, 2H, J = 8.4 Hz), 7.26 (s, 1H), 7.15 (d, 2H, J = 8.4 Hz), 6.54 (s, 1H), 4.50 (dd, 1H, J = 9.3 Hz, 3.9 Hz), 3.46 (dd, 1H, J = 14.4 Hz, 3.9 Hz), 3.22 (dd, 1H, J = 14.4 Hz, 9.3 Hz), 1.52 (s, 9H).

(Process 2)

A solution of the compound (15)(4.23 g) in dichloromethane (20 ml) and trifluoroacetic acid (10 ml) was stirred at room temperature for 15 min. After evaporation of the solvent under reduced pressure, the residue was recrystallized from diisopropyl ether to give 3.8 g of the compound (16).

¹H NMR(DMSO-d₆, δ ppm) 7.25 (d, 2H, J = 8.4 Hz), 7.09 (d, 2H, J = 8.4 Hz), 4.90 (dd, 1H, J = 8.7 Hz, 4.5 Hz), 4.35 (dd, 1H, J = 14.4 Hz, 4.5 Hz), 3.12 (dd, 1H, J = 14.4 Hz, 8.7 Hz).


(Process 3)

To a solution of the compound (16)(220 mg) in dioxane (50 ml) were added pyridine (121 μ l) and 3,5-dichlorobenzoyl chloride (180 μ l) and then the reaction solution was stirred at room temperature for 3 hours. After evaporation of the solvent under reduced pressure, the residue was purified with a column chromatography (hexane-ethyl acetate ; 2:1) to yield 103 mg of the compound (L-1).

^1H NMR(DMSO- d_6 , δ ppm) 12.02 (bs, 1H), 10.41 (s, 1H), 7.97 (d, 2H, J = 1.9 Hz), 7.87 (t, 1H, J = 1.9 Hz), 7.69 (d, 2H, J = 8.5 Hz), 7.24 (d, 2H, J = 8.5 Hz), 4.91 (dd, 1H, J = 8.8 Hz, 4.4 Hz), 3.36 (dd, 1H, J = 14.3 Hz, 4.4 Hz), 3.12 (dd, 1H, J = 14.3 Hz, 8.8 Hz)


Compound (L-2) to Compound (L-3) were synthesized in a manner similar to above-mentioned method. Their physical data were shown in Table 23.

Table 23



| Example No. | Compound No. | X | T | ¹ H-NMR (δ) ppm (DMSO d-6) |
|-------------|--------------|---|---|---|
| 179 | L-2 | | O | 12.04 (bs, 1H), 10.47 (s, 1H), 8.14 (d, 2H, J = 8.2 Hz), 7.92 (d, 2H, J = 8.2 Hz), 7.72 (d, 2H, J = 8.5 Hz), 7.25 (d, 2H, J = 8.5 Hz), 4.92 (dd, 1H, J = 8.9 Hz, 4.4 Hz), 3.36 (dd, 1H, J = 14.4 Hz, 4.4 Hz), 3.12 (dd, 1H, J = 14.4 Hz, 8.9 Hz) |
| 180 | L-3 | | O | 12.05 (bs, 1H), 10.56 (s, 1H), 7.86 (d, 2H, J = 8.4 Hz), 7.71 (d, 2H, J = 8.7 Hz), 7.34 (d, 2H, J = 8.7 Hz), 7.22 (d, 2H, J = 8.4 Hz), 4.91 (dd, 1H, J = 9.0 Hz, 4.5 Hz), 3.34 (dd, 1H, J = 13.8 Hz, 4.5 Hz), 3.10 (dd, 1H, J = 13.8 Hz, 9.0 Hz), 2.66 (t, 2H, J = 7.5 Hz), 1.58 (quant, 2H, J = 8.1 Hz), 1.26 - 1.37 (m, 2H), 0.91 (t, 3H, J = 7.5 Hz) |

Example 181




(Process 1)

5 A mixture of the compound (3)(3 g) prepared in Example 1-Process 2 in dioxane (20 ml) and thionyl chloride (10 ml) was heated and dissolved at 100°C. Evaporation of the solvent under reduced pressure gave carboxylic acid chloride. The carboxylic acid chloride was not purified and used in further reactions. After a solution of the carboxylic acid chloride (143 mg),
10 ammonium thiocyanate (42 mg) in dioxane (25 ml) was stirred at room temperature for 15 min, 3,4-dichloroaniline was added thereto. The reaction solution was stirred at room temperature for 1 hour and the solvent was evaporated under reduced pressure. To the residue were added methanol (6 ml) and water (2 ml) and the precipitated crystal was filtrated.
15 Recrystallization from DMF obtained 104 mg of the compound (M-1).

¹H NMR (DMSO-d₆, δ ppm): 13.91 (bs, 1H), 12.49 (s, 1H), 11.83 (s, 1H), 8.07 - 8.12 (m, 3H), 7.63 - 7.76 (m, 5H).

The following compound was synthesized in a manner similar to
20 above-mentioned method.



Abbreviation described below are used.

Me:methyl, Et:ethyl, nPr:n-propyl, iPr:isobutyl, nBu:n-butyl, iBu:isobutyl, tBu:t-butyl, Pen:n-pentyl, Ph:phenyl, Bn:benzyl, Bz:benzoyl, Ac:acetyl,

5 diF:difluoro, diCl:dichloro, diBr:dibromo, diI:diiodo, diMe:dimethyl, thiophene:thiophene, thienyl:thienyl, Py:pyridil, pyridine:pyridine, pyridinium: pyridinium, Quinoline: Quinoline, Benzodioxole: Benzodioxole, pyrazinyl: pyrazinyl, pyrrolyl: pyrrolyl, pyrrole: pyrrole, oxide: oxide, indole: indole, imidazolyl: imidazolyl, morpholino: morpholino, piperazinyl:

10 piperazinyl, furyl: furyl, furan: furan, thiazolyl: thiazolyl, benzodioxin: benzodioxin, and benzo[b]furan:benzo[b]furan

(Compound No: R⁶, R⁷, M, T) = (N-1: Ph, Me, S, S), (N-3: 4-Br-Ph, Me, S, S), (N-4: 4-Me-Ph, Me, S, S), (N-5: 4-Ph-Ph, Me, S, S), (N-6: 4-OMe-Ph, Me, S, S), (N-7: 4-tBu-Ph, Me, S, S), (N-8: 4-COOMe-Ph, Me, S, S), (N-9: 4-Pen-Ph, Me, S, S),
15 S), (N-10: 4-NO₂-Ph, Me, S, S), (N-11: 5-Cl-thiophene-2-yl, Me, S, S), (N-12: 3-Thienyl, Me, S, S), (N-13: 2-Py, Me, S, S), (N-14: 3-Py, Me, S, S), (N-15: 4-Py, Me, S, S), (N-16: 3,4-diF-Ph, Me, S, S), (N-17: 5-Br-thiophene-2-yl, Me, S, S), (N-18: 4-CONH₂-Ph, Me, S, S), (N-19: 4-CON(Me)H-Ph, Me, S, S), (N-20: 4-CON(Me)₂-Ph, Me, S, S), (N-21: 4-iPrOC(=O)-Ph, Me, S, S), (N-22: 4-nBuOC(=O)-Ph, Me, S, S), (N-23: 6-Me-pyridine-3-yl, Me, S, S), (N-24: Quinoline-3-yl, Me, S, S), (N-25: 4-NH₂-Ph, Me, S, S), (N-26: 4-N(Ac)H-Ph, Me, S, S), (N-27: 4-OH-Ph, Me, S, S), (N-28: 3,4-di(OH)₂-Ph, Me, S, S), (N-29: 3,4-di(NH₂)-Ph, Me, S, S), (N-30: 3:4-[N(Ac)H]₂-Ph, Me, S, S), (N-31: 4-SH-Ph, Me, S, S), (N-32: 4-SMe-Ph, Me, S, S), (N-33: 3,4-diBr-Ph, Me, S, S), (N-34: 4-N(Me)H-Ph, Me, S, S), (N-35: 4-N(Me)₂-Ph, Me, S, S), (N-36: 4-N(Me)₃⁺-Ph, Me, S, S), (N-37: 4-Et-Ph, Me, S, S), (N-38: 4-iPr-Ph, Me, S, S), (N-39: 4-nPr-Ph, Me, S, S), (N-40: 4-nBu-Ph, Me, S, S), (N-41: 4-iBu-Ph, Me, S, S), (N-42: 3,4-

- diMe-Ph, Me, S, S), (N-43: 1,3-Benzodioxole-5-yl, Me, S, S), (N-44: N-Me-pyridinium-4-yl, Me, S, S), (N-45: N-Me-pyridinium-3-yl, Me, S, S), (N-46: 5-Me-Pyridine-2-yl, Me, S, S), (N-47: 2-Pyrazinyl, Me, S, S), (N-48: 3-Pyrrolyl, Me, S, S), (N-49: 1-Me-pyrrole-3-yl, Me, S, S), (N-50: Pyridine N-oxide-4-yl, Me, S, S), (N-51: Pyridine N-oxide-3-yl, Me, S, S), (N-52: 6-OH-pyridine-3-yl, Me, S, S), (N-53: 6-SH-pyridine-3-yl, Me, S, S), (N-54: 1-Ac-pyrrole-3-yl, Me, S, S), (N-55: 4-CF₃-Ph, Me, S, S), (N-56: 4-CN-Ph, Me, S, S), (N-57: 4-CHO-Ph, Me, S, S), (N-58: 3-Cl-Ph, Me, S, S), (N-59: 3-Br-Ph, Me, S, S), (N-60: 3-F-Ph, Me, S, S), (N-61: 3-I-Ph, Me, S, S), (N-62: 4-I-Ph, Me, S, S), (N-63: 4-OCF₃-Ph, Me, S, S), (N-64: 3,4-diI-Ph, Me, S, S), (N-65: Indole-6-yl, Me, S, S), (N-66: 1-Ac-indole-6-yl, Me, S, S), (N-67: 1-Me-indole-6-yl, Me, S, S), (N-68: 4-(1-Imidazolyl)-Ph, Me, S, S), (N-69: 4-Morpholino-Ph, Me, S, S), (N-70: 4-(1-Piperazinyl)-Ph, Me, S, S), (N-71: 2:5-diMe-thiophene-3-yl, Me, S, S), (N-72: 2-Furyl, Me, S, S), (N-73: 5-Me-furan-2-yl, Me, S, S), (N-74: 5-Me-furan-2-yl, Me, S, S), (N-75: 2-Thiazolyl, Me, S, S), (N-76: 1:4-Benzodioxin-6-yl, Me, S, S), (N-77: Benzo[b]furan-2-yl, Me, S, S), (N-78: 4-NH₂CH₂-Ph, Me, S, S), (N-79: 4-N(Me)HCH₂-Ph, Me, S, S), (N-80: 4-N(Me)₂CH₂-Ph, Me, S, S), (N-81: 6-Cl-pyridine-3-yl, Me, S, S), (N-82: 5,6-diCl-pyridine-3-yl, Me, S, S), (N-83: 5-Cl-pyridine-2-yl, Me, S, S), (N-84: 4:5-diCl-pyridine-2-yl, Me, S, S), (N-85: 4-ClCH₂-Bn, Me, S, S), (N-86: Bn, Me, S, S), (N-87: 4-Cl-Bn, Me, S, S), (N-88: 4-Br-Bn, Me, S, S), (N-89: 4-F-Bn, Me, S, S), (N-90: 3,4-diCl-Bn, Me, S, S), (N-91: 3,4-diBr-Bn, Me, S, S), (N-92: 3,4-diF-Bn, Me, S, S), (N-93: 4-Cl-Bz, Me, S, S), (N-94: 3,4-diCl-Bz, Me, S, S), (N-95: 4-Br-Bz, Me, S, S), (N-96: 3,4-diBr-Bz, Me, S, S), (N-97: 4-F-Bz, Me, S, S), (N-98: 3,4-diF-Bz, Me, S, S), (N-99: 4-NO₂-Bn, Me, S, S), (N-100: 4-CN-Bn, Me, S, S), (N-101: Ph, Et, S, S), (N-102: 4-F-Ph, Et, S, S), (N-103: 4-Br-Ph, Et, S, S), (N-104: 4-Me-Ph, Et, S, S), (N-105: 4-Ph-Ph, Et, S, S), (N-106: 4-OMe-Ph, Et, S, S), (N-107: 4-tBu-Ph, Et,

- S, S), (N-108: 4-COOMe-Ph, Et, S, S), (N-109: 4-Pen-Ph, Et, S, S), (N-110: 4-NO₂-Ph, Et, S, S), (N-111: 5-Cl-thiophene-2-yl, Et, S, S), (N-112: 3-Thienyl, Et, S, S), (N-113: 2-Py, Et, S, S), (N-114: 3-Py, Et, S, S), (N-115: 4-Py, Et, S, S), (N-116: 3,4-diF-Ph, Et, S, S), (N-117: 5-Br-thiophene-2-yl, Et, S, S), (N-118: 4-CONH₂-Ph, Et, S, S), (N-119: 4-CON(Me)H-Ph, Et, S, S), (N-120: 4-CON(Me)₂-Ph, Et, S, S), (N-121: 4-iPrOC(=O)-Ph, Et, S, S), (N-122: 4-nBuOC(=O)-Ph, Et, S, S), (N-123: 6-Me-pyridine-3-yl, Et, S, S), (N-124: Quinoline-3-yl, Et, S, S), (N-125: 4-NH₂-Ph, Et, S, S), (N-126: 4-N(Ac)H-Ph, Et, S, S), (N-127: 4-OH-Ph, Et, S, S), (N-128: 3,4-di(OH)₂-Ph, Et, S, S), (N-129: 3,4-di(NH₂)-Ph, Et, S, S), (N-130: 3,4-[N(Ac)H]₂-Ph, Et, S, S), (N-131: 4-SH-Ph, Et, S, S), (N-132: 4-SMe-Ph, Et, S, S), (N-133: 3,4-diBr-Ph, Et, S, S), (N-134: 4-N(Me)H-Ph, Et, S, S), (N-135: 4-N(Me)₂-Ph, Et, S, S), (N-136: 4-N(Me)₃⁺-Ph, Et, S, S), (N-137: 4-Et-Ph, Et, S, S), (N-138: 4-iPr-Ph, Et, S, S), (N-139: 4-nPr-Ph, Et, S, S), (N-140: 4-nBu-Ph, Et, S, S), (N-141: 4-iBu-Ph, Et, S, S), (N-142: 3,4-diMe-Ph, Et, S, S), (N-143: 1,3-Benzodioxole-5-yl, Et, S, S), (N-144: N-Me-pyridinium-4-yl, Et, S, S), (N-145: N-Me-pyridinium-3-yl, Et, S, S), (N-146: 5-Me-Pyridine-2-yl, Et, S, S), (N-147: 2-Pyrazinyl, Et, S, S), (N-148: 3-Pyrrolyl, Et, S, S), (N-149: 1-Me-pyrrole-3-yl, Et, S, S), (N-150: Pyridine N-oxide-4-yl, Et, S, S), (N-151: Pyridine N-oxide-3-yl, Et, S, S), (N-152: 6-OH-pyridine-3-yl, Et, S, S), (N-153: 6-SH-pyridine-3-yl, Et, S, S), (N-154: 1-Ac-pyrrole-3-yl, Et, S, S), (N-155: 4-CF₃-Ph, Et, S, S), (N-156: 4-CN-Ph, Et, S, S), (N-157: 4-CHO-Ph, Et, S, S), (N-158: 3-Cl-Ph, Et, S, S), (N-159: 3-Br-Ph, Et, S, S), (N-160: 3-F-Ph, Et, S, S), (N-161: 3-I-Ph, Et, S, S), (N-162: 4-I-Ph, Et, S, S), (N-163: 4-OCF₃-Ph, Et, S, S), (N-164: 3,4-diI-Ph, Et, S, S), (N-165: Indole-6-yl, Et, S, S), (N-166: 1-Ac-indole-6-yl, Et, S, S), (N-167: 1-Me-indole-6-yl, Et, S, S), (N-168: 4-(1-Imidazolyl)-Ph, Et, S, S), (N-169: 4-Morphorino-Ph, Et, S, S), (N-170: 4-(1-Piperazinyl)-Ph, Et, S, S), (N-171: 2:5-diMe-thiophene-3-yl, Et, S,

- S), (N-172: 2-Furyl, Et, S, S), (N-173: 5-Me-furan-2-yl, Et, S, S), (N-174: 5-Me-furan-2-yl, Et, S, S), (N-175: 2-Thiazolyl, Et, S, S), (N-176: 1:4-Benzodioxin-6-yl, Et, S, S), (N-177: Benzo[b]furan-2-yl, Et, S, S), (N-178: 4-NH₂CH₂-Ph, Et, S, S), (N-179: 4-N(Me)HCH₂-Ph, Et, S, S), (N-180: 4-N(Me)₂CH₂-Ph, Et, S, S), (N-181: 6-Cl-pyridine-3-yl, Et, S, S), (N-182: 5,6-diCl-pyridine-3-yl, Et, S, S), (N-183: 5-Cl-pyridine-2-yl, Et, S, S), (N-184: 4:5-diCl-pyridine-2-yl, Et, S, S), (N-185: 4-ClCH₂-Bn, Et, S, S), (N-186: Bn, Et, S, S), (N-187: 4-Cl-Bn, Et, S, S), (N-188: 4-Br-Bn, Et, S, S), (N-189: 4-F-Bn, Et, S, S), (N-190: 3,4-diCl-Bn, Et, S, S), (N-191: 3,4-diBr-Bn, Et, S, S), (N-192: 3,4-diF-Bn, Et, S, S), (N-193: 4-Cl-Bz, Et, S, S), (N-194: 3,4-diCl-Bz, Et, S, S), (N-195: 4-Br-Bz, Et, S, S), (N-196: 3,4-diBr-Bz, Et, S, S), (N-197: 4-F-Bz, Et, S, S), (N-198: 3,4-diF-Bz, Et, S, S), (N-199: 4-NO₂-Bn, Et, S, S), (N-200: 4-CN-Bn, Et, S, S), (N-201: Ph, COOMe, S, S), (N-203: 4-Br-Ph, COOMe, S, S), (N-204: 4-Me-Ph, COOMe, S, S), (N-205: 4-Ph-Ph, COOMe, S, S), (N-206: 4-OMe-Ph, COOMe, S, S), (N-207: 4-tBu-Ph, COOMe, S, S), (N-208: 4-COOMe-Ph, COOMe, S, S), (N-209: 4-Pen-Ph, COOMe, S, S), (N-210: 4-NO₂-Ph, COOMe, S, S), (N-211: 5-Cl-thiophene-2-yl, COOMe, S, S), (N-212: 3-Thienyl, COOMe, S, S), (N-213: 2-Py, COOMe, S, S), (N-214: 3-Py, COOMe, S, S), (N-215: 4-Py, COOMe, S, S), (N-216: 3,4-diF-Ph, COOMe, S, S), (N-217: 5-Br-thiophene-2-yl, COOMe, S, S), (N-218: 4-CONH₂-Ph, COOMe, S, S), (N-219: 4-CON(Me)H-Ph, COOMe, S, S), (N-220: 4-CON(Me)₂-Ph, COOMe, S, S), (N-221: 4-iPrOC(=O)-Ph, COOMe, S, S), (N-222: 4-nBuOC(=O)-Ph, COOMe, S, S), (N-223: 6-Me-pyridine-3-yl, COOMe, S, S), (N-224: Quinoline-3-yl, COOMe, S, S), (N-225: 4-NH₂-Ph, COOMe, S, S), (N-226: 4-N(Ac)H-Ph, COOMe, S, S), (N-227: 4-OH-Ph, COOMe, S, S), (N-228: 3,4-di(OH)₂-Ph, COOMe, S, S), (N-229: 3,4-di(NH₂)-Ph, COOMe, S, S), (N-230: 3:4-[N(Ac)H]₂-Ph, COOMe, S, S), (N-231: 4-SH-Ph, COOMe, S, S), (N-232: 4-SMe-Ph, COOMe, S, S), (N-233: 3,4-diBr-Ph,

- COOMe, S, S), (N-234: 4-N(Me)H-Ph, COOMe, S, S), (N-235: 4-N(Me)₂-Ph, COOMe, S, S), (N-236: 4-N(Me)₃⁺-Ph, COOMe, S, S), (N-237: 4-Et-Ph, COOMe, S, S), (N-238: 4-iPr-Ph, COOMe, S, S), (N-239: 4-nPr-Ph, COOMe, S, S), (N-240: 4-nBu-Ph, COOMe, S, S), (N-241: 4-iBu-Ph, COOMe, S, S), (N-242: 3,4-diMe-Ph, COOMe, S, S), (N-243: 1,3-Benzodioxole-5-yl, COOMe, S, S), (N-244: N-Me-pyridinium-4-yl, COOMe, S, S), (N-245: N-Me-pyridinium-3-yl, COOMe, S, S), (N-246: 5-Me-Pyridine-2-yl, COOMe, S, S), (N-247: 2-Pyrazinyl, COOMe, S, S), (N-248: 3-Pyrrolyl, COOMe, S, S), (N-249: 1-Me-pyrrole-3-yl, COOMe, S, S), (N-250: Pyridine N-oxide-4-yl, COOMe, S, S), (N-251: Pyridine N-oxide-3-yl, COOMe, S, S), (N-252: 6-OH-pyridine-3-yl, COOMe, S, S), (N-253: 6-SH-pyridine-3-yl, COOMe, S, S), (N-254: 1-Ac-pyrrole-3-yl, COOMe, S, S), (N-255: 4-CF₃-Ph, COOMe, S, S), (N-256: 4-CN-Ph, COOMe, S, S), (N-257: 4-CHO-Ph, COOMe, S, S), (N-258: 3-Cl-Ph, COOMe, S, S), (N-259: 3-Br-Ph, COOMe, S, S), (N-260: 3-F-Ph, COOMe, S, S), (N-261: 3-I-Ph, COOMe, S, S), (N-262: 4-I-Ph, COOMe, S, S), (N-263: 4-OCF₃-Ph, COOMe, S, S), (N-264: 3,4-diI-Ph, COOMe, S, S), (N-265: Indole-6-yl, COOMe, S, S), (N-266: 1-Ac-indole-6-yl, COOMe, S, S), (N-267: 1-Me-indole-6-yl, COOMe, S, S), (N-268: 4-(1-Imidazolyl)-Ph, COOMe, S, S), (N-269: 4-Morpholino-Ph, COOMe, S, S), (N-270: 4-(1-Piperazinyl)-Ph, COOMe, S, S), (N-271: 2:5-diMe-thiophene-3-yl, COOMe, S, S), (N-272: 2-Furyl, COOMe, S, S), (N-273: 5-Me-furan-2-yl, COOMe, S, S), (N-274: 5-Me-furan-2-yl, COOMe, S, S), (N-275: 2-Thiazolyl, COOMe, S, S), (N-276: 1:4-Benzodioxin-6-yl, COOMe, S, S), (N-277: Benzo[b]furan-2-yl, COOMe, S, S), (N-278: 4-NH₂CH₂-Ph, COOMe, S, S), (N-279: 4-N(Me)HCH₂-Ph, COOMe, S, S), (N-280: 4-N(Me)₂CH₂-Ph, COOMe, S, S), (N-281: 6-Cl-pyridine-3-yl, COOMe, S, S), (N-282: 5,6-diCl-pyridine-3-yl, COOMe, S, S), (N-283: 5-Cl-pyridine-2-yl, COOMe, S, S), (N-284: 4:5-diCl-pyridine-2-yl, COOMe, S, S), (N-285: 4-ClCH₂-Bn, COOMe, S, S), (N-286: Bn, COOMe, S, S),

- (N-287: 4-Cl-Bn, COOMe, S, S), (N-288: 4-Br-Bn, COOMe, S, S), (N-289: 4-F-Bn, COOMe, S, S), (N-290: 3,4-diCl-Bn, COOMe, S, S), (N-291: 3,4-diBr-Bn, COOMe, S, S), (N-292: 3,4-diF-Bn, COOMe, S, S), (N-293: 4-Cl-Bz, COOMe, S, S), (N-294: 3,4-diCl-Bz, COOMe, S, S), (N-295: 4-Br-Bz, COOMe, S, S), (N-296: 3,4-diBr-Bz, COOMe, S, S), (N-297: 4-F-Bz, COOMe, S, S), (N-298: 3,4-diF-Bz, COOMe, S, S), (N-299: 4-NO₂-Bn, COOMe, S, S), (N-300: 4-CN-Bn, COOMe, S, S), (N-302: H, 4-F-Ph, S, S), (N-303: H, 4-Br-Ph, S, S), (N-304: H, 4-Me-Ph, S, S), (N-305: H, 4-Ph-Ph, S, S), (N-306: H, 4-OMe-Ph, S, S), (N-307: H, 4-tBu-Ph, S, S), (N-308: H, 4-COOMe-Ph, S, S), (N-309: H, 4-Pen-Ph, S, S), (N-310: H, 4-NO₂-Ph, S, S), (N-311: H, 5-Cl-thiophene-2-yl, S, S), (N-312: H, 3-Thienyl, S, S), (N-313: H, 2-Py, S, S), (N-314: H, 3-Py, S, S), (N-315: H, 4-Py, S, S), (N-316: H, 3,4-diF-Ph, S, S), (N-317: H, 5-Br-thiophene-2-yl, S, S), (N-318: H, 4-CONH₂-Ph, S, S), (N-319: H, 4-CON(Me)H-Ph, S, S), (N-320: H, 4-CON(Me)₂-Ph, S, S), (N-321: H, 4-iPrOC(=O)-Ph, S, S), (N-322: H, 4-nBuOC(=O)-Ph, S, S), (N-323: H, 6-Me-pyridine-3-yl, S, S), (N-324: H, Quinoline-3-yl, S, S), (N-325: H, 4-NH₂-Ph, S, S), (N-326: H, 4-N(Ac)H-Ph, S, S), (N-327: H, 4-OH-Ph, S, S), (N-328: H, 3,4-di(OH)₂-Ph, S, S), (N-329: H, 3,4-di(NH₂)-Ph, S, S), (N-330: H, 3:4-[N(Ac)H]₂-Ph, S, S), (N-331: H, 4-SH-Ph, S, S), (N-332: H, 4-SMe-Ph, S, S), (N-333: H, 3,4-diBr-Ph, S, S), (N-334: H, 4-N(Me)H-Ph, S, S), (N-335: H, 4-N(Me)₂-Ph, S, S), (N-336: H, 4-N(Me)₃⁺-Ph, S, S), (N-337: H, 4-Et-Ph, S, S), (N-338: H, 4-iPr-Ph, S, S), (N-339: H, 4-nPr-Ph, S, S), (N-340: H, 4-nBu-Ph, S, S), (N-341: H, 4-iBu-Ph, S, S), (N-342: H, 3,4-diMe-Ph, S, S), (N-343: H, 1,3-Benzodioxole-5-yl, S, S), (N-344: H, N-Me-pyridinium-4-yl, S, S), (N-345: H, N-Me-pyridinium-3-yl, S, S), (N-346: H, 5-Me-Pyridine-2-yl, S, S), (N-347: H, 2-Pyrazinyl, S, S), (N-348: H, 3-Pyrrolyl, S, S), (N-349: H, 1-Me-pyrrole-3-yl, S, S), (N-350: H, Pyridine N-oxide-4-yl, S, S), (N-351: H, Pyridine N-oxide-3-yl, S, S), (N-352: H, 6-OH-pyridine-3-yl, S, S), (N-353: H, 6-SH-pyridine-3-yl, S, S),

- (N-354: H, 1-Ac-pyrrole-3-yl, S, S), (N-355: H, 4-CF₃-Ph, S, S), (N-356: H, 4-CN-Ph, S, S), (N-357: H, 4-CHO-Ph, S, S), (N-358: H, 3-Cl-Ph, S, S), (N-359: H, 3-Br-Ph, S, S), (N-360: H, 3-F-Ph, S, S), (N-361: H, 3-I-Ph, S, S), (N-362: H, 4-I-Ph, S, S), (N-363: H, 4-OCF₃-Ph, S, S), (N-364: H, 3,4-diI-Ph, S, S), (N-365: H, Indole-6-yl, S, S), (N-366: H, 1-Ac-indole-6-yl, S, S), (N-367: H, 1-Me-indole-6-yl, S, S), (N-368: H, 4-(1-Imidazolyl)-Ph, S, S), (N-369: H, 4-Morpholino-Ph, S, S), (N-370: H, 4-(1-Piperazinyl)-Ph, S, S), (N-371: H, 2:5-diMe-thiophene-3-yl, S, S), (N-372: H, 2-Furyl, S, S), (N-373: H, 5-Me-furan-2-yl, S, S), (N-374: H, 5-Me-furan-2-yl, S, S), (N-375: H, 2-Thiazolyl, S, S),
- 10 (N-376: H, 1:4-Benzodioxin-6-yl, S, S), (N-377: H, Benzo[b]furan-2-yl, S, S), (N-378: H, 4-NH₂CH₂-Ph, S, S), (N-379: H, 4-N(Me)HCH₂-Ph, S, S), (N-380: H, 4-N(Me)₂CH₂-Ph, S, S), (N-381: H, 6-Cl-pyridine-3-yl, S, S), (N-382: H, 5,6-diCl-pyridine-3-yl, S, S), (N-383: H, 5-Cl-pyridine-2-yl, S, S), (N-384: H, 4:5-diCl-pyridine-2-yl, S, S), (N-385: H, 4-ClCH₂-Bn, S, S), (N-386: H, Bn, S, S),
- 15 (N-387: H, 4-Cl-Bn, S, S), (N-388: H, 4-Br-Bn, S, S), (N-389: H, 4-F-Bn, S, S), (N-390: H, 3,4-diCl-Bn, S, S), (N-391: H, 3,4-diBr-Bn, S, S), (N-392: H, 3,4-diF-Bn, S, S), (N-393: H, 4-Cl-Bz, S, S), (N-394: H, 3,4-diCl-Bz, S, S), (N-395: H, 4-Br-Bz, S, S), (N-396: H, 3,4-diBr-Bz, S, S), (N-397: H, 4-F-Bz, S, S), (N-398: H, 3,4-diF-Bz, S, S), (N-399: H, 4-NO₂-Bn, S, S), (N-400: H, 4-CN-Bn, S, S),
- 20 (N-401: Me, Ph, S, S), (N-402: Me, 4-F-Ph, S, S), (N-403: Me, 4-Br-Ph, S, S), (N-404: Me, 4-Me-Ph, S, S), (N-405: Me, 4-Ph-Ph, S, S), (N-406: Me, 4-OMe-Ph, S, S), (N-407: Me, 4-tBu-Ph, S, S), (N-408: Me, 4-COOMe-Ph, S, S), (N-409: Me, 4-Pen-Ph, S, S), (N-410: Me, 4-NO₂-Ph, S, S), (N-411: Me, 5-Cl-thiophene-2-yl, S, S), (N-412: Me, 3-Thienyl, S, S), (N-413: Me, 2-Py, S, S), (N-414: Me, 3-Py, S, S),
- 25 S), (N-415: Me, 4-Py, S, S), (N-416: Me, 3,4-diF-Ph, S, S), (N-417: Me, 5-Br-thiophene-2-yl, S, S), (N-418: Me, 4-CONH₂-Ph, S, S), (N-419: Me, 4-CON(Me)H-Ph, S, S), (N-420: Me, 4-CON(Me)₂-Ph, S, S), (N-421: Me, 4-

- iPrOC(=O)-Ph, S, S), (N-422: Me, 4-nBuOC(=O)-Ph, S, S), (N-423: Me, 6-Me-pyridine-3-yl, S, S), (N-424: Me, Quinoline-3-yl, S, S), (N-425: Me, 4-NH₂-Ph, S, S), (N-426: Me, 4-N(Ac)H-Ph, S, S), (N-427: Me, 4-OH-Ph, S, S), (N-428: Me, 3,4-di(OH)₂-Ph, S, S), (N-429: Me, 3,4-di(NH₂)-Ph, S, S), (N-430: Me, 3:4-
- 5 [N(Ac)H]₂-Ph, S, S), (N-431: Me, 4-SH-Ph, S, S), (N-432: Me, 4-SMe-Ph, S, S), (N-433: Me, 3,4-diBr-Ph, S, S), (N-434: Me, 4-N(Me)H-Ph, S, S), (N-435: Me, 4-N(Me)₂-Ph, S, S), (N-436: Me, 4-N(Me)₃⁺-Ph, S, S), (N-437: Me, 4-Et-Ph, S, S), (N-438: Me, 4-iPr-Ph, S, S), (N-439: Me, 4-nPr-Ph, S, S), (N-440: Me, 4-nBu-Ph, S, S), (N-441: Me, 4-iBu-Ph, S, S), (N-442: Me, 3,4-diMe-Ph, S, S), (N-443: Me,
- 10 1,3-Benzodioxole-5-yl, S, S), (N-444: Me, N-Me-pyridinium-4-yl, S, S), (N-445: Me, N-Me-pyridinium-3-yl, S, S), (N-446: Me, 5-Me-Pyridine-2-yl, S, S), (N-447: Me, 2-Pyrazinyl, S, S), (N-448: Me, 3-Pyrrolyl, S, S), (N-449: Me, 1-Me-pyrrole-3-yl, S, S), (N-450: Me, Pyridine N-oxide-4-yl, S, S), (N-451: Me, Pyridine N-oxide-3-yl, S, S), (N-452: Me, 6-OH-pyridine-3-yl, S, S), (N-453: Me,
- 15 6-SH-pyridine-3-yl, S, S), (N-454: Me, 1-Ac-pyrrole-3-yl, S, S), (N-455: Me, 4-CF₃-Ph, S, S), (N-456: Me, 4-CN-Ph, S, S), (N-457: Me, 4-CHO-Ph, S, S), (N-458: Me, 3-Cl-Ph, S, S), (N-459: Me, 3-Br-Ph, S, S), (N-460: Me, 3-F-Ph, S, S), (N-461: Me, 3-I-Ph, S, S), (N-462: Me, 4-I-Ph, S, S), (N-463: Me, 4-OCF₃-Ph, S, S), (N-464: Me, 3,4-diI-Ph, S, S), (N-465: Me, Indole-6-yl, S, S), (N-466: Me,
- 20 1-Ac-indole-6-yl, S, S), (N-467: Me, 1-Me-indole-6-yl, S, S), (N-468: Me, 4-(1-Imidazolyl)-Ph, S, S), (N-469: Me, 4-Morpholino-Ph, S, S), (N-470: Me, 4-(1-Piperazinyl)-Ph, S, S), (N-471: Me, 2:5-diMe-thiophene-3-yl, S, S), (N-472: Me, 2-Furyl, S, S), (N-473: Me, 5-Me-furan-2-yl, S, S), (N-474: Me, 5-Me-furan-2-yl, S, S), (N-475: Me, 2-Thiazolyl, S, S), (N-476: Me, 1:4-Benzodioxin-6-yl, S, S),
- 25 (N-477: Me, Benzo[b]furan-2-yl, S, S), (N-478: Me, 4-NH₂CH₂-Ph, S, S), (N-479: Me, 4-N(Me)HCH₂-Ph, S, S), (N-480: Me, 4-N(Me)₂CH₂-Ph, S, S), (N-481: Me, 6-Cl-pyridine-3-yl, S, S), (N-482: Me, 5,6-diCl-pyridine-3-yl, S, S), (N-483:

- Me, 5-Cl-pyridine-2-yl, S, S), (N-484: Me, 4:5-diCl-pyridine-2-yl, S, S), (N-485: Me, 4-ClCH₂-Bn, S, S), (N-486: Me, Bn, S, S), (N-487: Me, 4-Cl-Bn, S, S), (N-488: Me, 4-Br-Bn, S, S), (N-489: Me, 4-F-Bn, S, S), (N-490: Me, 3,4-diCl-Bn, S, S), (N-491: Me, 3,4-diBr-Bn, S, S), (N-492: Me, 3,4-diF-Bn, S, S), (N-493: Me, 4-Cl-Bz, S, S), (N-494: Me, 3,4-diCl-Bz, S, S), (N-495: Me, 4-Br-Bz, S, S), (N-496: Me, 3,4-diBr-Bz, S, S), (N-497: Me, 4-F-Bz, S, S), (N-498: Me, 3,4-diF-Bz, S, S), (N-499: Me, 4-NO₂-Bn, S, S), (N-500: Me, 4-CN-Bn, S, S), (N-501: Et, Ph, S, S), (N-502: Et, 4-F-Ph, S, S), (N-503: Et, 4-Br-Ph, S, S), (N-504: Et, 4-Me-Ph, S, S), (N-505: Et, 4-Ph-Ph, S, S), (N-506: Et, 4-OMe-Ph, S, S), (N-507: Et, 4-tBu-Ph, S, S), (N-508: Et, 4-COOMe-Ph, S, S), (N-509: Et, 4-Pen-Ph, S, S), (N-510: Et, 4-NO₂-Ph, S, S), (N-511: Et, 5-Cl-thiophene-2-yl, S, S), (N-512: Et, 3-Thienyl, S, S), (N-513: Et, 2-Py, S, S), (N-514: Et, 3-Py, S, S), (N-515: Et, 4-Py, S, S), (N-516: Et, 3,4-diF-Ph, S, S), (N-517: Et, 5-Br-thiophene-2-yl, S, S), (N-518: Et, 4-CONH₂-Ph, S, S), (N-519: Et, 4-CON(Me)H-Ph, S, S), (N-520: Et, 4-CON(Me)₂-Ph, S, S), (N-521: Et, 4-iPrOC(=O)-Ph, S, S), (N-522: Et, 4-nBuOC(=O)-Ph, S, S), (N-523: Et, 6-Me-pyridine-3-yl, S, S), (N-524: Et, Quinoline-3-yl, S, S), (N-525: Et, 4-NH₂-Ph, S, S), (N-526: Et, 4-N(Ac)H-Ph, S, S), (N-527: Et, 4-OH-Ph, S, S), (N-528: Et, 3,4-di(OH)₂-Ph, S, S), (N-529: Et, 3,4-di(NH₂)-Ph, S, S), (N-530: Et, 3:4-[N(Ac)H]₂-Ph, S, S), (N-531: Et, 4-SH-Ph, S, S), (N-532: Et, 4-SMe-Ph, S, S), (N-533: Et, 3,4-diBr-Ph, S, S), (N-534: Et, 4-N(Me)H-Ph, S, S), (N-535: Et, 4-N(Me)₂-Ph, S, S), (N-536: Et, 4-N(Me)₃⁺-Ph, S, S), (N-537: Et, 4-Et-Ph, S, S), (N-538: Et, 4-iPr-Ph, S, S), (N-539: Et, 4-nPr-Ph, S, S), (N-540: Et, 4-nBu-Ph, S, S), (N-541: Et, 4-iBu-Ph, S, S), (N-542: Et, 3,4-diMe-Ph, S, S), (N-543: Et, 1,3-Benzodioxole-5-yl, S, S), (N-544: Et, N-Me-pyridinium-4-yl, S, S), (N-545: Et, N-Me-pyridinium-3-yl, S, S), (N-546: Et, 5-Me-Pyridine-2-yl, S, S), (N-547: Et, 2-Pyrazinyl, S, S), (N-548: Et, 3-Pyrrolyl, S, S), (N-549: Et, 1-Me-pyrrole-3-yl, S, S), (N-550: Et, Pyridine N-

- oxide-4-yl, S, S), (N-551: Et, Pyridine N-oxide-3-yl, S, S), (N-552: Et, 6-OH-pyridine-3-yl, S, S), (N-553: Et, 6-SH-pyridine-3-yl, S, S), (N-554: Et, 1-Ac-pyrrole-3-yl, S, S), (N-555: Et, 4-CF₃-Ph, S, S), (N-556: Et, 4-CN-Ph, S, S), (N-557: Et, 4-CHO-Ph, S, S), (N-558: Et, 3-Cl-Ph, S, S), (N-559: Et, 3-Br-Ph, S, S), (N-560: Et, 3-F-Ph, S, S), (N-561: Et, 3-I-Ph, S, S), (N-562: Et, 4-I-Ph, S, S), (N-563: Et, 4-OCF₃-Ph, S, S), (N-564: Et, 3,4-diI-Ph, S, S), (N-565: Et, Indole-6-yl, S, S), (N-566: Et, 1-Ac-indole-6-yl, S, S), (N-567: Et, 1-Me-indole-6-yl, S, S), (N-568: Et, 4-(1-Imidazolyl)-Ph, S, S), (N-569: Et, 4-Morpholino-Ph, S, S), (N-570: Et, 4-(1-Piperazinyl)-Ph, S, S), (N-571: Et, 2:5-diMe-thiophene-3-yl, S, S), (N-572: Et, 2-Furyl, S, S), (N-573: Et, 5-Me-furan-2-yl, S, S), (N-574: Et, 5-Me-furan-2-yl, S, S), (N-475: Et, 2-Thiazolyl, S, S), (N-576: Et, 1:4-Benzodioxin-6-yl, S, S), (N-577: Et, Benzo[b]furan-2-yl, S, S), (N-578: Et, 4-NH₂CH₂-Ph, S, S), (N-579: Et, 4-N(Me)HCH₂-Ph, S, S), (N-580: Et, 4-N(Me)₂CH₂-Ph, S, S), (N-581: Et, 6-Cl-pyridine-3-yl, S, S), (N-582: Et, 5,6-diCl-pyridine-3-yl, S, S), (N-583: Et, 5-Cl-pyridine-2-yl, S, S), (N-584: Et, 4:5-diCl-pyridine-2-yl, S, S), (N-585: Et, 4-ClCH₂-Bn, S, S), (N-586: Et, Bn, S, S), (N-587: Et, 4-Cl-Bn, S, S), (N-588: Et, 4-Br-Bn, S, S), (N-589: Et, 4-F-Bn, S, S), (N-590: Et, 3,4-diCl-Bn, S, S), (N-591: Et, 3,4-diBr-Bn, S, S), (N-592: Et, 3,4-diF-Bn, S, S), (N-593: Et, 4-Cl-Bz, S, S), (N-594: Et, 3,4-diCl-Bz, S, S), (N-595: Et, 4-Br-Bz, S, S), (N-596: Et, 3,4-diBr-Bz, S, S), (N-597: Et, 4-F-Bz, S, S), (N-598: Et, 3,4-diF-Bz, S, S), (N-599: Et, 4-NO₂-Bn, S, S), (N-600: Et, 4-CN-Bn, S, S), (N-601: COOMe, Ph, S, S), (N-602: COOMe, 4-F-Ph, S, S), (N-603: COOMe, 4-Br-Ph, S, S), (N-604: COOMe, 4-Me-Ph, S, S), (N-605: COOMe, 4-Ph-Ph, S, S), (N-606: COOMe, 4-Ome-Ph, S, S), (N-607: COOMe, 4-tBu-Ph, S, S), (N-608: COOMe, 4-COOMe-Ph, S, S), (N-609: COOMe, 4-Pen-Ph, S, S), (N-510: COOMe, 4-NO₂-Ph, S, S), (N-611: COOMe, 5-Cl-thiophene-2-yl, S, S), (N-612: COOMe, 3-Thienyl, S, S), (N-513: COOMe, 2-Py, S, S), (N-614: COOMe,

- 3-Py, S, S), (N-615: COOMe, 4-Py, S, S), (N-616: COOMe, 3,4-diF-Ph, S, S),
 (N-617: COOMe, 5-Br-thiophene-2-yl, S, S), (N-618: COOMe, 4-CONH₂-Ph, S,
 S), (N-619: COOMe, 4-CON(Me)H-Ph, S, S), (N-620: COOMe, 4-CON(Me)₂-Ph,
 S, S), (N-621: COOMe, 4-iPrOC(=O)-Ph, S, S), (N-622: COOMe, 4-
 5 nBuOC(=O)-Ph, S, S), (N-623: COOMe, 6-Me-pyridine-3-yl, S, S), (N-624:
 COOMe, Quinoline-3-yl, S, S), (N-625: COOMe, 4-NH₂-Ph, S, S), (N-626:
 COOMe, 4-N(Ac)H-Ph, S, S), (N-627: COOMe, 4-OH-Ph, S, S), (N-628: COOMe,
 3,4-di(OH)₂-Ph, S, S), (N-629: COOMe, 3,4-di(NH₂)-Ph, S, S), (N-630: COOMe,
 3:4-[N(Ac)H]₂-Ph, S, S), (N-631: COOMe, 4-SH-Ph, S, S), (N-632: COOMe, 4-
 10 SMe-Ph, S, S), (N-633: COOMe, 3,4-diBr-Ph, S, S), (N-634: COOMe, 4-
 N(Me)H-Ph, S, S), (N-635: COOMe, 4-N(Me)₂-Ph, S, S), (N-636: COOMe, 4-
 N(Me)₃⁺-Ph, S, S), (N-637: COOMe, 4-Et-Ph, S, S), (N-638: COOMe, 4-iPr-Ph, S,
 S), (N-639: COOMe, 4-nPr-Ph, S, S), (N-640: COOMe, 4-nBu-Ph, S, S), (N-641:
 COOMe, 4-iBu-Ph, S, S), (N-642: COOMe, 3,4-diMe-Ph, S, S), (N-643: COOMe,
 15 1,3-Benzodioxole-5-yl, S, S), (N-644: COOMe, N-Me-pyridinium-4-yl, S, S),
 (N-645: COOMe, N-Me-pyridinium-3-yl, S, S), (N-646: COOMe, 5-Me-
 Pyridine-2-yl, S, S), (N-647: COOMe, 2-Pyrazinyl, S, S), (N-648: COOMe, 3-
 Pyrrolyl, S, S), (N-649: COOMe, 1-Me-pyrrole-3-yl, S, S), (N-650: COOMe,
 Pyridine N-oxide-4-yl, S, S), (N-651: COOMe, Pyridine N-oxide-3-yl, S, S),
 20 (N-652: COOMe, 6-OH-pyridine-3-yl, S, S), (N-653: COOMe, 6-SH-pyridine-3-
 yl, S, S), (N-654: COOMe, 1-Ac-pyrrole-3-yl, S, S), (N-655: COOMe, 4-CF₃-Ph,
 S, S), (N-656: COOMe, 4-CN-Ph, S, S), (N-657: COOMe, 4-CHO-Ph, S, S), (N-
 658: COOMe, 3-Cl-Ph, S, S), (N-659: COOMe, 3-Br-Ph, S, S), (N-660: COOMe,
 3-F-Ph, S, S), (N-661: COOMe, 3-I-Ph, S, S), (N-662: COOMe, 4-I-Ph, S, S),
 25 (N-663: COOMe, 4-OCF₃-Ph, S, S), (N-664: COOMe, 3,4-diI-Ph, S, S), (N-665:
 COOMe, Indole-6-yl, S, S), (N-666: COOMe, 1-Ac-indole-6-yl, S, S), (N-667:
 COOMe, 1-Me-indole-6-yl, S, S), (N-668: COOMe, 4-(1-Imidazolyl)-Ph, S, S),

- (N-669: COOMe, 4-Morpholino-Ph, S, S), (N-670: COOMe, 4-(1-Piperazinyl)-Ph, S, S), (N-671: COOMe, 2:5-diMe-thiophene-3-yl, S, S), (N-672: COOMe, 2-Furyl, S, S), (N-673: COOMe, 5-Me-furan-2-yl, S, S), (N-674: COOMe, 5-Me-furan-2-yl, S, S), (N-675: COOMe, 2-Thiazolyl, S, S), (N-676: COOMe, 1:4-Benzodioxin-6-yl, S, S), (N-577: COOMe, Benzo[b]furan-2-yl, S, S), (N-678: COOMe, 4-NH₂CH₂-Ph, S, S), (N-679: COOMe, 4-N(Me)HCH₂-Ph, S, S), (N-680: COOMe, 4-N(Me)₂CH₂-Ph, S, S), (N-681: COOMe, 6-Cl-pyridine-3-yl, S, S), (N-682: COOMe, 5,6-diCl-pyridine-3-yl, S, S), (N-683: COOMe, 5-Cl-pyridine-2-yl, S, S), (N-684: COOMe, 4:5-diCl-pyridine-2-yl, S, S), (N-685: COOMe, 4-ClCH₂-Bn, S, S), (N-686: COOMe, Bn, S, S), (N-687: COOMe, 4-Cl-Bn, S, S), (N-688: COOMe, 4-Br-Bn, S, S), (N-689: COOMe, 4-F-Bn, S, S), (N-690: COOMe, 3,4-diCl-Bn, S, S), (N-691: COOMe, 3,4-diBr-Bn, S, S), (N-692: COOMe, 3,4-diF-Bn, S, S), (N-693: COOMe, 4-Cl-Bz, S, S), (N-694: COOMe, 3,4-diCl-Bz, S, S), (N-695: COOMe, 4-Br-Bz, S, S), (N-696: COOMe, 3,4-diBr-Bz, S, S), (N-697: COOMe, 4-F-Bz, S, S), (N-698: COOMe, 3,4-diF-Bz, S, S), (N-699: COOMe, 4-NO₂-Bn, S, S), (N-700: COOMe, 4-CN-Bn, S, S), (N-701: Ph, H, O, S), (N-702: 4-F-Ph, H, O, S), (N-703: 4-Br-Ph, H, O, S), (N-704: 4-Me-Ph, H, O, S), (N-705: 4-Ph-Ph, H, O, S), (N-706: 4-OMe-Ph, H, O, S), (N-707: 4-tBu-Ph, H, O, S), (N-708: 4-COOMe-Ph, H, O, S), (N-709: 4-Pen-Ph, H, O, S), (N-710: 4-NO₂-Ph, H, O, S), (N-711: 5-Cl-thiophene-2-yl, H, O, S), (N-712: 3-Thienyl, H, O, S), (N-713: 2-Py, H, O, S), (N-714: 3-Py, H, O, S), (N-715: 4-Py, H, O, S), (N-716: 3,4-diF-Ph, H, O, S), (N-717: 5-Br-thiophene-2-yl, H, O, S), (N-718: 4-CONH₂-Ph, H, O, S), (N-719: 4-CON(Me)H-Ph, H, O, S), (N-720: 4-CON(Me)₂-Ph, H, O, S), (N-721: 4-iPrOC(=O)-Ph, H, O, S), (N-722: 4-nBuOC(=O)-Ph, H, O, S), (N-723: 6-Me-pyridine-3-yl, H, O, S), (N-724: Quinoline-3-yl, H, O, S), (N-725: 4-NH₂-Ph, H, O, S), (N-726: 4-N(Ac)H-Ph, H, O, S), (N-727: 4-OH-Ph, H, O, S), (N-728: 3,4-di(OH)₂-Ph, H, O, S), (N-729:

- 3,4-di(NH₂)-Ph, H, O, S), (N-730: 3:4-[N(Ac)H]₂-Ph, H, O, S), (N-731: 4-SH-Ph, H, O, S), (N-732: 4-SMe-Ph, H, O, S), (N-733: 3,4-diBr-Ph, H, O, S), (N-734: 4-N(Me)H-Ph, H, O, S), (N-735: 4-N(Me)₂-Ph, H, O, S), (N-736: 4-N(Me)₃⁺-Ph, H, O, S), (N-737: 4-Et-Ph, H, O, S), (N-738: 4-iPr-Ph, H, O, S), (N-739: 4-nPr-Ph, H, O, S), (N-740: 4-nBu-Ph, H, O, S), (N-741: 4-iBu-Ph, H, O, S), (N-742: 3,4-diMe-Ph, H, O, S), (N-743: 1,3-Benzodioxole-5-yl, H, O, S), (N-744: N-Me-pyridinium-4-yl, H, O, S), (N-745: N-Me-pyridinium-3-yl, H, O, S), (N-746: 5-Me-Pyridine-2-yl, H, O, S), (N-747: 2-Pyrazinyl, H, O, S), (N-748: 3-Pyrrolyl, H, O, S), (N-749: 1-Me-pyrrole-3-yl, H, O, S), (N-750: Pyridine N-oxide-4-yl, H, O, S), (N-751: Pyridine N-oxide-3-yl, H, O, S), (N-752: 6-OH-pyridine-3-yl, H, O, S), (N-753: 6-SH-pyridine-3-yl, H, O, S), (N-754: 1-Ac-pyrrole-3-yl, H, O, S), (N-755: 4-CF₃-Ph, H, O, S), (N-756: 4-CN-Ph, H, O, S), (N-757: 4-CHO-Ph, H, O, S), (N-758: 3-Cl-Ph, H, O, S), (N-759: 3-Br-Ph, H, O, S), (N-760: 3-F-Ph, H, O, S), (N-761: 3-I-Ph, H, O, S), (N-762: 4-I-Ph, H, O, S), (N-763: 4-OCF₃-Ph, H, O, S), (N-764: 3,4-diI-Ph, H, O, S), (N-765: Indole-6-yl, H, O, S), (N-766: 1-Ac-indole-6-yl, H, O, S), (N-767: 1-Me-indole-6-yl, H, O, S), (N-768: 4-(1-Imidazolyl)-Ph, H, O, S), (N-769: 4-Morphorino-Ph, H, O, S), (N-770: 4-(1-Piperazinyl)-Ph, H, O, S), (N-771: 2:5-diMe-thiophene-3-yl, H, O, S), (N-772: 2-Furyl, H, O, S), (N-773: 5-Me-furan-2-yl, H, O, S), (N-774: 5-Me-furan-2-yl, H, O, S), (N-775: 2-Thiazolyl, H, O, S), (N-776: 1:4-Benzodioxin-6-yl, H, O, S), (N-777: Benzo[b]furan-2-yl, H, O, S), (N-778: 4-NH₂CH₂-Ph, H, O, S), (N-779: 4-N(Me)HCH₂-Ph, H, O, S), (N-780: 4-N(Me)₂CH₂-Ph, H, O, S), (N-781: 6-Cl-pyridine-3-yl, H, O, S), (N-782: 5,6-diCl-pyridine-3-yl, H, O, S), (N-783: 5-Cl-pyridine-2-yl, H, O, S), (N-784: 4:5-diCl-pyridine-2-yl, H, O, S), (N-785: 4-ClCH₂-Bn, H, O, S), (N-786: Bn, H, O, S), (N-787: 4-Cl-Bn, H, O, S), (N-788: 4-Br-Bn, H, O, S), (N-789: 4-F-Bn, H, O, S), (N-790: 3,4-diCl-Bn, H, O, S), (N-791: 3,4-diBr-Bn, H, O, S), (N-792: 3,4-diF-Bn, H, O, S), (N-793: 4-Cl-Bz, H, O,

- S), (N-794: 3,4-diCl-Bz, H, O, S), (N-795: 4-Br-Bz, H, O, S), (N-796: 3,4-diBr-Bz, H, O, S), (N-797: 4-F-Bz, H, O, S), (N-798: 3,4-diF-Bz, H, O, S), (N-799: 4-NO₂-Bn, H, O, S), (N-800: 4-CN-Bn, H, O, S), (N-801: Ph, Me, O, S), (N-802: 4-F-Ph, Me, O, S), (N-803: 4-Br-Ph, Me, O, S), (N-804: 4-Me-Ph, Me, O, S),
- 5 (N-805: 4-Ph-Ph, Me, O, S), (N-806: 4-OMe-Ph, Me, O, S), (N-807: 4-tBu-Ph, Me, O, S), (N-808: 4-COOMe-Ph, Me, O, S), (N-809: 4-Pen-Ph, Me, O, S), (N-810: 4-NO₂-Ph, Me, O, S), (N-811: 5-Cl-thiophene-2-yl, Me, O, S), (N-812: 3-Thienyl, Me, O, S), (N-813: 2-Py, Me, O, S), (N-814: 3-Py, Me, O, S), (N-815: 4-Py, Me, O, S), (N-816: 3,4-diF-Ph, Me, O, S), (N-817: 5-Br-thiophene-2-yl, Me,
- 10 O, S), (N-818: 4-CONH₂-Ph, Me, O, S), (N-819: 4-CON(Me)H-Ph, Me, O, S), (N-820: 4-CON(Me)₂-Ph, Me, O, S), (N-821: 4-iPrOC(=O)-Ph, Me, O, S), (N-822: 4-nBuOC(=O)-Ph, Me, O, S), (N-823: 6-Me-pyridine-3-yl, Me, O, S), (N-824: Quinoline-3-yl, Me, O, S), (N-825: 4-NH₂-Ph, Me, O, S), (N-826: 4-N(Ac)H-Ph, Me, O, S), (N-827: 4-OH-Ph, Me, O, S), (N-828: 3,4-di(OH)₂-Ph, Me, O, S), (N-
- 15 829: 3,4-di(NH₂)-Ph, Me, O, S), (N-830: 3:4-[N(Ac)H]₂-Ph, Me, O, S), (N-831: 4-SH-Ph, Me, O, S), (N-832: 4-SMe-Ph, Me, O, S), (N-833: 3,4-diBr-Ph, Me, O, S), (N-834: 4-N(Me)H-Ph, Me, O, S), (N-835: 4-N(Me)₂-Ph, Me, O, S), (N-836: 4-N(Me)₃⁺-Ph, Me, O, S), (N-837: 4-Et-Ph, Me, O, S), (N-838: 4-iPr-Ph, Me, O,
- S), (N-839: 4-nPr-Ph, Me, O, S), (N-840: 4-nBu-Ph, Me, O, S), (N-841: 4-iBu-Ph,
- 20 Me, O, S), (N-842: 3,4-diMe-Ph, Me, O, S), (N-843: 1,3-Benzodioxole-5-yl, Me, O, S), (N-844: N-Me-pyridinium-4-yl, Me, O, S), (N-845: N-Me-pyridinium-3-yl, Me, O, S), (N-846: 5-Me-Pyridine-2-yl, Me, O, S), (N-847: 2-Pyrazinyl, Me, O, S), (N-848: 3-Pyrrolyl, Me, O, S), (N-849: 1-Me-pyrrole-3-yl, Me, O, S), (N-850: Pyridine N-oxide-4-yl, Me, O, S), (N-851: Pyridine N-oxide-3-yl, Me, O, S),
- 25 (N-852: 6-OH-pyridine-3-yl, Me, O, S), (N-853: 6-SH-pyridine-3-yl, Me, O, S), (N-854: 1-Ac-pyrrole-3-yl, Me, O, S), (N-855: 4-CF₃-Ph, Me, O, S), (N-856: 4-CN-Ph, Me, O, S), (N-857: 4-CHO-Ph, Me, O, S), (N-858: 3-Cl-Ph, Me, O, S),

- (N-859: 3-Br-Ph, Me, O, S), (N-860: 3-F-Ph, Me, O, S), (N-861: 3-I-Ph, Me, O, S),
 (N-862: 4-I-Ph, Me, O, S), (N-863: 4-OCF₃-Ph, Me, O, S), (N-864: 3,4-diI-Ph,
 Me, O, S), (N-865: Indole-6-yl, Me, O, S), (N-866: 1-Ac-indole-6-yl, Me, O, S),
 (N-867: 1-Me-indole-6-yl, Me, O, S), (N-868: 4-(1-imidazolyl)-Ph, Me, O, S),
 5 (N-869: 4-Morphorino-Ph, Me, O, S), (N-870: 4-(1-PiperazinyI)-Ph, Me, O, S),
 (N-871: 2:5-diMe-thiophene-3-yl, Me, O, S), (N-872: 2-FuryI, Me, O, S), (N-873:
 5-Me-furan-2-yl, Me, O, S), (N-874: 5-Me-furan-2-yl, Me, O, S), (N-875: 2-
 Thiazolyl, Me, O, S), (N-876: 1:4-Benzodioxin-6-yl, Me, O, S), (N-877:
 Benzo[b]furan-2-yl, Me, O, S), (N-878: 4-NH₂CH₂-Ph, Me, O, S), (N-879: 4-
 10 N(Me)HCH₂-Ph, Me, O, S), (N-880: 4-N(Me)₂CH₂-Ph, Me, O, S), (N-881: 6-Cl-
 pyridine-3-yl, Me, O, S), (N-882: 5,6-diCl-pyridine-3-yl, Me, O, S), (N-883: 5-
 Cl-pyridine-2-yl, Me, O, S), (N-884: 4:5-diCl-pyridine-2-yl, Me, O, S), (N-885:
 4-ClCH₂-Bn, Me, O, S), (N-886: Bn, Me, O, S), (N-887: 4-Cl-Bn, Me, O, S), (N-
 888: 4-Br-Bn, Me, O, S), (N-889: 4-F-Bn, Me, O, S), (N-890: 3,4-diCl-Bn, Me, O,
 15 S), (N-891: 3,4-diBr-Bn, Me, O, S), (N-892: 3,4-diF-Bn, Me, O, S), (N-893: 4-
 Cl-Bz, Me, O, S), (N-894: 3,4-diCl-Bz, Me, O, S), (N-895: 4-Br-Bz, Me, O, S),
 (N-896: 3,4-diBr-Bz, Me, O, S), (N-897: 4-F-Bz, Me, O, S), (N-898: 3,4-diF-Bz,
 Me, O, S), (N-899: 4-NO₂-Bn, Me, O, S), (N-900: 4-CN-Bn, Me, O, S), (N-901:
 Ph, Et, O, S), (N-902: 4-F-Ph, Et, O, S), (N-903: 4-Br-Ph, Et, O, S), (N-904: 4-
 20 Me-Ph, Et, O, S), (N-905: 4-Ph-Ph, Et, O, S), (N-906: 4-OMe-Ph, Et, O, S), (N-
 907: 4-tBu-Ph, Et, O, S), (N-908: 4-COOMe-Ph, Et, O, S), (N-909: 4-Pen-Ph, Et,
 O, S), (N-910: 4-NO₂-Ph, Et, O, S), (N-911: 5-Cl-thiophene-2-yl, Et, O, S), (N-
 912: 3-Thienyl, Et, O, S), (N-913: 2-Py, Et, O, S), (N-914: 3-Py, Et, O, S), (N-
 915: 4-Py, Et, O, S), (N-916: 3,4-diF-Ph, Et, O, S), (N-917: 5-Br-thiophene-2-yl,
 25 Et, O, S), (N-918: 4-CONH₂-Ph, Et, O, S), (N-919: 4-CON(Me)H-Ph, Et, O, S),
 (N-920: 4-CON(Me)₂-Ph, Et, O, S), (N-921: 4-iPrOC(=O)-Ph, Et, O, S), (N-922:
 4-nBuOC(=O)-Ph, Et, O, S), (N-923: 6-Me-pyridine-3-yl, Et, O, S), (N-924:

- Quinoline-3-yl, Et, O, S), (N-925: 4-NH₂-Ph, Et, O, S), (N-926: 4-N(Ac)H-Ph, Et, O, S), (N-927: 4-OH-Ph, Et, O, S), (N-928: 3,4-di(OH)₂-Ph, Et, O, S), (N-929: 3,4-di(NH₂)-Ph, Et, O, S), (N-930: 3:4-[N(Ac)H]₂-Ph, Et, O, S), (N-931: 4-SH-Ph, Et, O, S), (N-932: 4-SMe-Ph, Et, O, S), (N-933: 3,4-diBr-Ph, Et, O, S),
- 5 (N-934: 4-N(Me)H-Ph, Et, O, S), (N-935: 4-N(Me)₂-Ph, Et, O, S), (N-936: 4-N(Me)₃⁺-Ph, Et, O, S), (N-937: 4-Et-Ph, Et, O, S), (N-938: 4-iPr-Ph, Et, O, S), (N-939: 4-nPr-Ph, Et, O, S), (N-940: 4-nBu-Ph, Et, O, S), (N-941: 4-iBu-Ph, Et, O, S), (N-942: 3,4-diMe-Ph, Et, O, S), (N-943: 1,3-Benzodioxole-5-yl, Et, O, S), (N-944: N-Me-pyridinium-4-yl, Et, O, S), (N-945: N-Me-pyridinium-3-yl, Et, O,
- 10 S), (N-946: 5-Me-Pyridine-2-yl, Et, O, S), (N-947: 2-Pyrazinyl, Et, O, S), (N-948: 3-Pyrrolyl, Et, O, S), (N-949: 1-Me-pyrrole-3-yl, Et, O, S), (N-950: Pyridine N-oxide-4-yl, Et, O, S), (N-951: Pyridine N-oxide-3-yl, Et, O, S), (N-952: 6-OH-pyridine-3-yl, Et, O, S), (N-953: 6-SH-pyridine-3-yl, Et, O, S), (N-954: 1-Ac-pyrrole-3-yl, Et, O, S), (N-955: 4-CF₃-Ph, Et, O, S), (N-956: 4-CN-Ph,
- 15 Et, O, S), (N-957: 4-CHO-Ph, Et, O, S), (N-958: 3-Cl-Ph, Et, O, S), (N-959: 3-Br-Ph, Et, O, S), (N-960: 3-F-Ph, Et, O, S), (N-961: 3-I-Ph, Et, O, S), (N-962: 4-I-Ph, Et, O, S), (N-963: 4-OCF₃-Ph, Et, O, S), (N-964: 3,4-diI-Ph, Et, O, S), (N-965: Indole-6-yl, Et, O, S), (N-966: 1-Ac-indole-6-yl, Et, O, S), (N-967: 1-Me-indole-6-yl, Et, O, S), (N-968: 4-(1-Imidazolyl)-Ph, Et, O, S), (N-969: 4-
- 20 Morphorino-Ph, Et, O, S), (N-970: 4-(1-Piperazinyl)-Ph, Et, O, S), (N-971: 2:5-diMe-thiophene-3-yl, Et, O, S), (N-972: 2-Furyl, Et, O, S), (N-973: 5-Me-furan-2-yl, Et, O, S), (N-974: 5-Me-furan-2-yl, Et, O, S), (N-975: 2-Thiazolyl, Et, O, S), (N-976: 1:4-Benzodioxin-6-yl, Et, O, S), (N-977: Benzo[b]furan-2-yl, Et, O, S), (N-978: 4-NH₂CH₂-Ph, Et, O, S), (N-979: 4-N(Me)HCH₂-Ph, Et, O, S),
- 25 (N-980: 4-N(Me)₂CH₂-Ph, Et, O, S), (N-981: 6-Cl-pyridine-3-yl, Et, O, S), (N-982: 5,6-diCl-pyridine-3-yl, Et, O, S), (N-983: 5-Cl-pyridine-2-yl, Et, O, S), (N-984: 4:5-diCl-pyridine-2-yl, Et, O, S), (N-985: 4-ClCH₂-Bn, Et, O, S), (N-

- 986: Bn, Et, O, S), (N-987: 4-Cl-Bn, Et, O, S), (N-988: 4-Br-Bn, Et, O, S), (N-989: 4-F-Bn, Et, O, S), (N-990: 3,4-diCl-Bn, Et, O, S), (N-991: 3,4-diBr-Bn, Et, O, S), (N-992: 3,4-diF-Bn, Et, O, S), (N-993: 4-Cl-Bz, Et, O, S), (N-994: 3,4-diCl-Bz, Et, O, S), (N-995: 4-Br-Bz, Et, O, S), (N-996: 3,4-diBr-Bz, Et, O, S),
5 (N-997: 4-F-Bz, Et, O, S), (N-998: 3,4-diF-Bz, Et, O, S), (N-999: 4-NO₂-Bn, Et, O, S), (N-1000: 4-CN-Bn, Et, O, S), (N-1001: Ph, COOMe, O, S), (N-1002: 4-F-Ph, COOMe, O, S), (N-1003: 4-Br-Ph, COOMe, O, S), (N-1004: 4-Me-Ph, COOMe, O, S), (N-1005: 4-Ph-Ph, COOMe, O, S), (N-1006: 4-OMe-Ph, COOMe, O, S), (N-1007: 4-tBu-Ph, COOMe, O, S), (N-1008: 4-COOMe-Ph, COOMe, O, S),
10 (N-1009: 4-Pen-Ph, COOMe, O, S), (N-1010: 4-NO₂-Ph, COOMe, O, S), (N-1011: 5-Cl-thiophene-2-yl, COOMe, O, S), (N-1012: 3-Thienyl, COOMe, O, S), (N-1013: 2-Py, COOMe, O, S), (N-1014: 3-Py, COOMe, O, S), (N-1015: 4-Py, COOMe, O, S), (N-1016: 3,4-diF-Ph, COOMe, O, S), (N-1017: 5-Br-thiophene-2-yl, COOMe, O, S), (N-1018: 4-CONH₂-Ph, COOMe, O, S), (N-1019: 4-CON(Me)H-Ph, COOMe, O, S),
15 (N-1020: 4-CON(Me)₂-Ph, COOMe, O, S), (N-1021: 4-iPrOC(=O)-Ph, COOMe, O, S), (N-1022: 4-nBuOC(=O)-Ph, COOMe, O, S), (N-1023: 6-Me-pyridine-3-yl, COOMe, O, S), (N-1024: Quinoline-3-yl, COOMe, O, S), (N-1025: 4-NH₂-Ph, COOMe, O, S), (N-1026: 4-N(Ac)H-Ph, COOMe, O, S), (N-1027: 4-OH-Ph, COOMe, O, S), (N-1028: 3,4-di(OH)₂-Ph, COOMe, O, S),
20 (N-1029: 3,4-di(NH₂)₂-Ph, COOMe, O, S), (N-1030: 3:4-[N(Ac)H]₂-Ph, COOMe, O, S), (N-1031: 4-SH-Ph, COOMe, O, S), (N-1032: 4-SMe-Ph, COOMe, O, S), (N-1033: 3,4-diBr-Ph, COOMe, O, S), (N-1034: 4-N(Me)H-Ph, COOMe, O, S), (N-1035: 4-N(Me)₂-Ph, COOMe, O, S), (N-1036: 4-N(Me)₃⁺-Ph, COOMe, O, S), (N-1037: 4-Et-Ph, COOMe, O, S), (N-1038: 4-iPr-Ph, COOMe, O, S),
25 (N-1039: 4-nPr-Ph, COOMe, O, S), (N-1040: 4-nBu-Ph, COOMe, O, S), (N-1041: 4-iBu-Ph, COOMe, O, S), (N-1042: 3,4-diMe-Ph, COOMe, O, S), (N-1043: 1,3-Benzodioxole-5-yl, COOMe, O, S), (N-1044: N-

- Me-pyridinium-4-yl, COOMe, O, S), (N-1045: N-Me-pyridinium-3-yl, COOMe, O, S), (N-1046: 5-Me-Pyridine-2-yl, COOMe, O, S), (N-1047: 2-Pyrazinyl, COOMe, O, S), (N-1048: 3-Pyrrolyl, COOMe, O, S), (N-1049: 1-Me-pyrrole-3-yl, COOMe, O, S), (N-1050: Pyridine N-oxide-4-yl, COOMe, O, S), (N-1051: 5 Pyridine N-oxide-3-yl, COOMe, O, S), (N-1052: 6-OH-pyridine-3-yl, COOMe, O, S), (N-1053: 6-SH-pyridine-3-yl, COOMe, O, S), (N-1054: 1-Ac-pyrrole-3-yl, COOMe, O, S), (N-1055: 4-CF₃-Ph, COOMe, O, S), (N-1056: 4-CN-Ph, COOMe, O, S), (N-1057: 4-CHO-Ph, COOMe, O, S), (N-1058: 3-Cl-Ph, COOMe, O, S), (N-1059: 3-Br-Ph, COOMe, O, S), (N-1060: 3-F-Ph, COOMe, O, S), (N-1061: 3-10 I-Ph, COOMe, O, S), (N-1062: 4-I-Ph, COOMe, O, S), (N-1063: 4-OCF₃-Ph, COOMe, O, S), (N-1064: 3,4-diI-Ph, COOMe, O, S), (N-1065: Indole-6-yl, COOMe, O, S), (N-1066: 1-Ac-indole-6-yl, COOMe, O, S), (N-1067: 1-Me-indole-6-yl, COOMe, O, S), (N-1068: 4-(1-Imidazolyl)-Ph, COOMe, O, S), (N-1069: 4-Morphorino-Ph, COOMe, O, S), (N-1070: 4-(1-Piperazinyl)-Ph, COOMe, 15 O, S), (N-1071: 2,5-diMe-thiophene-3-yl, COOMe, O, S), (N-1072: 2-Furyl, COOMe, O, S), (N-1073: 5-Me-furan-2-yl, COOMe, O, S), (N-1074: 5-Me-furan-2-yl, COOMe, O, S), (N-1075: 2-Thiazolyl, COOMe, O, S), (N-1076: 1:4-Benzodioxin-6-yl, COOMe, O, S), (N-1077: Benzo[b]furan-2-yl, COOMe, O, S), (N-1078: 4-NH₂CH₂-Ph, COOMe, O, S), (N-1079: 4-N(Me)HCH₂-Ph, COOMe, O, 20 S), (N-1080: 4-N(Me)₂CH₂-Ph, COOMe, O, S), (N-1081: 6-Cl-pyridine-3-yl, COOMe, O, S), (N-1082: 5,6-diCl-pyridine-3-yl, COOMe, O, S), (N-1083: 5-Cl-pyridine-2-yl, COOMe, O, S), (N-1084: 4:5-diCl-pyridine-2-yl, COOMe, O, S), (N-1085: 4-ClCH₂-Bn, COOMe, O, S), (N-1086: Bn, COOMe, O, S), (N-1087: 4-Cl-Bn, COOMe, O, S), (N-1088: 4-Br-Bn, COOMe, O, S), (N-1089: 4-F-Bn, 25 COOMe, O, S), (N-1090: 3,4-diCl-Bn, COOMe, O, S), (N-1091: 3,4-diBr-Bn, COOMe, O, S), (N-1092: 3,4-diF-Bn, COOMe, O, S), (N-1093: 4-Cl-Bz, COOMe, O, S), (N-1094: 3,4-diCl-Bz, COOMe, O, S), (N-1095: 4-Br-Bz, COOMe, O, S),

(N-1096: 3,4-diBr-Bz, COOMe, O, S), (N-1097: 4-F-Bz, COOMe, O, S), (N-1098: 3,4-diF-Bz, COOMe, O, S), (N-1099: 4-NO₂-Bn, COOMe, O, S), (N-1100: 4-CN-Bn, COOMe, O, S), (N-1101: H, Ph, O, S), (N-1102: H, 4-F-Ph, O, S), (N-1103: H, 4-Br-Ph, O, S), (N-1104: H, 4-Me-Ph, O, S), (N-1105: H, 4-Ph-Ph, O, S), (N-1106: H, 4-OMe-Ph, O, S), (N-1107: H, 4-tBu-Ph, O, S), (N-1108: H, 4-COOMe-Ph, O, S), (N-1109: H, 4-Pen-Ph, O, S), (N-1110: H, 4-NO₂-Ph, O, S), (N-1111: H, 5-Cl-thiophene-2-yl, O, S), (N-1112: H, 3-Thienyl, O, S), (N-1113: H, 2-Py, O, S), (N-1114: H, 3-Py, O, S), (N-1115: H, 4-Py, O, S), (N-1116: H, 3,4-diF-Ph, O, S), (N-1117: H, 5-Br-thiophene-2-yl, O, S), (N-1118: H, 4-CONH₂-Ph, O, S), (N-1119: H, 4-CON(Me)H-Ph, O, S), (N-1120: H, 4-CON(Me)₂-Ph, O, S), (N-1121: H, 4-iPrOC(=O)-Ph, O, S), (N-1122: H, 4-nBuOC(=O)-Ph, O, S), (N-1123: H, 6-Me-pyridine-3-yl, O, S), (N-1124: H, Quinoline-3-yl, O, S), (N-1125: H, 4-NH₂-Ph, O, S), (N-1126: H, 4-N(Ac)H-Ph, O, S), (N-1127: H, 4-OH-Ph, O, S), (N-1128: H, 3,4-di(OH)₂-Ph, O, S), (N-1129: H, 3,4-di(NH₂)-Ph, O, S), (N-1130: H, 3:4-[N(Ac)H]₂-Ph, O, S), (N-1131: H, 4-SH-Ph, O, S), (N-1132: H, 4-SMe-Ph, O, S), (N-1133: H, 3,4-diBr-Ph, O, S), (N-1134: H, 4-N(Me)H-Ph, O, S), (N-1135: H, 4-N(Me)₂-Ph, O, S), (N-1136: H, 4-N(Me)₃⁺-Ph, O, S), (N-1137: H, 4-Et-Ph, O, S), (N-1138: H, 4-iPr-Ph, O, S), (N-1139: H, 4-nPr-Ph, O, S), (N-1140: H, 4-nBu-Ph, O, S), (N-1141: H, 4-iBu-Ph, O, S), (N-1142: H, 3,4-diMe-Ph, O, S), (N-1143: H, 1,3-Benzodioxole-5-yl, O, S), (N-1144: H, N-Me-pyridinium-4-yl, O, S), (N-1145: H, N-Me-pyridinium-3-yl, O, S), (N-1146: H, 5-Me-Pyridine-2-yl, O, S), (N-1147: H, 2-Pyrazinyl, O, S), (N-1148: H, 3-Pyrrolyl, O, S), (N-1149: H, 1-Me-pyrrole-3-yl, O, S), (N-1150: H, Pyridine N-oxide-4-yl, O, S), (N-1151: H, Pyridine N-oxide-3-yl, O, S), (N-1152: H, 6-OH-pyridine-3-yl, O, S), (N-1153: H, 6-SH-pyridine-3-yl, O, S), (N-1154: H, 1-Ac-pyrrole-3-yl, O, S), (N-1155: H, 4-CF₃-Ph, O, S), (N-1156: H, 4-CN-Ph, O, S), (N-1157: H, 4-CHO-Ph, O, S), (N-1158: H, 3-Cl-Ph, O, S), (N-

- 1159: H, 3-Br-Ph, O, S), (N-1160: H, 3-F-Ph, O, S), (N-1161: H, 3-I-Ph, O, S),
 (N-1162: H, 4-I-Ph, O, S), (N-1163: H, 4-OCF₃-Ph, O, S), (N-1164: H, 3,4-diI-Ph,
 O, S), (N-1165: H, Indole-6-yl, O, S), (N-1166: H, 1-Ac-indole-6-yl, O, S), (N-
 1167: H, 1-Me-indole-6-yl, O, S), (N-1168: H, 4-(1-Imidazolyl)-Ph, O, S), (N-
 5 1169: H, 4-Morpholino-Ph, O, S), (N-1170: H, 4-(1-Piperazinyl)-Ph, O, S), (N-
 1171: H, 2:5-diMe-thiophene-3-yl, O, S), (N-1172: H, 2-Furyl, O, S), (N-1173: H,
 5-Me-furan-2-yl, O, S), (N-1174: H, 5-Me-furan-2-yl, O, S), (N-1175: H, 2-
 Thiazolyl, O, S), (N-1176: H, 1:4-Benzodioxin-6-yl, O, S), (N-1177: H,
 Benzo[b]furan-2-yl, O, S), (N-1178: H, 4-NH₂CH₂-Ph, O, S), (N-1179: H, 4-
 10 N(Me)HCH₂-Ph, O, S), (N-1180: H, 4-N(Me)₂CH₂-Ph, O, S), (N-1181: H, 6-Cl-
 pyridine-3-yl, O, S), (N-1182: H, 5,6-diCl-pyridine-3-yl, O, S), (N-1183: H, 5-
 Cl-pyridine-2-yl, O, S), (N-1184: H, 4:5-diCl-pyridine-2-yl, O, S), (N-1185: H,
 4-ClCH₂-Bn, O, S), (N-1186: H, Bn, O, S), (N-1187: H, 4-Cl-Bn, O, S), (N-1188:
 H, 4-Br-Bn, O, S), (N-1189: H, 4-F-Bn, O, S), (N-1190: H, 3,4-diCl-Bn, O, S),
 15 (N-1191: H, 3,4-diBr-Bn, O, S), (N-1192: H, 3,4-diF-Bn, O, S), (N-1193: H, 4-
 Cl-Bz, O, S), (N-1194: H, 3,4-diCl-Bz, O, S), (N-1195: H, 4-Br-Bz, O, S), (N-
 1196: H, 3,4-diBr-Bz, O, S), (N-1197: H, 4-F-Bz, O, S), (N-1198: H, 3,4-diF-Bz,
 O, S), (N-1199: H, 4-NO₂-Bn, O, S), (N-1200: H, 4-CN-Bn, O, S), (N-1201: Me,
 Ph, O, S), (N-1202: Me, 4-F-Ph, O, S), (N-1203: Me, 4-Br-Ph, O, S), (N-1204: Me,
 20 4-Me-Ph, O, S), (N-1205: Me, 4-Ph-Ph, O, S), (N-1206: Me, 4-OMe-Ph, O, S),
 (N-1207: Me, 4-tBu-Ph, O, S), (N-1208: Me, 4-COOMe-Ph, O, S), (N-1209: Me,
 4-Pen-Ph, O, S), (N-1210: Me, 4-NO₂-Ph, O, S), (N-1211: Me, 5-Cl-thiophene-
 2-yl, O, S), (N-1212: Me, 3-Thienyl, O, S), (N-1213: Me, 2-Py, O, S), (N-1214:
 Me, 3-Py, O, S), (N-1215: Me, 4-Py, O, S), (N-1216: Me, 3,4-diF-Ph, O, S), (N-
 25 1217: Me, 5-Br-thiophene-2-yl, O, S), (N-1218: Me, 4-CONH₂-Ph, O, S), (N-
 1219: Me, 4-CON(Me)H-Ph, O, S), (N-1220: Me, 4-CON(Me)₂-Ph, O, S), (N-
 1221: Me, 4-iPrOC(=O)-Ph, O, S), (N-1222: Me, 4-nBuOC(=O)-Ph, O, S), (N-

- 1223: Me, 6-Me-pyridine-3-yl, O, S), (N-1224: Me, Quinoline-3-yl, O, S), (N-1225: Me, 4-NH₂-Ph, O, S), (N-1226: Me, 4-N(Ac)H-Ph, O, S), (N-1227: Me, 4-OH-Ph, O, S), (N-1228: Me, 3,4-di(OH)₂-Ph, O, S), (N-1229: Me, 3,4-di(NH₂)-Ph, O, S), (N-1230: Me, 3:4-[N(Ac)H]₂-Ph, O, S), (N-1231: Me, 4-SH-Ph, O, S), (N-1232: Me, 4-SMe-Ph, O, S), (N-1233: Me, 3,4-diBr-Ph, O, S), (N-1234: Me, 4-N(Me)H-Ph, O, S), (N-1235: Me, 4-N(Me)₂-Ph, O, S), (N-1236: Me, 4-N(Me)₃⁺-Ph, O, S), (N-1237: Me, 4-Et-Ph, O, S), (N-1238: Me, 4-iPr-Ph, O, S), (N-1239: Me, 4-nPr-Ph, O, S), (N-1240: Me, 4-nBu-Ph, O, S), (N-1241: Me, 4-iBu-Ph, O, S), (N-1242: Me, 3,4-diMe-Ph, O, S), (N-1243: Me, 1,3-Benzodioxole-5-yl, O, S), (N-1244: Me, N-Me-pyridinium-4-yl, O, S), (N-1245: Me, N-Me-pyridinium-3-yl, O, S), (N-1246: Me, 5-Me-Pyridine-2-yl, O, S), (N-1247: Me, 2-Pyrazinyl, O, S), (N-1248: Me, 3-Pyrrolyl, O, S), (N-1249: Me, 1-Me-pyrrole-3-yl, O, S), (N-1250: Me, Pyridine N-oxide-4-yl, O, S), (N-1251: Me, Pyridine N-oxide-3-yl, O, S), (N-1252: Me, 6-OH-pyridine-3-yl, O, S), (N-1253: Me, 6-SH-pyridine-3-yl, O, S), (N-1254: Me, 1-Ac-pyrrole-3-yl, O, S), (N-1255: Me, 4-CF₃-Ph, O, S), (N-1256: Me, 4-CN-Ph, O, S), (N-1257: Me, 4-CHO-Ph, O, S), (N-1258: Me, 3-Cl-Ph, O, S), (N-1259: Me, 3-Br-Ph, O, S), (N-1260: Me, 3-F-Ph, O, S), (N-1261: Me, 3-I-Ph, O, S), (N-1262: Me, 4-I-Ph, O, S), (N-1263: Me, 4-OCF₃-Ph, O, S), (N-1264: Me, 3,4-diI-Ph, O, S), (N-1265: Me, Indole-6-yl, O, S), (N-1266: Me, 1-Ac-indole-6-yl, O, S), (N-1267: Me, 1-Me-indole-6-yl, O, S), (N-1268: Me, 4-(1-Imidazolyl)-Ph, O, S), (N-1269: Me, 4-Morphorino-Ph, O, S), (N-1270: Me, 4-(1-Piperazinyl)-Ph, O, S), (N-1271: Me, 2:5-diMe-thiophene-3-yl, O, S), (N-1272: Me, 2-Furyl, O, S), (N-1273: Me, 5-Me-furan-2-yl, O, S), (N-1274: Me, 5-Me-furan-2-yl, O, S), (N-1275: Me, 2-Thiazolyl, O, S), (N-1276: Me, 1:4-Benzodioxin-6-yl, O, S), (N-1277: Me, Benzo[b]furan-2-yl, O, S), (N-1278: Me, 4-NH₂CH₂-Ph, O, S), (N-1279: Me, 4-N(Me)HCH₂-Ph, O, S), (N-1280: Me, 4-N(Me)₂CH₂-Ph, O, S), (N-1281: Me, 6-Cl-pyridine-3-yl, O, S), (N-1282: Me,

- 5,6-diCl-pyridine-3-yl, O, S), (N-1283: Me, 5-Cl-pyridine-2-yl, O, S), (N-1284: Me, 4:5-diCl-pyridine-2-yl, O, S), (N-1285: Me, 4-ClCH₂-Bn, O, S), (N-1286: Me, Bn, O, S), (N-1287: Me, 4-Cl-Bn, O, S), (N-1288: Me, 4-Br-Bn, O, S), (N-1289: Me, 4-F-Bn, O, S), (N-1290: Me, 3,4-diCl-Bn, O, S), (N-1291: Me, 3,4-diBr-Bn, O, S), (N-1292: Me, 3,4-diF-Bn, O, S), (N-1293: Me, 4-Cl-Bz, O, S), (N-1294: Me, 3,4-diCl-Bz, O, S), (N-1295: Me, 4-Br-Bz, O, S), (N-1296: Me, 3,4-diBr-Bz, O, S), (N-1297: Me, 4-F-Bz, O, S), (N-1298: Me, 3,4-diF-Bz, O, S), (N-1299: Me, 4-NO₂-Bn, O, S), (N-1300: Me, 4-CN-Bn, O, S), (N-1301: Et, Ph, O, S), (N-1302: Et, 4-F-Ph, O, S), (N-1303: Et, 4-Br-Ph, O, S), (N-1304: Et, 4-Me-Ph, O, S), (N-1305: Et, 4-Ph-Ph, O, S), (N-1306: Et, 4-OMe-Ph, O, S), (N-1307: Et, 4-tBu-Ph, O, S), (N-1308: Et, 4-COOMe-Ph, O, S), (N-1309: Et, 4-Pen-Ph, O, S), (N-1310: Et, 4-NO₂-Ph, O, S), (N-1311: Et, 5-Cl-thiophene-2-yl, O, S), (N-1312: Et, 3-Thienyl, O, S), (N-1313: Et, 2-Py, O, S), (N-1314: Et, 3-Py, O, S), (N-1315: Et, 4-Py, O, S), (N-1316: Et, 3,4-diF-Ph, O, S), (N-1317: Et, 5-Br-thiophene-2-yl, O, S), (N-1318: Et, 4-CONH₂-Ph, O, S), (N-1319: Et, 4-CON(Me)H-Ph, O, S), (N-1320: Et, 4-CON(Me)₂-Ph, O, S), (N-1321: Et, 4-iPrOC(=O)-Ph, O, S), (N-1322: Et, 4-nBuOC(=O)-Ph, O, S), (N-1323: Et, 6-Me-pyridine-3-yl, O, S), (N-1324: Et, Quinoline-3-yl, O, S), (N-1325: Et, 4-NH₂-Ph, O, S), (N-1326: Et, 4-N(Ac)H-Ph, O, S), (N-1327: Et, 4-OH-Ph, O, S), (N-1328: Et, 3,4-di(OH)₂-Ph, O, S), (N-1329: Et, 3,4-di(NH₂)-Ph, O, S), (N-1330: Et, 3:4-[N(Ac)H]₂-Ph, O, S), (N-1331: Et, 4-SH-Ph, O, S), (N-1332: Et, 4-SMe-Ph, O, S), (N-1333: Et, 3,4-diBr-Ph, O, S), (N-1334: Et, 4-N(Me)H-Ph, O, S), (N-1335: Et, 4-N(Me)₂-Ph, O, S), (N-1336: Et, 4-N(Me)₃⁺-Ph, O, S), (N-1337: Et, 4-Et-Ph, O, S), (N-1338: Et, 4-iPr-Ph, O, S), (N-1339: Et, 4-nPr-Ph, O, S), (N-1340: Et, 4-nBu-Ph, O, S), (N-1341: Et, 4-iBu-Ph, O, S), (N-1342: Et, 3,4-diMe-Ph, O, S), (N-1343: Et, 1,3-Benzodioxole-5-yl, O, S), (N-1344: Et, N-Me-pyridinium-4-yl, O, S), (N-1345: Et, N-Me-pyridinium-3-yl, O, S), (N-1346: Et, 5-Me-Pyridine-2-yl, O, S),

- (N-1347: Et, 2-Pyrazinyl, O, S), (N-1348: Et, 3-Pyrrolyl, O, S), (N-1349: Et, 1-Me-pyrrole-3-yl, O, S), (N-1350: Et, Pyridine N-oxide-4-yl, O, S), (N-1351: Et, Pyridine N-oxide-3-yl, O, S), (N-1352: Et, 6-OH-pyridine-3-yl, O, S), (N-1353: Et, 6-SH-pyridine-3-yl, O, S), (N-1354: Et, 1-Ac-pyrrole-3-yl, O, S), (N-1355: Et, 4-CF₃-Ph, O, S), (N-1356: Et, 4-CN-Ph, O, S), (N-1357: Et, 4-CHO-Ph, O, S), (N-1358: Et, 3-Cl-Ph, O, S), (N-1359: Et, 3-Br-Ph, O, S), (N-1360: Et, 3-F-Ph, O, S), (N-1361: Et, 3-I-Ph, O, S), (N-1362: Et, 4-I-Ph, O, S), (N-1363: Et, 4-OCF₃-Ph, O, S), (N-1364: Et, 3,4-diI-Ph, O, S), (N-1365: Et, Indole-6-yl, O, S), (N-1366: Et, 1-Ac-indole-6-yl, O, S), (N-1367: Et, 1-Me-indole-6-yl, O, S), (N-1368: Et, 4-(1-Imidazolyl)-Ph, O, S), (N-1369: Et, 4-Morpholino-Ph, O, S), (N-1370: Et, 4-(1-Piperazinyl)-Ph, O, S), (N-1371: Et, 2,5-diMe-thiophene-3-yl, O, S), (N-1372: Et, 2-Furyl, O, S), (N-1373: Et, 5-Me-furan-2-yl, O, S), (N-1374: Et, 5-Me-furan-2-yl, O, S), (N-1375: Et, 2-Thiazolyl, O, S), (N-1376: Et, 1:4-Benzodioxin-6-yl, O, S), (N-1377: Et, Benzo[b]furan-2-yl, O, S), (N-1378: Et, 4-NH₂CH₂-Ph, O, S), (N-1379: Et, 4-N(Me)HCH₂-Ph, O, S), (N-1380: Et, 4-N(Me)₂CH₂-Ph, O, S), (N-1381: Et, 6-Cl-pyridine-3-yl, O, S), (N-1382: Et, 5,6-diCl-pyridine-3-yl, O, S), (N-1383: Et, 5-Cl-pyridine-2-yl, O, S), (N-1384: Et, 4:5-diCl-pyridine-2-yl, O, S), (N-1385: Et, 4-ClCH₂-Bn, O, S), (N-1386: Et, Bn, O, S), (N-1387: Et, 4-Cl-Bn, O, S), (N-1388: Et, 4-Br-Bn, O, S), (N-1389: Et, 4-F-Bn, O, S), (N-1390: Et, 3,4-diCl-Bn, O, S), (N-1391: Et, 3,4-diBr-Bn, O, S), (N-1392: Et, 3,4-diF-Bn, O, S), (N-1393: Et, 4-Cl-Bz, O, S), (N-1394: Et, 3,4-diCl-Bz, O, S), (N-1395: Et, 4-Br-Bz, O, S), (N-1396: Et, 3,4-diBr-Bz, O, S), (N-1397: Et, 4-F-Bz, O, S), (N-1398: Et, 3,4-diF-Bz, O, S), (N-1399: Et, 4-NO₂-Bn, O, S), (N-1400: Et, 4-CN-Bn, O, S), (N-1401: COOMe, Ph, O, S), (N-1402: COOMe, 4-F-Ph, O, S), (N-1403: COOMe, 4-Br-Ph, O, S), (N-1404: COOMe, 4-Me-Ph, O, S), (N-1405: COOMe, 4-Ph-Ph, O, S), (N-1406: COOMe, 4-OMe-Ph, O, S), (N-1407: COOMe, 4-tBu-Ph, O, S), (N-1408: COOMe, 4-COOMe-Ph, O, S),

- (N-1409: COOMe, 4-Pen-Ph, O, S), (N-1410: COOMe, 4-NO₂-Ph, O, S), (N-1411: COOMe, 5-Cl-thiophene-2-yl, O, S), (N-1412: COOMe, 3-Thienyl, O, S), (N-1413: COOMe, 2-Py, O, S), (N-1414: COOMe, 3-Py, O, S), (N-1415: COOMe, 4-Py, O, S), (N-1416: COOMe, 3,4-diF-Ph, O, S), (N-1417: COOMe, 5-Br-thiophene-2-yl, O, S), (N-1418: COOMe, 4-CONH₂-Ph, O, S), (N-1419: COOMe, 4-CON(Me)H-Ph, O, S), (N-1420: COOMe, 4-CON(Me)₂-Ph, O, S), (N-1421: COOMe, 4-iPrOC(=O)-Ph, O, S), (N-1422: COOMe, 4-nBuOC(=O)-Ph, O, S), (N-1423: COOMe, 6-Me-pyridine-3-yl, O, S), (N-1424: COOMe, Quinoline-3-yl, O, S), (N-1425: COOMe, 4-NH₂-Ph, O, S), (N-1426: COOMe, 4-N(Ac)H-Ph, O, S), (N-1427: COOMe, 4-OH-Ph, O, S), (N-1428: COOMe, 3,4-di(OH)₂-Ph, O, S), (N-1429: COOMe, 3,4-di(NH₂)-Ph, O, S), (N-1430: COOMe, 3:4-[N(Ac)H]₂-Ph, O, S), (N-1431: COOMe, 4-SH-Ph, O, S), (N-1432: COOMe, 4-SMe-Ph, O, S), (N-1433: COOMe, 3,4-diBr-Ph, O, S), (N-1434: COOMe, 4-N(Me)H-Ph, O, S), (N-1435: COOMe, 4-N(Me)₂-Ph, O, S), (N-1436: COOMe, 4-N(Me)₃⁺-Ph, O, S), (N-1437: COOMe, 4-Et-Ph, O, S), (N-1438: COOMe, 4-iPr-Ph, O, S), (N-1439: COOMe, 4-nPr-Ph, O, S), (N-1440: COOMe, 4-nBu-Ph, O, S), (N-1441: COOMe, 4-iBu-Ph, O, S), (N-1442: COOMe, 3,4-diMe-Ph, O, S), (N-1443: COOMe, 1,3-Benzodioxole-5-yl, O, S), (N-1444: COOMe, N-Me-pyridinium-4-yl, O, S), (N-1445: COOMe, N-Me-pyridinium-3-yl, O, S), (N-1446: COOMe, 5-Me-Pyridine-2-yl, O, S), (N-1447: COOMe, 2-Pyrazinyl, O, S), (N-1448: COOMe, 3-Pyrrolyl, O, S), (N-1449: COOMe, 1-Me-pyrrole-3-yl, O, S), (N-1450: COOMe, Pyridine N-oxide-4-yl, O, S), (N-1451: COOMe, Pyridine N-oxide-3-yl, O, S), (N-1452: COOMe, 6-OH-pyridine-3-yl, O, S), (N-1453: COOMe, 6-SH-pyridine-3-yl, O, S), (N-1454: COOMe, 1-Ac-pyrrole-3-yl, O, S), (N-1455: COOMe, 4-CF₃-Ph, O, S), (N-1456: COOMe, 4-CN-Ph, O, S), (N-1457: COOMe, 4-CHO-Ph, O, S), (N-1458: COOMe, 3-Cl-Ph, O, S), (N-1459: COOMe, 3-Br-Ph, O, S), (N-1460: COOMe, 3-F-Ph, O, S), (N-1461: COOMe, 3-I-Ph, O, S), (N-

- 1462: COOMe, 4-I-Ph, O, S), (N-1463: COOMe, 4-OCF₃-Ph, O, S), (N-1464: COOMe, 3,4-diI-Ph, O, S), (N-1465: COOMe, Indole-6-yl, O, S), (N-1466: COOMe, 1-Ac-indole-6-yl, O, S), (N-1467: COOMe, 1-Me-indole-6-yl, O, S), (N-1468: COOMe, 4-(1-Imidazolyl)-Ph, O, S), (N-1469: COOMe, 4-Morpholino-Ph, O, S), (N-1470: COOMe, 4-(1-Piperazinyl)-Ph, O, S), (N-1471: COOMe, 2:5-diMe-thiophene-3-yl, O, S), (N-1472: COOMe, 2-Furyl, O, S), (N-1473: COOMe, 5-Me-furan-2-yl, O, S), (N-1474: COOMe, 5-Me-furan-2-yl, O, S), (N-1475: COOMe, 2-Thiazolyl, O, S), (N-1476: COOMe, 1:4-Benzodioxin-6-yl, O, S), (N-1477: COOMe, Benzo[b]furan-2-yl, O, S), (N-1478: COOMe, 4-NH₂CH₂-Ph, O, S), (N-1479: COOMe, 4-N(Me)HCH₂-Ph, O, S), (N-1480: COOMe, 4-N(Me)₂CH₂-Ph, O, S), (N-1481: COOMe, 6-Cl-pyridine-3-yl, O, S), (N-1482: COOMe, 5,6-diCl-pyridine-3-yl, O, S), (N-1483: COOMe, 5-Cl-pyridine-2-yl, O, S), (N-1484: COOMe, 4:5-diCl-pyridine-2-yl, O, S), (N-1485: COOMe, 4-ClCH₂-Bn, O, S), (N-1486: COOMe, Bn, O, S), (N-1487: COOMe, 4-Cl-Bn, O, S), (N-1488: COOMe, 4-Br-Bn, O, S), (N-1489: COOMe, 4-F-Bn, O, S), (N-1490: COOMe, 3,4-diCl-Bn, O, S), (N-1491: COOMe, 3,4-diBr-Bn, O, S), (N-1492: COOMe, 3,4-diF-Bn, O, S), (N-1493: COOMe, 4-Cl-Bz, O, S), (N-1494: COOMe, 3,4-diCl-Bz, O, S), (N-1495: COOMe, 4-Br-Bz, O, S), (N-1496: COOMe, 3,4-diBr-Bz, O, S), (N-1497: COOMe, 4-F-Bz, O, S), (N-1498: COOMe, 3,4-diF-Bz, O, S), (N-1499: COOMe, 4-NO₂-Bn, O, S), (N-1500: COOMe, 4-CN-Bn, O, S), (N-1501: Ph, Me, S, O), (N-1502: 4-F-Ph, Me, S, O), (N-1503: 4-Br-Ph, Me, S, O), (N-1504: 4-Me-Ph, Me, S, O), (N-1505: 4-Ph-Ph, Me, S, O), (N-1506: 4-OMe-Ph, Me, S, O), (N-1507: 4-tBu-Ph, Me, S, O), (N-1508: 4-COOMe-Ph, Me, S, O), (N-1509: 4-Pen-Ph, Me, S, O), (N-1510: 4-NO₂-Ph, Me, S, O), (N-1511: 5-Cl-thiophene-2-yl, Me, S, O), (N-1512: 3-Thienyl, Me, S, O), (N-1513: 2-Py, Me, S, O), (N-1514: 3-Py, Me, S, O), (N-1515: 4-Py, Me, S, O), (N-1516: 3,4-diF-Ph, Me, S, O), (N-1517: 5-Br-thiophene-2-yl, Me, S, O), (N-1518: 4-CONH₂-Ph, Me, S,

- O), (N-1519: 4-CON(Me)H-Ph, Me, S, O), (N-1520: 4-CON(Me)₂-Ph, Me, S, O),
 (N-1521: 4-iPrOC(=O)-Ph, Me, S, O), (N-1522: 4-nBuOC(=O)-Ph, Me, S, O),
 (N-1523: 6-Me-pyridine-3-yl, Me, S, O), (N-1524: Quinoline-3-yl, Me, S, O),
 (N-1525: 4-NH₂-Ph, Me, S, O), (N-1526: 4-N(Ac)H-Ph, Me, S, O), (N-1527: 4-
 5 OH-Ph, Me, S, O), (N-1528: 3,4-di(OH)₂-Ph, Me, S, O), (N-1529: 3,4-di(NH₂)-Ph,
 Me, S, O), (N-1530: 3:4-[N(Ac)H]₂-Ph, Me, S, O), (N-1531: 4-SH-Ph, Me, S, O),
 (N-1532: 4-SMe-Ph, Me, S, O), (N-1533: 3,4-diBr-Ph, Me, S, O), (N-1534: 4-
 N(Me)H-Ph, Me, S, O), (N-1535: 4-N(Me)₂-Ph, Me, S, O), (N-1536: 4-N(Me)₃⁺-
 Ph, Me, S, O), (N-1537: 4-Et-Ph, Me, S, O), (N-1538: 4-iPr-Ph, Me, S, O), (N-
 10 1539: 4-nPr-Ph, Me, S, O), (N-1540: 4-nBu-Ph, Me, S, O), (N-1541: 4-iBu-Ph,
 Me, S, O), (N-1542: 3,4-diMe-Ph, Me, S, O), (N-1543: 1,3-Benzodioxole-5-yl, Me,
 S, O), (N-1544: N-Me-pyridinium-4-yl, Me, S, O), (N-1545: N-Me-pyridinium-
 3-yl, Me, S, O), (N-1546: 5-Me-Pyridine-2-yl, Me, S, O), (N-1547: 2-Pyrazinyl,
 Me, S, O), (N-1548: 3-Pyrrolyl, Me, S, O), (N-1549: 1-Me-pyrrole-3-yl, Me, S,
 15 O), (N-1550: Pyridine N-oxide-4-yl, Me, S, O), (N-1551: Pyridine N-oxide-3-yl,
 Me, S, O), (N-1552: 6-OH-pyridine-3-yl, Me, S, O), (N-1553: 6-SH-pyridine-3-
 yl, Me, S, O), (N-1554: 1-Ac-pyrrole-3-yl, Me, S, O), (N-1555: 4-CF₃-Ph, Me, S,
 O), (N-1556: 4-CN-Ph, Me, S, O), (N-1557: 4-CHO-Ph, Me, S, O), (N-1558: 3-
 Cl-Ph, Me, S, O), (N-1559: 3-Br-Ph, Me, S, O), (N-1560: 3-F-Ph, Me, S, O),
 20 (N-1561: 3-I-Ph, Me, S, O), (N-1562: 4-I-Ph, Me, S, O), (N-1563: 4-OCF₃-Ph, Me,
 S, O), (N-1564: 3,4-diI-Ph, Me, S, O), (N-1565: Indole-6-yl, Me, S, O), (N-1566:
 1-Ac-indole-6-yl, Me, S, O), (N-1567: 1-Me-indole-6-yl, Me, S, O), (N-1568: 4-
 (1-Imidazolyl)-Ph, Me, S, O), (N-1569: 4-Morpholino-Ph, Me, S, O), (N-1570:
 4-(1-Piperazinyl)-Ph, Me, S, O), (N-1571: 2,5-diMe-thiophene-3-yl, Me, S, O),
 25 (N-1572: 2-Furyl, Me, S, O), (N-1573: 5-Me-furan-2-yl, Me, S, O), (N-1574: 5-
 Me-furan-2-yl, Me, S, O), (N-1575: 2-Thiazolyl, Me, S, O), (N-1576: 1:4-
 Benzodioxin-6-yl, Me, S, O), (N-1577: Benzo[b]furan-2-yl, Me, S, O), (N-1578:

- 4-NH₂CH₂-Ph, Me, S, O), (N-1579: 4-N(Me)HCH₂-Ph, Me, S, O), (N-1580: 4-N(Me)₂CH₂-Ph, Me, S, O), (N-1581: 6-Cl-pyridine-3-yl, Me, S, O), (N-1582: 5,6-diCl-pyridine-3-yl, Me, S, O), (N-1583: 5-Cl-pyridine-2-yl, Me, S, O), (N-1584: 4:5-diCl-pyridine-2-yl, Me, S, O), (N-1585: 4-ClCH₂-Bn, Me, S, O), (N-1586: Bn, Me, S, O), (N-1587: 4-Cl-Bn, Me, S, O), (N-1588: 4-Br-Bn, Me, S, O), (N-1589: 4-F-Bn, Me, S, O), (N-1590: 3,4-diCl-Bn, Me, S, O), (N-1591: 3,4-diBr-Bn, Me, S, O), (N-1592: 3,4-diF-Bn, Me, S, O), (N-1593: 4-Cl-Bz, Me, S, O), (N-1594: 3,4-diCl-Bz, Me, S, O), (N-1595: 4-Br-Bz, Me, S, O), (N-1596: 3,4-diBr-Bz, Me, S, O), (N-1597: 4-F-Bz, Me, S, O), (N-1598: 3,4-diF-Bz, Me, S, O), (N-1599: 4-NO₂-Bn, Me, S, O), (N-1600: 4-CN-Bn, Me, S, O), (N-1602: 4-F-Ph, Et, S, O), (N-1603: 4-Br-Ph, Et, S, O), (N-1604: 4-Me-Ph, Et, S, O), (N-1605: 4-Ph-Ph, Et, S, O), (N-1606: 4-OMe-Ph, Et, S, O), (N-1607: 4-tBu-Ph, Et, S, O), (N-1608: 4-COOMe-Ph, Et, S, O), (N-1609: 4-Pen-Ph, Et, S, O), (N-1610: 4-NO₂-Ph, Et, S, O), (N-1611: 5-Cl-thiophene-2-yl, Et, S, O), (N-1612: 3-Thienyl, Et, S, O), (N-1613: 2-Py, Et, S, O), (N-1614: 3-Py, Et, S, O), (N-1615: 4-Py, Et, S, O), (N-1616: 3,4-diF-Ph, Et, S, O), (N-1617: 5-Br-thiophene-2-yl, Et, S, O), (N-1618: 4-CONH₂-Ph, Et, S, O), (N-1619: 4-CON(Me)H-Ph, Et, S, O), (N-1620: 4-CON(Me)₂-Ph, Et, S, O), (N-1621: 4-iPrOC(=O)-Ph, Et, S, O), (N-1622: 4-nBuOC(=O)-Ph, Et, S, O), (N-1623: 6-Me-pyridine-3-yl, Et, S, O), (N-1624: Quinoline-3-yl, Et, S, O), (N-1625: 4-NH₂-Ph, Et, S, O), (N-1626: 4-N(Ac)H-Ph, Et, S, O), (N-1627: 4-OH-Ph, Et, S, O), (N-1628: 3,4-di(OH)₂-Ph, Et, S, O), (N-1629: 3,4-di(NH₂)-Ph, Et, S, O), (N-1630: 3:4-[N(Ac)H]₂-Ph, Et, S, O), (N-1631: 4-SH-Ph, Et, S, O), (N-1632: 4-SMe-Ph, Et, S, O), (N-1633: 3,4-diBr-Ph, Et, S, O), (N-1634: 4-N(Me)H-Ph, Et, S, O), (N-1635: 4-N(Me)₂-Ph, Et, S, O), (N-1636: 4-N(Me)₃*-Ph, Et, S, O), (N-1637: 4-Et-Ph, Et, S, O), (N-1638: 4-iPr-Ph, Et, S, O), (N-1639: 4-nPr-Ph, Et, S, O), (N-1640: 4-nBu-Ph, Et, S, O), (N-1641: 4-iBu-Ph, Et, S, O), (N-1642: 3,4-diMe-Ph, Et, S, O), (N-1643: 1,3-Benzodioxole-

- 5-yl, Et, S, O), (N-1644: N-Me-pyridinium-4-yl, Et, S, O), (N-1645: N-Me-pyridinium-3-yl, Et, S, O), (N-1646: 5-Me-Pyridine-2-yl, Et, S, O), (N-1647: 2-Pyrazinyl, Et, S, O), (N-1648: 3-Pyrrolyl, Et, S, O), (N-1649: 1-Me-pyrrole-3-yl, Et, S, O), (N-1650: Pyridine N-oxide-4-yl, Et, S, O), (N-1651: Pyridine N-oxide-3-yl, Et, S, O), (N-1652: 6-OH-pyridine-3-yl, Et, S, O), (N-1653: 6-SH-pyridine-3-yl, Et, S, O), (N-1654: 1-Ac-pyrrole-3-yl, Et, S, O), (N-1655: 4-CF₃-Ph, Et, S, O), (N-1656: 4-CN-Ph, Et, S, O), (N-1657: 4-CHO-Ph, Et, S, O), (N-1658: 3-Cl-Ph, Et, S, O), (N-1659: 3-Br-Ph, Et, S, O), (N-1660: 3-F-Ph, Et, S, O), (N-1661: 3-I-Ph, Et, S, O), (N-1662: 4-I-Ph, Et, S, O), (N-1663: 4-OCF₃-Ph, Et, S, O), (N-1664: 3,4-diI-Ph, Et, S, O), (N-1665: Indole-6-yl, Et, S, O), (N-1666: 1-Ac-indole-6-yl, Et, S, O), (N-1667: 1-Me-indole-6-yl, Et, S, O), (N-1668: 4-(1-Imidazolyl)-Ph, Et, S, O), (N-1669: 4-Morpholino-Ph, Et, S, O), (N-1670: 4-(1-Piperazinyl)-Ph, Et, S, O), (N-1671: 2:5-diMe-thiophene-3-yl, Et, S, O), (N-1672: 2-Furyl, Et, S, O), (N-1673: 5-Me-furan-2-yl, Et, S, O), (N-1674: 5-Me-furan-2-yl, Et, S, O), (N-1675: 2-Thiazolyl, Et, S, O), (N-1676: 1:4-Benzodioxin-6-yl, Et, S, O), (N-1677: Benzo[b]furan-2-yl, Et, S, O), (N-1678: 4-NH₂CH₂-Ph, Et, S, O), (N-1679: 4-N(Me)HCH₂-Ph, Et, S, O), (N-1680: 4-N(Me)₂CH₂-Ph, Et, S, O), (N-1681: 6-Cl-pyridine-3-yl, Et, S, O), (N-1682: 5,6-diCl-pyridine-3-yl, Et, S, O), (N-1683: 5-Cl-pyridine-2-yl, Et, S, O), (N-1684: 4:5-diCl-pyridine-2-yl, Et, S, O), (N-1685: 4-ClCH₂-Bn, Et, S, O), (N-1686: Bn, Et, S, O), (N-1687: 4-Cl-Bn, Et, S, O), (N-1688: 4-Br-Bn, Et, S, O), (N-1689: 4-F-Bn, Et, S, O), (N-1690: 3,4-diCl-Bn, Et, S, O), (N-1691: 3,4-diBr-Bn, Et, S, O), (N-1692: 3,4-diF-Bn, Et, S, O), (N-1693: 4-Cl-Bz, Et, S, O), (N-1694: 3,4-diCl-Bz, Et, S, O), (N-1695: 4-Br-Bz, Et, S, O), (N-1696: 3,4-diBr-Bz, Et, S, O), (N-1697: 4-F-Bz, Et, S, O), (N-1698: 3,4-diF-Bz, Et, S, O), (N-1699: 4-NO₂-Bn, Et, S, O), (N-1700: 4-CN-Bn, Et, S, O), (N-1701: Ph, COOMe, S, O), (N-1702: 4-F-Ph, COOMe, S, O), (N-1703: 4-Br-Ph, COOMe, S, O), (N-1704: 4-Me-Ph,

- COOMe, S, O), (N-1705: 4-Ph-Ph, COOMe, S, O), (N-1706: 4-OMe-Ph, COOMe, S, O), (N-1707: 4-tBu-Ph, COOMe, S, O), (N-1708: 4-COOMe-Ph, COOMe, S, O), (N-1709: 4-Pen-Ph, COOMe, S, O), (N-1710: 4-NO₂-Ph, COOMe, S, O), (N-1711: 5-Cl-thiophene-2-yl, COOMe, S, O), (N-1712: 3-Thienyl, COOMe, S, O), (N-1713: 2-Py, COOMe, S, O), (N-1714: 3-Py, COOMe, S, O), (N-1715: 4-Py, COOMe, S, O), (N-1716: 3,4-diF-Ph, COOMe, S, O), (N-1717: 5-Br-thiophene-2-yl, COOMe, S, O), (N-1718: 4-CONH₂-Ph, COOMe, S, O), (N-1719: 4-CON(Me)H-Ph, COOMe, S, O), (N-1720: 4-CON(Me)₂-Ph, COOMe, S, O), (N-1721: 4-iPrOC(=O)-Ph, COOMe, S, O), (N-1722: 4-nBuOC(=O)-Ph, COOMe, S, O), (N-1723: 6-Me-pyridine-3-yl, COOMe, S, O), (N-1724: Quinoline-3-yl, COOMe, S, O), (N-1725: 4-NH₂-Ph, COOMe, S, O), (N-1726: 4-N(Ac)H-Ph, COOMe, S, O), (N-1727: 4-OH-Ph, COOMe, S, O), (N-1728: 3,4-di(OH)₂-Ph, COOMe, S, O), (N-1729: 3,4-di(NH₂)-Ph, COOMe, S, O), (N-1730: 3:4-[N(Ac)H]₂-Ph, COOMe, S, O), (N-1731: 4-SH-Ph, COOMe, S, O), (N-1732: 4-SMe-Ph, COOMe, S, O), (N-1733: 3,4-diBr-Ph, COOMe, S, O), (N-1734: 4-N(Me)H-Ph, COOMe, S, O), (N-1735: 4-N(Me)₂-Ph, COOMe, S, O), (N-1736: 4-N(Me)₃⁺-Ph, COOMe, S, O), (N-1737: 4-Et-Ph, COOMe, S, O), (N-1738: 4-iPr-Ph, COOMe, S, O), (N-1739: 4-nPr-Ph, COOMe, S, O), (N-1740: 4-nBu-Ph, COOMe, S, O), (N-1741: 4-iBu-Ph, COOMe, S, O), (N-1742: 3,4-diMe-Ph, COOMe, S, O), (N-1743: 1,3-Benzodioxole-5-yl, COOMe, S, O), (N-1744: N-Me-pyridinium-4-yl, COOMe, S, O), (N-1745: N-Me-pyridinium-3-yl, COOMe, S, O), (N-1746: 5-Me-Pyridine-2-yl, COOMe, S, O), (N-1747: 2-Pyrazinyl, COOMe, S, O), (N-1748: 3-Pyrrolyl, COOMe, S, O), (N-1749: 1-Me-pyrrole-3-yl, COOMe, S, O), (N-1750: Pyridine N-oxide-4-yl, COOMe, S, O), (N-1751: Pyridine N-oxide-3-yl, COOMe, S, O), (N-1752: 6-OH-pyridine-3-yl, COOMe, S, O), (N-1753: 6-SH-pyridine-3-yl, COOMe, S, O), (N-1754: 1-Ac-pyrrole-3-yl, COOMe, S, O), (N-1755: 4-CF₃-Ph, COOMe, S, O), (N-1756: 4-CN-Ph, COOMe,

- S, O), (N-1757: 4-CHO-Ph, COOMe, S, O), (N-1758: 3-Cl-Ph, COOMe, S, O),
 (N-1759: 3-Br-Ph, COOMe, S, O), (N-1760: 3-F-Ph, COOMe, S, O), (N-1761: 3-I-Ph, COOMe, S, O), (N-1762: 4-I-Ph, COOMe, S, O), (N-1763: 4-OCF₃-Ph, COOMe, S, O), (N-1764: 3,4-diI-Ph, COOMe, S, O), (N-1765: Indole-6-yl, COOMe, S, O), (N-1766: 1-Ac-indole-6-yl, COOMe, S, O), (N-1767: 1-Me-indole-6-yl, COOMe, S, O), (N-1768: 4-(1-Imidazolyl)-Ph, COOMe, S, O), (N-1769: 4-Morphorino-Ph, COOMe, S, O), (N-1770: 4-(1-Piperazinyl)-Ph, COOMe, S, O), (N-1771: 2,5-diMe-thiophene-3-yl, COOMe, S, O), (N-1772: 2-Furyl, COOMe, S, O), (N-1773: 5-Me-furan-2-yl, COOMe, S, O), (N-1774: 5-Me-furan-2-yl, COOMe, S, O), (N-1775: 2-Thiazolyl, COOMe, S, O), (N-1776: 1:4-Benzodioxin-6-yl, COOMe, S, O), (N-1777: Benzo[b]furan-2-yl, COOMe, S, O), (N-1778: 4-NH₂CH₂-Ph, COOMe, S, O), (N-1779: 4-N(Me)HCH₂-Ph, COOMe, S, O), (N-1780: 4-N(Me)₂CH₂-Ph, COOMe, S, O), (N-1781: 6-Cl-pyridine-3-yl, COOMe, S, O), (N-1782: 5,6-diCl-pyridine-3-yl, COOMe, S, O), (N-1783: 5-Cl-pyridine-2-yl, COOMe, S, O), (N-1784: 4:5-diCl-pyridine-2-yl, COOMe, S, O), (N-1785: 4-ClCH₂-Bn, COOMe, S, O), (N-1786: Bn, COOMe, S, O), (N-1787: 4-Cl-Bn, COOMe, S, O), (N-1788: 4-Br-Bn, COOMe, S, O), (N-1789: 4-F-Bn, COOMe, S, O), (N-1790: 3,4-diCl-Bn, COOMe, S, O), (N-1791: 3,4-diBr-Bn, COOMe, S, O), (N-1792: 3,4-diF-Bn, COOMe, S, O), (N-1793: 4-Cl-Bz, COOMe, S, O), (N-1794: 3,4-diCl-Bz, COOMe, S, O), (N-1795: 4-Br-Bz, COOMe, S, O), (N-1796: 3,4-diBr-Bz, COOMe, S, O), (N-1797: 4-F-Bz, COOMe, S, O), (N-1798: 3,4-diF-Bz, COOMe, S, O), (N-1799: 4-NO₂-Bn, COOMe, S, O), (N-1800: 4-CN-Bn, COOMe, S, O), (N-1801: H, Ph, S, O), (N-1802: H, 4-F-Ph, S, O), (N-1803: H, 4-Br-Ph, S, O), (N-1804: H, 4-Me-Ph, S, O), (N-1805: H, 4-Ph-Ph, S, O), (N-1806: H, 4-OMe-Ph, S, O), (N-1807: H, 4-tBu-Ph, S, O), (N-1808: H, 4-COOMe-Ph, S, O), (N-1809: H, 4-Pen-Ph, S, O), (N-1810: H, 4-NO₂-Ph, S, O), (N-1811: H, 5-Cl-thiophene-2-yl, S, O), (N-1812: H, 3-Thienyl, S, O), (N-1813:

- H, 2-Py, S, O), (N-1814: H, 3-Py, S, O), (N-1815: H, 4-Py, S, O), (N-1816: H, 3,4-diF-Ph, S, O), (N-1817: H, 5-Br-thiophene-2-yl, S, O), (N-1818: H, 4-CONH₂-Ph, S, O), (N-1819: H, 4-CON(Me)H-Ph, S, O), (N-1820: H, 4-CON(Me)₂-Ph, S, O), (N-1821: H, 4-iPrOC(=O)-Ph, S, O), (N-1822: H, 4-nBuOC(=O)-Ph, S, O), (N-1823: H, 6-Me-pyridine-3-yl, S, O), (N-1824: H, Quinoline-3-yl, S, O), (N-1825: H, 4-NH₂-Ph, S, O), (N-1826: H, 4-N(Ac)H-Ph, S, O), (N-1827: H, 4-OH-Ph, S, O), (N-1828: H, 3,4-di(OH)₂-Ph, S, O), (N-1829: H, 3,4-di(NH₂)-Ph, S, O), (N-1830: H, 3:4-[N(Ac)H]₂-Ph, S, O), (N-1831: H, 4-SH-Ph, S, O), (N-1832: H, 4-SMe-Ph, S, O), (N-1833: H, 3,4-diBr-Ph, S, O), (N-1834: H, 4-N(Me)H-Ph, S, O), (N-1835: H, 4-N(Me)₂-Ph, S, O), (N-1836: H, 4-N(Me)₃⁺-Ph, S, O), (N-1837: H, 4-Et-Ph, S, O), (N-1838: H, 4-iPr-Ph, S, O), (N-1839: H, 4-nPr-Ph, S, O), (N-1840: H, 4-nBu-Ph, S, O), (N-1841: H, 4-iBu-Ph, S, O), (N-1842: H, 3,4-diMe-Ph, S, O), (N-1843: H, 1,3-Benzodioxole-5-yl, S, O), (N-1844: H, N-Me-pyridinium-4-yl, S, O), (N-1845: H, N-Me-pyridinium-3-yl, S, O), (N-1846: H, 5-Me-Pyridine-2-yl, S, O), (N-1847: H, 2-Pyrazinyl, S, O), (N-1848: H, 3-Pyrrolyl, S, O), (N-1849: H, 1-Me-pyrrole-3-yl, S, O), (N-1850: H, Pyridine N-oxide-4-yl, S, O), (N-1851: H, Pyridine N-oxide-3-yl, S, O), (N-1852: H, 6-OH-pyridine-3-yl, S, O), (N-1853: H, 6-SH-pyridine-3-yl, S, O), (N-1854: H, 1-Ac-pyrrole-3-yl, S, O), (N-1855: H, 4-CF₃-Ph, S, O), (N-1856: H, 4-CN-Ph, S, O), (N-1857: H, 4-CHO-Ph, S, O), (N-1858: H, 3-Cl-Ph, S, O), (N-1859: H, 3-Br-Ph, S, O), (N-1860: H, 3-F-Ph, S, O), (N-1861: H, 3-I-Ph, S, O), (N-1862: H, 4-I-Ph, S, O), (N-1863: H, 4-OCF₃-Ph, S, O), (N-1864: H, 3,4-diI-Ph, S, O), (N-1865: H, Indole-6-yl, S, O), (N-1866: H, 1-Ac-indole-6-yl, S, O), (N-1867: H, 1-Me-indole-6-yl, S, O), (N-1868: H, 4-(1-Imidazolyl)-Ph, S, O), (N-1869: H, 4-Morphorino-Ph, S, O), (N-1870: H, 4-(1-Piperazinyl)-Ph, S, O), (N-1871: H, 2:5-diMe-thiophene-3-yl, S, O), (N-1872: H, 2-Furyl, S, O), (N-1873: H, 5-Me-furan-2-yl, S, O), (N-1874: H, 5-Me-furan-2-yl, S, O), (N-1875: H, 2-

- Thiazolyl, S, O), (N-1876: H, 1:4-Benzodioxin-6-yl, S, O), (N-1877: H, Benzo[b]furan-2-yl, S, O), (N-1878: H, 4-NH₂CH₂-Ph, S, O), (N-1879: H, 4-N(Me)HCH₂-Ph, S, O), (N-1880: H, 4-N(Me)₂CH₂-Ph, S, O), (N-1881: H, 6-Cl-pyridine-3-yl, S, O), (N-1882: H, 5,6-diCl-pyridine-3-yl, S, O), (N-1883: H, 5-Cl-pyridine-2-yl, S, O), (N-1884: H, 4:5-diCl-pyridine-2-yl, S, O), (N-1885: H, 4-ClCH₂-Bn, S, O), (N-1886: H, Bn, S, O), (N-1887: H, 4-Cl-Bn, S, O), (N-1888: H, 4-Br-Bn, S, O), (N-1889: H, 4-F-Bn, S, O), (N-1890: H, 3,4-diCl-Bn, S, O), (N-1891: H, 3,4-diBr-Bn, S, O), (N-1892: H, 3,4-diF-Bn, S, O), (N-1893: H, 4-Cl-Bz, S, O), (N-1894: H, 3,4-diCl-Bz, S, O), (N-1895: H, 4-Br-Bz, S, O), (N-1896: H, 3,4-diBr-Bz, S, O), (N-1897: H, 4-F-Bz, S, O), (N-1898: H, 3,4-diF-Bz, S, O), (N-1899: H, 4-NO₂-Bn, S, O), (N-1900: H, 4-CN-Bn, S, O), (N-1901: Et, Ph, S, O), (N-1902: Et, 4-F-Ph, S, O), (N-1903: Et, 4-Br-Ph, S, O), (N-1904: Et, 4-Me-Ph, S, O), (N-1905: Et, 4-Ph-Ph, S, O), (N-1906: Et, 4-OMe-Ph, S, O), (N-1907: Et, 4-tBu-Ph, S, O), (N-1908: Et, 4-COOMe-Ph, S, O), (N-1909: Et, 4-Pen-Ph, S, O), (N-1910: Et, 4-NO₂-Ph, S, O), (N-1911: Et, 5-Cl-thiophene-2-yl, S, O), (N-1912: Et, 3-Thienyl, S, O), (N-1913: Et, 2-Py, S, O), (N-1914: Et, 3-Py, S, O), (N-1915: Et, 4-Py, S, O), (N-1916: Et, 3,4-diF-Ph, S, O), (N-1917: Et, 5-Br-thiophene-2-yl, S, O), (N-1918: Et, 4-CONH₂-Ph, S, O), (N-1919: Et, 4-CON(Me)H-Ph, S, O), (N-1920: Et, 4-CON(Me)₂-Ph, S, O), (N-1921: Et, 4-iPrOC(=O)-Ph, S, O), (N-1922: Et, 4-nBuOC(=O)-Ph, S, O), (N-1923: Et, 6-Me-pyridine-3-yl, S, O), (N-1924: Et, Quinoline-3-yl, S, O), (N-1925: Et, 4-NH₂-Ph, S, O), (N-1926: Et, 4-N(Ac)H-Ph, S, O), (N-1927: Et, 4-OH-Ph, S, O), (N-1928: Et, 3,4-di(OH)₂-Ph, S, O), (N-1929: Et, 3,4-di(NH₂)-Ph, S, O), (N-1930: Et, 3:4-[N(Ac)H]₂-Ph, S, O), (N-1931: Et, 4-SH-Ph, S, O), (N-1932: Et, 4-SMe-Ph, S, O), (N-1933: Et, 3,4-diBr-Ph, S, O), (N-1934: Et, 4-N(Me)H-Ph, S, O), (N-1935: Et, 4-N(Me)₂-Ph, S, O), (N-1936: Et, 4-N(Me)₃⁺-Ph, S, O), (N-1937: Et, 4-Et-Ph, S, O), (N-1938: Et, 4-iPr-Ph, S, O), (N-1939: Et, 4-nPr-Ph, S, O),

- (N-1940: Et, 4-nBu-Ph, S, O), (N-1941: Et, 4-iBu-Ph, S, O), (N-1942: Et, 3,4-diMe-Ph, S, O), (N-1943: Et, 1,3-Benzodioxole-5-yl, S, O), (N-1944: Et, N-Me-pyridinium-4-yl, S, O), (N-1945: Et, N-Me-pyridinium-3-yl, S, O), (N-1946: Et, 5-Me-Pyridine-2-yl, S, O), (N-1947: Et, 2-Pyrazinyl, S, O), (N-1948: Et, 3-Pyrrolyl, S, O), (N-1949: Et, 1-Me-pyrrole-3-yl, S, O), (N-1950: Et, Pyridine N-oxide-4-yl, S, O), (N-1951: Et, Pyridine N-oxide-3-yl, S, O), (N-1952: Et, 6-OH-pyridine-3-yl, S, O), (N-1953: Et, 6-SH-pyridine-3-yl, S, O), (N-1954: Et, 1-Ac-pyrrole-3-yl, S, O), (N-1955: Et, 4-CF₃-Ph, S, O), (N-1956: Et, 4-CN-Ph, S, O), (N-1957: Et, 4-CHO-Ph, S, O), (N-1958: Et, 3-Cl-Ph, S, O), (N-1959: Et, 3-Br-Ph, S, O), (N-1960: Et, 3-F-Ph, S, O), (N-1961: Et, 3-I-Ph, S, O), (N-1962: Et, 4-I-Ph, S, O), (N-1963: Et, 4-OCF₃-Ph, S, O), (N-1964: Et, 3,4-diI-Ph, S, O), (N-1965: Et, Indole-6-yl, S, O), (N-1966: Et, 1-Ac-indole-6-yl, S, O), (N-1967: Et, 1-Me-indole-6-yl, S, O), (N-1968: Et, 4-(1-Imidazolyl)-Ph, S, O), (N-1969: Et, 4-Morpholino-Ph, S, O), (N-1970: Et, 4-(1-Piperazinyl)-Ph, S, O), (N-1971: Et, 2,5-diMe-thiophene-3-yl, S, O), (N-1972: Et, 2-Furyl, S, O), (N-1973: Et, 5-Me-furan-2-yl, S, O), (N-1974: Et, 5-Me-furan-2-yl, S, O), (N-1975: Et, 2-Thiazolyl, S, O), (N-1976: Et, 1:4-Benzodioxin-6-yl, S, O), (N-1977: Et, Benzo[b]furan-2-yl, S, O), (N-1978: Et, 4-NH₂CH₂-Ph, S, O), (N-1979: Et, 4-N(Me)HCH₂-Ph, S, O), (N-1980: Et, 4-N(Me)₂CH₂-Ph, S, O), (N-1981: Et, 6-Cl-pyridine-3-yl, S, O), (N-1982: Et, 5,6-diCl-pyridine-3-yl, S, O), (N-1983: Et, 5-Cl-pyridine-2-yl, S, O), (N-1984: Et, 4:5-diCl-pyridine-2-yl, S, O), (N-1985: Et, 4-ClCH₂-Bn, S, O), (N-1986: Et, Bn, S, O), (N-1987: Et, 4-Cl-Bn, S, O), (N-1988: Et, 4-Br-Bn, S, O), (N-1989: Et, 4-F-Bn, S, O), (N-1990: Et, 3,4-diCl-Bn, S, O), (N-1991: Et, 3,4-diBr-Bn, S, O), (N-1992: Et, 3,4-diF-Bn, S, O), (N-1993: Et, 4-Cl-Bz, S, O), (N-1994: Et, 3,4-diCl-Bz, S, O), (N-1995: Et, 4-Br-Bz, S, O), (N-1996: Et, 3,4-diBr-Bz, S, O), (N-1997: Et, 4-F-Bz, S, O), (N-1998: Et, 3,4-diF-Bz, S, O), (N-1999: Et, 4-NO₂-Bn, S, O), (N-2000: Et, 4-CN-Bn, S, O),

(N-2001: COOMe, Ph, S, O), (N-2002: COOMe, 4-F-Ph, S, O), (N-2003: COOMe, 4-Br-Ph, S, O), (N-2004: COOMe, 4-Me-Ph, S, O), (N-2005: COOMe, 4-Ph-Ph, S, O), (N-2006: COOMe, 4-OMe-Ph, S, O), (N-2007: COOMe, 4-tBu-Ph, S, O), (N-2008: COOMe, 4-COOMe-Ph, S, O), (N-2009: COOMe, 4-Pen-Ph, S, O), (N-2010: COOMe, 4-NO₂-Ph, S, O), (N-2011: COOMe, 5-Cl-thiophene-2-yl, S, O), (N-2012: COOMe, 3-Thienyl, S, O), (N-2013: COOMe, 2-Py, S, O), (N-2014: COOMe, 3-Py, S, O), (N-2015: COOMe, 4-Py, S, O), (N-2016: COOMe, 3,4-diF-Ph, S, O), (N-2017: COOMe, 5-Br-thiophene-2-yl, S, O), (N-2018: COOMe, 4-CONH₂-Ph, S, O), (N-2019: COOMe, 4-CON(Me)H-Ph, S, O), (N-2020: COOMe, 4-CON(Me)₂-Ph, S, O), (N-2021: COOMe, 4-iPrOC(=O)-Ph, S, O), (N-2022: COOMe, 4-nBuOC(=O)-Ph, S, O), (N-2023: COOMe, 6-Me-pyridine-3-yl, S, O), (N-2024: COOMe, Quinoline-3-yl, S, O), (N-2025: COOMe, 4-NH₂-Ph, S, O), (N-2026: COOMe, 4-N(Ac)H-Ph, S, O), (N-2027: COOMe, 4-OH-Ph, S, O), (N-2028: COOMe, 3,4-di(OH)₂-Ph, S, O), (N-2029: COOMe, 3,4-di(NH₂)-Ph, S, O), (N-2030: COOMe, 3:4-[N(Ac)H]₂-Ph, S, O), (N-2031: COOMe, 4-SH-Ph, S, O), (N-2032: COOMe, 4-SMe-Ph, S, O), (N-2033: COOMe, 3,4-diBr-Ph, S, O), (N-2034: COOMe, 4-N(Me)H-Ph, S, O), (N-2035: COOMe, 4-N(Me)₂-Ph, S, O), (N-2036: COOMe, 4-N(Me)₃⁺-Ph, S, O), (N-2037: COOMe, 4-Et-Ph, S, O), (N-2038: COOMe, 4-iPr-Ph, S, O), (N-2039: COOMe, 4-nPr-Ph, S, O), (N-2040: COOMe, 4-nBu-Ph, S, O), (N-2041: COOMe, 4-iBu-Ph, S, O), (N-2042: COOMe, 3,4-diMe-Ph, S, O), (N-2043: COOMe, 1,3-Benzodioxole-5-yl, S, O), (N-2044: COOMe, N-Me-pyridinium-4-yl, S, O), (N-2045: COOMe, N-Me-pyridinium-3-yl, S, O), (N-2046: COOMe, 5-Me-Pyridine-2-yl, S, O), (N-2047: COOMe, 2-Pyrazinyl, S, O), (N-2048: COOMe, 3-Pyrrolyl, S, O), (N-2049: COOMe, 1-Me-pyrrole-3-yl, S, O), (N-2050: COOMe, Pyridine N-oxide-4-yl, S, O), (N-2051: COOMe, Pyridine N-oxide-3-yl, S, O), (N-2052: COOMe, 6-OH-pyridine-3-yl, S, O), (N-2053: COOMe, 6-SH-pyridine-3-yl, S, O), (N-2054: COOMe, 1-Ac-

- pyrrole-3-yl, S, O), (N-2055: COOMe, 4-CF₃-Ph, S, O), (N-2056: COOMe, 4-CN-Ph, S, O), (N-2057: COOMe, 4-CHO-Ph, S, O), (N-2058: COOMe, 3-Cl-Ph, S, O), (N-2059: COOMe, 3-Br-Ph, S, O), (N-2060: COOMe, 3-F-Ph, S, O), (N-2061: COOMe, 3-I-Ph, S, O), (N-2062: COOMe, 4-I-Ph, S, O), (N-2063: COOMe, 4-OCF₃-Ph, S, O), (N-2064: COOMe, 3,4-diI-Ph, S, O), (N-2065: COOMe, Indole-6-yl, S, O), (N-2066: COOMe, 1-Ac-indole-6-yl, S, O), (N-2067: COOMe, 1-Me-indole-6-yl, S, O), (N-2068: COOMe, 4-(1-Imidazolyl)-Ph, S, O), (N-2069: COOMe, 4-Morpholino-Ph, S, O), (N-2070: COOMe, 4-(1-Piperazinyl)-Ph, S, O), (N-2071: COOMe, 2:5-diMe-thiophene-3-yl, S, O), (N-2072: COOMe, 2-Furyl, S, O), (N-2073: COOMe, 5-Me-furan-2-yl, S, O), (N-2074: COOMe, 5-Me-furan-2-yl, S, O), (N-2075: COOMe, 2-Thiazolyl, S, O), (N-2076: COOMe, 1:4-Benzodioxin-6-yl, S, O), (N-2077: COOMe, Benzo[b]furan-2-yl, S, O), (N-2078: COOMe, 4-NH₂CH₂-Ph, S, O), (N-2079: COOMe, 4-N(Me)HCH₂-Ph, S, O), (N-2080: COOMe, 4-N(Me)₂CH₂-Ph, S, O), (N-2081: COOMe, 6-Cl-pyridine-3-yl, S, O), (N-2082: COOMe, 5,6-diCl-pyridine-3-yl, S, O), (N-2083: COOMe, 5-Cl-pyridine-2-yl, S, O), (N-2084: COOMe, 4:5-diCl-pyridine-2-yl, S, O), (N-2085: COOMe, 4-ClCH₂-Bn, S, O), (N-2086: COOMe, Bn, S, O), (N-2087: COOMe, 4-Cl-Bn, S, O), (N-2088: COOMe, 4-Br-Bn, S, O), (N-2089: COOMe, 4-F-Bn, S, O), (N-2090: COOMe, 3,4-diCl-Bn, S, O), (N-2091: COOMe, 3,4-diBr-Bn, S, O), (N-2092: COOMe, 3,4-diF-Bn, S, O), (N-2093: COOMe, 4-Cl-Bz, S, O), (N-2094: COOMe, 3,4-diCl-Bz, S, O), (N-2095: COOMe, 4-Br-Bz, S, O), (N-2096: COOMe, 3,4-diBr-Bz, S, O), (N-2097: COOMe, 4-F-Bz, S, O), (N-2098: COOMe, 3,4-diF-Bz, S, O), (N-2099: COOMe, 4-NO₂-Bn, S, O), (N-2100: COOMe, 4-CN-Bn, S, O), (N-2101: Ph, Me, O, O), (N-2102: 4-F-Ph, Me, O, O), (N-2103: 4-Br-Ph, Me, O, O), (N-2104: 4-Me-Ph, Me, O, O), (N-2105: 4-Ph-Ph, Me, O, O), (N-2106: 4-OMe-Ph, Me, O, O), (N-2107: 4-tBu-Ph, Me, O, O), (N-2108: 4-COOMe-Ph, Me, O, O), (N-2109: 4-Pen-Ph, Me, O, O), (N-2110: 4-NO₂-Ph, Me, O, O), (N-2111:

- 5-Cl-thiophene-2-yl, Me, O, O), (N-2112: 3-Thienyl, Me, O, O), (N-2113: 2-Py, Me, O, O), (N-2114: 3-Py, Me, O, O), (N-2115: 4-Py, Me, O, O), (N-2116: 3,4-diF-Ph, Me, O, O), (N-2117: 5-Br-thiophene-2-yl, Me, O, O), (N-2118: 4-CONH₂-Ph, Me, O, O), (N-2119: 4-CON(Me)H-Ph, Me, O, O), (N-2120: 4-CON(Me)₂-Ph, Me, O, O), (N-2121: 4-iPrOC(=O)-Ph, Me, O, O), (N-2122: 4-nBuOC(=O)-Ph, Me, O, O), (N-2123: 6-Me-pyridine-3-yl, Me, O, O), (N-2124: Quinoline-3-yl, Me, O, O), (N-2125: 4-NH₂-Ph, Me, O, O), (N-2126: 4-N(Ac)H-Ph, Me, O, O), (N-2127: 4-OH-Ph, Me, O, O), (N-2128: 3,4-di(OH)₂-Ph, Me, O, O), (N-2129: 3,4-di(NH₂)-Ph, Me, O, O), (N-2130: 3:4-[N(Ac)H]₂-Ph, Me, O, O), (N-2131: 4-SH-Ph, Me, O, O), (N-2132: 4-SMe-Ph, Me, O, O), (N-2133: 3,4-diBr-Ph, Me, O, O), (N-2134: 4-N(Me)H-Ph, Me, O, O), (N-2135: 4-N(Me)₂-Ph, Me, O, O), (N-2136: 4-N(Me)₃⁺-Ph, Me, O, O), (N-2137: 4-Et-Ph, Me, O, O), (N-2138: 4-iPr-Ph, Me, O, O), (N-2139: 4-nPr-Ph, Me, O, O), (N-2140: 4-nBu-Ph, Me, O, O), (N-2141: 4-iBu-Ph, Me, O, O), (N-2142: 3,4-diMe-Ph, Me, O, O), (N-2143: 1,3-Benzodioxole-5-yl, Me, O, O), (N-2144: N-Me-pyridinium-4-yl, Me, O, O), (N-2145: N-Me-pyridinium-3-yl, Me, O, O), (N-2146: 5-Me-Pyridine-2-yl, Me, O, O), (N-2147: 2-Pyrazinyl, Me, O, O), (N-2148: 3-Pyrrolyl, Me, O, O), (N-2149: 1-Me-pyrrole-3-yl, Me, O, O), (N-2150: Pyridine N-oxide-4-yl, Me, O, O), (N-2151: Pyridine N-oxide-3-yl, Me, O, O), (N-2152: 6-OH-pyridine-3-yl, Me, O, O), (N-2153: 6-SH-pyridine-3-yl, Me, O, O), (N-2154: 1-Ac-pyrrole-3-yl, Me, O, O), (N-2155: 4-CF₃-Ph, Me, O, O), (N-2156: 4-CN-Ph, Me, O, O), (N-2157: 4-CHO-Ph, Me, O, O), (N-2158: 3-Cl-Ph, Me, O, O), (N-2159: 3-Br-Ph, Me, O, O), (N-2160: 3-F-Ph, Me, O, O), (N-2161: 3-I-Ph, Me, O, O), (N-2162: 4-I-Ph, Me, O, O), (N-2163: 4-OCF₃-Ph, Me, O, O), (N-2164: 3,4-diI-Ph, Me, O, O), (N-2165: Indole-6-yl, Me, O, O), (N-2166: 1-Ac-indole-6-yl, Me, O, O), (N-2167: 1-Me-indole-6-yl, Me, O, O), (N-2168: 4-(1-Imidazolyl)-Ph, Me, O, O), (N-2169: 4-Morphorino-Ph, Me, O, O), (N-2170: 4-(1-Piperazinyl)-Ph, Me, O, O), (N-

- 2171: 2:5-diMe-thiophene-3-yl, Me, O, O), (N-2172: 2-Furyl, Me, O, O), (N-2173: 5-Me-furan-2-yl, Me, O, O), (N-2174: 5-Me-furan-2-yl, Me, O, O), (N-2175: 2-Thiazolyl, Me, O, O), (N-2176: 1:4-Benzodioxin-6-yl, Me, O, O), (N-2177: Benzo[b]furan-2-yl, Me, O, O), (N-2178: 4-NH₂CH₂-Ph, Me, O, O), (N-2179: 4-N(Me)HCH₂-Ph, Me, O, O), (N-2180: 4-N(Me)₂CH₂-Ph, Me, O, O), (N-2181: 6-Cl-pyridine-3-yl, Me, O, O), (N-2182: 5,6-diCl-pyridine-3-yl, Me, O, O), (N-2183: 5-Cl-pyridine-2-yl, Me, O, O), (N-2184: 4:5-diCl-pyridine-2-yl, Me, O, O), (N-2185: 4-ClCH₂-Bn, Me, O, O), (N-2186: Bn, Me, O, O), (N-2187: 4-Cl-Bn, Me, O, O), (N-2188: 4-Br-Bn, Me, O, O), (N-2189: 4-F-Bn, Me, O, O), (N-2190: 3,4-diCl-Bn, Me, O, O), (N-2191: 3,4-diBr-Bn, Me, O, O), (N-2192: 3,4-diF-Bn, Me, O, O), (N-2193: 4-Cl-Bz, Me, O, O), (N-2194: 3,4-diCl-Bz, Me, O, O), (N-2195: 4-Br-Bz, Me, O, O), (N-2196: 3,4-diBr-Bz, Me, O, O), (N-2197: 4-F-Bz, Me, O, O), (N-2198: 3,4-diF-Bz, Me, O, O), (N-2199: 4-NO₂-Bn, Me, O, O), (N-2200: 4-CN-Bn, Me, O, O), (N-2201: Ph, Et, O, O), (N-2202: 4-F-Ph, Et, O, O), (N-2203: 4-Br-Ph, Et, O, O), (N-2204: 4-Me-Ph, Et, O, O), (N-2205: 4-Ph-Ph, Et, O, O), (N-2206: 4-OMe-Ph, Et, O, O), (N-2207: 4-tBu-Ph, Et, O, O), (N-2208: 4-COOMe-Ph, Et, O, O), (N-2209: 4-Pen-Ph, Et, O, O), (N-2210: 4-NO₂-Ph, Et, O, O), (N-2211: 5-Cl-thiophene-2-yl, Et, O, O), (N-2212: 3-Thienyl, Et, O, O), (N-2213: 2-Py, Et, O, O), (N-2214: 3-Py, Et, O, O), (N-2215: 4-Py, Et, O, O), (N-2216: 3,4-diF-Ph, Et, O, O), (N-2217: 5-Br-thiophene-2-yl, Et, O, O), (N-2218: 4-CONH₂-Ph, Et, O, O), (N-2219: 4-CON(Me)H-Ph, Et, O, O), (N-2220: 4-CON(Me)₂-Ph, Et, O, O), (N-2221: 4-iPrOC(=O)-Ph, Et, O, O), (N-2222: 4-nBuOC(=O)-Ph, Et, O, O), (N-2223: 6-Me-pyridine-3-yl, Et, O, O), (N-2224: Quinoline-3-yl, Et, O, O), (N-2225: 4-NH₂-Ph, Et, O, O), (N-2226: 4-N(Ac)H-Ph, Et, O, O), (N-2227: 4-OH-Ph, Et, O, O), (N-2228: 3,4-di(OH)₂-Ph, Et, O, O), (N-2229: 3,4-di(NH₂)-Ph, Et, O, O), (N-2230: 3:4-[N(Ac)H]₂-Ph, Et, O, O), (N-2231: 4-SH-Ph, Et, O, O), (N-2232: 4-SMe-Ph, Et, O, O), (N-2233: 3,4-diBr-Ph,

- Et, O, O), (N-2234: 4-N(Me)H-Ph, Et, O, O), (N-2235: 4-N(Me)₂-Ph, Et, O, O),
 (N-2236: 4-N(Me)₃⁺-Ph, Et, O, O), (N-2237: 4-Et-Ph, Et, O, O), (N-2238: 4-iPr-
 Ph, Et, O, O), (N-2239: 4-nPr-Ph, Et, O, O), (N-2240: 4-nBu-Ph, Et, O, O), (N-
 2241: 4-iBu-Ph, Et, O, O), (N-2242: 3,4-diMe-Ph, Et, O, O), (N-2243: 1,3-
 5 Benzodioxole-5-yl, Et, O, O), (N-2244: N-Me-pyridinium-4-yl, Et, O, O), (N-
 2245: N-Me-pyridinium-3-yl, Et, O, O), (N-2246: 5-Me-Pyridine-2-yl, Et, O, O),
 (N-2247: 2-Pyrazinyl, Et, O, O), (N-2248: 3-Pyrrolyl, Et, O, O), (N-2249: 1-
 Me-pyrrole-3-yl, Et, O, O), (N-2250: Pyridine N-oxide-4-yl, Et, O, O), (N-2251:
 Pyridine N-oxide-3-yl, Et, O, O), (N-2252: 6-OH-pyridine-3-yl, Et, O, O), (N-
 10 2253: 6-SH-pyridine-3-yl, Et, O, O), (N-2254: 1-Ac-pyrrole-3-yl, Et, O, O), (N-
 2255: 4-CF₃-Ph, Et, O, O), (N-2256: 4-CN-Ph, Et, O, O), (N-2257: 4-CHO-Ph, Et,
 O, O), (N-2258: 3-Cl-Ph, Et, O, O), (N-2259: 3-Br-Ph, Et, O, O), (N-2260: 3-F-
 Ph, Et, O, O), (N-2261: 3-I-Ph, Et, O, O), (N-2262: 4-I-Ph, Et, O, O), (N-2263:
 4-OCF₃-Ph, Et, O, O), (N-2264: 3,4-diI-Ph, Et, O, O), (N-2265: Indole-6-yl, Et,
 15 O, O), (N-2266: 1-Ac-indole-6-yl, Et, O, O), (N-2267: 1-Me-indole-6-yl, Et, O,
 O), (N-2268: 4-(1-Imidazolyl)-Ph, Et, O, O), (N-2269: 4-Morphorino-Ph, Et, O,
 O), (N-2270: 4-(1-Piperazinyl)-Ph, Et, O, O), (N-2271: 2:5-diMe-thiophene-3-yl,
 Et, O, O), (N-2272: 2-Furyl, Et, O, O), (N-2273: 5-Me-furan-2-yl, Et, O, O),
 (N-2274: 5-Me-furan-2-yl, Et, O, O), (N-2275: 2-Thiazolyl, Et, O, O), (N-2276:
 20 1:4-Benzodioxin-6-yl, Et, O, O), (N-2277: Benzo[b]furan-2-yl, Et, O, O), (N-
 2278: 4-NH₂CH₂-Ph, Et, O, O), (N-2279: 4-N(Me)HCH₂-Ph, Et, O, O), (N-2280:
 4-N(Me)₂CH₂-Ph, Et, O, O), (N-2281: 6-Cl-pyridine-3-yl, Et, O, O), (N-2282:
 5,6-diCl-pyridine-3-yl, Et, O, O), (N-2283: 5-Cl-pyridine-2-yl, Et, O, O), (N-
 2284: 4:5-diCl-pyridine-2-yl, Et, O, O), (N-2285: 4-ClCH₂-Bn, Et, O, O), (N-
 25 2286: Bn, Et, O, O), (N-2287: 4-Cl-Bn, Et, O, O), (N-2288: 4-Br-Bn, Et, O, O),
 (N-2289: 4-F-Bn, Et, O, O), (N-2290: 3,4-diCl-Bn, Et, O, O), (N-2291: 3,4-
 diBr-Bn, Et, O, O), (N-2292: 3,4-diF-Bn, Et, O, O), (N-2293: 4-Cl-Bz, Et, O, O),

- (N-2294: 3,4-diCl-Bz, Et, O, O), (N-2295: 4-Br-Bz, Et, O, O), (N-2296: 3,4-diBr-Bz, Et, O, O), (N-2297: 4-F-Bz, Et, O, O), (N-2298: 3,4-diF-Bz, Et, O, O), (N-2299: 4-NO₂-Bn, Et, O, O), (N-2300: 4-CN-Bn, Et, O, O), (N-2301: Ph, COOMe, O, O), (N-2302: 4-F-Ph, COOMe, O, O), (N-2303: 4-Br-Ph, COOMe, O, O), (N-2304: 4-Me-Ph, COOMe, O, O), (N-2305: 4-Ph-Ph, COOMe, O, O), (N-2306: 4-OMe-Ph, COOMe, O, O), (N-2307: 4-tBu-Ph, COOMe, O, O), (N-2308: 4-COOMe-Ph, COOMe, O, O), (N-2309: 4-Pen-Ph, COOMe, O, O), (N-2310: 4-NO₂-Ph, COOMe, O, O), (N-2311: 5-Cl-thiophene-2-yl, COOMe, O, O), (N-2312: 3-Thienyl, COOMe, O, O), (N-2313: 2-Py, COOMe, O, O), (N-2314: 3-Py, COOMe, O, O), (N-2315: 4-Py, COOMe, O, O), (N-2316: 3,4-diF-Ph, COOMe, O, O), (N-2317: 5-Br-thiophene-2-yl, COOMe, O, O), (N-2318: 4-CONH₂-Ph, COOMe, O, O), (N-2319: 4-CON(Me)H-Ph, COOMe, O, O), (N-2320: 4-CON(Me)₂-Ph, COOMe, O, O), (N-2321: 4-iPrOC(=O)-Ph, COOMe, O, O), (N-2322: 4-nBuOC(=O)-Ph, COOMe, O, O), (N-2323: 6-Me-pyridine-3-yl, COOMe, O, O), (N-2324: Quinoline-3-yl, COOMe, O, O), (N-2325: 4-NH₂-Ph, COOMe, O, O), (N-2326: 4-N(Ac)H-Ph, COOMe, O, O), (N-2327: 4-OH-Ph, COOMe, O, O), (N-2328: 3,4-di(OH)₂-Ph, COOMe, O, O), (N-2329: 3,4-di(NH₂)-Ph, COOMe, O, O), (N-2330: 3:4-[N(Ac)H]₂-Ph, COOMe, O, O), (N-2331: 4-SH-Ph, COOMe, O, O), (N-2332: 4-SMe-Ph, COOMe, O, O), (N-2333: 3,4-diBr-Ph, COOMe, O, O), (N-2334: 4-N(Me)H-Ph, COOMe, O, O), (N-2335: 4-N(Me)₂-Ph, COOMe, O, O), (N-2336: 4-N(Me)₃⁺-Ph, COOMe, O, O), (N-2337: 4-Et-Ph, COOMe, O, O), (N-2338: 4-iPr-Ph, COOMe, O, O), (N-2339: 4-nPr-Ph, COOMe, O, O), (N-2340: 4-nBu-Ph, COOMe, O, O), (N-2341: 4-iBu-Ph, COOMe, O, O), (N-2342: 3,4-diMe-Ph, COOMe, O, O), (N-2343: 1,3-Benzodioxole-5-yl, COOMe, O, O), (N-2344: N-Me-pyridinium-4-yl, COOMe, O, O), (N-2345: N-Me-pyridinium-3-yl, COOMe, O, O), (N-2346: 5-Me-Pyridine-2-yl, COOMe, O, O), (N-2347: 2-Pyrazinyl, COOMe, O, O), (N-2348: 3-Pyrrolyl, COOMe, O, O), (N-2349: 1-

- Me-pyrrole-3-yl, COOMe, O, O), (N-2350: Pyridine N-oxide-4-yl, COOMe, O, O), (N-2351: Pyridine N-oxide-3-yl, COOMe, O, O), (N-2352: 6-OH-pyridine-3-yl, COOMe, O, O), (N-2353: 6-SH-pyridine-3-yl, COOMe, O, O), (N-2354: 1-Ac-pyrrole-3-yl, COOMe, O, O), (N-2355: 4-CF₃-Ph, COOMe, O, O), (N-2356: 4-CN-Ph, COOMe, O, O), (N-2357: 4-CHO-Ph, COOMe, O, O), (N-2358: 3-Cl-Ph, COOMe, O, O), (N-2359: 3-Br-Ph, COOMe, O, O), (N-2360: 3-F-Ph, COOMe, O, O), (N-2361: 3-I-Ph, COOMe, O, O), (N-2362: 4-I-Ph, COOMe, O, O), (N-2363: 4-OCF₃-Ph, COOMe, O, O), (N-2364: 3,4-diI-Ph, COOMe, O, O), (N-2365: Indole-6-yl, COOMe, O, O), (N-2366: 1-Ac-indole-6-yl, COOMe, O, O), (N-2367: 1-Me-indole-6-yl, COOMe, O, O), (N-2368: 4-(1-Imidazolyl)-Ph, COOMe, O, O), (N-2369: 4-Morpholino-Ph, COOMe, O, O), (N-2370: 4-(1-Piperazinyl)-Ph, COOMe, O, O), (N-2371: 2:5-diMe-thiophene-3-yl, COOMe, O, O), (N-2372: 2-Furyl, COOMe, O, O), (N-2373: 5-Me-furan-2-yl, COOMe, O, O), (N-2374: 5-Me-furan-2-yl, COOMe, O, O), (N-2375: 2-Thiazolyl, COOMe, O, O), (N-2376: 1:4-Benzodioxin-6-yl, COOMe, O, O), (N-2377: Benzo[b]furan-2-yl, COOMe, O, O), (N-2378: 4-NH₂CH₂-Ph, COOMe, O, O), (N-2379: 4-N(Me)HCH₂-Ph, COOMe, O, O), (N-2380: 4-N(Me)₂CH₂-Ph, COOMe, O, O), (N-2381: 6-Cl-pyridine-3-yl, COOMe, O, O), (N-2382: 5,6-diCl-pyridine-3-yl, COOMe, O, O), (N-2383: 5-Cl-pyridine-2-yl, COOMe, O, O), (N-2384: 4:5-diCl-pyridine-2-yl, COOMe, O, O), (N-2385: 4-ClCH₂-Bn, COOMe, O, O), (N-2386: Bn, COOMe, O, O), (N-2387: 4-Cl-Bn, COOMe, O, O), (N-2388: 4-Br-Bn, COOMe, O, O), (N-2389: 4-F-Bn, COOMe, O, O), (N-2390: 3,4-diCl-Bn, COOMe, O, O), (N-2391: 3,4-diBr-Bn, COOMe, O, O), (N-2392: 3,4-diF-Bn, COOMe, O, O), (N-2393: 4-Cl-Bz, COOMe, O, O), (N-2394: 3,4-diCl-Bz, COOMe, O, O), (N-2395: 4-Br-Bz, COOMe, O, O), (N-2396: 3,4-diBr-Bz, COOMe, O, O), (N-2397: 4-F-Bz, COOMe, O, O), (N-2398: 3,4-diF-Bz, COOMe, O, O), (N-2399: 4-NO₂-Bn, COOMe, O, O), (N-2400: 4-CN-Bn, COOMe, O, O), (N-2401: H, Ph, O, O), (N-2402: H, 4-F-Ph,

- O, O), (N-2403: H, 4-Br-Ph, O, O), (N-2404: H, 4-Me-Ph, O, O), (N-2405: H, 4-Ph-Ph, O, O), (N-2406: H, 4-OMe-Ph, O, O), (N-2407: H, 4-tBu-Ph, O, O), (N-2408: H, 4-COOMe-Ph, O, O), (N-2409: H, 4-Pen-Ph, O, O), (N-2410: H, 4-NO₂-Ph, O, O), (N-2411: H, 5-Cl-thiophene-2-yl, O, O), (N-2412: H, 3-Thienyl, O, O), (N-2413: H, 2-Py, O, O), (N-2414: H, 3-Py, O, O), (N-2415: H, 4-Py, O, O), (N-2416: H, 3,4-diF-Ph, O, O), (N-2417: H, 5-Br-thiophene-2-yl, O, O), (N-2418: H, 4-CONH₂-Ph, O, O), (N-2419: H, 4-CON(Me)H-Ph, O, O), (N-2420: H, 4-CON(Me)₂-Ph, O, O), (N-2421: H, 4-iPrOC(=O)-Ph, O, O), (N-2422: H, 4-nBuOC(=O)-Ph, O, O), (N-2423: H, 6-Me-pyridine-3-yl, O, O), (N-2424: H, Quinoline-3-yl, O, O), (N-2425: H, 4-NH₂-Ph, O, O), (N-2426: H, 4-N(Ac)H-Ph, O, O), (N-2427: H, 4-OH-Ph, O, O), (N-2428: H, 3,4-di(OH)₂-Ph, O, O), (N-2429: H, 3,4-di(NH₂)-Ph, O, O), (N-2430: H, 3,4-[N(Ac)H]₂-Ph, O, O), (N-2431: H, 4-SH-Ph, O, O), (N-2432: H, 4-SMe-Ph, O, O), (N-2433: H, 3,4-diBr-Ph, O, O), (N-2434: H, 4-N(Me)H-Ph, O, O), (N-2435: H, 4-N(Me)₂-Ph, O, O), (N-2436: H, 4-N(Me)₃⁺-Ph, O, O), (N-2437: H, 4-Et-Ph, O, O), (N-2438: H, 4-iPr-Ph, O, O), (N-2439: H, 4-nPr-Ph, O, O), (N-2440: H, 4-nBu-Ph, O, O), (N-2441: H, 4-iBu-Ph, O, O), (N-2442: H, 3,4-diMe-Ph, O, O), (N-2443: H, 1,3-Benzodioxole-5-yl, O, O), (N-2444: H, N-Me-pyridinium-4-yl, O, O), (N-2445: H, N-Me-pyridinium-3-yl, O, O), (N-2446: H, 5-Me-Pyridine-2-yl, O, O), (N-2447: H, 2-Pyrazinyl, O, O), (N-2448: H, 3-Pyrrolyl, O, O), (N-2449: H, 1-Me-pyrrole-3-yl, O, O), (N-2450: H, Pyridine N-oxide-4-yl, O, O), (N-2451: H, Pyridine N-oxide-3-yl, O, O), (N-2452: H, 6-OH-pyridine-3-yl, O, O), (N-2453: H, 6-SH-pyridine-3-yl, O, O), (N-2454: H, 1-Ac-pyrrole-3-yl, O, O), (N-2455: H, 4-CF₃-Ph, O, O), (N-2456: H, 4-CN-Ph, O, O), (N-2457: H, 4-CHO-Ph, O, O), (N-2458: H, 3-Cl-Ph, O, O), (N-2459: H, 3-Br-Ph, O, O), (N-2460: H, 3-F-Ph, O, O), (N-2461: H, 3-I-Ph, O, O), (N-2462: H, 4-I-Ph, O, O), (N-2463: H, 4-OCF₃-Ph, O, O), (N-2464: H, 3,4-diI-Ph, O, O), (N-2465: H, Indole-6-yl, O, O), (N-2466: H, 1-

- Ac-indole-6-yl, O, O), (N-2467: H, 1-Me-indole-6-yl, O, O), (N-2468: H, 4-(1-Imidazolyl)-Ph, O, O), (N-2469: H, 4-Morphorino-Ph, O, O), (N-2470: H, 4-(1-Piperazinyl)-Ph, O, O), (N-2471: H, 2:5-diMe-thiophene-3-yl, O, O), (N-2472: H, 2-Furyl, O, O), (N-2473: H, 5-Me-furan-2-yl, O, O), (N-2474: H, 5-Me-furan-2-yl, O, O), (N-2475: H, 2-Thiazolyl, O, O), (N-2476: H, 1:4-Benzodioxin-6-yl, O, O), (N-2477: H, Benzo[b]furan-2-yl, O, O), (N-2478: H, 4-NH₂CH₂-Ph, O, O), (N-2479: H, 4-N(Me)HCH₂-Ph, O, O), (N-2480: H, 4-N(Me)₂CH₂-Ph, O, O), (N-2481: H, 6-Cl-pyridine-3-yl, O, O), (N-2482: H, 5,6-diCl-pyridine-3-yl, O, O), (N-2483: H, 5-Cl-pyridine-2-yl, O, O), (N-2484: H, 4:5-diCl-pyridine-2-yl, O, O), (N-2485: H, 4-ClCH₂-Bn, O, O), (N-2486: H, Bn, O, O), (N-2487: H, 4-Cl-Bn, O, O), (N-2488: H, 4-Br-Bn, O, O), (N-2489: H, 4-F-Bn, O, O), (N-2490: H, 3,4-diCl-Bn, O, O), (N-2491: H, 3,4-diBr-Bn, O, O), (N-2492: H, 3,4-diF-Bn, O, O), (N-2493: H, 4-Cl-Bz, O, O), (N-2494: H, 3,4-diCl-Bz, O, O), (N-2495: H, 4-Br-Bz, O, O), (N-2496: H, 3,4-diBr-Bz, O, O), (N-2497: H, 4-F-Bz, O, O), (N-2498: H, 3,4-diF-Bz, O, O), (N-2499: H, 4-NO₂-Bn, O, O), (N-2500: H, 4-CN-Bn, O, O), (N-2501: Me, Ph, O, O), (N-2502: Me, 4-F-Ph, O, O), (N-2503: Me, 4-Br-Ph, O, O), (N-2504: Me, 4-Me-Ph, O, O), (N-2505: Me, 4-Ph-Ph, O, O), (N-2506: Me, 4-OMe-Ph, O, O), (N-2507: Me, 4-tBu-Ph, O, O), (N-2508: Me, 4-COOMe-Ph, O, O), (N-2509: Me, 4-Pen-Ph, O, O), (N-2510: Me, 4-NO₂-Ph, O, O), (N-2511: Me, 5-Cl-thiophene-2-yl, O, O), (N-2512: Me, 3-Thienyl, O, O), (N-2513: Me, 2-Py, O, O), (N-2514: Me, 3-Py, O, O), (N-2515: Me, 4-Py, O, O), (N-2516: Me, 3,4-diF-Ph, O, O), (N-2517: Me, 5-Br-thiophene-2-yl, O, O), (N-2518: Me, 4-CONH₂-Ph, O, O), (N-2519: Me, 4-CON(Me)H-Ph, O, O), (N-2520: Me, 4-CON(Me)₂-Ph, O, O), (N-2521: Me, 4-iPrOC(=O)-Ph, O, O), (N-2522: Me, 4-nBuOC(=O)-Ph, O, O), (N-2523: Me, 6-Me-pyridine-3-yl, O, O), (N-2524: Me, Quinoline-3-yl, O, O), (N-2525: Me, 4-NH₂-Ph, O, O), (N-2526: Me, 4-N(Ac)H-Ph, O, O), (N-2527: Me, 4-OH-Ph, O, O), (N-2528: Me, 3,4-di(OH)₂-Ph, O, O),

- (N-2529: Me, 3,4-di(NH₂)-Ph, O, O), (N-2530: Me, 3:4-[N(Ac)H]₂-Ph, O, O),
 (N-2531: Me, 4-SH-Ph, O, O), (N-2532: Me, 4-SMe-Ph, O, O), (N-2533: Me,
 3,4-diBr-Ph, O, O), (N-2534: Me, 4-N(Me)H-Ph, O, O), (N-2535: Me, 4-N(Me)₂-
 Ph, O, O), (N-2536: Me, 4-N(Me)₃⁺-Ph, O, O), (N-2537: Me, 4-Et-Ph, O, O), (N-
 5 2538: Me, 4-iPr-Ph, O, O), (N-2539: Me, 4-nPr-Ph, O, O), (N-2540: Me, 4-nBu-
 Ph, O, O), (N-2541: Me, 4-iBu-Ph, O, O), (N-2542: Me, 3,4-diMe-Ph, O, O), (N-
 2543: Me, 1,3-Benzodioxole-5-yl, O, O), (N-2544: Me, N-Me-pyridinium-4-yl, O,
 O), (N-2545: Me, N-Me-pyridinium-3-yl, O, O), (N-2546: Me, 5-Me-Pyridine-2-
 yl, O, O), (N-2547: Me, 2-Pyrazinyl, O, O), (N-2548: Me, 3-Pyrrolyl, O, O), (N-
 10 2549: Me, 1-Me-pyrrole-3-yl, O, O), (N-2550: Me, Pyridine N-oxide-4-yl, O, O),
 (N-2551: Me, Pyridine N-oxide-3-yl, O, O), (N-2552: Me, 6-OH-pyridine-3-yl, O,
 O), (N-2553: Me, 6-SH-pyridine-3-yl, O, O), (N-2554: Me, 1-Ac-pyrrole-3-yl, O,
 O), (N-2555: Me, 4-CF₃-Ph, O, O), (N-2556: Me, 4-CN-Ph, O, O), (N-2557: Me,
 4-CHO-Ph, O, O), (N-2558: Me, 3-Cl-Ph, O, O), (N-2559: Me, 3-Br-Ph, O, O),
 15 (N-2560: Me, 3-F-Ph, O, O), (N-2561: Me, 3-I-Ph, O, O), (N-2562: Me, 4-I-Ph, O,
 O), (N-2563: Me, 4-OCF₃-Ph, O, O), (N-2564: Me, 3,4-diI-Ph, O, O), (N-2565:
 Me, Indole-6-yl, O, O), (N-2566: Me, 1-Ac-indole-6-yl, O, O), (N-2567: Me, 1-
 Me-indole-6-yl, O, O), (N-2568: Me, 4-(1-Imidazolyl)-Ph, O, O), (N-2569: Me,
 4-Morpholino-Ph, O, O), (N-2570: Me, 4-(1-Piperazinyl)-Ph, O, O), (N-2571:
 20 Me, 2:5-diMe-thiophene-3-yl, O, O), (N-2572: Me, 2-Furyl, O, O), (N-2573: Me,
 5-Me-furan-2-yl, O, O), (N-2574: Me, 5-Me-furan-2-yl, O, O), (N-2575: Me, 2-
 Thiazolyl, O, O), (N-2576: Me, 1:4-Benzodioxin-6-yl, O, O), (N-2577: Me,
 Benzo[b]furan-2-yl, O, O), (N-2578: Me, 4-NH₂CH₂-Ph, O, O), (N-2579: Me, 4-
 N(Me)HCH₂-Ph, O, O), (N-2580: Me, 4-N(Me)₂CH₂-Ph, O, O), (N-2581: Me, 6-
 25 Cl-pyridine-3-yl, O, O), (N-2582: Me, 5,6-diCl-pyridine-3-yl, O, O), (N-2583:
 Me, 5-Cl-pyridine-2-yl, O, O), (N-2584: Me, 4:5-diCl-pyridine-2-yl, O, O), (N-
 2585: Me, 4-ClCH₂-Bn, O, O), (N-2586: Me, Bn, O, O), (N-2587: Me, 4-Cl-Bn, O,

- O), (N-2588: Me, 4-Br-Bn, O, O), (N-2589: Me, 4-F-Bn, O, O), (N-2590: Me, 3,4-diCl-Bn, O, O), (N-2591: Me, 3,4-diBr-Bn, O, O), (N-2592: Me, 3,4-diF-Bn, O, O), (N-2593: Me, 4-Cl-Bz, O, O), (N-2594: Me, 3,4-diCl-Bz, O, O), (N-2595: Me, 4-Br-Bz, O, O), (N-2596: Me, 3,4-diBr-Bz, O, O), (N-2597: Me, 4-F-Bz, O, O), (N-2598: Me, 3,4-diF-Bz, O, O), (N-2599: Me, 4-NO₂-Bn, O, O), (N-2600: Me, 4-CN-Bn, O, O), (N-2601: Et, Ph, O, O), (N-2602: Et, 4-F-Ph, O, O), (N-2603: Et, 4-Br-Ph, O, O), (N-2604: Et, 4-Me-Ph, O, O), (N-2605: Et, 4-Ph-Ph, O, O), (N-2606: Et, 4-OMe-Ph, O, O), (N-2607: Et, 4-tBu-Ph, O, O), (N-2608: Et, 4-COOMe-Ph, O, O), (N-2609: Et, 4-Pen-Ph, O, O), (N-2610: Et, 4-NO₂-Ph, O, O), (N-2611: Et, 5-Cl-thiophene-2-yl, O, O), (N-2612: Et, 3-Thienyl, O, O), (N-2613: Et, 2-Py, O, O), (N-2614: Et, 3-Py, O, O), (N-2615: Et, 4-Py, O, O), (N-2616: Et, 3,4-diF-Ph, O, O), (N-2617: Et, 5-Br-thiophene-2-yl, O, O), (N-2618: Et, 4-CONH₂-Ph, O, O), (N-2619: Et, 4-CON(Me)H-Ph, O, O), (N-2620: Et, 4-CON(Me)₂-Ph, O, O), (N-2621: Et, 4-iPrOC(=O)-Ph, O, O), (N-2622: Et, 4-nBuOC(=O)-Ph, O, O), (N-2623: Et, 6-Me-pyridine-3-yl, O, O), (N-2624: Et, Quinoline-3-yl, O, O), (N-2625: Et, 4-NH₂-Ph, O, O), (N-2626: Et, 4-N(Ac)H-Ph, O, O), (N-2627: Et, 4-OH-Ph, O, O), (N-2628: Et, 3,4-di(OH)₂-Ph, O, O), (N-2629: Et, 3,4-di(NH₂)-Ph, O, O), (N-2630: Et, 3:4-[N(Ac)H]₂-Ph, O, O), (N-2631: Et, 4-SH-Ph, O, O), (N-2632: Et, 4-SMe-Ph, O, O), (N-2633: Et, 3,4-diBr-Ph, O, O), (N-2634: Et, 4-N(Me)H-Ph, O, O), (N-2635: Et, 4-N(Me)₂-Ph, O, O), (N-2636: Et, 4-N(Me)₃⁺-Ph, O, O), (N-2637: Et, 4-Et-Ph, O, O), (N-2638: Et, 4-iPr-Ph, O, O), (N-2639: Et, 4-nPr-Ph, O, O), (N-2640: Et, 4-nBu-Ph, O, O), (N-2641: Et, 4-iBu-Ph, O, O), (N-2642: Et, 3,4-diMe-Ph, O, O), (N-2643: Et, 1,3-Benzodioxole-5-yl, O, O), (N-2644: Et, N-Me-pyridinium-4-yl, O, O), (N-2645: Et, N-Me-pyridinium-3-yl, O, O), (N-2646: Et, 5-Me-Pyridine-2-yl, O, O), (N-2647: Et, 2-Pyrazinyl, O, O), (N-2648: Et, 3-Pyrrolyl, O, O), (N-2649: Et, 1-Me-pyrrole-3-yl, O, O), (N-2650: Et, Pyridine N-oxide-4-yl, O, O), (N-2651: Et,

- Pyridine N-oxide-3-yl, O, O), (N-2652: Et, 6-OH-pyridine-3-yl, O, O), (N-2653: Et, 6-SH-pyridine-3-yl, O, O), (N-2654: Et, 1-Ac-pyrrole-3-yl, O, O), (N-2655: Et, 4-CF₃-Ph, O, O), (N-2656: Et, 4-CN-Ph, O, O), (N-2657: Et, 4-CHO-Ph, O, O), (N-2658: Et, 3-Cl-Ph, O, O), (N-2659: Et, 3-Br-Ph, O, O), (N-2660: Et, 3-F-Ph, O, O), (N-2661: Et, 3-I-Ph, O, O), (N-2662: Et, 4-I-Ph, O, O), (N-2663: Et, 4-OCF₃-Ph, O, O), (N-2664: Et, 3,4-diI-Ph, O, O), (N-2665: Et, Indole-6-yl, O, O), (N-2666: Et, 1-Ac-indole-6-yl, O, O), (N-2667: Et, 1-Me-indole-6-yl, O, O), (N-2668: Et, 4-(1-Imidazolyl)-Ph, O, O), (N-2669: Et, 4-Morphorino-Ph, O, O), (N-2670: Et, 4-(1-Piperazinyl)-Ph, O, O), (N-2671: Et, 2:5-diMe-thiophene-3-yl, O, O), (N-2672: Et, 2-Furyl, O, O), (N-2673: Et, 5-Me-furan-2-yl, O, O), (N-2674: Et, 5-Me-furan-2-yl, O, O), (N-2675: Et, 2-Thiazolyl, O, O), (N-2676: Et, 1:4-Benzodioxin-6-yl, O, O), (N-2677: Et, Benzo[h]furan-2-yl, O, O), (N-2678: Et, 4-NH₂CH₂-Ph, O, O), (N-2679: Et, 4-N(Me)HCH₂-Ph, O, O), (N-2680: Et, 4-N(Me)₂CH₂-Ph, O, O), (N-2681: Et, 6-Cl-pyridine-3-yl, O, O), (N-2682: Et, 5,6-diCl-pyridine-3-yl, O, O), (N-2683: Et, 5-Cl-pyridine-2-yl, O, O), (N-2684: Et, 4:5-diCl-pyridine-2-yl, O, O), (N-2685: Et, 4-ClCH₂-Bn, O, O), (N-2686: Et, Bn, O, O), (N-2687: Et, 4-Cl-Bn, O, O), (N-2688: Et, 4-Br-Bn, O, O), (N-2689: Et, 4-F-Bn, O, O), (N-2690: Et, 3,4-diCl-Bn, O, O), (N-2691: Et, 3,4-diBr-Bn, O, O), (N-2692: Et, 3,4-diF-Bn, O, O), (N-2693: Et, 4-Cl-Bz, O, O), (N-2694: Et, 3,4-diCl-Bz, O, O), (N-2695: Et, 4-Br-Bz, O, O), (N-2696: Et, 3,4-diBr-Bz, O, O), (N-2697: Et, 4-F-Bz, O, O), (N-2698: Et, 3,4-diF-Bz, O, O), (N-2699: Et, 4-NO₂-Bn, O, O), (N-2700: Et, 4-CN-Bn, O, O), (N-2701: COOMe, Ph, O, O), (N-2702: COOMe, 4-F-Ph, O, O), (N-2703: COOMe, 4-Br-Ph, O, O), (N-2704: COOMe, 4-Me-Ph, O, O), (N-2705: COOMe, 4-Ph-Ph, O, O), (N-2706: COOMe, 4-OMe-Ph, O, O), (N-2707: COOMe, 4-tBu-Ph, O, O), (N-2708: COOMe, 4-COOMe-Ph, O, O), (N-2709: COOMe, 4-Pen-Ph, O, O), (N-2710: COOMe, 4-NO₂-Ph, O, O), (N-2711: COOMe, 5-Cl-thiophene-2-yl, O, O), (N-2712: COOMe,

3-Thienyl, O, O), (N-2713: COOMe, 2-Py, O, O), (N-2714: COOMe, 3-Py, O, O),
 (N-2715: COOMe, 4-Py, O, O), (N-2716: COOMe, 3,4-diF-Ph, O, O), (N-2717:
 COOMe, 5-Br-thiophene-2-yl, O, O), (N-2718: COOMe, 4-CONH₂-Ph, O, O),
 (N-2719: COOMe, 4-CON(Me)H-Ph, O, O), (N-2720: COOMe, 4-CON(Me)₂-Ph,
 5 O, O), (N-2721: COOMe, 4-iPrOC(=O)-Ph, O, O), (N-2722: COOMe, 4-
 nBuOC(=O)-Ph, O, O), (N-2723: COOMe, 6-Me-pyridine-3-yl, O, O), (N-2724:
 COOMe, Quinoline-3-yl, O, O), (N-2725: COOMe, 4-NH₂-Ph, O, O), (N-2726:
 COOMe, 4-N(Ac)H-Ph, O, O), (N-2727: COOMe, 4-OH-Ph, O, O), (N-2728:
 COOMe, 3,4-di(OH)₂-Ph, O, O), (N-2729: COOMe, 3,4-di(NH₂)-Ph, O, O), (N-
 10 2730: COOMe, 3:4-[N(Ac)H]₂-Ph, O, O), (N-2731: COOMe, 4-SH-Ph, O, O), (N-
 2732: COOMe, 4-SMe-Ph, O, O), (N-2733: COOMe, 3,4-diBr-Ph, O, O), (N-2734:
 COOMe, 4-N(Me)H-Ph, O, O), (N-2735: COOMe, 4-N(Me)₂-Ph, O, O), (N-2736:
 COOMe, 4-N(Me)₃⁺-Ph, O, O), (N-2737: COOMe, 4-Et-Ph, O, O), (N-2738:
 COOMe, 4-iPr-Ph, O, O), (N-2739: COOMe, 4-nPr-Ph, O, O), (N-2740: COOMe,
 15 4-nBu-Ph, O, O), (N-2741: COOMe, 4-iBu-Ph, O, O), (N-2742: COOMe, 3,4-
 diMe-Ph, O, O), (N-2743: COOMe, 1,3-Benzodioxole-5-yl, O, O), (N-2744:
 COOMe, N-Me-pyridinium-4-yl, O, O), (N-2745: COOMe, N-Me-pyridinium-3-
 yl, O, O), (N-2746: COOMe, 5-Me-Pyridine-2-yl, O, O), (N-2747: COOMe, 2-
 Pyrazinyl, O, O), (N-2748: COOMe, 3-Pyrrolyl, O, O), (N-2749: COOMe, 1-
 20 Me-pyrrole-3-yl, O, O), (N-2750: COOMe, Pyridine N-oxide-4-yl, O, O), (N-
 2751: COOMe, Pyridine N-oxide-3-yl, O, O), (N-2752: COOMe, 6-OH-
 pyridine-3-yl, O, O), (N-2753: COOMe, 6-SH-pyridine-3-yl, O, O), (N-2754:
 COOMe, 1-Ac-pyrrole-3-yl, O, O), (N-2755: COOMe, 4-CF₃-Ph, O, O), (N-2756:
 COOMe, 4-CN-Ph, O, O), (N-2757: COOMe, 4-CHO-Ph, O, O), (N-2758: COOMe,
 25 3-Cl-Ph, O, O), (N-2759: COOMe, 3-Br-Ph, O, O), (N-2760: COOMe, 3-F-Ph, O,
 O), (N-2761: COOMe, 3-I-Ph, O, O), (N-2762: COOMe, 4-I-Ph, O, O), (N-2763:
 COOMe, 4-OCF₃-Ph, O, O), (N-2764: COOMe, 3,4-diI-Ph, O, O), (N-2765:

- COOMe, Indole-6-yl, O, O), (N-2766: COOMe, 1-Ac-indole-6-yl, O, O), (N-2767: COOMe, 1-Me-indole-6-yl, O, O), (N-2768: COOMe, 4-(1-Imidazolyl)-Ph, O, O), (N-2769: COOMe, 4-Morpholino-Ph, O, O), (N-2770: COOMe, 4-(1-Piperazinyl)-Ph, O, O), (N-2771: COOMe, 2:5-diMe-thiophene-3-yl, O, O), (N-2772: COOMe, 2-Furyl, O, O), (N-2773: COOMe, 5-Me-furan-2-yl, O, O), (N-2774: COOMe, 5-Me-furan-2-yl, O, O), (N-2775: COOMe, 2-Thiazolyl, O, O), (N-2776: COOMe, 1:4-Benzodioxin-6-yl, O, O), (N-2777: COOMe, Benzo[b]furan-2-yl, O, O), (N-2778: COOMe, 4-NH₂CH₂-Ph, O, O), (N-2779: COOMe, 4-N(Me)HCH₂-Ph, O, O), (N-2780: COOMe, 4-N(Me)₂CH₂-Ph, O, O), (N-2781: COOMe, 6-Cl-pyridine-3-yl, O, O), (N-2782: COOMe, 5,6-diCl-pyridine-3-yl, O, O), (N-2783: COOMe, 5-Cl-pyridine-2-yl, O, O), (N-2784: COOMe, 4:5-diCl-pyridine-2-yl, O, O), (N-2785: COOMe, 4-ClCH₂-Bn, O, O), (N-2786: COOMe, Bn, O, O), (N-2787: COOMe, 4-Cl-Bn, O, O), (N-2788: COOMe, 4-Br-Bn, O, O), (N-2789: COOMe, 4-F-Bn, O, O), (N-2790: COOMe, 3,4-diCl-Bn, O, O), (N-2791: COOMe, 3,4-diBr-Bn, O, O), (N-2792: COOMe, 3,4-diF-Bn, O, O), (N-2793: COOMe, 4-Cl-Bz, O, O), (N-2794: COOMe, 3,4-diCl-Bz, O, O), (N-2795: COOMe, 4-Br-Bz, O, O), (N-2796: COOMe, 3,4-diBr-Bz, O, O), (N-2797: COOMe, 4-F-Bz, O, O), (N-2798: COOMe, 3,4-diF-Bz, O, O), (N-2799: COOMe, 4-NO₂-Bn, O, O), (N-2800: COOMe, 4-CN-Bn, O, O), (N-2801: 4-F-Ph, CONH₂, S, S), (N-2802: 4-Br-Ph, CONH₂, S, S), (N-2803: 5-Cl-thiophene-2-yl, CONH₂, S, S), (N-2804: 3,4-diF-Ph, CONH₂, S, S), (N-2805: 5-Br-thiophene-2-yl, CONH₂, S, S), (N-2806: 3,4-diBr-Ph, CONH₂, S, S), (N-2807: 4-CF₃-Ph, CONH₂, S, S), (N-2808: 3-Cl-Ph, CONH₂, S, S), (N-2809: 3-Br-Ph, CONH₂, S, S), (N-2810: 3-F-Ph, CONH₂, S, S), (N-2811: 4-F-Ph, CO₂NHCH₃, S, S), (N-2812: 4-Br-Ph, CO₂NHCH₃, S, S), (N-2813: 5-Cl-thiophene-2-yl, CO₂NHCH₃, S, S), (N-2814: 3,4-diF-Ph, CO₂NHCH₃, S, S), (N-2815: 5-Br-thiophene-2-yl, CO₂NHCH₃, S, S), (N-2816: 3,4-diBr-Ph,

- CO₂NHCH₃, S, S), (N-2817: 4-CF₃-Ph, CO₂NHCH₃, S, S), (N-2818: 3-Cl-Ph, CO₂NHCH₃, S, S), (N-2819: 3-Br-Ph, CO₂NHCH₃, S, S), (N-2820: 3-F-Ph, CO₂NHCH₃, S, S), (N-2821: 4-F-Ph, CO₂N(CH₃)₂, S, S), (N-2822: 4-Br-Ph, CO₂N(CH₃)₂, S, S), (N-2823: 5-Cl-thiophene-2-yl, CO₂N(CH₃)₂, S, S), (N-2824: 5
- 3,4-diF-Ph, CO₂N(CH₃)₂, S, S), (N-2825: 5-Br-thiophene-2-yl, CO₂N(CH₃)₂, S, S), (N-2826: 3,4-diBr-Ph, CO₂N(CH₃)₂, S, S), (N-2827: 4-CF₃-Ph, CO₂N(CH₃)₂, S, S), (N-2828: 3-Cl-Ph, CO₂N(CH₃)₂, S, S), (N-2829: 3-Br-Ph, CO₂N(CH₃)₂, S, S), (N-2830: 3-F-Ph, CO₂N(CH₃)₂, S, S), (N-2831: 4-F-Ph, CO₂H, S, S), (N-2832: 4-Br-Ph, CO₂H, S, S), (N-2833: 5-Cl-thiophene-2-yl, CO₂H, S, S), (N-2834: 10
- 3,4-diF-Ph, CO₂H, S, S), (N-2835: 5-Br-thiophene-2-yl, CO₂H, S, S), (N-2836: 3,4-diBr-Ph, CO₂H, S, S), (N-2837: 4-CF₃-Ph, CO₂H, S, S), (N-2838: 3-Cl-Ph, CO₂H, S, S), (N-2839: 3-Br-Ph, CO₂H, S, S), (N-2840: 3-F-Ph, CO₂H, S, S), (N-2841: 4-F-Ph, NH₂, S, S), (N-2842: 4-Br-Ph, NH₂, S, S), (N-2843: 5-Cl-thiophene-2-yl, NH₂, S, S), (N-2844: 3,4-diF-Ph, NH₂, S, S), (N-2845: 5-Br-thiophene-2-yl, NH₂, S, S), (N-2846: 3,4-diBr-Ph, NH₂, S, S), (N-2847: 4-CF₃-15
- Ph, NH₂, S, S), (N-2848: 3-Cl-Ph, NH₂, S, S), (N-2849: 3-Br-Ph, NH₂, S, S), (N-2850: 3-F-Ph, NH₂, S, S), (N-2851: 4-F-Ph, CH₂COOMe, S, S), (N-2852: 4-Br-Ph, CH₂COOMe, S, S), (N-2853: 5-Cl-thiophene-2-yl, CH₂COOMe, S, S), (N-2854: 3,4-diF-Ph, CH₂COOMe, S, S), (N-2855: 5-Br-thiophene-2-yl, CH₂COOMe, S, S), (N-2856: 3,4-diBr-Ph, CH₂COOMe, S, S), (N-2857: 4-CF₃-Ph, CH₂COOMe, S, S), (N-2858: 3-Cl-Ph, CH₂COOMe, S, S), (N-2859: 3-Br-Ph, CH₂COOMe, S, S), (N-2860: 3-F-Ph, CH₂COOMe, S, S), (N-2861: 4-F-Ph, CH₂CH₂COOMe, S, S), (N-2862: 4-Br-Ph, CH₂CH₂COOMe, S, S), (N-2863: 5-Cl-thiophene-2-yl, CH₂CH₂COOMe, S, S), (N-2864: 3,4-diF-Ph, CH₂CH₂COOMe, S, S), (N-2865: 5-Br-thiophene-2-yl, CH₂CH₂COOMe, S, S), (N-2866: 3,4-diBr-Ph, CH₂CH₂COOMe, S, S), (N-2867: 4-CF₃-Ph, CH₂CH₂COOMe, S, S), (N-2868: 3-Cl-Ph, CH₂CH₂COOMe, S, S), (N-2869: 3-

- Br-Ph, $\text{CH}_2\text{CH}_2\text{COOMe}$, S, S), (N-2870: 3-F-Ph, $\text{CH}_2\text{CH}_2\text{COOMe}$, S, S), (N-2871: 4-F-Ph, $\text{CH}_2\text{COONH}_2$, S, S), (N-2872: 4-Br-Ph, $\text{CH}_2\text{COONH}_2$, S, S), (N-2873: 5-Cl-thiophene-2-yl, $\text{CH}_2\text{COONH}_2$, S, S), (N-2874: 3,4-diF-Ph, $\text{CH}_2\text{COONH}_2$, S, S), (N-2875: 5-Br-thiophene-2-yl, $\text{CH}_2\text{COONH}_2$, S, S), (N-2876: 3,4-diBr-Ph, $\text{CH}_2\text{COONH}_2$, S, S), (N-2877: 4- CF_3 -Ph, $\text{CH}_2\text{COONH}_2$, S, S), (N-2878: 3-Cl-Ph, $\text{CH}_2\text{COONH}_2$, S, S), (N-2879: 3-Br-Ph, $\text{CH}_2\text{COONH}_2$, S, S), (N-2880: 3-F-Ph, $\text{CH}_2\text{COONH}_2$, S, S), (N-2881: 4-F-Ph, $\text{CH}_2\text{COONHCH}_3$, S, S), (N-2882: 4-Br-Ph, $\text{CH}_2\text{COONHCH}_3$, S, S), (N-2883: 5-Cl-thiophene-2-yl, $\text{CH}_2\text{COONHCH}_3$, S, S), (N-2884: 3,4-diF-Ph, $\text{CH}_2\text{COONHCH}_3$, S, S), (N-2885: 5-Br-thiophene-2-yl, $\text{CH}_2\text{COONHCH}_3$, S, S), (N-2886: 3,4-diBr-Ph, $\text{CH}_2\text{COONHCH}_3$, S, S), (N-2887: 4- CF_3 -Ph, $\text{CH}_2\text{COONHCH}_3$, S, S), (N-2888: 3-Cl-Ph, $\text{CH}_2\text{COONHCH}_3$, S, S), (N-2889: 3-Br-Ph, $\text{CH}_2\text{COONHCH}_3$, S, S), (N-2890: 3-F-Ph, $\text{CH}_2\text{COONHCH}_3$, S, S), (N-2893: 5-Cl-thiophene-2-yl, $\text{CH}_2\text{CH}_2\text{Cl}$, S, S), (N-2894: 3,4-diF-Ph, $\text{CH}_2\text{CH}_2\text{Cl}$, S, S), (N-2895: 5-Br-thiophene-2-yl, $\text{CH}_2\text{CH}_2\text{Cl}$, S, S), (N-2896: 3,4-diBr-Ph, $\text{CH}_2\text{CH}_2\text{Cl}$, S, S), (N-2897: 4- CF_3 -Ph, $\text{CH}_2\text{CH}_2\text{Cl}$, S, S), (N-2898: 3-Cl-Ph, $\text{CH}_2\text{CH}_2\text{Cl}$, S, S), (N-2899: 3-Br-Ph, $\text{CH}_2\text{CH}_2\text{Cl}$, S, S), (N-2900: 3-F-Ph, $\text{CH}_2\text{CH}_2\text{Cl}$, S, S), (N-2901: 4-F-Ph, CONH_2 , O, S), (N-2902: 4-Br-Ph, CONH_2 , O, S), (N-2903: 5-Cl-thiophene-2-yl, CONH_2 , O, S), (N-2904: 3,4-diF-Ph, CONH_2 , O, S), (N-2905: 5-Br-thiophene-2-yl, CONH_2 , O, S), (N-2906: 3,4-diBr-Ph, CONH_2 , O, S), (N-2907: 4- CF_3 -Ph, CONH_2 , O, S), (N-2908: 3-Cl-Ph, CONH_2 , O, S), (N-2909: 3-Br-Ph, CONH_2 , O, S), (N-2910: 3-F-Ph, CONH_2 , O, S), (N-2911: 4-F-Ph, CO_2NHCH_3 , O, S), (N-2912: 4-Br-Ph, CO_2NHCH_3 , O, S), (N-2913: 5-Cl-thiophene-2-yl, CO_2NHCH_3 , O, S), (N-2914: 3,4-diF-Ph, CO_2NHCH_3 , O, S), (N-2915: 5-Br-thiophene-2-yl, CO_2NHCH_3 , O, S), (N-2916: 3,4-diBr-Ph, CO_2NHCH_3 , O, S), (N-2917: 4- CF_3 -Ph, CO_2NHCH_3 , O, S), (N-2918: 3-Cl-Ph, CO_2NHCH_3 , O, S), (N-2919: 3-Br-Ph, CO_2NHCH_3 , O, S), (N-2920: 3-F-Ph, CO_2NHCH_3 , O, S), (N-2921: 4-F-Ph,

- CO₂N(CH₃)₂, O, S), (N-2922: 4-Br-Ph, CO₂N(CH₃)₂, O, S), (N-2923: 5-Cl-thiophene-2-yl, CO₂N(CH₃)₂, O, S), (N-2924: 3,4-diF-Ph, CO₂N(CH₃)₂, O, S), (N-2925: 5-Br-thiophene-2-yl, CO₂N(CH₃)₂, O, S), (N-2926: 3,4-diBr-Ph, CO₂N(CH₃)₂, O, S), (N-2927: 4-CF₃-Ph, CO₂N(CH₃)₂, O, S), (N-2928: 3-Cl-Ph, CO₂N(CH₃)₂, O, S), (N-2929: 3-Br-Ph, CO₂N(CH₃)₂, O, S), (N-2930: 3-F-Ph, CO₂N(CH₃)₂, O, S), (N-2931: 4-F-Ph, CO₂H, O, S), (N-2932: 4-Br-Ph, CO₂H, O, S), (N-2933: 5-Cl-thiophene-2-yl, CO₂H, O, S), (N-2934: 3,4-diF-Ph, CO₂H, O, S), (N-2935: 5-Br-thiophene-2-yl, CO₂H, O, S), (N-2936: 3,4-diBr-Ph, CO₂H, O, S), (N-2937: 4-CF₃-Ph, CO₂H, O, S), (N-2938: 3-Cl-Ph, CO₂H, O, S), (N-2939: 3-Br-Ph, CO₂H, O, S), (N-2940: 3-F-Ph, CO₂H, O, S), (N-2941: 4-F-Ph, NH₂, O, S), (N-2942: 4-Br-Ph, NH₂, O, S), (N-2943: 5-Cl-thiophene-2-yl, NH₂, O, S), (N-2944: 3,4-diF-Ph, NH₂, O, S), (N-2945: 5-Br-thiophene-2-yl, NH₂, O, S), (N-2946: 3,4-diBr-Ph, NH₂, O, S), (N-2947: 4-CF₃-Ph, NH₂, O, S), (N-2948: 3-Cl-Ph, NH₂, O, S), (N-2949: 3-Br-Ph, NH₂, O, S), (N-2950: 3-F-Ph, NH₂, O, S), (N-2951: 4-F-Ph, CH₂COOMe, O, S), (N-2952: 4-Br-Ph, CH₂COOMe, O, S), (N-2953: 5-Cl-thiophene-2-yl, CH₂COOMe, O, S), (N-2954: 3,4-diF-Ph, CH₂COOMe, O, S), (N-2955: 5-Br-thiophene-2-yl, CH₂COOMe, O, S), (N-2956: 3,4-diBr-Ph, CH₂COOMe, O, S), (N-2957: 4-CF₃-Ph, CH₂COOMe, O, S), (N-2958: 3-Cl-Ph, CH₂COOMe, O, S), (N-2959: 3-Br-Ph, CH₂COOMe, O, S), (N-2960: 3-F-Ph, CH₂COOMe, O, S), (N-2961: 4-F-Ph, CH₂CH₂COOMe, O, S), (N-2962: 4-Br-Ph, CH₂CH₂COOMe, O, S), (N-2963: 5-Cl-thiophene-2-yl, CH₂CH₂COOMe, O, S), (N-2964: 3,4-diF-Ph, CH₂CH₂COOMe, O, S), (N-2965: 5-Br-thiophene-2-yl, CH₂CH₂COOMe, O, S), (N-2966: 3,4-diBr-Ph, CH₂CH₂COOMe, O, S), (N-2967: 4-CF₃-Ph, CH₂CH₂COOMe, O, S), (N-2968: 3-Cl-Ph, CH₂CH₂COOMe, O, S), (N-2969: 3-Br-Ph, CH₂CH₂COOMe, O, S), (N-2970: 3-F-Ph, CH₂CH₂COOMe, O, S), (N-2971: 4-F-Ph, CH₂COONH₂, O, S), (N-2972: 4-Br-Ph, CH₂COONH₂, O, S), (N-2973: 5-Cl-thiophene-2-yl,

- CH₂COONH₂, O, S), (N-2974: 3,4-diF-Ph, CH₂COONH₂, O, S), (N-2975: 5-Br-thiophene-2-yl, CH₂COONH₂, O, S), (N-2976: 3,4-diBr-Ph, CH₂COONH₂, O, S), (N-2977: 4-CF₃-Ph, CH₂COONH₂, O, S), (N-2978: 3-Cl-Ph, CH₂COONH₂, O, S), (N-2979: 3-Br-Ph, CH₂COONH₂, O, S), (N-2980: 3-F-Ph, CH₂COONH₂, O, S),
- 5 (N-2981: 4-F-Ph, CH₂COONHCH₃, O, S), (N-2982: 4-Br-Ph, CH₂COONHCH₃, O, S), (N-2983: 5-Cl-thiophene-2-yl, CH₂COONHCH₃, O, S), (N-2984: 3,4-diF-Ph, CH₂COONHCH₃, O, S), (N-2985: 5-Br-thiophene-2-yl, CH₂COONHCH₃, O, S), (N-2986: 3,4-diBr-Ph, CH₂COONHCH₃, O, S), (N-2987: 4-CF₃-Ph, CH₂COONHCH₃, O, S), (N-2988: 3-Cl-Ph, CH₂COONHCH₃, O, S), (N-2989: 3-Br-Ph, CH₂COONHCH₃, O, S), (N-2990: 3-F-Ph, CH₂COONHCH₃, O, S), (N-2991: 4-F-Ph, CH₂CH₂Cl, O, S), (N-2992: 4-Br-Ph, CH₂CH₂Cl, O, S), (N-2993: 5-Cl-thiophene-2-yl, CH₂CH₂Cl, O, S), (N-2994: 3,4-diF-Ph, CH₂CH₂Cl, O, S), (N-2995: 5-Br-thiophene-2-yl, CH₂CH₂Cl, O, S), (N-2996: 3,4-diBr-Ph, CH₂CH₂Cl, O, S), (N-2997: 4-CF₃-Ph, CH₂CH₂Cl, O, S), (N-2998: 3-Cl-Ph, CH₂CH₂Cl, O, S), (N-2999: 3-Br-Ph, CH₂CH₂Cl, O, S), (N-3000: 3-F-Ph, CH₂CH₂Cl, O, S), (N-3001: 4-F-Ph, CONH₂, S, O), (N-3002: 4-Br-Ph, CONH₂, S, O), (N-3003: 5-Cl-thiophene-2-yl, CONH₂, S, O), (N-3004: 3,4-diF-Ph, CONH₂, S, O), (N-3005: 5-Br-thiophene-2-yl, CONH₂, S, O), (N-3006: 3,4-diBr-Ph, CONH₂, S, O), (N-3007: 4-CF₃-Ph, CONH₂, S, O), (N-3008: 3-Cl-Ph, CONH₂, S, O), (N-3009: 3-Br-Ph, CONH₂, S, O), (N-3010: 3-F-Ph, CONH₂, S, O), (N-3011: 4-F-Ph, CO₂NHCH₃, S, O), (N-3012: 4-Br-Ph, CO₂NHCH₃, S, O), (N-3013: 5-Cl-thiophene-2-yl, CO₂NHCH₃, S, O), (N-3014: 3,4-diF-Ph, CO₂NHCH₃, S, O), (N-3015: 5-Br-thiophene-2-yl, CO₂NHCH₃, S, O), (N-3016: 3,4-diBr-Ph, CO₂NHCH₃, S, O), (N-3017: 4-CF₃-Ph, CO₂NHCH₃, S, O), (N-3018: 3-Cl-Ph, CO₂NHCH₃, S, O), (N-3019: 3-Br-Ph, CO₂NHCH₃, S, O), (N-3020: 3-F-Ph, CO₂NHCH₃, S, O), (N-3021: 4-F-Ph, CO₂N(CH₃)₂, S, O), (N-3022: 4-Br-Ph, CO₂N(CH₃)₂, S, O), (N-3023: 5-Cl-thiophene-2-yl, CO₂N(CH₃)₂, S, O), (N-3024:
- 20
- 15
- 20

- 3,4-diF-Ph, $\text{CO}_2\text{N}(\text{CH}_3)_2$, S, O), (N-3025: 5-Br-thiophene-2-yl, $\text{CO}_2\text{N}(\text{CH}_3)_2$, S, O), (N-3026: 3,4-diBr-Ph, $\text{CO}_2\text{N}(\text{CH}_3)_2$, S, O), (N-3027: 4- CF_3 -Ph, $\text{CO}_2\text{N}(\text{CH}_3)_2$, S, O), (N-3028: 3-Cl-Ph, $\text{CO}_2\text{N}(\text{CH}_3)_2$, S, O), (N-3029: 3-Br-Ph, $\text{CO}_2\text{N}(\text{CH}_3)_2$, S, O), (N-3030: 3-F-Ph, $\text{CO}_2\text{N}(\text{CH}_3)_2$, S, O), (N-3031: 4-F-Ph, CO_2H , S, O), (N-3032: 4-Br-Ph, CO_2H , S, O), (N-3033: 5-Cl-thiophene-2-yl, CO_2H , S, O), (N-3034: 3,4-diF-Ph, CO_2H , S, O), (N-3035: 5-Br-thiophene-2-yl, CO_2H , S, O), (N-3036: 3,4-diBr-Ph, CO_2H , S, O), (N-3037: 4- CF_3 -Ph, CO_2H , S, O), (N-3038: 3-Cl-Ph, CO_2H , S, O), (N-3039: 3-Br-Ph, CO_2H , S, O), (N-3040: 3-F-Ph, CO_2H , S, O), (N-3041: 4-F-Ph, NH_2 , S, O), (N-3042: 4-Br-Ph, NH_2 , S, O), (N-3043: 5-Cl-thiophene-2-yl, NH_2 , S, O), (N-3044: 3,4-diF-Ph, NH_2 , S, O), (N-3045: 5-Br-thiophene-2-yl, NH_2 , S, O), (N-3046: 3,4-diBr-Ph, NH_2 , S, O), (N-3047: 4- CF_3 -Ph, NH_2 , S, O), (N-3048: 3-Cl-Ph, NH_2 , S, O), (N-3049: 3-Br-Ph, NH_2 , S, O), (N-3050: 3-F-Ph, NH_2 , S, O), (N-3051: 4-F-Ph, CH_2COOMe , S, O), (N-3052: 4-Br-Ph, CH_2COOMe , S, O), (N-3053: 5-Cl-thiophene-2-yl, CH_2COOMe , S, O), (N-3054: 3,4-diF-Ph, CH_2COOMe , S, O), (N-3055: 5-Br-thiophene-2-yl, CH_2COOMe , S, O), (N-3056: 3,4-diBr-Ph, CH_2COOMe , S, O), (N-3057: 4- CF_3 -Ph, CH_2COOMe , S, O), (N-3058: 3-Cl-Ph, CH_2COOMe , S, O), (N-3059: 3-Br-Ph, CH_2COOMe , S, O), (N-3060: 3-F-Ph, CH_2COOMe , S, O), (N-3061: 4-F-Ph, $\text{CH}_2\text{CH}_2\text{COOMe}$, S, O), (N-3062: 4-Br-Ph, $\text{CH}_2\text{CH}_2\text{COOMe}$, S, O), (N-3063: 5-Cl-thiophene-2-yl, $\text{CH}_2\text{CH}_2\text{COOMe}$, S, O), (N-3064: 3,4-diF-Ph, $\text{CH}_2\text{CH}_2\text{COOMe}$, S, O), (N-3065: 5-Br-thiophene-2-yl, $\text{CH}_2\text{CH}_2\text{COOMe}$, S, O), (N-3066: 3,4-diBr-Ph, $\text{CH}_2\text{CH}_2\text{COOMe}$, S, O), (N-3067: 4- CF_3 -Ph, $\text{CH}_2\text{CH}_2\text{COOMe}$, S, O), (N-3068: 3-Cl-Ph, $\text{CH}_2\text{CH}_2\text{COOMe}$, S, O), (N-3069: 3-Br-Ph, $\text{CH}_2\text{CH}_2\text{COOMe}$, S, O), (N-3070: 3-F-Ph, $\text{CH}_2\text{CH}_2\text{COOMe}$, S, O), (N-3071: 4-F-Ph, $\text{CH}_2\text{COONH}_2$, S, O), (N-3072: 4-Br-Ph, $\text{CH}_2\text{COONH}_2$, S, O), (N-3073: 5-Cl-thiophene-2-yl, $\text{CH}_2\text{COONH}_2$, S, O), (N-3074: 3,4-diF-Ph, $\text{CH}_2\text{COONH}_2$, S, O), (N-3075: 5-Br-thiophene-2-yl, $\text{CH}_2\text{COONH}_2$, S, O), (N-

- 3076: 3,4-diBr-Ph, CH₂COONH₂, S, O), (N-3077: 4-CF₃-Ph, CH₂COONH₂, S, O),
 (N-3078: 3-Cl-Ph, CH₂COONH₂, S, O), (N-3079: 3-Br-Ph, CH₂COONH₂, S, O),
 (N-3080: 3-F-Ph, CH₂COONH₂, S, O), (N-3081: 4-F-Ph, CH₂COONHCH₃, S, O),
 (N-3082: 4-Br-Ph, CH₂COONHCH₃, S, O), (N-3083: 5-Cl-thiophene-2-yl,
 5 CH₂COONHCH₃, S, O), (N-3084: 3,4-diF-Ph, CH₂COONHCH₃, S, O), (N-3085:
 5-Br-thiophene-2-yl, CH₂COONHCH₃, S, O), (N-3086: 3,4-diBr-Ph,
 CH₂COONHCH₃, S, O), (N-3087: 4-CF₃-Ph, CH₂COONHCH₃, S, O), (N-3088:
 3-Cl-Ph, CH₂COONHCH₃, S, O), (N-3089: 3-Br-Ph, CH₂COONHCH₃, S, O),
 (N-3090: 3-F-Ph, CH₂COONHCH₃, S, O), (N-3091: 4-F-Ph, CH₂CH₂Cl, S, O),
 10 (N-3092: 4-Br-Ph, CH₂CH₂Cl, S, O), (N-3093: 5-Cl-thiophene-2-yl, CH₂CH₂Cl,
 S, O), (N-3094: 3,4-diF-Ph, CH₂CH₂Cl, S, O), (N-3095: 5-Br-thiophene-2-yl,
 CH₂CH₂Cl, S, O), (N-3096: 3,4-diBr-Ph, CH₂CH₂Cl, S, O), (N-3097: 4-CF₃-Ph,
 CH₂CH₂Cl, S, O), (N-3098: 3-Cl-Ph, CH₂CH₂Cl, S, O), (N-3099: 3-Br-Ph,
 CH₂CH₂Cl, S, O), (N-3100: 3-F-Ph, CH₂CH₂Cl, S, O), (N-3101: 4-F-Ph, CONH₂,
 15 O, O), (N-3102: 4-Br-Ph, CONH₂, O, O), (N-3103: 5-Cl-thiophene-2-yl, CONH₂,
 O, O), (N-3104: 3,4-diF-Ph, CONH₂, O, O), (N-3105: 5-Br-thiophene-2-yl,
 CONH₂, O, O), (N-3106: 3,4-diBr-Ph, CONH₂, O, O), (N-3107: 4-CF₃-Ph,
 CONH₂, O, O), (N-3108: 3-Cl-Ph, CONH₂, O, O), (N-3109: 3-Br-Ph, CONH₂, O,
 O), (N-3110: 3-F-Ph, CONH₂, O, O), (N-3111: 4-F-Ph, CO₂NHCH₃, O, O), (N-
 20 3112: 4-Br-Ph, CO₂NHCH₃, O, O), (N-3113: 5-Cl-thiophene-2-yl, CO₂NHCH₃, O,
 O), (N-3114: 3,4-diF-Ph, CO₂NHCH₃, O, O), (N-3115: 5-Br-thiophene-2-yl,
 CO₂NHCH₃, O, O), (N-3116: 3,4-diBr-Ph, CO₂NHCH₃, O, O), (N-3117: 4-CF₃-
 Ph, CO₂NHCH₃, O, O), (N-3118: 3-Cl-Ph, CO₂NHCH₃, O, O), (N-3119: 3-Br-Ph,
 CO₂NHCH₃, O, O), (N-3120: 3-F-Ph, CO₂NHCH₃, O, O), (N-3121: 4-F-Ph,
 25 CO₂N(CH₃)₂, O, O), (N-3122: 4-Br-Ph, CO₂N(CH₃)₂, O, O), (N-3123: 5-Cl-
 thiophene-2-yl, CO₂N(CH₃)₂, O, O), (N-3124: 3,4-diF-Ph, CO₂N(CH₃)₂, O, O),
 (N-3125: 5-Br-thiophene-2-yl, CO₂N(CH₃)₂, O, O), (N-3126: 3,4-diBr-Ph,

- CO₂N(CH₃)₂, O, O), (N-3127: 4-CF₃-Ph, CO₂N(CH₃)₂, O, O), (N-3128: 3-Cl-Ph, CO₂N(CH₃)₂, O, O), (N-3129: 3-Br-Ph, CO₂N(CH₃)₂, O, O), (N-3130: 3-F-Ph, CO₂N(CH₃)₂, O, O), (N-3131: 4-F-Ph, CO₂H, O, O), (N-3132: 4-Br-Ph, CO₂H, O, O), (N-3133: 5-Cl-thiophene-2-yl, CO₂H, O, O), (N-3134: 3,4-diF-Ph, CO₂H, O, O), (N-3135: 5-Br-thiophene-2-yl, CO₂H, O, O), (N-3136: 3,4-diBr-Ph, CO₂H, O, O), (N-3137: 4-CF₃-Ph, CO₂H, O, O), (N-3138: 3-Cl-Ph, CO₂H, O, O), (N-3139: 3-Br-Ph, CO₂H, O, O), (N-3140: 3-F-Ph, CO₂H, O, O), (N-3141: 4-F-Ph, NH₂, O, O), (N-3142: 4-Br-Ph, NH₂, O, O), (N-3143: 5-Cl-thiophene-2-yl, NH₂, O, O), (N-3144: 3,4-diF-Ph, NH₂, O, O), (N-3145: 5-Br-thiophene-2-yl, NH₂, O, O), (N-3146: 3,4-diBr-Ph, NH₂, O, O), (N-3147: 4-CF₃-Ph, NH₂, O, O), (N-3148: 3-Cl-Ph, NH₂, O, O), (N-3149: 3-Br-Ph, NH₂, O, O), (N-3150: 3-F-Ph, NH₂, O, O), (N-3151: 4-F-Ph, CH₂COOMe, O, O), (N-3152: 4-Br-Ph, CH₂COOMe, O, O), (N-3153: 5-Cl-thiophene-2-yl, CH₂COOMe, O, O), (N-3154: 3,4-diF-Ph, CH₂COOMe, O, O), (N-3155: 5-Br-thiophene-2-yl, CH₂COOMe, O, O), (N-3156: 3,4-diBr-Ph, CH₂COOMe, O, O), (N-3157: 4-CF₃-Ph, CH₂COOMe, O, O), (N-3158: 3-Cl-Ph, CH₂COOMe, O, O), (N-3159: 3-Br-Ph, CH₂COOMe, O, O), (N-3160: 3-F-Ph, CH₂COOMe, O, O), (N-3161: 4-F-Ph, CH₂CH₂COOMe, O, O), (N-3162: 4-Br-Ph, CH₂CH₂COOMe, O, O), (N-3163: 5-Cl-thiophene-2-yl, CH₂CH₂COOMe, O, O), (N-3164: 3,4-diF-Ph, CH₂CH₂COOMe, O, O), (N-3165: 5-Br-thiophene-2-yl, CH₂CH₂COOMe, O, O), (N-3166: 3,4-diBr-Ph, CH₂CH₂COOMe, O, O), (N-3167: 4-CF₃-Ph, CH₂CH₂COOMe, O, O), (N-3168: 3-Cl-Ph, CH₂CH₂COOMe, O, O), (N-3169: 3-Br-Ph, CH₂CH₂COOMe, O, O), (N-3170: 3-F-Ph, CH₂CH₂COOMe, O, O), (N-3171: 4-F-Ph, CH₂COONH₂, O, O), (N-3172: 4-Br-Ph, CH₂COONH₂, O, O), (N-3173: 5-Cl-thiophene-2-yl, CH₂COONH₂, O, O), (N-3174: 3,4-diF-Ph, CH₂COONH₂, O, O), (N-3175: 5-Br-thiophene-2-yl, CH₂COONH₂, O, O), (N-3176: 3,4-diBr-Ph, CH₂COONH₂, O, O), (N-3177: 4-CF₃-Ph, CH₂COONH₂, O, O), (N-3178: 3-Cl-Ph, CH₂COONH₂, O, O),

(N-3179: 3-Br-Ph, CH₂COONH₂, O, O), (N-3180: 3-F-Ph, CH₂COONH₂, O, O),
 (N-3181: 4-F-Ph, CH₂COONHCH₃, O, O), (N-3182: 4-Br-Ph, CH₂COONHCH₃,
 O, O), (N-3183: 5-Cl-thiophene-2-yl, CH₂COONHCH₃, O, O), (N-3184: 3,4-diF-
 Ph, CH₂COONHCH₃, O, O), (N-3185: 5-Br-thiophene-2-yl, CH₂COONHCH₃, O,
 5 O), (N-3186: 3,4-diBr-Ph, CH₂COONHCH₃, O, O), (N-3187: 4-CF₃-Ph,
 CH₂COONHCH₃, O, O), (N-3188: 3-Cl-Ph, CH₂COONHCH₃, O, O), (N-3189: 3-
 Br-Ph, CH₂COONHCH₃, O, O), (N-3190: 3-F-Ph, CH₂COONHCH₃, O, O), (N-
 3192: 4-Br-Ph, CH₂CH₂Cl, O, O), (N-3193: 5-Cl-thiophene-2-yl, CH₂CH₂Cl, O,
 O), (N-3194: 3,4-diF-Ph, CH₂CH₂Cl, O, O), (N-3195: 5-Br-thiophene-2-yl,
 10 CH₂CH₂Cl, O, O), (N-3196: 3,4-diBr-Ph, CH₂CH₂Cl, O, O), (N-3197: 4-CF₃-Ph,
 CH₂CH₂Cl, O, O), (N-3198: 3-Cl-Ph, CH₂CH₂Cl, O, O), (N-3199: 3-Br-Ph,
 CH₂CH₂Cl, O, O), (N-3200: 3-F-Ph, CH₂CH₂Cl, O, O), (N-3301: CONH₂, 4-F-Ph,
 S, S), (N-3302: CONH₂, 4-Br-Ph, S, S), (N-3303: CONH₂, 5-Cl-thiophene-2-yl,
 S, S), (N-3304: CONH₂, 3,4-diF-Ph, S, S), (N-3305: CONH₂, 5-Br-thiophene-2-
 15 yl, S, S), (N-3306: CONH₂, 3,4-diBr-Ph, S, S), (N-3307: CONH₂, 4-CF₃-Ph, S, S),
 (N-3308: CONH₂, 3-Cl-Ph, S, S), (N-3309: CONH₂, 3-Br-Ph, S, S), (N-3310:
 CONH₂, 3-F-Ph, S, S), (N-3311: CO₂NHCH₃, 4-F-Ph, S, S), (N-3312:
 CO₂NHCH₃, 4-Br-Ph, S, S), (N-3313: CO₂NHCH₃, 5-Cl-thiophene-2-yl, S, S),
 (N-3314: CO₂NHCH₃, 3,4-diF-Ph, S, S), (N-3315: CO₂NHCH₃, 5-Br-thiophene-
 20 2-yl, S, S), (N-3316: CO₂NHCH₃, 3,4-diBr-Ph, S, S), (N-3317: CO₂NHCH₃, 4-
 CF₃-Ph, S, S), (N-3318: CO₂NHCH₃, 3-Cl-Ph, S, S), (N-3319: CO₂NHCH₃, 3-
 Br-Ph, S, S), (N-3320: CO₂NHCH₃, 3-F-Ph, S, S), (N-3321: CO₂N(CH₃)₂, 4-F-Ph,
 S, S), (N-3322: CO₂N(CH₃)₂, 4-Br-Ph, S, S), (N-3323: CO₂N(CH₃)₂, 5-Cl-
 thiophene-2-yl, S, S), (N-3324: CO₂N(CH₃)₂, 3,4-diF-Ph, S, S), (N-3325:
 25 CO₂N(CH₃)₂, 5-Br-thiophene-2-yl, S, S), (N-3326: CO₂N(CH₃)₂, 3,4-diBr-Ph, S,
 S), (N-3327: CO₂N(CH₃)₂, 4-CF₃-Ph, S, S), (N-3328: CO₂N(CH₃)₂, 3-Cl-Ph, S, S),
 (N-3329: CO₂N(CH₃)₂, 3-Br-Ph, S, S), (N-3330: CO₂N(CH₃)₂, 3-F-Ph, S, S), (N-

- 3331: CO₂H, 4-F-Ph, S, S), (N-3332: CO₂H, 4-Br-Ph, S, S), (N-3333: CO₂H, 5-Cl-thiophene-2-yl, S, S), (N-3334: CO₂H, 3,4-diF-Ph, S, S), (N-3335: CO₂H, 5-Br-thiophene-2-yl, S, S), (N-3336: CO₂H, 3,4-diBr-Ph, S, S), (N-3337: CO₂H, 4-CF₃-Ph, S, S), (N-3338: CO₂H, 3-Cl-Ph, S, S), (N-3339: CO₂H, 3-Br-Ph, S, S),
- 5 (N-3340: CO₂H, 3-F-Ph, S, S), (N-3341: NH₂, 4-F-Ph, S, S), (N-3342: NH₂, 4-Br-Ph, S, S), (N-3343: NH₂, 5-Cl-thiophene-2-yl, S, S), (N-3344: NH₂, 3,4-diF-Ph, S, S), (N-3345: NH₂, 5-Br-thiophene-2-yl, S, S), (N-3346: NH₂, 3,4-diBr-Ph, S, S), (N-3347: NH₂, 4-CF₃-Ph, S, S), (N-3348: NH₂, 3-Cl-Ph, S, S), (N-3349: NH₂, 3-Br-Ph, S, S), (N-3350: NH₂, 3-F-Ph, S, S), (N-3351: CH₂COOMe, 4-F-Ph, S, S), (N-3352: CH₂COOMe, 4-Br-Ph, S, S), (N-3353: CH₂COOMe, 5-Cl-thiophene-2-yl, S, S), (N-3354: CH₂COOMe, 3,4-diF-Ph, S, S), (N-3355: CH₂COOMe, 5-Br-thiophene-2-yl, S, S), (N-3356: CH₂COOMe, 3,4-diBr-Ph, S, S), (N-3357: CH₂COOMe, 4-CF₃-Ph, S, S), (N-3358: CH₂COOMe, 3-Cl-Ph, S, S), (N-3359: CH₂COOMe, 3-Br-Ph, S, S), (N-3360: CH₂COOMe, 3-F-Ph, S, S), (N-3361: CH₂CH₂COOMe, 4-F-Ph, S, S), (N-3362: CH₂CH₂COOMe, 4-Br-Ph, S, S), (N-3363: CH₂CH₂COOMe, 5-Cl-thiophene-2-yl, S, S), (N-3364: CH₂CH₂COOMe, 3,4-diF-Ph, S, S), (N-3365: CH₂CH₂COOMe, 5-Br-thiophene-2-yl, S, S), (N-3366: CH₂CH₂COOMe, 3,4-diBr-Ph, S, S), (N-3367: CH₂CH₂COOMe, 4-CF₃-Ph, S, S), (N-3368: CH₂CH₂COOMe, 3-Cl-Ph, S, S), (N-3369: CH₂CH₂COOMe, 3-Br-Ph, S, S), (N-3370: CH₂CH₂COOMe, 3-F-Ph, S, S), (N-3371: CH₂COONH₂, 4-F-Ph, S, S), (N-3372: CH₂COONH₂, 4-Br-Ph, S, S), (N-3373: CH₂COONH₂, 5-Cl-thiophene-2-yl, S, S), (N-3374: CH₂COONH₂, 3,4-diF-Ph, S, S), (N-3375: CH₂COONH₂, 5-Br-thiophene-2-yl, S, S), (N-3376: CH₂COONH₂, 3,4-diBr-Ph, S, S), (N-3377: CH₂COONH₂, 4-CF₃-Ph, S, S), (N-3378: CH₂COONH₂, 3-Cl-Ph, S, S), (N-3379: CH₂COONH₂, 3-Br-Ph, S, S), (N-3380: CH₂COONH₂, 3-F-Ph, S, S), (N-3381: CH₂COONHCH₃, 4-F-Ph, S, S), (N-3382: CH₂COONHCH₃, 4-Br-Ph, S, S), (N-3383: CH₂COONHCH₃, 5-Cl-thiophene-2-yl, S, S), (N-3384:
- 10
- 15
- 20
- 25

CH₂COONHCH₃, 3,4-diF-Ph, S, S), (N-3385: CH₂COONHCH₃, 5-Br-thiophene-2-yl, S, S), (N-3386: CH₂COONHCH₃, 3,4-diBr-Ph, S, S), (N-3387: CH₂COONHCH₃, 4-CF₃-Ph, S, S), (N-3388: CH₂COONHCH₃, 3-Cl-Ph, S, S), (N-3389: CH₂COONHCH₃, 3-Br-Ph, S, S), (N-3390: CH₂COONHCH₃, 3-F-Ph, S, S), (N-3391: CH₂CH₂Cl, 4-F-Ph, S, S), (N-3392: CH₂CH₂Cl, 4-Br-Ph, S, S), (N-3393: CH₂CH₂Cl, 5-Cl-thiophene-2-yl, S, S), (N-3394: CH₂CH₂Cl, 3,4-diF-Ph, S, S), (N-3395: CH₂CH₂Cl, 5-Br-thiophene-2-yl, S, S), (N-3396: CH₂CH₂Cl, 3,4-diBr-Ph, S, S), (N-3397: CH₂CH₂Cl, 4-CF₃-Ph, S, S), (N-3398: CH₂CH₂Cl, 3-Cl-Ph, S, S), (N-3399: CH₂CH₂Cl, 3-Br-Ph, S, S), (N-3400: CH₂CH₂Cl, 3-F-Ph, S, S), (N-3401: CONH₂, 4-F-Ph, S, O), (N-3402: CONH₂, 4-Br-Ph, S, O), (N-3403: CONH₂, 5-Cl-thiophene-2-yl, S, O), (N-3404: CONH₂, 3,4-diF-Ph, S, O), (N-3405: CONH₂, 5-Br-thiophene-2-yl, S, O), (N-3406: CONH₂, 3,4-diBr-Ph, S, O), (N-3407: CONH₂, 4-CF₃-Ph, S, O), (N-3408: CONH₂, 3-Cl-Ph, S, O), (N-3409: CONH₂, 3-Br-Ph, S, O), (N-3410: CONH₂, 3-F-Ph, S, O), (N-3411: CO₂NHCH₃, 4-F-Ph, S, O), (N-3412: CO₂NHCH₃, 4-Br-Ph, S, O), (N-3413: CO₂NHCH₃, 5-Cl-thiophene-2-yl, S, O), (N-3414: CO₂NHCH₃, 3,4-diF-Ph, S, O), (N-3415: CO₂NHCH₃, 5-Br-thiophene-2-yl, S, O), (N-3416: CO₂NHCH₃, 3,4-diBr-Ph, S, O), (N-3417: CO₂NHCH₃, 4-CF₃-Ph, S, O), (N-3418: CO₂NHCH₃, 3-Cl-Ph, S, O), (N-3419: CO₂NHCH₃, 3-Br-Ph, S, O), (N-3420: CO₂NHCH₃, 3-F-Ph, S, O), (N-3421: CO₂N(CH₃)₂, 4-F-Ph, S, O), (N-3422: CO₂N(CH₃)₂, 4-Br-Ph, S, O), (N-3423: CO₂N(CH₃)₂, 5-Cl-thiophene-2-yl, S, O), (N-3424: CO₂N(CH₃)₂, 3,4-diF-Ph, S, O), (N-3425: CO₂N(CH₃)₂, 5-Br-thiophene-2-yl, S, O), (N-3426: CO₂N(CH₃)₂, 3,4-diBr-Ph, S, O), (N-3427: CO₂N(CH₃)₂, 4-CF₃-Ph, S, O), (N-3428: CO₂N(CH₃)₂, 3-Cl-Ph, S, O), (N-3429: CO₂N(CH₃)₂, 3-Br-Ph, S, O), (N-3430: CO₂N(CH₃)₂, 3-F-Ph, S, O), (N-3431: CO₂H, 4-F-Ph, S, O), (N-3432: CO₂H, 4-Br-Ph, S, O), (N-3433: CO₂H, 5-Cl-thiophene-2-yl, S, O), (N-3434: CO₂H, 3,4-diF-Ph, S, O), (N-3435: CO₂H, 5-Br-thiophene-2-yl, S, O),

- (N-3436: CO₂H, 3,4-diBr-Ph, S, O), (N-3437: CO₂H, 4-CF₃-Ph, S, O), (N-3438: CO₂H, 3-Cl-Ph, S, O), (N-3439: CO₂H, 3-Br-Ph, S, O), (N-3440: CO₂H, 3-F-Ph, S, O), (N-3441: NH₂, 4-F-Ph, S, O), (N-3442: NH₂, 4-Br-Ph, S, O), (N-3443: NH₂, 5-Cl-thiophene-2-yl, S, O), (N-3444: NH₂, 3,4-diF-Ph, S, O), (N-3445: NH₂, 5-Br-thiophene-2-yl, S, O), (N-3446: NH₂, 3,4-diBr-Ph, S, O), (N-3447: NH₂, 4-CF₃-Ph, S, O), (N-3448: NH₂, 3-Cl-Ph, S, O), (N-3449: NH₂, 3-Br-Ph, S, O), (N-3450: NH₂, 3-F-Ph, S, O), (N-3451: CH₂COOMe, 4-F-Ph, S, O), (N-3452: CH₂COOMe, 4-Br-Ph, S, O), (N-3453: CH₂COOMe, 5-Cl-thiophene-2-yl, S, O), (N-3454: CH₂COOMe, 3,4-diF-Ph, S, O), (N-3455: CH₂COOMe, 5-Br-thiophene-2-yl, S, O), (N-3456: CH₂COOMe, 3,4-diBr-Ph, S, O), (N-3457: CH₂COOMe, 4-CF₃-Ph, S, O), (N-3458: CH₂COOMe, 3-Cl-Ph, S, O), (N-3459: CH₂COOMe, 3-Br-Ph, S, O), (N-3460: CH₂COOMe, 3-F-Ph, S, O), (N-3461: CH₂CH₂COOMe, 4-F-Ph, S, O), (N-3462: CH₂CH₂COOMe, 4-Br-Ph, S, O), (N-3463: CH₂CH₂COOMe, 5-Cl-thiophene-2-yl, S, O), (N-3464: CH₂CH₂COOMe, 3,4-diF-Ph, S, O), (N-3465: CH₂CH₂COOMe, 5-Br-thiophene-2-yl, S, O), (N-3466: CH₂CH₂COOMe, 3,4-diBr-Ph, S, O), (N-3467: CH₂CH₂COOMe, 4-CF₃-Ph, S, O), (N-3468: CH₂CH₂COOMe, 3-Cl-Ph, S, O), (N-3469: CH₂CH₂COOMe, 3-Br-Ph, S, O), (N-3470: CH₂CH₂COOMe, 3-F-Ph, S, O), (N-3471: CH₂COONH₂, 4-F-Ph, S, O), (N-3472: CH₂COONH₂, 4-Br-Ph, S, O), (N-3473: CH₂COONH₂, 5-Cl-thiophene-2-yl, S, O), (N-3474: CH₂COONH₂, 3,4-diF-Ph, S, O), (N-3475: CH₂COONH₂, 5-Br-thiophene-2-yl, S, O), (N-3476: CH₂COONH₂, 3,4-diBr-Ph, S, O), (N-3477: CH₂COONH₂, 4-CF₃-Ph, S, O), (N-3478: CH₂COONH₂, 3-Cl-Ph, S, O), (N-3479: CH₂COONH₂, 3-Br-Ph, S, O), (N-3480: CH₂COONH₂, 3-F-Ph, S, O), (N-3481: CH₂COONHCH₃, 4-F-Ph, S, O), (N-3482: CH₂COONHCH₃, 4-Br-Ph, S, O), (N-3483: CH₂COONHCH₃, 5-Cl-thiophene-2-yl, S, O), (N-3484: CH₂COONHCH₃, 3,4-diF-Ph, S, O), (N-3485: CH₂COONHCH₃, 5-Br-thiophene-2-yl, S, O), (N-3486: CH₂COONHCH₃, 3,4-diBr-Ph, S, O), (N-3487:

- CH₂COONHCH₃, 4-CF₃-Ph, S, O), (N-3488: CH₂COONHCH₃, 3-Cl-Ph, S, O),
 (N-3489: CH₂COONHCH₃, 3-Br-Ph, S, O), (N-3490: CH₂COONHCH₃, 3-F-Ph, S,
 O), (N-3491: CH₂CH₂Cl, 4-F-Ph, S, O), (N-3492: CH₂CH₂Cl, 4-Br-Ph, S, O),
 (N-3493: CH₂CH₂Cl, 5-Cl-thiophene-2-yl, S, O), (N-3494: CH₂CH₂Cl, 3,4-diF-
 5 Ph, S, O), (N-3495: CH₂CH₂Cl, 5-Br-thiophene-2-yl, S, O), (N-3496: CH₂CH₂Cl,
 3,4-diBr-Ph, S, O), (N-347: CH₂CH₂Cl, 4-CF₃-Ph, S, O), (N-3498: CH₂CH₂Cl,
 3-Cl-Ph, S, O), (N-3499: CH₂CH₂Cl, 3-Br-Ph, S, O), (N-3500: CH₂CH₂Cl, 3-F-
 Ph, S, O), (N-3501: CONH₂, 4-F-Ph, O, S), (N-3502: CONH₂, 4-Br-Ph, O, S),
 (N-3503: CONH₂, 5-Cl-thiophene-2-yl, O, S), (N-3504: CONH₂, 3,4-diF-Ph, O,
 10 S), (N-3505: CONH₂, 5-Br-thiophene-2-yl, O, S), (N-3506: CONH₂, 3,4-diBr-Ph,
 O, S), (N-3507: CONH₂, 4-CF₃-Ph, O, S), (N-3508: CONH₂, 3-Cl-Ph, O, S), (N-
 3509: CONH₂, 3-Br-Ph, O, S), (N-3510: CONH₂, 3-F-Ph, O, S), (N-3511:
 CO₂NHCH₃, 4-F-Ph, O, S), (N-3512: CO₂NHCH₃, 4-Br-Ph, O, S), (N-3513:
 CO₂NHCH₃, 5-Cl-thiophene-2-yl, O, S), (N-3514: CO₂NHCH₃, 3,4-diF-Ph, O, S),
 15 (N-3515: CO₂NHCH₃, 5-Br-thiophene-2-yl, O, S), (N-3516: CO₂NHCH₃, 3,4-
 diBr-Ph, O, S), (N-3517: CO₂NHCH₃, 4-CF₃-Ph, O, S), (N-3518: CO₂NHCH₃,
 3-Cl-Ph, O, S), (N-3519: CO₂NHCH₃, 3-Br-Ph, O, S), (N-3520: CO₂NHCH₃, 3-
 F-Ph, O, S), (N-3521: CO₂N(CH₃)₂, 4-F-Ph, O, S), (N-3522: CO₂N(CH₃)₂, 4-Br-
 Ph, O, S), (N-3523: CO₂N(CH₃)₂, 5-Cl-thiophene-2-yl, O, S), (N-3524:
 20 CO₂N(CH₃)₂, 3,4-diF-Ph, O, S), (N-3525: CO₂N(CH₃)₂, 5-Br-thiophene-2-yl, O,
 S), (N-3526: CO₂N(CH₃)₂, 3,4-diBr-Ph, O, S), (N-3527: CO₂N(CH₃)₂, 4-CF₃-Ph,
 O, S), (N-3528: CO₂N(CH₃)₂, 3-Cl-Ph, O, S), (N-3529: CO₂N(CH₃)₂, 3-Br-Ph, O,
 S), (N-3530: CO₂N(CH₃)₂, 3-F-Ph, O, S), (N-3531: CO₂H, 4-F-Ph, O, S), (N-
 3532: CO₂H, 4-Br-Ph, O, S), (N-353: CO₂H, 5-Cl-thiophene-2-yl, O, S), (N-
 25 3534: CO₂H, 3,4-diF-Ph, O, S), (N-3535: CO₂H, 5-Br-thiophene-2-yl, O, S),
 (N-3536: CO₂H, 3,4-diBr-Ph, O, S), (N-3537: CO₂H, 4-CF₃-Ph, O, S), (N-3538:
 CO₂H, 3-Cl-Ph, O, S), (N-3539: CO₂H, 3-Br-Ph, O, S), (N-3540: CO₂H, 3-F-Ph,

- O, S), (N-3541: NH_2 , 4-F-Ph, O, S), (N-3542: NH_2 , 4-Br-Ph, O, S), (N-3543: NH_2 , 5-Cl-thiophene-2-yl, O, S), (N-3544: NH_2 , 3,4-diF-Ph, O, S), (N-3545: NH_2 , 5-Br-thiophene-2-yl, O, S), (N-3546: NH_2 , 3,4-diBr-Ph, O, S), (N-3547: NH_2 , 4-CF₃-Ph, O, S), (N-3548: NH_2 , 3-Cl-Ph, O, S), (N-3549: NH_2 , 3-Br-Ph, O, S),
- 5 (N-3550: NH_2 , 3-F-Ph, O, S), N35-51: CH_2COOMe , 4-F-Ph, O, S), (N-3552: CH_2COOMe , 4-Br-Ph, O, S), (N-3553: CH_2COOMe , 5-Cl-thiophene-2-yl, O, S), (N-3554: CH_2COOMe , 3,4-diF-Ph, O, S), (N-3555: CH_2COOMe , 5-Br-thiophene-2-yl, O, S), (N-3556: CH_2COOMe , 3,4-diBr-Ph, O, S), (N-3557: CH_2COOMe , 4-CF₃-Ph, O, S), (N-3558: CH_2COOMe , 3-Cl-Ph, O, S), (N-3559: CH_2COOMe , 3-Br-Ph, O, S), (N-3560: CH_2COOMe , 3-F-Ph, O, S), (N-3561: $\text{CH}_2\text{CH}_2\text{COOMe}$, 4-F-Ph, O, S), (N-3562: $\text{CH}_2\text{CH}_2\text{COOMe}$, 4-Br-Ph, O, S), (N-3563: $\text{CH}_2\text{CH}_2\text{COOMe}$, 5-Cl-thiophene-2-yl, O, S), (N-3564: $\text{CH}_2\text{CH}_2\text{COOMe}$, 3,4-diF-Ph, O, S), (N-3565: $\text{CH}_2\text{CH}_2\text{COOMe}$, 5-Br-thiophene-2-yl, O, S), (N-3566: $\text{CH}_2\text{CH}_2\text{COOMe}$, 3,4-diBr-Ph, O, S), (N-3567: $\text{CH}_2\text{CH}_2\text{COOMe}$, 4-CF₃-Ph, O, S),
- 15 (N-3568: $\text{CH}_2\text{CH}_2\text{COOMe}$, 3-Cl-Ph, O, S), (N-3569: $\text{CH}_2\text{CH}_2\text{COOMe}$, 3-Br-Ph, O, S), (N-3570: $\text{CH}_2\text{CH}_2\text{COOMe}$, 3-F-Ph, O, S), (N-3571: $\text{CH}_2\text{COONH}_2$, 4-F-Ph, O, S), (N-3572: $\text{CH}_2\text{COONH}_2$, 4-Br-Ph, O, S), (N-3573: $\text{CH}_2\text{COONH}_2$, 5-Cl-thiophene-2-yl, O, S), (N-3574: $\text{CH}_2\text{COONH}_2$, 3,4-diF-Ph, O, S), (N-3575: $\text{CH}_2\text{COONH}_2$, 5-Br-thiophene-2-yl, O, S), (N-3576: $\text{CH}_2\text{COONH}_2$, 3,4-diBr-Ph, O, S), (N-3577: $\text{CH}_2\text{COONH}_2$, 4-CF₃-Ph, O, S), (N-3578: $\text{CH}_2\text{COONH}_2$, 3-Cl-Ph, O, S), (N-3579: $\text{CH}_2\text{COONH}_2$, 3-Br-Ph, O, S), (N-3580: $\text{CH}_2\text{COONH}_2$, 3-F-Ph, O, S), (N-3581: $\text{CH}_2\text{COONHCH}_3$, 4-F-Ph, O, S), (N-3582: $\text{CH}_2\text{COONHCH}_3$, 4-Br-Ph, O, S), (N-3583: $\text{CH}_2\text{COONHCH}_3$, 5-Cl-thiophene-2-yl, O, S), (N-3584: $\text{CH}_2\text{COONHCH}_3$, 3,4-diF-Ph, O, S), (N-3585: $\text{CH}_2\text{COONHCH}_3$, 5-Br-thiophene-2-yl, O, S), (N-3586: $\text{CH}_2\text{COONHCH}_3$, 3,4-diBr-Ph, O, S), (N-3587: $\text{CH}_2\text{COONHCH}_3$, 4-CF₃-Ph, O, S), (N-3588: $\text{CH}_2\text{COONHCH}_3$, 3-Cl-Ph, O, S), (N-3589: $\text{CH}_2\text{COONHCH}_3$, 3-Br-Ph, O, S), (N-3590: $\text{CH}_2\text{COONHCH}_3$, 3-F-Ph, O,
- 25

- S), (N-3591: $\text{CH}_2\text{CH}_2\text{Cl}$, 4-F-Ph, O, S), (N-3592: $\text{CH}_2\text{CH}_2\text{Cl}$, 4-Br-Ph, O, S),
 (N-3593: $\text{CH}_2\text{CH}_2\text{Cl}$, 5-Cl-thiophene-2-yl, O, S), (N-3594: $\text{CH}_2\text{CH}_2\text{Cl}$, 3,4-diF-
 Ph, O, S), (N-3595: $\text{CH}_2\text{CH}_2\text{Cl}$, 5-Br-thiophene-2-yl, O, S), (N-356: $\text{CH}_2\text{CH}_2\text{Cl}$,
 3,4-diBr-Ph, O, S), (N-3597: $\text{CH}_2\text{CH}_2\text{Cl}$, 4- CF_3 -Ph, O, S), (N-3598: $\text{CH}_2\text{CH}_2\text{Cl}$,
 5 3-Cl-Ph, O, S), (N-3599: $\text{CH}_2\text{CH}_2\text{Cl}$, 3-Br-Ph, O, S), (N-3600: $\text{CH}_2\text{CH}_2\text{Cl}$, 3-F-
 Ph, O, S), (N-3601: CONH_2 , 4-F-Ph, O, O), (N-3602: CONH_2 , 4-Br-Ph, O, O),
 (N-3603: CONH_2 , 5-Cl-thiophene-2-yl, O, O), (N-3604: CONH_2 , 3,4-diF-Ph, O,
 O), (N-3605: CONH_2 , 5-Br-thiophene-2-yl, O, O), (N-3606: CONH_2 , 3,4-diBr-Ph,
 O, O), (N-3607: CONH_2 , 4- CF_3 -Ph, O, O), (N-3608: CONH_2 , 3-Cl-Ph, O, O),
 10 (N-3609: CONH_2 , 3-Br-Ph, O, O), (N-3610: CONH_2 , 3-F-Ph, O, O), (N-3611:
 CO_2NHCH_3 , 4-F-Ph, O, O), (N-3612: CO_2NHCH_3 , 4-Br-Ph, O, O), (N-3613:
 CO_2NHCH_3 , 5-Cl-thiophene-2-yl, O, O), (N-3614: CO_2NHCH_3 , 3,4-diF-Ph, O,
 O), (N-3615: CO_2NHCH_3 , 5-Br-thiophene-2-yl, O, O), (N-3616: CO_2NHCH_3 ,
 3,4-diBr-Ph, O, O), (N-3617: CO_2NHCH_3 , 4- CF_3 -Ph, O, O), (N-3618:
 15 CO_2NHCH_3 , 3-Cl-Ph, O, O), (N-3619: CO_2NHCH_3 , 3-Br-Ph, O, O), (N-3620:
 CO_2NHCH_3 , 3-F-Ph, O, O), (N-3621: $\text{CO}_2\text{N}(\text{CH}_3)_2$, 4-F-Ph, O, O), (N-3622:
 $\text{CO}_2\text{N}(\text{CH}_3)_2$, 4-Br-Ph, O, O), (N-3623: $\text{CO}_2\text{N}(\text{CH}_3)_2$, 5-Cl-thiophene-2-yl, O, O),
 (N-3624: $\text{CO}_2\text{N}(\text{CH}_3)_2$, 3,4-diF-Ph, O, O), (N-3625: $\text{CO}_2\text{N}(\text{CH}_3)_2$, 5-Br-
 thiophene-2-yl, O, O), (N-3626: $\text{CO}_2\text{N}(\text{CH}_3)_2$, 3,4-diBr-Ph, O, O), (N-3627:
 20 $\text{CO}_2\text{N}(\text{CH}_3)_2$, 4- CF_3 -Ph, O, O), (N-3628: $\text{CO}_2\text{N}(\text{CH}_3)_2$, 3-Cl-Ph, O, O), (N-3629:
 $\text{CO}_2\text{N}(\text{CH}_3)_2$, 3-Br-Ph, O, O), (N-3630: $\text{CO}_2\text{N}(\text{CH}_3)_2$, 3-F-Ph, O, O), (N-3631:
 CO_2H , 4-F-Ph, O, O), (N-3632: CO_2H , 4-Br-Ph, O, O), (N-3633: CO_2H , 5-Cl-
 thiophene-2-yl, O, O), (N-3634: CO_2H , 3,4-diF-Ph, O, O), (N-3635: CO_2H , 5-
 Br-thiophene-2-yl, O, O), (N-3636: CO_2H , 3,4-diBr-Ph, O, O), (N-3637: CO_2H ,
 25 4- CF_3 -Ph, O, O), (N-3638: CO_2H , 3-Cl-Ph, O, O), (N-3639: CO_2H , 3-Br-Ph, O, O),
 (N-3640: CO_2H , 3-F-Ph, O, O), (N-3641: NH_2 , 4-F-Ph, O, O), (N-3642: NH_2 , 4-
 Br-Ph, O, O), (N-3643: NH_2 , 5-Cl-thiophene-2-yl, O, O), (N-3644: NH_2 , 3,4-

- diF-Ph, O, O), (N-3645: NH₂, 5-Br-thiophene-2-yl, O, O), (N-3646: NH₂, 3,4-diBr-Ph, O, O), (N-3647: NH₂, 4-CF₃-Ph, O, O), (N-3648: NH₂, 3-Cl-Ph, O, O), (N-3649: NH₂, 3-Br-Ph, O, O), (N-3650: NH₂, 3-F-Ph, O, O), (N-3651: CH₂COOMe, 4-F-Ph, O, O), (N-3652: CH₂COOMe, 4-Br-Ph, O, O), (N-3653: CH₂COOMe, 5-Cl-thiophene-2-yl, O, O), (N-3654: CH₂COOMe, 3,4-diF-Ph, O, O), (N-3655: CH₂COOMe, 5-Br-thiophene-2-yl, O, O), (N-3656: CH₂COOMe, 3,4-diBr-Ph, O, O), (N-3657: CH₂COOMe, 4-CF₃-Ph, O, O), (N-3658: CH₂COOMe, 3-Cl-Ph, O, O), (N-3659: CH₂COOMe, 3-Br-Ph, O, O), (N-3660: CH₂COOMe, 3-F-Ph, O, O), (N-3661: CH₂CH₂COOMe, 4-F-Ph, O, O), (N-3662: CH₂CH₂COOMe, 4-Br-Ph, O, O), (N-3663: CH₂CH₂COOMe, 5-Cl-thiophene-2-yl, O, O), (N-3664: CH₂CH₂COOMe, 3,4-diF-Ph, O, O), (N-3665: CH₂CH₂COOMe, 5-Br-thiophene-2-yl, O, O), (N-3666: CH₂CH₂COOMe, 3,4-diBr-Ph, O, O), (N-3667: CH₂CH₂COOMe, 4-CF₃-Ph, O, O), (N-3668: CH₂CH₂COOMe, 3-Cl-Ph, O, O), (N-3669: CH₂CH₂COOMe, 3-Br-Ph, O, O), (N-3670: CH₂CH₂COOMe, 3-F-Ph, O, O), (N-3671: CH₂COONH₂, 4-F-Ph, O, O), (N-3672: CH₂COONH₂, 4-Br-Ph, O, O), (N-3673: CH₂COONH₂, 5-Cl-thiophene-2-yl, O, O), (N-3674: CH₂COONH₂, 3,4-diF-Ph, O, O), (N-3675: CH₂COONH₂, 5-Br-thiophene-2-yl, O, O), (N-3676: CH₂COONH₂, 3,4-diBr-Ph, O, O), (N-3677: CH₂COONH₂, 4-CF₃-Ph, O, O), (N-3678: CH₂COONH₂, 3-Cl-Ph, O, O), (N-3679: CH₂COONH₂, 3-Br-Ph, O, O), (N-3680: CH₂COONH₂, 3-F-Ph, O, O), (N-3681: CH₂COONHCH₃, 4-F-Ph, O, O), (N-3682: CH₂COONHCH₃, 4-Br-Ph, O, O), (N-3683: CH₂COONHCH₃, 5-Cl-thiophene-2-yl, O, O), (N-3684: CH₂COONHCH₃, 3,4-diF-Ph, O, O), (N-3685: CH₂COONHCH₃, 5-Br-thiophene-2-yl, O, O), (N-3686: CH₂COONHCH₃, 3,4-diBr-Ph, O, O), (N-3687: CH₂COONHCH₃, 4-CF₃-Ph, O, O), (N-3688: CH₂COONHCH₃, 3-Cl-Ph, O, O), (N-3689: CH₂COONHCH₃, 3-Br-Ph, O, O), (N-3690: CH₂COONHCH₃, 3-F-Ph, O, O), (N-3691: CH₂CH₂Cl, 4-F-Ph, O, O), (N-3692: CH₂CH₂Cl, 4-Br-Ph, O, O),

- (N-3693: $\text{CH}_2\text{CH}_2\text{Cl}$, 5-Cl-thiophene-2-yl, O, O), (N-3694: $\text{CH}_2\text{CH}_2\text{Cl}$, 3,4-diF-Ph, O, O), (N-3695: $\text{CH}_2\text{CH}_2\text{Cl}$, 5-Br-thiophene-2-yl, O, O), (N-3696: $\text{CH}_2\text{CH}_2\text{Cl}$, 3,4-diBr-Ph, O, O), (N-3697: $\text{CH}_2\text{CH}_2\text{Cl}$, 4- CF_3 -Ph, O, O), (N-3698: $\text{CH}_2\text{CH}_2\text{Cl}$, 3-Cl-Ph, O, O), (N-3699: $\text{CH}_2\text{CH}_2\text{Cl}$, 3-Br-Ph, O, O), (N-3700: $\text{CH}_2\text{CH}_2\text{Cl}$, 3-F-Ph, O, O), (N-3701: 4- NH_2 -Ph, H, S, S), (N-3702: 4-N(Ac)H-Ph, H, S, S), (N-3703: 4-OH-Ph, H, S, S), (N-3704: 3,4-di(OH) $_2$ -Ph, H, S, S), (N-3705: 3,4-di(NH_2)-Ph, H, S, S), (N-3706: 3:4-[N(Ac)H] $_2$ -Ph, H, S, S), (N-3707: 4-SH-Ph, H, S, S), (N-3708: 4-SMe-Ph, H, S, S), (N-3709: 3,4-diBr-Ph, H, S, S), (N-3710: 4-N(Me)H-Ph, H, S, S), (N-3711: 4-N(Me) $_2$ -Ph, H, S, S), (N-3712: 4-N(Me) $_3^+$ -Ph, H, S, S), (N-3713: 4-Et-Ph, H, S, S), (N-3714: 4-iPr-Ph, H, S, S), (N-3715: 4-nPr-Ph, H, S, S), (N-3716: 4-nBu-Ph, H, S, S), (N-3717: 4-iBu-Ph, H, S, S), (N-3718: 3,4-diMe-Ph, H, S, S), (N-3719: 1,3-Benzodioxole-5-yl, H, S, S), (N-3720: N-Me-pyridinium-4-yl, H, S, S), (N-3721: N-Me-pyridinium-3-yl, H, S, S), (N-3722: 5-Me-Pyridine-2-yl, H, S, S), (N-3723: 2-Pyrazinyl, H, S, S), (N-3724: 3-Pyrrolyl, H, S, S), (N-3725: 1-Me-pyrrole-3-yl, H, S, S), (N-3726: Pyridine N-oxide-4-yl, H, S, S), (N-3727: Pyridine N-oxide-3-yl, H, S, S), (N-3728: 6-OH-pyridine-3-yl, H, S, S), (N-3729: 6-SH-pyridine-3-yl, H, S, S), (N-3730: 1-Ac-pyrrole-3-yl, H, S, S), (N-3731: 4- CF_3 -Ph, H, S, S), (N-3732: 4-CN-Ph, H, S, S), (N-3733: 4-CHO-Ph, H, S, S), (N-3734: 3-Cl-Ph, H, S, S), (N-3735: 3-Br-Ph, H, S, S), (N-3736: 3-F-Ph, H, S, S), (N-3737: 3-I-Ph, H, S, S), (N-3738: 4-I-Ph, H, S, S), (N-3739: 4-OCF $_3$ -Ph, H, S, S), (N-3740: 3,4-diI-Ph, H, S, S), (N-3741: Indole-6-yl, H, S, S), (N-3742: 1-Ac-indole-6-yl, H, S, S), (N-3743: 1-Me-indole-6-yl, H, S, S), (N-3744: 4-(1-Imidazolyl)-Ph, H, S, S), (N-3745: 4-Morphorino-Ph, H, S, S), (N-3746: 4-(1-Piperazinyl)-Ph, H, S, S), (N-3747: 2:5-diMe-thiophene-3-yl, H, S, S), (N-3748: 2-Furyl, H, S, S), (N-3749: 5-Me-furan-2-yl, H, S, S), (N-3750: 5-Me-furan-2-yl, H, S, S), (N-3751: 2-Thiazolyl, H, S, S), (N-3752: 1:4-Benzodioxin-6-yl, H, S, S), (N-3753: Benzo[b]furan-2-yl,

H, S, S), (N-3754: 4-NH₂CH₂-Ph, H, S, S), (N-3755: 4-N(Me)HCH₂-Ph, H, S, S),
 (N-3756: 4-N(Me)₂CH₂-Ph, H, S, S), (N-3757: 6-Cl-pyridine-3-yl, H, S, S), (N-
 3758: 5,6-diCl-pyridine-3-yl, H, S, S), (N-3759: 5-Cl-pyridine-2-yl, H, S, S),
 (N-3760: 4:5-diCl-pyridine-2-yl, H, S, S), (N-3761: 4-ClCH₂-Bn, H, S, S), (N-
 3762: Bn, H, S, S), (N-3763: 4-Cl-Bn, H, S, S), (N-3764: 4-Br-Bn, H, S, S), (N-
 3765: 4-F-Bn, H, S, S), (N-3766: 3,4-diCl-Bn, H, S, S), (N-3767: 3,4-diBr-Bn, H,
 S, S), (N-3768: 3,4-diF-Bn, H, S, S), (N-3769: 4-Cl-Bz, H, S, S), (N-3770: 3,4-
 diCl-Bz, H, S, S), (N-3771: 4-Br-Bz, H, S, S), (N-3772: 3,4-diBr-Bz, H, S, S),
 (N-3773: 4-F-Bz, H, S, S), (N-3774: 3,4-diF-Bz, H, S, S), (N-3775: 4-NH₂-Ph, H,
 S, O), (N-3776: 4-N(Ac)H-Ph, H, S, O), (N-3777: 4-OH-Ph, H, S, O), (N-3778:
 3,4-di(OH)₂-Ph, H, S, O), (N-3779: 3,4-di(NH₂)-Ph, H, S, O), (N-3780: 3:4-
 [N(Ac)H]₂-Ph, H, S, O), (N-3781: 4-SH-Ph, H, S, O), (N-3782: 4-SMe-Ph, H, S,
 O), (N-3783: 3,4-diBr-Ph, H, S, O), (N-3784: 4-N(Me)H-Ph, H, S, O), (N-3785:
 4-N(Me)₂-Ph, H, S, O), (N-3786: 4-N(Me)₃⁺-Ph, H, S, O), (N-3787: 4-Et-Ph, H, S,
 O), (N-3788: 4-iPr-Ph, H, S, O), (N-3789: 4-nPr-Ph, H, S, O), (N-3790: 4-nBu-
 Ph, H, S, O), (N-3791: 4-iBu-Ph, H, S, O), (N-3792: 3,4-diMe-Ph, H, S, O), (N-
 3793: 1,3-Benzodioxole-5-yl, H, S, O), (N-3794: N-Me-pyridinium-4-yl, H, S, O),
 (N-3795: N-Me-pyridinium-3-yl, H, S, O), (N-3796: 5-Me-Pyridine-2-yl, H, S,
 O), (N-3797: 2-Pyrazinyl, H, S, O), (N-3798: 3-Pyrrolyl, H, S, O), (N-3799: 1-
 Me-pyrrole-3-yl, H, S, O), (N-3800: Pyridine N-oxide-4-yl, H, S, O), (N-3801:
 Pyridine N-oxide-3-yl, H, S, O), (N-3802: 6-OH-pyridine-3-yl, H, S, O), (N-
 3803: 6-SH-pyridine-3-yl, H, S, O), (N-3804: 1-Ac-pyrrole-3-yl, H, S, O), (N-
 3805: 4-CF₃-Ph, H, S, O), (N-3806: 4-CN-Ph, H, S, O), (N-3807: 4-CHO-Ph, H, S,
 O), (N-3808: 3-Cl-Ph, H, S, O), (N-3809: 3-Br-Ph, H, S, O), (N-3810: 3-F-Ph, H,
 S, O), (N-3811: 3-I-Ph, H, S, O), (N-3812: 4-I-Ph, H, S, O), (N-3813: 4-OCF₃-Ph,
 H, S, O), (N-3814: 3,4-diI-Ph, H, S, O), (N-3815: Indole-6-yl, H, S, O), (N-3816:
 1-Ac-indole-6-yl, H, S, O), (N-3817: 1-Me-indole-6-yl, H, S, O), (N-3818: 4-(1-

Imidazolyl)-Ph, H, S, O), (N-3819: 4-Morpholino-Ph, H, S, O), (N-3820: 4-(1-Piperazinyl)-Ph, H, S, O), (N-3821: 2:5-diMe-thiophene-3-yl, H, S, O), (N-3822: 2-Furyl, H, S, O), (N-3823: 5-Me-furan-2-yl, H, S, O), (N-3824: 5-Me-furan-2-yl, H, S, O), (N-3825: 2-Thiazolyl, H, S, O), (N-3826: 1:4-Benzodioxin-6-yl, H, S, O), (N-3827: Benzo[b]furan-2-yl, H, S, O), (N-3828: 4-NH₂CH₂-Ph, H, S, O), (N-3829: 4-N(Me)HCH₂-Ph, H, S, O), (N-3830: 4-N(Me)₂CH₂-Ph, H, S, O), (N-3831: 6-Cl-pyridine-3-yl, H, S, O), (N-3832: 5,6-diCl-pyridine-3-yl, H, S, O), (N-3833: 5-Cl-pyridine-2-yl, H, S, O), (N-3834: 4:5-diCl-pyridine-2-yl, H, S, O), (N-3835: 4-ClCH₂-Bn, H, S, O), (N-3836: Bn, H, S, O), (N-3837: 4-Cl-Bn, H, S, O), (N-3838: 4-Br-Bn, H, S, O), (N-3839: 4-F-Bn, H, S, O), (N-3840: 3,4-diCl-Bn, H, S, O), (N-3841: 3,4-diBr-Bn, H, S, O), (N-3842: 3,4-diF-Bn, H, S, O), (N-3843: 4-Cl-Bz, H, S, O), (N-3844: 3,4-diCl-Bz, H, S, O), (N-3845: 4-Br-Bz, H, S, O), (N-3846: 3,4-diBr-Bz, H, S, O), (N-3847: 4-F-Bz, H, S, O), (N-3848: 3,4-diF-Bz, H, S, O), (N-3849: 4-NO₂-Bn, H, S, O), (N-3850: 4-CN-Bn, H, S, O)

Test Example 1

Isolation and purification of Thrombopoietin (TPO)

Human TPO (hTPO) and murine TPO (mTPO) were purchased from R&D Systems.

Test Example 2 The increasing effect in vitro of the megakaryocyte colonies with the compound (A-1), (B-17), and (C-1)

We examined the ability of the compound in promoting differentiation of human hematopoietic progenitor cells into mature megakaryocytes. Human bone marrow cells (2.2 X 10⁶ cells) were plated in 3-cm dishes and cultured in methylcellulose in Iscove's Modified Dulbecco's medium in the presence of 1% of the compound (A-1, B-17, C-1) dissolved in 10% ethanol. After incubation at

37°C for 7 days in the 5% CO₂ incubator, the megakaryocyte colonies were counted. The result is shown in Fig. 1.

Test Example 3 The thrombopoietic activity of the compound (B-17)

5 The TPO dependent BaF/hTPOR cell line which was established by introducing human TPO receptor (hTPOR) into BaF-B03 cells according to Collins et al (J. Cell. Physiol., 137:293-298 (1988)) was used to test the thrombopoietic activity of the present compound (B-17). The DNA sequences and encoded peptide sequences for human hTPOR have been described by
10 Vigon et al (Proc. Natl. Acad. Sci. USA, 89:5640-5644 (1992)). TPO dose not have any ability to support proliferation of interleukin-3 dependent parental cell line BaF-B03. BAF/hTPOR cells were maintained in RPMI medium and WEHI-3B conditioned medium as a source of murine interleukin-3 (IL-3). These cells were washed and resuspended in RPMI medium without a source of
15 murine IL-3 and seeded into each well of 96-well microtiter plates at a density of 5×10^4 cells per well in the absence or presence of various concentration of hTPO or the present compound. After incubation at 37°C for 20 hours in the 5% CO₂ incubator, 10% WST-1 reagent (Takara Biomedicals, Japan) was added to each wells and the cells were further incubated for 4 hours. The absorbance
20 at 450 nm was measured and the result is shown in Fig. 2. Effect of the present compound on the growth of the parental cell line BaF-B03 not expressing TPOR is shown in Fig. 3. Effect of the present compound on the growth of the BaF-B03 expressing murine TPOR is shown in Fig. 4. Table 24 exemplifies the ED₅₀ for tested compounds of the present invention, wherein
25 the ED₅₀ is the half concentration of the concentration showing the maximum thrombopoietic activity

Table 24

| Compound No. | ED ₅₀ (μM) | Compound No. | ED ₅₀ (μM) | Compound No. | ED ₅₀ (μM) |
|--------------|-----------------------|--------------|-----------------------|--------------|-----------------------|
| A-1 | 0.012 | A-32 | 0.077 | A-73 | 0.070 |
| A-2 | 0.058 | A-37 | 0.027 | B-1 | 0.071 |
| A-3 | 0.017 | A-38 | 0.047 | B-2 | 0.011 |
| A-4 | 0.036 | A-42 | 0.072 | B-3 | 0.047 |
| A-5 | 0.022 | A-43 | 0.073 | B-4 | 0.037 |
| A-6 | 0.045 | A-49 | 0.035 | B-5 | 0.047 |
| A-7 | 0.060 | A-50 | 0.026 | B-6 | 0.072 |
| A-11 | 0.031 | A-53 | 0.023 | B-14 | 0.023 |
| A-12 | 0.011 | A-56 | 0.096 | B-15 | 0.077 |
| A-13 | 0.021 | A-59 | 0.084 | B-16 | 0.020 |
| A-14 | 0.015 | A-61 | 0.069 | B-17 | 0.030 |
| A-15 | 0.026 | A-63 | 0.016 | B-18 | 0.016 |
| A-16 | 0.049 | A-64 | 0.047 | B-21 | 0.084 |
| A-20 | 0.029 | A-67 | 0.050 | C-1 | 0.068 |
| A-21 | 0.041 | A-70 | 0.020 | E-2 | 0.062 |
| A-25 | 0.099 | A-71 | 0.080 | H-5 | 0.047 |
| A-26 | 0.072 | A-72 | 0.035 | | |

Test Example 4 The compound(B-17)-Induced signal transduction via hTPOR

Drachman et al (J. Biol. Chem, 270: 4979-4982 (1995)) reported that TPO induced tyrosine phosphorylation of Jak2, Shc, and c-Mpl. To compare the signaling pathway of TPO and the compound of the present invention, we analyzed the tyrosine phosphorylation of signal transducers by stimulation of the compound according to the method reported by Drachman. Briefly, BaF/hTPOR cells suspended in the RPMI medium (1×10^7 cells/ml) without WEHI-3B were incubated for 4 hours at 37°C . 25 ng/ml of TPO or 200 nM of the compound (B-17) was added to cells and incubated for 10 min at 37°C . After the cells were washed twice with PBS then lysed in a buffer composed of 1% Triton X-100. After the sample were spun in a centrifuge and the supernatant were immunoprecipitated by using antibodies against several proteins related to intracellular signal transduction. Immune complexes were separated by SDS-polyacrylamide gel electrophoresis. Protein was electrophoretically transferred to nitrocellulose sheets and tyrosine phosphorylated protein was detected by anti-phosphotyrosine antibody. Results were summarized in Table 25.

Table 25

| | Vehicle | Compound (B-17) | TPO |
|----------------|---------|--------------------|-----|
| Jak1 | - | - | - |
| Jak2 | - | + | + |
| Jak3 | - | - | - |
| Tyk2 | - | + | + |
| STAT1 | - | - | - |
| STAT3 | - | + | + |
| STAT5 | - | + | + |
| STAT6 | - | - | - |
| Mpl | - | + | + |
| Shc | - | + | + |
| Cbl | - | + | + |
| Vav | - | + | + |
| Ship | - | - | - |
| SHPTP2 | - | + | + |
| PI3K | - | - | - |
| PLC γ 1 | - | + | + |
| MAPK | - | + | + |
| SAPK | - | + | + |
| p38MAPK | - | + | + |

As shown in Fig.1, addition of the compounds of the present invention induced forming megakaryocyte colonies and the number of colonies increased depending on the concentration of the compounds. This result revealed that the compounds of the present invention induced the differentiation of human bone marrow cells and produce megakaryocytes having ability of producing platelet.

The compound supported the proliferation of TPO-dependent BaF/hTPOR in a dose-dependent manner as shown in Fig.2. Parental BaF cells bearing no TPOR was not induced the proliferation by compounds as shown in Fig. 3.

BaF/mTPOR expressing murine TPOR was not induced the proliferation by compounds as shown in Fig. 4. These results suggest that the compound of the present invention exert the thrombopoietic activity by interacting with hTPOR because it is active only in cells expressing hTPOR.

As shown in Table 25, the compound induced phosphorylation of following the same intracellular signal transducing molecules as TPO did: Jak2, Tyk2, STAT3, STAT5, Shc, Vav, SHPTP2, Mpl, PLC γ 1, Cbl, MAPK, SAPK, and p38MAPK. Therefore, the compounds elicit thrombopoietic activity by stimulating the signal transduction pathways identical to those of TPO.

Formulation example

Formulation example 1

Granules are prepared using the following ingredients.

| | | |
|-------------|---|---------|
| Ingredients | The compound represented by the formula (I) | 10 mg |
| | Lactose | 700 mg |
| | Corn starch | 274 mg |
| | HPC-L | 16 mg |
| | | 1000 mg |

The compound represented by the formula (I) and lactose are made pass through a 60 mesh sieve. Corn starch is made pass through a 120 mesh sieve. They are mixed by a twin shell blender. An aqueous solution of HPC-L (low mucosity hydroxypropylcellulose) is added to the mixture and the resulting mixture is kneaded, granulated (by the extrusion with pore size 0.5 to 1 mm mesh), and dried. The dried granules thus obtained are sieved by a swing sieve (12/60 mesh) to yield the granules.

Formulation 2

Powders for filling capsules are prepared using the following ingredients.

| | | |
|-------------|---|--------|
| Ingredients | The compound represented by the formula (I) | 10 mg |
| | Lactose | 79 mg |
| | Corn starch | 10 mg |
| | Magnesium stearate | 1 mg |
| | | 100 mg |

The compound represented by the formula (I) and lactose are made pass through a 60 mesh sieve. Corn starch is made pass through a 120 mesh sieve. These ingredients and magnesium stearate are mixed by a twin shell blender. 100 mg of the 10-fold trituration is filled into a No. 5 hard gelatin capsule.

Formulation 3

Granules for filling capsules are prepared using the following ingredients.

| | | |
|-------------|---|-------|
| Ingredients | The compound represented by the formula (I) | 15 mg |
| | Lactose | 90 mg |

| | |
|-------------|--------|
| Corn starch | 42 mg |
| HPC-L | 3 mg |
| | 150 mg |

The compound represented by the formula (I) and lactose are made pass through a 60 mesh sieve. Corn starch is made pass through a 120 mesh sieve. After mixing them, an aqueous solution of HPC-L is added to the mixture and the resulting mixture is kneaded, granulated, and dried. After the dried granules are lubricated, 150 mg of that are filled into a No. 4 hard gelatin capsule.

Formulation 4

Tablets are prepared using the following ingredients.

| | | |
|-------------|---|--------|
| Ingredients | The compound represented by the formula (I) | 10 mg |
| | Lactose | 90 mg |
| | Microcrystal cellulose | 30 mg |
| | CMC-Na | 15 mg |
| | Magnesium stearate | 5 mg |
| | | 150 mg |

The compound represented by the formula (I), lactose, microcrystal cellulose, and CMC-Na (carboxymethylcellulose sodium salt) are made pass through a 60 mesh sieve and then mixed. The resulting mixture is mixed with magnesium stearate to obtain the mixed powder for the tablet formulation. The mixed powder is compressed to yield tablets of 150 mg.

Industrial Applicability


The compounds of the present invention have thrombopoietin receptor agonism and are useful as the treating or preventing agent for

hemopathy accompanied with unusual count of platelet, for example,
thrombocytopenia and the like

10048008-012502

10048008 "012000

1. A pharmaceutical composition exhibiting thrombopoietin agonism which contains as an active ingredient a compound of the formula (I):




wherein X¹ is optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, or optionally substituted non-aromatic heterocyclic group;

$$\begin{aligned} & Y^1 \text{ is } \text{-NR}^A\text{CO} \cdot (\text{CH}_2)_{0-2}, \text{-NR}^A\text{CO} \cdot (\text{CH}_2)_{0-2}\text{-W}, \text{-NR}^A\text{CO} \cdot \text{CH}=\text{CH}, \text{-W} \cdot (\text{CH}_2)_{1-5} \cdot \\ & \text{NR}^A\text{CO} \cdot (\text{CH}_2)_{0-2}, \text{-W} \cdot (\text{CH}_2)_{1-5} \cdot \text{CONR}^A \cdot (\text{CH}_2)_{0-2}, \text{-CONR}^A \cdot (\text{CH}_2)_{0-2}, \text{-(CH}_2\text{)}_{0-5} \cdot \\ & \text{NR}^A \cdot \text{SO}_2 \cdot (\text{CH}_2)_{0-5}, \text{-(CH}_2\text{)}_{0-5} \cdot \text{SO}_2 \cdot \text{NR}^A \cdot (\text{CH}_2)_{0-5}, \text{-NR}^A \cdot (\text{CH}_2)_{0-2}, \text{-NR}^A \cdot \text{CO} \cdot \\ & \text{NR}^A, \text{-NR}^A \cdot \text{CS} \cdot \text{NR}^A, \text{-N}=\text{C}(\text{SR}^A) \cdot \text{NR}^A, \text{-NR}^A \text{CSNR}^A \text{CO}, \text{-N}=\text{C}(\text{SR}^A) \cdot \text{NR}^A \text{CO}, \\ & \text{-NR}^A \cdot (\text{CH}_2)_{1-2} \cdot \text{NR}^A \cdot \text{CO}, \text{-NR}^A \text{CONR}^A \text{NR}^A \text{CO}, \text{ or } \text{-N}=\text{C}(\text{NR}^A) \cdot \text{NR}^A \cdot \text{CO}, \end{aligned}$$

wherein R^A is each independently a hydrogen atom, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl, R^F is a hydrogen atom or optionally substituted aryl, W is an oxygen atom or a sulfur atom;

Z¹ is optionally substituted arylene, optionally substituted heteroarylene, optionally substituted non-aromatic heterocycle-diyl, or optionally substituted cycloalkyl-diyl;

A^1 is a ring represented by the formula:




wherein R¹ and R² are both hydrogen atoms or taken together may form an

oxygen atom or a sulfur atom; R³ and R⁴ are both hydrogen atoms or taken together may form an oxygen atom or a sulfur atom; R⁵ is a hydrogen atom or lower alkyl; Q and V are each independently -O-, -S-, -NR^B- (wherein R^B is a hydrogen atom or lower alkyl), or -CH₂-; m is 1, 2, or 3;


a broken line (---) represents the presence or absence of a bond, its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.

2. A pharmaceutical composition exhibiting thrombopoietin agonism which contains a compound of claim 1, wherein X¹ is optionally substituted 5-member heteroaryl or a group represented by the formula:



wherein E is -(CH₂)₁₋₃-, -O-CH₂-, or -S-CH₂-; R⁶ and R⁷ are each independently a hydrogen atom, optionally substituted lower alkyl, carboxy, lower alkyloxycarbonyl, optionally substituted aminocarbonyl, optionally substituted thienyl, or optionally substituted phenyl.

3. A pharmaceutical composition exhibiting thrombopoietin agonism which contains a compound of claim 1, wherein X¹ is a group represented by the formula:




wherein E is -(CH₂)₁₋₃-, -O-CH₂-, or -S-CH₂-; R⁶ and R⁷ are each independently a hydrogen atom, optionally substituted lower alkyl, carboxy, lower alkyloxycarbonyl, optionally substituted aminocarbonyl, optionally substituted thienyl, or optionally substituted phenyl; R⁸ is a hydrogen atom or lower alkyl.

4. A pharmaceutical composition of any one of claims 1 to 3, wherein Y¹ is -NHCO-, -CONH-, -NHCH₂-, or -NHSO₂-.

5. A pharmaceutical composition of any one of claims 1 to 4, wherein Z¹ is 1,4-phenylene.

6. A pharmaceutical composition of any one of claims 1 to 6, wherein A¹ is a ring represented by the formula:



wherein R⁸ is a hydrogen atom or lower alkyl; M is -S-, -O-, -N(R⁹)-, or -CH₂- (wherein R⁹ is a hydrogen atom or lower alkyl); T is an oxygen atom or a sulfur atom.

7. A pharmaceutical composition of any one of claims 1 to 6, wherein the broken line represents the presence of a bond.

8. A pharmaceutical composition of any one of claims 1 to 7, which is for treating or preventing hemopathy.

9. A pharmaceutical composition of any one of claims 1 to 7, which is a platelet production modifier.

10. Use of a compound of any one of claims 1 to 7 for preparation of a pharmaceutical composition for treating hemopathy.


11. A method for treating hemopathy of a mammal, including a human, which comprises administration to said mammal of a compound of any one of claims 1 to 7 in a pharmaceutically effective amount.

12. A compound represented by the formula (II)



wherein X² is optionally substituted 5-member heteroaryl or a group

represented by the formula:




wherein E is $-(CH_2)_{1-3}$ -, $-O-CH_2$ -, or $-S-CH_2$ -; R^6 and R^7 are each independently a hydrogen atom, optionally substituted lower alkyl, carboxy, lower alkyloxycarbonyl, optionally substituted aminocarbonyl, optionally substituted thienyl, or optionally substituted phenyl;

Y^2 is $-NR^GCO-(CH_2)_{0-2}$ -, $-NR^GCO-(CH_2)_{0-2}-W$ -, $-NR^GCO-CH=CH$ -, $-W-(CH_2)_{1-5}-NR^GCO-(CH_2)_{0-2}$ -, $-W-(CH_2)_{1-5}-CONR^G-(CH_2)_{0-2}$ -, $-CONR^G-(CH_2)_{0-2}$ -, $-(CH_2)_{0-5}-NR^G-SO_2-(CH_2)_{0-5}$ -, $-(CH_2)_{0-5}-SO_2-NR^G-(CH_2)_{0-5}$ -, $-NR^G-(CH_2)_{0-2}$ -, $-NR^G-CO-NR^G$ -, $-NR^G-CS-NR^G$ -, $-N=C(-SR^G)-NR^G$ -, $-NR^GCSNR^GCO$ -, $-N=C(-SR^G)-NR^GCO$ -, $-NR^G-(CH_2)_{1-2}-NR^G-CO$ -, $-NR^GCONR^GNR^FCO$ -, or $-N=C(-NR^GR^G)-NR^G-CO$ -,

wherein R^G is each independently a hydrogen atom or optionally substituted lower alkyl, R^F is a hydrogen atom or optionally substituted aryl, W is an oxygen atom or a sulfur atom;

Z^2 is optionally substituted phenylene, optionally substituted 2,5-pyridine-diyl, optionally substituted 2,5-thiophene-diyl, or optionally substituted 2,5-furan-diyl;

A^2 is a ring represented by the formula:



wherein R^1 and R^2 are both hydrogen atoms or taken together may form an oxygen atom or a sulfur atom; R^3 and R^4 are both hydrogen atoms or taken together may form an oxygen atom or a sulfur atom; R^5 is a hydrogen atom or


lower alkyl; Q and V are each independently -O-, -S-, -NR^B- (wherein R^B is a hydrogen atom or lower alkyl), or -CH₂-; m is 1, 2, or 3;

a broken line (---) represents the presence or absence of a bond,

provided that X² is not oxazole,

5 its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.


13. A compound of claim 12, wherein X² is a group represented by the formula:



wherein E is -(CH₂)₁₋₃-, -O-CH₂-, or -S-CH₂-; R⁶ and R⁷ are each
10 independently a hydrogen atom, optionally substituted lower alkyl, carboxy,
lower alkyloxycarbonyl, optionally substituted aminocarbonyl, optionally
substituted thienyl, or optionally substituted phenyl; R⁸ is a hydrogen atom or
lower alkyl,

its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.

14. A compound of claim 12, wherein X² is a group represented by the
formula:



wherein E is as defined in claim 12;

R⁹ is a hydrogen atom, optionally substituted lower alkyl, carboxy, lower

alkyloxycarbonyl, or optionally substituted aminocarbonyl;

R¹⁰ and R¹¹ are each independently a hydrogen atom, halogen, carboxy, lower alkyloxycarbonyl, optionally substituted aminocarbonyl, nitro, or optionally substituted amino,

5 its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.


15. A compound of any one of claims 12 to 14, wherein Y² is -NHCO-, -CONH-, -NHCH₂-, or -NHSO₂-,

its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.

16. A compound of any one of claims 12 to 15, wherein Z² is 1,4-phenylene,

10 its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.

17. A compound of any one of claims 12 to 16, wherein A² is a ring represented by the formula:



wherein R⁸ is a hydrogen atom or lower alkyl; M is -S-, -O-, -N(R^c)-, or -CH₂-


15 (wherein R^c is a hydrogen atom or lower alkyl); T is an oxygen atom or a sulfur atom,

its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.

18. A compound of any one of claims 12 to 17, wherein the broken line represents the presence of a bond,

20 its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.

19. A compound represented by the formula III-A:




wherein, R⁹ is a hydrogen atom, optionally substituted lower alkyl, carboxy,

lower alkyloxycarbonyl, or optionally substituted aminocarbonyl;

R¹⁰ and R¹¹ are each independently a hydrogen atom, halogen, carboxy, lower alkyloxycarbonyl, optionally substituted aminocarbonyl, nitro, or optionally substituted amino;

5 Y³ is -NHCO- or -CONH-;


A³ is a ring represented by the formula:



wherein R⁸ is a hydrogen atom or lower alkyl; M is -S-, -O-, -N(R⁸)-, or -CH₂-
(wherein R⁸ is a hydrogen atom or lower alkyl); T is an oxygen atom or a sulfur
atom,

its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.

20. A compound represented by the formula III-B:



wherein R⁹, R¹⁰, R¹¹, Y³, and A³ ring are as defined in claim 19,

15 its prodrug, or their pharmaceutically acceptable salt, or solvate thereof.

21. A pharmaceutical composition containing a compound of any one of claims 12 to 20 as an active ingredient.

22. A pharmaceutical composition which contains as an active ingredient a compound of any one of claims 12 to 20 for exhibiting thrombopoietin
agonism.

23. An agent for treating or preventing hemopathy which contains as the active ingredient a compound of any one of claims 12 to 20.

24. A pharmaceutical composition containing as the active ingredient a

compound of any one of claims 12 to 20, which is a platelet production modifier.

25. Use of a compound of any one of claims 12 to 20 for preparation of a pharmaceutical composition for treating hemopathy.

- 5 26. A method for treating hemopathy of a mammal, including a human, which comprises administration to said mammal of a compound of any one of claims 12 to 20 in a pharmaceutically effective amount.


10048008.012502

ABSTRACT

Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism:



wherein X^1 is optionally substituted heteroaryl or the like; Y^1 is $-\text{NR}^A\text{CO}-$ $(\text{CH}_2)_{0-2}-$ or the like (wherein R^A is a hydrogen or the like); Z^1 is optionally substituted arylene or the like; and A^1 is a ring represented by general formula (II) or (III):



or




Figure 1




Figure 2




Figure 3





Figure 4



Declaration and Power of Attorney For Patent Application

特許出願宣言書及び委任状

Japanese Language Declaration

日本語宣言書

下記の氏名の発明者として、私は以下の通り宣言します。

As a below named inventor, I hereby declare that:

私の住所、私書箱、国籍は下記の私の氏名の後に記載された通りです。

My residence, post office address and citizenship are as stated next to my name.

下記の名称の発明に関して請求範囲に記載され、特許出願している発明内容について、私が最初かつ唯一の発明者（下記の氏名が一つの場合）もしくは最初かつ共同発明者であると（下記の名称が複数の場合）信じています。

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

PHARMACEUTICAL COMPOSITIONS EXHIBITING

THROMBOPOIETIN RECEPTOR AGONISM

上記発明の明細書（下記の欄でx印がついていない場合は、本書に添付）は、

the specification of which is attached hereto unless the following box is checked:

☐ 月 日に提出され、米国出願番号または特許協定条約国際出願番号を _____ とし、
（該当する場合） _____ に訂正されました。

☐ was filed on July 24, 2000
as United States Application Number or
PCT International Application Number
PCT/JP00/04909 and was amended on _____
(if applicable).

私は、特許請求範囲を含む上記訂正後の明細書を検討し、内容を理解していることをここに表明します。

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

私は、連邦規則法典第37編第1条56項に定義されるとおり、特許資格の有無について重要な情報を開示する義務があることを認めます。

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Japanese Language Declaration

(日本語宣言書)

私は、米国法典第35編119条(a)-(d)項又は365条(b)項に基づき下記の、米国以外の国の少なくとも一か国を指定している特許協力条約365(a)項に基づき国際出願、又は外国での特許出願もしくは発明者証の出願についての外国優先権をここに主張するとともに、優先権を主張している、本出願の前に出願された特許または発明者証の外国出願を以下に、枠内をマークすることで、示しています。

Prior Foreign Application(s)

外国での先行出願

211264/1999

Japan

(Number)
(番号)(Country)
(国名)

26/07/1999

(Day/Month/Year Filed)
(出願年月日)

Priority Not Claimed

優先権主張なし

(Number)
(番号)(Country)
(国名)(Day/Month/Year Filed)
(出願年月日)

私は、第35編米国法典119条(e)項に基づいて下記の米国特許出願規定に記載された権利をここに主張いたします。

(Application No.)
(出願番号)(Filing Date)
(出願日)(Application No.)
(出願番号)(Filing Date)
(出願日)

私は、下記の米国法典第35編120条に基づいて下記の米国特許出願に記載された権利、又は米国を指定している特許協力条約365条(c)に基づき権利をここに主張します。また、本出願の各請求範囲の内容が米国法典第35編112条第1項又は特許協力条約で規定された方法で先行する米国特許出願に開示されていない限り、その先行米国出願書提出日以降で本出願書の日本国内または特許協力条約国際提出日までの期間中に入手された、連邦規則法典第37編1条56項で定義された特許資格の有無に関する重要な情報について開示義務があることを認識しています。

(Application No.)
(出願番号)(Filing Date)
(出願日)(Status: Patented, Pending, Abandoned)
(現況: 特許許可済、係属中、放棄済)(Application No.)
(出願番号)(Filing Date)
(出願日)(Status: Patented, Pending, Abandoned)
(現況: 特許許可済、係属中、放棄済)

私は、私自身の知識に基づいて本宣言書中で私が行なう表明が真実であり、かつ私の入手した情報と私の信じているところに基づく表明が全て真実であると信じていること、さらに故意になされた虚偽の表明及びそれと同等の行為は米国法典第18編第1001条に基づき、罰金または拘禁、もしくはその両方により処罰されること、そしてそのような故意による虚偽の表明を行なえば、出願した、又は既に許可された特許の有効性が失われることを認識し、よってここに上記のごとく宣言を致します。

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s), or 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code Section 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of application.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Japanese Language Declaration

委任状：私は、下記発明者として、以下の弁理士及び代理人、またはそのいずれかをここに選任し、本願の手続きを遂行すること並びにこれに関する一切の行為を米国特許商標庁に対して行うことを委任する。(代理人氏名及び登録番号を明記のこと)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list agent's name(s) and registration number(s))

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, Reg. No. 22,540; Douglas B. Henderson, Reg. No. 20,291; Ford F. Farabow, Jr., Reg. No. 20,630; Arthur S. Garrett, Reg. No. 20,338; Donald R. Dunner, Reg. No. 19,073; Brian G. Brunsvold, Reg. No. 22,593; Tipton D. Jennings, IV, Reg. No. 20,645; Jerry D. Voight, Reg. No. 23,020; Laurence R. Hefter, Reg. No. 20,827; Kenneth E. Payne, Reg. No. 23,098; Herbert H. Mintz, Reg. No. 26,681; C. Larry O'Rourke, Reg. No. 26,014; Albert J. Santorelli, Reg. No. 22,610; Michael C. Elmer, Reg. No. 25,857; Richard H. Smith, Reg. No. 20,609; Stephen L. Peterson, Reg. No. 26,325; John M. Romary, Reg. No. 26,331; Bruce C. Zotter, Reg. No. 27,680; Dennis P. O'Relley, Reg. No. 27,832; Allen M. Sokal, Reg. No. 26,695; Robert D. Bajelsky, Reg. No. 25,387; Richard L. Stroup, Reg. No. 28,478; David W. Hill, Reg. No. 28,220; Thomas L. Irving, Reg. No. 28,619; Charles E. Lipsey, Reg. No. 28,185; Thomas W. Winland, Reg. No. 27,605; Basil J. Lewis, Reg. No. 28,818; Martin I. Fuchs, Reg. No. 28,508; E. Robert Yoches, Reg. No. 30,120; Barry W. Graham, Reg. No. 29,924; Susan Haberman Griffin, Reg. No. 30,907; Richard B. Racine, Reg. No. 30,415; Thomas H. Jenkins, Reg. No. 30,857; Robert E. Converse, Jr., Reg. No. 27,432; Clair X. Mullen, Jr., Reg. No. 20,348; Christopher P. Foley, Reg. No. 31,354; John C. Paul, Reg. No. 30,413; Roger D. Taylor, Reg. No. 28,992; David M. Kelly, Reg. No. 30,953; Kenneth J. Meyers, Reg. No. 25,146; Carol P. Einaudi, Reg. No. 32,220; Walter Y. Boyd, Jr., Reg. No. 31,739; Steven M. Anzalone, Reg. No. 32,095; Jean B. Fordis, Reg. No. 32,584; Barbara C. McCurdy, Reg. No. 32,120; James K. Hammond, Reg. No. 31,964; Richard V. Burgujian, Reg. No. 31,744; J. Michael Jakes, Reg. No. 32,824; Thomas W. Banks, Reg. No. 32,718; M. Paul Barker, Reg. No. 32,013; Bryan C. Diner, Reg. No. 32,409; Christopher P. Isaac, Reg. No. 32,618; Andrew C. Sonu, Reg. No. 33,457; Dirk D. Thomas, Reg. No. 32,600

書類の送付先：

Send Correspondence to:

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.
1300 I STREET, N.W.
WASHINGTON, D.C. 20005-3315

直通電話連絡先：(名称及び電話番号)

Direct Telephone Calls to: (name and telephone number)

ARTHUR S. GARRETT
202-408-4091

| | | | |
|-----------------|------|---|------------------|
| 唯一のまたは第一の発明者の氏名 | 1-00 | Full name of sole or first inventor | Hiroshi TAKEMOTO |
| 発明者の署名 | 日付 | Inventor's signature | Date |
| | | <i>Hiroshi Takemoto</i> | 25/12/2001 |
| 住所 | | Residence | |
| | | Osaka, JAPAN | JPX |
| 国籍 | | Citizenship | |
| | | Japan | |
| 郵便の宛先 | | Post Office Address | |
| | | c/o Shionogi & Co., Ltd. 12-4, Sagisu | |
| | | 5-chome, Fukushima-ku, Osaka-shi, Osaka | |
| | | 553-0002 JAPAN | |

| | | | |
|----------------------|------|--|-----------------|
| 第二の共同発明者の氏名 (該当する場合) | 2-00 | Full name of second joint inventor, if any | Masami TAKAYAMA |
| 同第二発明者の署名 | 日付 | Second inventor's signature | Date |
| | | <i>Masami Takayama</i> | 26/12/2001 |
| 住所 | | Residence | |
| | | Osaka, JAPAN | JPX |
| 国籍 | | Citizenship | |
| | | Japan | |
| 郵便の宛先 | | Post Office Address | |
| | | c/o Shionogi & Co., Ltd. 12-4, Sagisu | |
| | | 5-chome, Fukushima-ku, Osaka-shi, Osaka | |
| | | 553-0002 JAPAN | |

(第三またはそれ以降の共同発明者に対しても同様な情報及び署名を提供すること。)

(Supply similar information and signature for third and subsequent joint inventors.)

| | | | |
|----------------------|----|---|------|
| 第三の共同発明者の氏名 (該当する場合) | | Full name of third joint inventor, if any | |
| 同第三発明者の署名 | 日付 | Third inventor's signature | Date |
| 住所 | | Residence | |
| 国籍 | | Citizenship | |
| 郵便の宛先 | | Post Office Address | |
| | | 5-chome, Fukushima-ku, Osaka-shi, Osaka 553-0002 JAPAN | |

| | | | |
|----------------------|----|--|------|
| 第四の共同発明者の氏名 (該当する場合) | | Full name of fourth joint inventor, if any | |
| 同第四発明者の署名 | 日付 | Fourth inventor's signature | Date |
| 住所 | | Residence | |
| 国籍 | | Citizenship | |
| 郵便の宛先 | | Post Office Address | |
| | | | |

| | | | |
|----------------------|----|---|------|
| 第五の共同発明者の氏名 (該当する場合) | | Full name of fifth joint inventor, if any | |
| 同第五発明者の署名 | 日付 | Fifth inventor's signature | Date |
| 住所 | | Residence | |
| 国籍 | | Citizenship | |
| 郵便の宛先 | | Post Office Address | |
| | | | |

| | | | |
|----------------------|----|---|------|
| 第六の共同発明者の氏名 (該当する場合) | | Full name of sixth joint inventor, if any | |
| 同第六発明者の署名 | 日付 | Sixth inventor's signature | Date |
| 住所 | | Residence | |
| 国籍 | | Citizenship | |
| 郵便の宛先 | | Post Office Address | |
| | | | |

(第七またはそれ以降の共同発明者に対しても同様な情報及び署名を提供すること。)

(Supply similar information and signature for seventh and subsequent joint inventors.)